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Abstract
Abstract
Protein interactions are the key to our understanding of virtually all biological processes.
The entirety of protein interactions in a biological system is described by the term ‘in-
teractome’. Mass spectrometry-based proteomics is the method of choice to study the
protein interactome, because it is the only method that can identify and quantify pro-
teins directly and in an unbiased manner.
In this thesis, I present a large-scale study of the human interactome. This work is based
on an interaction proteomics method that captures protein interactions in a system as
close to the in vivo situation as possible. This method, called quantitative BAC-GFP
interactomics (QUBIC), uses cell lines expressing GFP-tagged proteins from bacterial
artificial chromosome (BAC) transgenes. These mimic the endogenous loci and ensure
near-endogenous expression levels and regulation patterns. I coordinated a proteome-
wide screen and acquired interactomics data for more than 1,100 tagged bait proteins.
To analyse these data, I developed strategies that enable the relative and absolute quan-
tification of proteins without the use of stable isotope labels. These strategies can be ap-
plied proteome-wide, from the lowest to highest abundant proteins in the cells, spanning
orders of magnitude of individual protein enrichment factors, and across thousands of
samples. Overall, the analysis revealed 28,000 interactions that connect more than half
of all proteins expressed in HeLa cells. This represents a valuable resource of unpreced-
ented size for the scientific community.
The combination of relative and absolute quantification is the foundation of a novel
concept of interactome analysis in three quantitative dimensions. The first dimension
discriminates specific interactors from background binders. The second dimension es-
timates the stoichiometries of interacting proteins. The third dimension quantifies their
cellular abundances.
A distinct stoichiometry signature identifies both known and novel stable protein com-
plexes. These complexes constitute a small minority among a wealth of weak interac-
tions. Strikingly, weak interactions turned out to be the most critical for the overall
structure of the network and are responsible for its ‘small world’ property. They explain
why most proteins are connected with each other via few intermediate steps.
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1 Introduction
1.1 Biological networks
Anetwork describes relationships between entities. In its graphical representation, these
entities are drawn as nodes (vertices) and relationships are drawn as edges connecting
the nodes. Many systems can be captured as networks: Social interactions between
people, the electrical power grid, the connectivity of servers and clients in the World
Wide Web, the ecological network of dependencies between species or the synapses
between neurons in the brain [1].
In molecular biology, metabolic networks describe chemical reactions catalysed by en-
zymes that interconvert metabolites (Figure 1 a). Gene regulatory networks capture the
interplay of factors governing gene expression (Figure 1 b): Upstream signalling mo-
lecules alter the binding state of transcription factors to genetic regions on the DNA,
thereby switching transcription on or off. Transcripts or proteins translated from them
may further exceed feedback signalling. In gene regulatory networks, nodes represent
genetic regions, mRNAs or proteins and edges indicate physical binding, translocation,
functional inhibition or activation of a process.
a b c
Figure 1: Types of biological net-
works
a. Metbolic network
b. Gene regulatory network
c. Protein interaction network
The prototypical biological network types describe interactions between genes or pro-
teins (Fig. 1 c). Genetic interactions denote mutual interdependencies of perturbations
of individual genes. Upon deletion of an individual gene, or knockdown or overexpres-
sion of its product, a certain phenotype is observed. If several genes are perturbed to-
gether, the resulting phenotype is typically a combination of the individual ones. For
functionally connected genes, however, the double perturbation phenotype can deviate
from the expected outcome: It may be aggravated, for instance in the case of genes that
encode functionally redundant proteins. In that case, loss of both gene products may
be well tolerated individually, but not in combination. In contrast, alleviating genetic
interactions denote that the double perturbation is less severe than the combination of
the individual ones. This can be the result of signalling cascades, where single or double
interruption block signal propagation alike, similar to one or multiple serial road-blocks
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having the same effect, as traffic is stopped in any case. Alternatively, alleviating genetic
interactionsmay occur for the genes encoding subunits of stable protein complexes: De-
letion of either subunit can render the complex non-functional, or trigger the degrad-
ation of unbound subunits. Genetic interactions only manifest in perturbed states of a
biological system. For practical reasons, genetic interaction phenotypes are usually read
out via cell growth or survival [2]. This limits the observable interaction space. On the
other hand, genetic interactions can be probed under diverse stress conditions, which
translate different biological functions to observable phenotypes. Upon discovery of a
genetic interaction, its mechanistic cause is not necessarily apparent. One way of elucid-
ating the nature of a functional relationship is to probe whether it is caused by a physical
interaction between proteins.
Proteins interact physically by forming macromolecular structures and stable protein
complexes. Interactions can also be of a transient or weak nature, as in the case of regu-
latory interactions or enzyme-substrate relationships. While a physical protein-protein
interaction is mechanistically very straightforward to interpret, its functional implica-
tions may be manifold. For that reason, genetic and physical interaction data ideally
complement each other.
1.1.1 Mapping protein-protein interaction networks
Global mapping of protein-protein interactions is the goal of a variety of methods [3].
Most of them can be classified as flavours of the yeast-two-hybrid (Y2H) approach (Fig.
2 a, b), or of affinity purification followed by mass spectrometry (AP-MS) (Fig. 2 c).
Figure 2: Approaches of protein-protein in-
teractionmapping.
a. Yeast-two-hybrid (Y2H). Bait and prey pro-
teins are fused to activation or DNA-binding
domains (AD, BD) and reconstitute an active
transcription factor upon interaction.
b. Split-ubiquitin system. Interaction of bait
and prey complements a split ubiquitin (Ub),
which leads to the proteolytic release of an act-
ive transcription factor that translocates into
the nucleus.
c. Affinity-purification followed by mass spec-
trometry (AP-MS). A (tagged) bait protein is
purified from a cell extract via affinity enrich-
ment. Co-purifying proteins are identified by
mass spectrometry.
a c
b
AD
BD
bait
prey
reporter gene antibody
anity matrix
mass spectrometerreporter gene
transcription
factor
bait
prey
Ub
tagprey
bait
Y2H and related split-protein methods map binary interactions between pairs of pro-
teins in a targeted fashion. To that end, each protein of the candidate pair is fused to one
‘half ’ of a split reporter protein. If the candidate proteins do interact, they bring the two
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‘halves’ of the reporter into close proximity, forming a functional reporter. In the clas-
sical yeast-two-hybrid approach, the Gal4 transcription factor serves as reporter and its
DNA-binding domain (BD) and activation domain (AD) are fused to either candidate
interactor [4]. Active Gal4 then leads to the transcription of reporter genes, which can
be read out via cell growth or chromophore formation (Fig. 2 a). Y2H is limited to pro-
teins that can be solubly expressed and that form a binary complex in the yeast nucleus.
This excludesmembrane proteins and proteins that are unstable or insoluble in isolation,
for instance outside of an obligate multiprotein complex. The split-ubiquitin method is
a variation of the Y2H concept that is applicable to integral or peripheral membrane
proteins [5] (Fig. 2 b). All current high-throughput implementations of the Y2H sys-
tem are carried out in a systematic fashion: Defined libraries of candidate interactors
are cloned into AD or BD fusion vectors and integrated into the yeast genome. Pairs are
then screened by selective mating. The attainable search space is the square of all pair-
wise combinations, that is
n(n−1)
2
combinations for n proteins. From this, one can derive
a static definition of the interactome as the sum of all binary protein-protein interac-
tions within this search space [6] (Fig. 3 a). Given that all interactions within the cell
can be decomposed into binary contacts, complete knowledge of this interactome mat-
rix should allow the delineation of all interactions happening in vivo. Y2H was used to
generate interactionmaps for variousmodel organisms, ranging from S. cerevisiae [7–9],
C. elegans [10],A. thaliana [11] to human [6, 12, 13]. Recent developments in theY2Hfield
include the use of robotics for cloning and yeast handling and the use of next-generation
sequencing as a quantitative readout rather than colony size [14, 15].
AP-MS takes a conceptually different route to protein-protein interaction mapping [16].
A protein assembly is purified from its endogenous source via an affinity matrix. In its
simplest form, endogenous protein complexes are purified to homogeneity by exploit-
ing available affinities or specific antibodies. Alternatively, one ‘bait’ protein is selected
and expressed as a fusion protein with an affinity tag. The composition of the complex is
then delineated, in the past typically by cutting out visible gel bands and subjecting them
to mass spectrometric analysis. This approach has three major drawbacks: (i) it requires
substantial amounts of inputmaterial; (ii) it is only applicable to those complexes against
which antibodies are available, which can be tagged or which possess inherent affinities
that can be used; and (iii) mass spectrometry is prone to identify co-purifying ‘contam-
inant’ proteins, generating many false positives.
One development addressing some of these shortcomings was the invention of the tan-
dem affinity purification (TAP) tag [17]. The budding yeast S. cerevisiae has a very effi-
cient homologous recombinationmachinery, enabling the straightforwardmodification
of endogenous loci, for instance by the insertion of a C-terminal affinity tag. The TAP tag
is a combination of a calmodulin binding peptide, a tobacco etch virus (TEV) protease
cleavage site and Staphylococcus aureus protein A. The protein complexes containing the
tagged protein can then be purified in several consecutive steps, first using the affinity of
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protein A to immunoglobulin G (IgG), followed by TEV cleavage and finally via a cal-
modulin column, from which highly purified complexes can be eluted by withdrawal of
calcium by EGTA. This procedure is the same for all tagged proteins and the amounts of
contaminant proteins are reduced, which enabled one of the first global studies of pro-
tein complexes in yeast [18]. However, it comes at the price of losing weak interactors
[19].
With the advent of modern mass spectrometers, the TAP-MS approach was faced with
the predicament that betterMS performance leads to worse data quality, because the no-
tion that each identified protein equals an interactor fails. Even seemingly clean prepar-
ations of protein complexes contain traces of many co-purifying proteins that sensitive
MS can detect. The remedy came in the form of quantitative proteomics [20, 21]. True
interactors can be distinguished from background binders by quantifying each identi-
fied protein in specific affinity purifications with a negative control sample. Background
binders are retrieved in either sample in roughly the same amounts, whereas specific
interactors are characterized by quantitative enrichment compared to the control. Even
with this realization, large-scale interaction proteomics datasets often failed to incorpor-
ate quantitative strategies, for various reasons. Initially, quantitative workflows required
the use of stable isotope labels, which was often cost-prohibitive. Early studies there-
fore relied on subtraction of frequently identified ‘contaminants’ [18, 22–24], which is an
overly simplistic concept that nonetheless persists to date [25]. Later, quantification, if
used at all, was done in a semi-quantitative fashion, for instance by counting how often
peptides derived from a certain protein were fragmented during MS analysis [26–29].
In recent years, however, truly quantitative approaches are gaining momentum, making
full use of the power of proteomics [30, 31].
Despite remaining methodological issues associated with AP-MS interactome datasets,
there is emerging evidence that, in contrast to binary datasets ofmutual protein affinities,
they are much better suited to describe the modular architecture of the interactome in
vivo [32, 33]. In this view, the interactome cannot be described as one static matrix of
all possible pair-wise combinations of interacting proteins. Rather, the interactome is a
reflection of the cellular proteome and integrates all subordinate layers such as protein
abundance, post-translational modifications and subcellular localization (Fig. 3 b).
Figure 3: Definitions of the inter-
actome.
a. Matrix of all possible binary
protein-protein interactions.
b. Additional layer on top of genome,
transcriptome and proteome.
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1.1 Biological networks
1.1.2 Network analysis
Many available datasets describe biological networks at a global scale. Such datasets can
not only be analysed at the level of individual interactions, but also from the perspective
of the network structure itself. In this way, network analysis is an essential technique for
systems biology, which seeks to describe, understand and predict life at the molecular
level in a holistic way. Mathematically speaking, a network is a graph and the analysis of
its properties is the subject of the field of graph theory, founded originally by Leonhard
Euler. In a seminal paper published in 1741, he solved a problem emerging from seven
bridges in the city of Königsberg, connecting the mainland on both sides of the river
Pregel via two river islands [34] (Fig. 4 a). The question was whether one could walk
across each bridge exactly once and visit all islands and each bank along the way. Euler
realized that the problem can be described as a graph, where each landmass represents
a node and each bridge an edge (Fig. 4 b). The graph describes only the connectivity
between landmasses but is agnostic to their actual geographical position. Looking at the
degree of connectivity, one quickly realizes that all nodes are of odd-numbered degree.
Because each node that is to be visited ‘in passing’ needs to have the same number of
incoming as outgoing edges, hence an even-numbered degree, there is no such path that
crosses each bridge exactly once.
a b c
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c
b
d
a
b
f
e
g
dcGrüne Brücke
Krämerbrücke
Schmiedebrücke
Köttelbrücke
Honigbrücke
Hohe Brücke
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=
Figure 4: The Königsberg Bridge Problem.
a. Reproduction of the original figure from Leonhard Euler [34]. Landmasses A–D are connected by
bridges a–g.
b. Graph representation of the same topological problem.
c. Illustration of the fact that the exact same graphs can be visualized differently.
This relatively simple problem can be expanded to answer all kinds of questions arising
frommore complex networks. A summary of the terminology of graph theory is presen-
ted in Box 1. One critical discovery around 15 years ago was a unique feature of network
structure: The degree distribution in real networks follows a power law. In other words,
most nodes have few connections whereas few nodes have many connections. Such
networks are called scale-free [35]. This network structure is highly non-random and
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Box 1 Glossary of graph theory
edge
degree=5
directed
edge
node
clique giant
component
shortest path
hub
high betweenness
centrality
The main elements of network graphs are nodes (vertices) and edges (links, connec-
tions) between pairs of nodes. The total number of edges is the size of a graph, and
the number of nodes its order. Edges can be directed or undirected. In the case of
directed edges, the relationship A→B is distinct fromB→A.Optionally,weightsmay
be assigned to individual edges, resulting in a weighted graph.
The number of edges connected to a node is called the degree of that node. For
directed networks, there is a distinction between the incoming and the outgoing de-
gree. Nodes with a comparatively high degree are called hubs; however there is no
universal threshold for calling a node a hub.
Cliques are sub-graphs where all possible pair-wise connections exist. Members of
cliques feature high clustering coefficients. The local clustering coefficient of a node
is the ratio of the number of actual edges between its neighbours over the number
of theoretically possible edges. Most real networks have a high average clustering
coefficient compared to random graphs of similar size and order.
Both in random and in real network graphs, a giant component emerges once a suffi-
cient number of edges has been added. This giant component is the largest entirely
connected sub-graph. A related concept is the small-worldness. In networks that
have a giant component, most nodes can be reached frommost other nodes via few
intermediate steps, denoted as the shortest paths. The longest of all shortest paths is
the diameter of a network. Somenodes adopt a critical role for network topology be-
cause many of the shortest paths run through these nodes. These nodes have a high
betweenness centrality, which is the fraction all of shortest paths running through
the given node.
Most real networks have a degree distribution that follows a power law: The prob-
ability P of a node to have k connections can be asymptotically described as P(k) ∼
k−γ. This behaviour results in self-similarity of the network, irrespective of the scale
at which it is observed. Therefore, local modules have similar characteristics as the
network as a whole in terms of their connectivity pattern. This phenomenon gives
such networks the scale-free attribute [35].
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thought to have originated through evolution from simpler networks by preferential at-
tachment of new nodes to existing ones. It has important implications for real networks.
First, it explains the so called ‘small world phenomenon’: almost all nodes can be reached
with few steps from each other node. The shortest paths in a network usually route via
a few highly connected hub proteins. Targeted removal of these hubs or critical edges
connecting them has dramatic consequences for overall network structure. Conversely,
the network is resilient towards random removal of nodes or edges [36]. This property
gives biological networks a remarkable degree of robustness.
When constructing protein interaction networks from experimental data, several as-
pects need to be taken into account: Y2H and related methods directly yield binary in-
teraction data, whereas AP-MS yields compositions of assemblies surrounding particu-
lar baits. Moreover, raw data contain varying amounts of noise and, depending on the
coverage and experimental biases, a large fraction of the interactome space may remain
unexplored. Networks can therefore be de-noised or completed by means of network
analysis [37, 38]. For instance, edges may be removed if reciprocal evidence is missing.
Conversely one can predict binary interactions between prey proteins co-purifying with
a given bait. Most network analysis approaches regard all edges as equal. However, for
the purpose of analysing network structure or for correcting noise or missing values,
assigning weight to the edges would be useful, reflecting their different nature and the
different degrees of certainty.
1.1.3 Network visualization
The graphical representation of a network is not trivial. Typically node-link diagrams
are used (Fig. 1); an alternative representation is a Boolean matrix of all possible pair-
wise combinations (Fig. 3) [39]. While simple node-link diagrams are intuitively inter-
pretable, they scale very badly with the size of the network, giving rise to the ‘hairball’
appearance of large network graphs. Another challenge is that conceptually, a network
describes only the connectivity of nodes, but not their position. Therefore, the exact
same networks can be represented in very different ways, which an observer will judge
to be different (Fig. 1 c). This is because the positioning of elements in a graph is the
strongest visual cue [40]. As a result, it is virtually impossible to compare large network
graphs and all that a viewer will absorb is a network’s rough size and its complexity. A
number of strategies have been developed to mitigate this problem and the search for
new visualization approaches often provided unforeseen insight into the nature of the
networks themselves. For instance, power graphs enable a compressed graphical repres-
entation of complex graphs [41]. The amount of compression in turn can be used as a
measure of data quality, because real networks are rich in highly compressible modules
[32, 42]. Hive plots tackle the visualization problem from a different angle, by projecting
nodes and edges to a defined coordinate system [43].
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1.2 Mass spectrometry-based proteomics
In the past two decades, mass spectrometry (MS) has emerged as the method of choice
for the global characterization of biological systems at the level of proteins, which are
the principal agents ofmost biological processes. Today,MS-based proteomics allows re-
searchers to identify and quantify proteins comprehensively inmany biological samples.
This development required concerted efforts from the scientific community, to which
our laboratory as contributed substantially: Early developments laid the foundations for
MS-based protein analysis, starting from the concept of electrospray ionization, which
first enabled the transfer of intact proteins or peptides into the vacuum inside the mass
spectrometer [44]. Later, sample preparation methods such as in-gel digestion allowed
researchers to couple their biochemical workflowswithmass spectrometric readout [45].
Sample preparation continues to be a critical part of the proteomics workflow, with re-
cent developments enabling the analysis of complete proteomes without systematic bi-
ases and from low amounts of inputmaterial [46, 47]. MS-based proteomics went quant-
itative with the introduction of stable isotope labelling techniques such as ICAT, SILAC,
TMT or iTRAQ [48–51]. Another critical ingredient was the maturation of the techno-
logical platform, with a swathe of high-resolution, fast mass spectrometers having been
introduced to the marked in recent years [52–54]. All wet-lab developments were closely
accompanied by computational advances, from strategies to deduce peptide sequences
from fragment spectra [55], via the development of statistical frameworks to tackle the
false discovery rate problem on a large scale [56] to user-friendly, end-to-end software
solutions for streamlined proteomics data analysis [57]. The bioinformatics pipeline is
slowly taking over responsibilities from the upfront wet-lab procedures. For instance,
label-free in silico quantification approaches are to some degree superseding isotope la-
bels or spike-in references. Furthermore, recalibration, normalization, deconvolution
and data integration steps can be applied in retrospect analysis. Together, these devel-
opments are now turning MS-based proteomics into a mature technology platform that
can be coupled to almost any biochemical workflow, providing functional readout about
proteins, their abundances, post-translational modifications (PTMs), interactions, loc-
alization and turnover.
1.3 Proteomic analysis of cellular systems
The utility of mass spectrometry-based proteomics for systems biology was the topic of
the opening chapter of the Handbook of Systems Biology. I wrote most of the chapter
together with Matthias Mann; Kirti Sharma contributed the section on PTM analysis
and Jürgen Cox wrote the part on computational proteomics.
Hein, M. Y., Sharma, K., Cox, J., & Mann, M. Handbook of Systems Biology: Concepts
and Insights: Proteomic Analysis of Cellular Systems, 3–25. Academic Press (2013).
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INTRODUCTION
A prerequisite for a system-wide understanding of cellular
processes is a precise knowledge of the principal actors
involved, which are biomolecules such as oligonucleotides,
proteins, carbohydrates and small molecules. Ever more
sophisticated methods to measure the identity and amount
of such biomolecules were an integral component of most
of the biological breakthroughs of the last century. At the
level of the genome, DNA sequencing technology can now
give us a complete inventory of the basic set of genetic
instructions of any organism of interest. Furthermore,
recent breakthroughs in next-generation sequencing are
promising to allow large-scale comparison of the genomes
of individuals. However, genomic sequences and their
variations between individuals are completely unin-
terpretable without knowledge of the encoded genes as well
as the biological processes in which they are involved.
Therefore, the growing ability to obtain genetic data
provides an increasing need and impetus to study the
functions of gene products individually (classic molecular
biology) and at a large scale (systems biology). The first
such system-wide studies were performed at the level of
mRNA (‘transcriptomics’). They enable an unbiased and
increasingly comprehensive view of which parts of the
genome are actually expressed in a given situation. Tran-
scriptomics also revealed that the relationship between the
genomic coding sequences and their corresponding RNA
molecules can be exceedingly complex. However, in terms
of cellular function, the transcriptome still represents only
a middle layer of information transmission, with no or little
function of its own. The actual ‘executives’ of the cell are
the proteins, which perform myriad roles, from orches-
trating gene expression to catalyzing chemical reactions,
directing the information flow of the cell and performing
structural roles in cells and organisms. This crucial role of
proteins is also underlined by the fact that diseases always
involve malfunctioning proteins, and that drugs are almost
invariably directed against proteins or modify their
expression levels.
Unfortunately, given the central importance of proteins,
until recently there were no methods of protein measure-
ment that were comparable to the powerful sequencing,
hybridization or amplification-based methods to charac-
terize oligonucleotides. This is finally beginning to change
owing to the introduction of mass spectrometry, first in
protein science and later for the large-scale study of
proteins, a field called mass spectrometry (MS)-based
proteomics [1].
The proteome of a cell designates the totality of all
expressed proteins in a given biological situation, and is
therefore a dynamic entity. It encompasses not only the
identity and amount of all proteins but also their state of
modification, their turnover, location in the cell, interaction
partners and e by some definitions e their structures and
functions. Clearly, the proteome of the cell is the most
complex and functionally most relevant level of cellular
regulation and function.
Accordingly, in systems biology it is usually the pro-
teome that is the object of modeling. Typically only very
small subsets of all proteins e those participating in
a defined function of interest e are included in these
models. Even then, reliable and relevant information on
Handbook of Systems Biology Concepts and Insights. http://dx.doi.org/10.1016/B978-0-12-385944-0.00001-0 3
Copyright  2013 Elsevier Inc. All rights reserved.
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these few proteins has been hard to come by. This has
meant that systems biological models suffered from
a paucity of hard parameters, and instead usually had to
make do with very rough estimates of the identities,
abundances, localization and modification states of the
involved proteins. Modern MS-based proteomics is now
ready to change this situation completely.
Its success in protein analysis comes as the last chapter
in the very long history of mass spectrometry, which began
with the observation of Kanalstrahlen (anode rays) by
Eugen Goldstein in 1886 and the construction of the first
mass spectrometer by Francis William Aston in 1919. The
first application to amino acids by Carl-Ove Andersson
dates back to 1958. Later, both the quadrupole and the
three-dimensional ion traps were developed by Wolfgang
Paul, for which in 1989 he received the Nobel Prize in
Physics, together with Hans Georg Dehmelt. However, the
breakthrough for MS in biology came with the develop-
ment of soft ionization technologies that enabled gentle
transfer of peptides or proteins into the mass spectrometer,
for which the Nobel Prize in Chemistry in 2002 was
awarded. The emergence of MS as a powerful ‘omics’
discipline was also enabled by continuous developments in
sample preparation, separation technologies and break-
throughs in the capabilities of the mass spectrometers
themselves, some of which are detailed below. In parallel
with these improvements on the ‘wet side’, data analysis
and computational strategies on the ‘in silico side’ over the
last 20 years have been just as important, as they allow the
identification of peptides in sequence databases from
a minimum of mass and fragmentation information. Orig-
inally applied to one peptide at a time in a manual fashion,
these algorithms now deal with hundreds of thousands of
peptides in multifaceted projects and require large-scale
data management issues to be addressed which are just as
demanding as they are in the other ‘omics’ technologies.
The development of relative and absolute quantification
methods over the last decade has been particularly crucial
to proteomics. Using the latest proteomics technologies, it
is now possible to quantify essentially complete proteomes
of model organisms such as yeast [2]. More complex
organisms are also coming within reach [3e5]. However,
quantitative proteomics not only permits precise proteome
quantification in one state compared to another (termed
‘expression proteomics’ and providing data conceptually
similar to transcriptomics) but also enables ‘functional
proteomics’, when combined with appropriate biochemical
workflows. This can, for example, identify specific protein
interactions or reveal the composition of subcellular
structures [6e8]. Together, these methods allow the pro-
teome to be studied in space and time, something that
cannot easily be done on a large scale and in an unbiased
manner by other technologies [9]. The resulting proteomic
data perfectly complement large-scale studies following
individual proteins in single cells, for instance by means of
immunostaining [10] or protein tagging [11].
One of the most important areas for MS-based proteo-
mics is the analysis of post-translational modifications
(PTMs) [12,13]. During recent years, MS-based proteomics
has revealed an unexpected diversity and extent of protein
modifications. For example, phosphorylation turns out to
occur not only on a few key proteins but on thousands of
them, which possibly also applies to less studied PTMs.
How to model their regulatory roles will long be a key
challenge for systems biology.
MS-based proteomics now for the first time opens up
the entire universe of cellular proteins to detailed study.
Protein amount, localization, modification state, turnover
and interactions can all be measured with increasing
precision and increasingly sophisticated approaches, as
detailed below. There is a unique opportunity to employ
these data as a crucial underpinning for building accurate
and comprehensive models of the cell [14].
MS-BASED PROTEOMICS WORKFLOW
The analysis of complex protein mixtures is very difficult.
Accordingly, the field of MS-based proteomics has been
made possible by seminal advances in technology that have
helped to overcome a number of critical challenges.
Together, they have resulted in a generic and general
‘shotgun’ workflow that can be applied to any source of
proteins and almost any problem that can be addressed by
MS-based proteomics (Figure 1.1). Here we explain the
principles of this workflow, but also point out variations to
the general theme.
Until the 1980s proteins or peptides were largely
incompatible with MS, as they could not be transferred into
the vacuum of the mass spectrometer without being
destroyed. Two alternative approaches solved this funda-
mental problem: electrospray ionization (ESI), for which
a share of the 2002 Nobel Prize in Chemistry was awarded
to John B. Fenn, and matrix-assisted laser desorption/
ionization (MALDI). MALDI involves embedding the
analyte in a solid matrix of an organic compound, followed
by transfer into the vacuum system. A laser pulse then
excites the matrix molecules, leading to their desorption
along with the ionized analyte molecules, whose mass is
measured in a time-of-flight (TOF) analyzer [15]. In
contrast, in electrospray a stream of liquid is dispersed into
a charged aerosol when high voltage is applied to the
emitter. Solvent molecules in aerosol droplets rapidly
evaporate, and charged analyte molecules are then trans-
ferred into the vacuum of the mass spectrometer, where
they finally arrive as ‘naked’ ions [16].
Even with appropriate ionization techniques at hand,
large intact proteins are usually difficult to handle, there-
fore the standard MS-based proteomic workflow follows
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the bottom-up principle: proteins are first digested to
peptides using a sequence-specific endoprotease. This is
typically trypsin, which cleaves C-terminal to arginine or
lysine. These peptides are analyzed by MS and afterwards
proteins are reconstructed in silico. For the general purpose
of identifying and quantifying proteins with high sensitivity
and in complex mixtures, this ‘bottom-up’ approach is
extremely powerful. This is due to the convenience of
handling peptides and the much superior characteristics of
the MS analysis of peptides compared to proteins. The
complementary ‘top-down’ approach omits the enzymatic
digestion step and analyzes intact protein species instead
[17]. Its principal merit is that it retains information about
the entire protein (such as co-occurring modifications), but
this advantage comes at the cost of vastly increased
experimental effort [18].
For an unbiased and comprehensive analysis of the
proteome, the cell or tissue lysis method must ensure
complete solubilization of all proteins contained in the
sample. This is particularly challenging with membrane
proteins, which demand a detergent-based solubilization
method even though detergents are known to interfere with
A: Sample preparation
B: Liquid chromatography - mass spectrometry
C: Spectra interpretation
cells or tissue
HPLC
Full MS MS/MS
peptide m/z, peptide intensities
stable isotope-pair ratios
b- and y-ion series
reporter ions, diagnostic peaks
precursor
selection,
isolation,
fragmentation
bottom-up
protein assembly
m/z m/z
ESI
time mass spectrometer
Cycles of full MS followed by
MS/MS of the most intense peaks
Full MS top1 top2 ... top n
MS2 MS2 MS2 MS2
proteins peptides
data dependent acquisiton
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enrichment*
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FIGURE 1.1 Outline of a typical shotgun proteomics workflow. A: Sample preparation: Proteins extracted from tissues or cells are digested into
peptides using proteases such as trypsin. A fractionation step may be applied at either the protein or peptide level to improve the coverage and dynamic
range. Peptides bearing specific post-translational modifications can be enriched using specialized approaches (see Figure 1.5A). B: Liquid chroma-
tography-mass spectrometry: Peptides are separated by high-performance liquid chromatography (HPLC) and electrosprayed directly into the mass
spectrometer. Peptide ions are measured at high resolution in a data-dependent mode: after each full MS scan, the most intense peptide ions are fragmented
to generate MS/MS spectra. C: Spectra interpretation: The full MS spectra provide information about the peptide mass, intensity, presence of a PTM and
stable isotope pairs. The mass of each fragmented peptide together with its fragment ion pattern is searched against databases for peptide identification and
bottom-up protein assembly.
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subsequent MS analysis. Furthermore, endoproteinases
work optimally in a detergent-free environment. The first
MS sample preparation methods successfully employed on
biological samples used detergent-mediated solubilization
followed by SDS polyacrylamide gel electrophoresis and
in-gel enzymatic digestion of proteins [19]. ‘In-solution’
digestion methods employed detergent-free protein
extraction using strong chaotropic agents such as urea, and
digestion of proteins under denaturing conditions. In the
early days of applying MS to protein identification, stained
protein bands were excised from one-dimensional gel
electrophoresis runs, in-gel digested and analyzed directly
in the mass spectrometer by MALDI or electrospray. For
samples containing peptides from only one or a few
proteins, the combination of several peptide masses may be
sufficient for identification. This technique is called ‘mass
fingerprinting’ and it is still often used in conjunction with
two-dimensional gel electrophoresis (2D-GE). However,
both mass fingerprinting and 2D-GE have serious analytical
limitations in the dynamic range of protein abundances that
they can handle, as well as many other issues, and they are
no longer generally used in proteomics. Today the inherent
complexity of proteomic samples is being addressed by
a combination of fractionation techniques as well as fast
and sensitive mass spectrometers, but it remains a major
challenge when the goal is to define complete proteomes
[20]. For these very complex mixtures, electrospray, and
not MALDI, is the ionization method of choice. This is
because electrospray handles analytes in solution, which
allows it to be coupled directly or ‘on-line’ to liquid
chromatography (LC) by applying the spray voltage to the
end of the chromatographic column. LC is arguably the
most powerful separation technique available for peptides,
which can then be analyzed sequentially as they elute from
the column. Current developments in peptide LC aim at
further improvements in separation as well as decreasing
flow rates and column diameters, which increases sensi-
tivity [21].
In addition, a multitude of gel-based and gel-free frac-
tionation techniques have been developed that are applied
on either the protein or the peptide level prior to the liquid
chromatography step [22e26]. While increasing the
number of separation steps generally increases the depth of
coverage of the proteome, it also increases the sample
processing and MS-measurement time, as well as require-
ments for sample amount. Therefore, proteomics experi-
ments should be planned with the minimum number of
fractionation steps possible. This is especially important
when several conditions are to be measured and compared.
Although online coupling of LC with MS via electro-
spray is clearly the method of choice for complex protein
mixtures, the MALDI method still offers advantages in
specific situations. For instance, in principle the spatial
resolution of the MALDI laser spot makes it possible to
‘image’ analytes in situ, e.g. on tissue slices treated with
appropriate MALDI matrices [27, 28].
Once peptides have been transferred into the vacuum of
the mass spectrometer, their mass-to-charge ratio (m/z) and
intensity have to be measured. For unambiguous identifi-
cation, it is additionally necessary to fragment each peptide
in turn and to record the resulting mass spectrum, a tech-
nique called MS/MS, MS2 or tandem mass spectrometry. In
the data-dependent ‘shotgun’ approach, the most abundant
peptide species eluting from the LC column at a given time
are isolated one at a time and activated in the mass spec-
trometer, usually by collisions at low pressure of an inert
gas. Peptides mainly dissociate at the amide bonds,
generating overlapping series of N-terminal and C-terminal
fragments (called b-ions and y-ions, respectively) [29]. In
principle, the peptide sequence can be reconstructed ‘de
novo’ from a complete fragment ion series. In practice, it is
much easier to match uninterpreted fragment information
to a comprehensive protein sequence database of the
organism under investigation. There are many different
algorithms and search engines for this (see section
Computational Proteomics), but virtually all are based on
the comparison of measured masses with the theoretical
masses of expected peptides and their fragments.
Determining accurate masses is a key step in this
procedure, and advances in mass spectrometric technology
in recent years have made significant contributions to the
achievable depth of analysis. Key characteristics of a high-
performance mass spectrometer are resolution, mass
accuracy, speed, sensitivity and dynamic range [30]. High
resolution is the ability to distinguish two peaks of only
slightly different m/z ratio, while mass accuracy describes
the difference between measured and theoretical mass [31].
Sensitivity is the capacity to detect low abundant analytes
whereas dynamic range of an instrument denotes the
difference between the lowest and highest abundant species
that are detected. Together, the aforementioned properties
should allow a high-performance instrument to perform
peptide sequencing at sufficiently high speed to obtain
adequate coverage of the complexity of the sample within
the timeframe of analysis. The Orbitrap mass analyzer is
a particularly powerful instrument in proteomics [32e34],
but modern TOF-based analyzers are also popular [35,36].
However, even today’s best mass spectrometers are
technically unable to isolate and sequence all peptide
species present in an LC-MS run, resulting in extensive
undersampling of the observable peptides [37]. This leads
to a certain degree of stochastic behavior between shotgun
runs, which can complicate analysis, especially in systems
biology applications. In such cases, it is often attractive to
measure only a subset of peptides e such as those of a few
key proteins e but to ensure that they are measured in each
of multiple conditions. This requirement has led to so-
called targeted approaches, where the mass spectrometer is
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fed with a list of predefined peptide species and their cor-
responding fragments. It then simply records series of
transitions from precursor to fragment ions; this is referred
to as multiple or selected reaction monitoring (SRM or
MRM) [38]. Both shotgun and targeted approaches have
their advantages and drawbacks: the shotgun approach does
not require prior development of peptide-specific assays
and in principle can measure the entire proteome. There-
fore, it is the method of choice for the discovery phase of
proteomic studies. However, it may require extensive
measurement time and proteins of interest may be missed.
In contrast, the targeted approach can be performed rapidly
and in principle without pre-fractionation, but is necessarily
biased in the sense that only predefined peptides are
measured.
The most promising approach is probably a hybrid one,
which is facilitated by the latest generation of mass spec-
trometric hardware: a combination of general shotgun
sequencing with targeted sequencing of a list of preselected
candidates. Another interesting hybrid approach has been
called SWATH-MS and involves the acquisition of frag-
ment data for all precursor masses in consecutive mass
windows of 25 m/z units (termed ‘swaths’) across the entire
mass scale in rapid succession. When combined with tar-
geted data extraction, this enables repeated scanning of the
same fragment ion maps for quantification of proteins or
peptides of interest [39].
Relative or absolute quantification has increasingly
become the focus of proteomics experiments and has
largely replaced the initial goal of only generating accurate
and complete lists of identified proteins [40]. This is
a challenging task because mass spectrometry is not
inherently quantitative. A number of elegant approaches
have been developed that now make MS the most quanti-
tatively accurate protein technology by far; these are
summarized in Box 1.1.
The correct identification and quantification of peptides
by MS/MS sequencing, the assembly of a series of peptide
sequences into protein identifications and the integration of
peptide quantification into protein quantification becomes
increasingly challenging as the complexity of the sample
increases. It can only be dealt with correctly using rigorous
statistical methods. To this end, a plethora of software tools
and mass spectra search engines have been developed,
which are discussed in the next section.
COMPUTATIONAL PROTEOMICS
An important aspect of high-throughput technologies is the
availability of suitable computational workflows support-
ing the analysis and interpretation of the large-scale data-
sets that are routinely generated in current systems biology.
Modern MS-based proteomics measurements produce data
at similar rates as deep sequencing experiments of cellular
DNA and RNA. For all of these technologies it is a chal-
lenging task to produce condensed representations of the
data in a form and amount suitable for biologic interpre-
tation in a reasonable timeframe within the constraints of
the available computer hardware. In the early days of MS-
based proteomics, the interpretation of spectra for the
purpose of identification and quantification of peptides and
proteins was done in a manual or semi-automatic fashion
[41]. Nowadays, however, a single mass spectrometer can
generate a million mass spectra per day [42]. Obviously, it
is impractical to interpret the entire raw data in a ‘one
spectrum at a time’ fashion by a human expert. Therefore, it
is a necessity to employ reliable and efficient computa-
tional workflows for the identification and quantification of
these enormous amounts of spectral data. Of particular
importance is the control of false positives, e.g. by calcu-
lating and enforcing false discovery rates (FDRs) by
statistical methods that take into account the multiple
hypotheses testing nature inherent in large MS datasets.
Historically, computational proteomics started from the
development of peptide search engines, and for this reason
software tools have evolved around them. Furthermore,
vendors strive to provide software enabling the computa-
tional analysis of the output of their instruments. These
often interface with popular peptide search engines. There
is much activity in software development for MS-based
proteomics and dedicated reviews have been published
[43e46].
All-encompassing end-to-end computational workflow
solutions have also been developed, for instance the freely
available trans-proteomic pipeline [47] and MaxQuant
software packages [48]. MaxQuant contains a comprehen-
sive set of data analysis functionalities and will be the basis
of the subsequent discussion. Furthermore, there is
a plethora of individual solutions for more specialized tasks.
As examples, ProSight assists in the analysis of top-down
protein fragmentation spectra [49,50], special search
engines have been developed to identify cross-linked
peptides [51,52], and commercial software for the ‘de novo’
interpretation of fragmentation spectra is available [53,54].
Here we focus on the computational steps that are
needed to generate quantitative protein expression values
from the raw data. Later chapters in this book focus on
subsequent analysis of this kind of expression data in terms
of multivariate data analysis, in the context of biomolecular
interaction networks or in the modeling of biochemical
reaction pathways. This initial part of the shotgun proteo-
mics data analysis pipeline can roughly be subdivided into
four main components (Figure 1.2): (a) feature detection
and processing, (b) peptide identification, (c) protein
identification and (d) quantification. Each of these consists
of several sub-tasks, some of which are obligatory
constituents of the generic data analysis workflow whereas
others address specific questions in particular datasets.
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Box 1.1 Quantification in MS-Based Proteomics
Mass spectrometric approaches providing relative and absolute
quantification have been a focus of many recent developments
in the field. MS-based quantification is non-trivial because for
different peptide species there is no proportionality between
their respective amounts and the signal intensities they generate
in the mass spectrometer. This is due to the very diverse
chemicophysical properties of peptides with different
sequences, resulting in widely varying ionization efficiencies.
For chemically identical peptides, however, signal intensity is
proportional to the amount e within the linear range of the
instrumente and this is the basis of all isotope labeling methods
as well as of many label-free quantification approaches. In
addition, it is often assumed that the most readily detected
peptides of each protein have roughly similar ionization effi-
ciencies across all proteins, and that their signal is therefore
a proxy for the protein amount.
Label-free approaches are appealing because they can be
used on any sample and do not require any additional experi-
mental steps. A basic version of label-free quantification is
called spectral counting, and simply compares the number of
times a peptide has been fragmented. Since there is a stochastic
tendency of shotgun proteomics to fragment more abundant
peptides more often, this provides a rough measure of peptide
abundance [180,181]. In a more accurate version of label-free
quantification, the MS signals of each peptide identifying
a protein are added and this protein intensity value is compared
between the different experiments [75]. Ideally, the intensities
of the same peptide species are directly compared across
experiment. Challenges in label-free workflows are day-to-day
variations in instrument performance or slight variations in
sample preparation, which can reduce accuracy. Nevertheless,
they are gaining ground owing to the increasing availability of
high-resolution mass spectrometers and the development of
sophisticated algorithms. They are best suited to cases where at
least several-fold changes in protein or peptide intensities are
expected.
The most accurate methods for quantification by MS make
use of the fact that the MS response of the same compound in
different isotopic states is the same. This principle has been
employed for decades in the small molecule field, where it is
sometimes called isotope dilution MS, and it has also been used
for many years with peptides. In proteomics, the peptide pop-
ulations from two different samples are labeled by the intro-
duction of light or heavy stable isotopes such as 12C vs. 13C and
14N vs. 15N, mixed and analyzed together. The mass spec-
trometer easily distinguishes heavy peptides from light peptides
by their mass shift, but since they are chemically equivalent
they behave the same during chromatographic separation and
ionization. The ratio of the heavy and light peak intensities
therefore represents the relative amounts of the corresponding
proteins in the samples to be compared. There are many
different methods of introducing labels, for example metabolic
labeling methods such as SILAC [182], or chemical ones such
as TMT [183], iTRAQ [184] and di-methyl labeling [185,186].
The metabolic methods have the principal advantage that the
two populations to be compared can be mixed at a very early
stage of sample preparation. All variations in sample prepara-
tion are then experienced by both samples equally, leading to
very high quantitative accuracy. Chemical methods are usually
applied at a later stage, by which time quantitative differences
due to separate sample preparation may already be established.
Furthermore, care has to be taken that the chemical labeling
procedure proceed to the same degrees of completeness in the
different samples and that chemical side reactions are
minimized.
Metabolic methods almost always quantify the peptide in
the intact form in the MS spectrum, whereas some of the
chemical methods use differentially isotope labeled fragment
ions (‘reporter ions’) to determine the relative ratios from the
MS/MS spectra. A disadvantage of the latter methods is that, in
complex mixtures, peptides apart from the intended one are co-
fragmented. These also contribute their identical reporter ions,
distorting measured ratios [77].
Targeted approaches (SRM or MRM) are also fragmentation-
based quantification methods but they aim to monitor only
transitions from precursor to sequence-specific fragments.
Several such transitions are monitored in rapid succession for
a single peptide and several peptides can be targeted at any
given elution time. This ensures that the recorded signal is due
to the intended peptide. For quantification, an isotope-labeled,
synthetic peptide standard for each peptide of interest needs to
be introduced. However, since synthesis, purification and
storage of many labeled peptides are resource-intensive, the
label-free transition data is often used for approximate quanti-
fication. In general, MRM-based quantification methods
require extensive method development because the most
sensitive and specific transitions need to be determined for each
peptide separately. There are therefore a number of large-scale
projects to construct such data on a global, organism-wide
scale [187e189].
Apart from relative quantification of two or more proteomes,
it is in many instances necessary to estimate the absolute
amounts of proteins. If a known amount of a synthetic, labeled
peptide is added to the sample, the ratio of the heavy to the light
version of the peptide immediately yields the absolute amount
of the endogenous peptide present (absolute quantification or
‘AQUA’ method [190]). If the extraction and digestion effi-
ciency of the protein in the sample is also known, this further-
more yields the absolute amount of protein in the sample. The
same principle also applies to spiking in known amounts of
proteins, except that this automatically controls for digestion
efficiency, including the tendency of the enzyme to produce
peptides with missed cleavages [191].
Absolute protein amounts can be converted into copy
numbers per cell, an important parameter for modeling.
Evidently, it is impractical to spike in reference peptides or
proteins for an entire proteome. Therefore, in the simplest case,
the MS signals of peptides identifying a given protein are
summed up and divided by the total MS signal of all proteins.
This procedure can be calibrated by the estimated total protein
amount or with the help of reference peptides or proteins for
a select subset of proteins across the dynamic range [2,86,91].
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The first group of tasks is concerned with extracting
features from the raw data that correspond to peptides in the
MS spectra and to peptide fragments in the MS/MS spectra
(Figure 1.2A). Depending on the specific details of the MS
technology employed, pre-processing steps may be
required, for instance subtraction of a background level, or
smoothing and filtering of the raw data [43]. Then, peaks
are detected, which in LC-MS constitute three-dimensional
‘hills’ over the mass-retention time plane. These 3D peaks
usually occur in co-eluting isotope patterns that correspond
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FIGURE 1.2 Overview of the main components of the computational workflow of shotgun proteomics. A: Detection and processing of peptide
features in LC-MS runs. B: Identification of peptides based on their characteristic fragmentation patterns. C: Assembly of peptides into proteins. D:
Quantification of peptides and proteins based on stable isotope labeling or by label-free quantification.
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to peptides with a given charge. For a peptide this pattern
is mainly due to the natural content of 13C atoms. In the case
of stable-isotope-based quantification methods the peptide
exists in different labeling states, such as heavy and light
SILAC partners. These have to be assigned to each other
based on characteristic mass differences and similarity of
elution profiles.
Often there are systematic errors in the measured
masses of these peptide features that vary continuously
with mass and retention time. Algorithms can be applied to
recalibrate the mass measurements and thereby remove
these systematic errors, resulting in very accurate mass
measurements with solely non-systematic and small
random errors remaining [55]. From the standard devia-
tions in the mass measurements one can calculate indi-
vidual mass tolerances for each peptide, which aid peptide
identification by restricting the possible molecules to
elemental compositions that are consistent with the indi-
vidual peptide mass tolerance. Similar to this recalibration
of mass measurements, the retention times of peptides can
also be recalibrated. Here the goal is to make the retention
times in different LC-MS runs as comparable to each other
as possible using computational means.
The next important computational block is concerned
with the identification of peptides from fragmentation
spectra [29,56] (Figure 1.2B). Here one can follow one of
two approaches: The de novo approach starts with inter-
preting mass differences between fragment peaks as amino
acids and tries to build up amino acid sequences, often by
representing MS/MS spectra as spectrum graphs [57]. This
either results in a de novo sequence of the whole peptide or
in a sequence tag within the peptide[58]. In the database
search approach one first digests the protein sequences of
an organism in-silico to obtain a list of peptides that
a certain protease, typically trypsin, can potentially
generate. Peptides are then identified by scoring MS/MS
spectra against the sequences from the database, either with
a cross-correlation approach as used in SEQUEST[59], or
with a probability-based strategy as used by the Mascot
[60] and Andromeda [61] search engines, for instance. In
the latter case, for each peptideespectrum comparison the
probability is calculated to obtain the observed number of
matching peaks between the spectrum and the theoretical
fragment series derived from the peptide sequence by
chance. The peptide identification rate can be further
improved by taking into account peptide properties such as
sequence length, number of missed cleavages, and others,
either with the help of bayesian methods [48,62] or with
machine learning techniques [63]. A false discovery rate
(FDR) can be imposed on the peptide identification process
by modeling of the score distribution [62] or by the target-
decoy approach [64]. Statistical techniques controlling the
FDR [65] are superior to simple ad hoc methods, such as
using a fixed score cutoff, since they properly take into
account multiple hypothesis testing and incorporate prop-
erties of the search space. Peptide identifications can be
transferred between LC-MS runs based on highly accurate
mass measurements and optimally aligned retention-time
values. We recently developed a method for determining an
FDR for this procedure [66]. Post-translational modifica-
tions of proteins can be identified by incorporating them
into the database search in the form of variable modifica-
tions. In principle, scoring is similar to the scoring of
unmodified peptides. However, the search space may
increase dramatically, especially when considering several
modifications at once. Additionally, the specific amino acid
that has been modified needs to be pinpointed. This posi-
tioning of the identified modifications can be carried out in
several ways, which usually provide scores that reflect the
certainty of the localization [67e71]. A larger class of
modifications can be detected with peptide sequence tags
[58], the error-tolerant search in Mascot [72], or with the
completely unbiased dependent peptide search [73], which
does, however, require the unmodified peptide to have been
fragmented and identified as well. Finally, in order to
validate the identification of peptides or proteins of
particular interest it is useful to visualize and export their
fragmentation spectra. At this stage extensive peak anno-
tation, including peaks resulting from neutral losses and
originating from other peptide chemistry reactions, can also
be provided.
Once peptides and their modifications are identified
they need to be assigned to proteins, a non-trivial task that
has been termed the ‘protein inference problem’
(Figure 1.2C) [74]. The basic challenge is that a peptide
may occur in several proteins. The reason might be that
these proteins result from alternative splicing and therefore
share common exons, or that the proteins originate from
distinct genomic locations that encode homologous genes
with very high sequence identity. A pragmatic approach to
the protein redundancy problem is to assemble proteins into
groups of non-distinguishable members based on the sets of
identified peptides either being identical between these
members or containing each other. Additionally, one can
map peptides to the protein coding regions of known
transcripts and investigate whether unknown splice variants
can be detected by identifying peptides that span new splice
junctions.
Most proteomics datasets that are generated with
current equipment are sufficiently large that one needs to
take care of the FDR on the protein level as well as the
peptide level. Approaches that have only a peptide-based
control of false identifications, even if it is quite stringent,
will accumulate false positive protein identifications if
sufficiently large amounts of data are measured, and should
therefore be used with caution.
After peptides and proteins are identified, the absolute
or relative amounts of proteins in different samples usually
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need to be calculated, which requires quantification of the
identified peptides (Box 1.1 and Figure 1.2D). In stable
isotope labeling approaches that produce pairs or higher
multiples of peptide isotope patterns in the MS spectra, one
can use algorithms that provide very precise estimates of
peptide abundance ratios. In MaxQuant this is done by
comparing the full elution profiles and isotope patterns of
the labeled partners. Once peptide ratios are calculated they
need to be combined in appropriate ways to obtain protein
ratios. In isobaric labeling techniques the relative peptide
abundances are read out at specific mass values in the MS/
MS spectra [75]. Here special attention needs to be devoted
to the distortion of the signal by co-fragmented peptides
and to filtering the peptides accordingly for quantification
[76e78]. Finally, samples can be measured without
isotopic labeling, which is referred to as ‘label-free quan-
tification’. In this case optimal alignment of the runs should
be performed, and further normalization steps should be
included to make peptide signals from different LC-MS
runs comparable to each other. This is computationally
challenging, in particular if the samples are each pre-frac-
tionated into several LC-MS runs.
In addition to the basic workflow described so far,
which provides quantitative protein expression data,
several additional downstream computational tasks need to
be performed. Fortunately, once the proteomic expression
data matrix has been obtained, many statistical and
computational methods that were developed for microarray
data analysis can be re-used for proteomics. For instance,
clustering, principal component analysis, tests for differ-
ential regulation, time series, pathway and ontology
enrichment analysis and many other methods can be
applied just as well to proteomics data. The Perseus module
of MaxQuant assembles these capabilities into a single,
user-friendly platform for high-resolution proteomic data.
Modeling in systems biology has so far relied on either
mRNA levels as proxies for protein expression or on small-
scale protein data that monitored only a few different
molecular species. In the future, modeling will surely
benefit from the increasing availability of large-scale and
precise proteomics data.
DEEP EXPRESSION PROTEOMICS
One of the limitations of proteomics so far has been its
inability to probe the proteome in great depth. Over the last
few decades, 2D gel electrophoresis, for instance, has
produced gels that visualized hundreds or thousands of
spots. Upon identification, however, they generally proved
to derive from a very small number of highly expressed
genes. The difficulties in exploring the proteome in depth
are mostly related to the ‘dynamic range problem’, that is,
the difficulty of measuring extremely low abundance
proteins in the presence of very high abundant ones. Until
a few years ago many thought that this problem would be
unsolvable even in principle [79]. Fortunately, it has now
become clear that the dramatic improvements in the pro-
teomic workflow do indeed allow complete characteriza-
tion of proteomes.
Like its genome, the proteome of the yeast model
system was the first to be completely analyzed [2]. Haploid
and diploid yeasts were SILAC-labeled, mixed and
measured together. With a combination of different
approaches, 4400 yeast proteins were identified with 99%
confidence, a larger number than detected either by
genome-wide TAP (tandem affinity purification) tagging or
GFP (green fluorescent protein) tagging of all yeast open
reading frames [11,80]. The most regulated genes belonged
to the yeast mating pathway, most of which are expressed at
very low levels and are only functionally relevant in
haploid yeast. However, not all members of this pathway
were differentially regulated, immediately highlighting that
they must have additional roles in other cellular processes.
The total dynamic range of the yeast proteome under these
basal conditions turned out to be between 104 and 105.
A targeted analysis of the yeast proteome likewise
identified proteins across its entire dynamic range [81].
SRM assays were developed on triple quadrupole instru-
ments for members of the glycolysis pathway, and
expression changes upon metabolic shifts were measured
across multiple time points in relatively short LC-MS runs.
Recently, our group has proposed ‘single-shot proteo-
mics’ as a complement to the shotgun and targeted
approaches: single-shot proteomics simply means the
analysis of as much of the proteome as possible by a single
LC MS/MS run [82]. Its attractions are that sample
consumption and measurement times are very low, while
still preserving the large-scale, unbiased and systems
biology character of the measurement. Employing recent
advances in chromatography, mass spectrometry and bio-
informatics, the yeast proteome can now be covered
almost completely in this mode. This was illustrated by
investigating the heat-shock response of the yeast pro-
teome in quadruplicate measurements with nearly
complete coverage and with about a day of total
measurement time [83].
The human proteome is more complex than the yeast
proteome (Figure 1.3A), but until very recently it was
unknown how many different proteins a single cell line
actually expresses. Using deep shotgun proteomics
approaches two different human cancer cell lines have
recently been investigated in depth by MS-based proteomics
[3,5]. Both studies found that such cell lines contain at least
10 000 different proteins. Saturation analysis [5] or
comparison to deep RNA-seq data [3] suggested that this
number is not very far from the total number of expressed
proteins with functional roles in these cells. A subsequent
study of 11 commonly used cell lines also identified
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>10000 proteins each [84]. Although none of the above
studies employed accurate quantification strategies, the
summed and normalized peptide intensities nevertheless
allow important insights into the proteome of cancer cell
lines. One such conclusion from the 11 cell lines study, and
an earlier study that also used deep transcriptome
sequencing and large-scale imaging with an antibody
collection [85], was that cellular proteomes are remarkably
similar in terms of the identity of their expressed proteins.
The expression levels even of household proteins, however,
often vary quite significantly across different cell lines [84].
The dynamic range of protein expression was larger than
that of the yeast proteome and was estimated to be more than
106 (Figure 1.3B), but at the same time, about 90% of the
proteome lies within a 60-fold expression range compared to
the median level in the HeLa proteome [84]. Rather than
being estimated indirectly from total proteome measure-
ments, copy numbers have also been measured by more
direct methods in microorganisms [86] or in human cell
lines [87]. In the latter study, copy numbers for 40 proteins
were determined in HeLa cells and ranged from 20 106 for
the cytoskeletal protein vimentin to 6000 copies for the
transcription factor FOS. Such data can now be generated
quite accurately and readily, and should greatly assist in
estimating parameters for systems biologic models.
Although proteomics is still in the process of
approaching comprehensiveness, by its nature it can answer
many questions that are outside of the scope of transcript-
based gene expression studies. The reason for this is that
the proteome integrates the effects of post-transcriptional
regulation as well as regulation by targeted protein degra-
dation. As an example, two studies have used proteomics to
delineate the effects of micro-RNAs on expression levels of
their targets [88,89]. These studies concluded that these
effects were relatively small and dispersed to many
substrates for each different micro-RNA.
The availability of deep and accurate proteome data
also sheds new light on the longstanding question of the
extent of correlation of transcript levels with the corre-
sponding protein levels. Many early studies had found very
poor correlation between levels of mRNA and protein.
However, this seems to have been caused in large part by
the relatively primitive state of the art of transcriptomics,
and especially proteomics, at the time. The technical
imperfections of the two technologies frequently led to
incorrectly measured protein or transcript levels; however,
because they are independent of each other, this suggested
artificially low correlation of message and protein levels.
Recent studies have revealed higher correlation coefficients
for steady-state levels, generally in the range of 0.6. The
correlation of mRNA changes with protein changes is even
higher [85,90]. This level of correlation is biologically
plausible, given the flow of genetic information from
mRNA to protein. Nevertheless, even when there is good
correlation, the level of protein change cannot easily be
predicted from the level of transcript change. Interestingly,
a recent cell line-based study has shown that the discrep-
ancies between message and protein levels can mostly be
explained by differences in mRNA translation rates [91].
However, these translation rates are themselves subject to
regulation, which cannot easily be measured without
determining protein levels and protein turnover.
More fundamentally, a major potential of proteomics is
that it can measure the protein expression levels as a func-
tion of subcellular compartment, as well as the redistribu-
tion of the proteome between compartments as a function
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of stimulus [92e94]. Given increasing coverage of the
proteome, even the isoform specific regulation of the pro-
teome can be investigated [95].
INTERACTION PROTEOMICS
Specific interactions of proteins with other proteins, with
nucleic acids, lipids, carbohydrates, and metabolites or
other small molecules, orchestrate all aspects of life at the
molecular level. The dissection of molecular assemblies
has been a longstanding goal of modern biology, which
requires identification of the constituent partners as the first
step. This is a field at which MS-based proteomics has
excelled from its early days. The ultimate goal is the
delineation of the ‘interactome’, which is defined as the
sum of all molecular interactions of a biological system.
The size of the interactome of a given organism is a matter
of debate and of how the definition is interpreted, but it is
undoubtedly far more complex than the genome or pro-
teome; current interactome datasets likely merely scratch
its surface [96].
Mass spectrometry has the unique ability to identify
very small amounts of any protein without prior knowl-
edge, and in principle it can therefore directly unravel the
protein composition of any molecular assembly. Alterna-
tive methods of unbiased interaction detection, such as
phage display [97] or the yeast two hybrid assay (Y2H)
[98], use genetic readouts that test for direct binding but do
not involve the formation of actual multi-protein
complexes. All approaches in MS-based interaction pro-
teomics are based on the assumption that a molecular
interaction is the result of an affinity that can be exploited
to purify or enrich the assembly from a crude mixture.
Typically, one molecule serves as the ‘bait’ which is
coupled to an affinity matrix. This can be done via an
antibody or a genetically encoded tag in the case of proteins
or via chemical synthesis in the case of peptides, nucleic
acids or small molecules. Mass spectrometry is then used to
identify the ‘prey’ proteins that interact with the bait. This
workflow is known as affinity purification followed by
mass spectrometry (AP-MS) (Figure 1.4A).
The first application of this methodology was the
identification of the members of protein complexes [99],
classically defined as entities that can be purified bio-
chemically. This was fuelled by the development of the
tandem affinity purification (TAP) tag, which resulted in
clean preparations of protein complexes from endogenous
sources by two consecutive purification steps [99,100].
This technology was mostly used for the generation of the
first large-scale AP-MS interaction datasets of model
organisms such as the budding yeast [101e104].
These datasets allowed the first comparisons of AP-MS
data with each other and with previously available large-
scale Y2H datasets [105,106]. The overlap turned out to be
surprisingly low, pointing to technical limitations of the
individual approaches and emphasizing that, despite being
large-scale, all datasets were non-saturating, sampling
different parts of a vast interactome [107]. In addition, it
also emphasizes the fundamentally different, but highly
complementary nature of AP-MS and Y2H [108]: Y2H
data consist of binary combinations of proteins with mutual
affinity, including weak interactions, which can be recorded
as long as they lead to activation in the genetic readout. In
contrast, AP-MS data provide lists of proteins that co-occur
in protein complexes e including indirect binders e but
provide no direct topological information. Comparison of
data from both sources therefore requires the conversion of
co-complex members into binary contacts, which can be
done using different models [107].
Weak or transient interactors tend to be under-repre-
sented in AP-MS datasets because they easily get lost
during washing steps in the sample preparation workflow.
These washing steps are necessary to reduce the number of
proteins that bind non-specifically to the affinity matrix.
Unspecific interactors have been the bane of interaction
proteomics and were originally dealt with by extensive
blacklisting of proteins that were identified across many
different affinity purifications. However, this is a less-than-
ideal solution as it inevitably leads to lower true positive
rates while also failing to remove many false positives.
Virtually all of these drawbacks have been overcome by
the advent of quantitative proteomics: specific interactors
can easily be distinguished from unspecific background
binders by directly comparing their quantities in affinity
purifications vs. controls [109,110]. This paved the way for
second-generation quantitative interaction proteomic
studies (Figure 1.4A). Isotopic labeling techniques allowed
the detection of interactions in the presence of high
amounts of background binders, and of molecular assem-
blies which could not be purified extensively. Importantly,
this principle is applicable to any conceivable bait molecule
that can be immobilized on the affinity matrix. For instance,
early highlights include the identification of proteins that
interact with specific post-translational modifications rep-
resented as modified, synthetic peptides [111,112]. Such
assays can be streamlined and used to probe the biological
relevance of large-scale PTM datasets. For instance,
synthetic peptides corresponding to phosphotyrosine sites
with potential key functions as molecular switches have
been synthesized and their cellular interaction partners
have been determined [113,114].
In a similar fashion, oligonucleotides can be immobi-
lized to identify proteins binding to specific DNA [115] or
RNA sequences [116]. In this way, quantitative interaction
proteomics identified the transcriptional repressor respon-
sible for the difference between a fat and a lean pig geno-
type, which is caused by a single nucleotide mutation
[117,118].
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‘Chemical proteomics’ approaches make use of
immobilized small molecule inhibitors to capture and
identify their cellular binding proteins [119]. Although this
constitutes a powerful and generic approach, synthesizing
a suitable, immobilizable derivative of an individual small
molecule of interest can be challenging and in some cases
impossible. Alternatively, broadly selective inhibitors can
be used for affinity-capture of a target protein class. This
has been successfully applied for profiling inhibitors tar-
geting kinases [120,121] and more recently histone
deacetylases [122]. Inhibitor affinity towards its binding
partners can be measured by quantitative, dose-dependent
assays by monitoring the binding response to different
concentrations of the free molecule. Quantitative drug
affinity purification experiments thereby provide a concep-
tual framework for identifying the protein targets that
mediate drug responsiveness and those that potentially
cause side effects. Proteome-wide determination of drug
targets may also reveal alternate therapeutic uses.
Quantitative MS-based approaches furthermore enable
researchers to determine the proteomes of subcellular
structures or organelles, which can only be enriched from
a whole-cell preparation, but not be purified biochemically
[123,124]. One principle is to profile proteins along
gradients or across different enrichment steps and to clas-
sify them by correlation to known marker proteins. This
approache termed protein correlation profilingewas used
to assign proteins to their respective compartments [125],
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and even substructures of organelles, such as the contact
sites between outer and inner mitochondrial membranes,
can be distinguished [126]. Another study integrated such
data with other MS-based datasets to comprehensively
identify chromosome-associated proteins across different
phases of the cell cycle [127].
For systems biological applications it is attractive to
generate datasets of sufficient size to capture a reasonably
large part of the interactome. Because isotopic labeling,
which helps to ensure accurate quantitative data, is more
challenging to perform at a very large scale, recent high-
throughput proteineprotein interaction datasets mostly
employed simple label-free quantification methods, such as
counting the number of times peptides belonging to
a certain protein have been sequenced as a proxy for its
abundance (see Box 1.1). Based on this technology, large
scale proteineprotein interaction datasets of human
[128,129] and Drosophila [130] have been published.
Today, high-resolution MS data are routinely available and
can be analyzed with very sophisticated label-free quanti-
fication algorithms. As a result, datasets with much higher
true positive and lower false negative rates should become
available for systems biological modeling.
Beyond the goal of accurate and comprehensive
mapping of the interactome into lists of proteins associated
in complexes, the next challenge is to provide additional
functionally relevant information such as topology and
stoichiometry. One future direction involves the use of
chemical cross-linkers in combination with bioinformatic
algorithms to help deduce the three-dimensional architec-
ture of protein complexes [131,132] (Figure 1.4B). This
technology is still under development and currently limited
to purified complexes, but it has the potential to be
extended towards more complex samples, ultimately
offering the vision of ‘the interactome in a single experi-
ment’. MS-based interaction proteomics is also uniquely
suited to measuring the dynamics of protein interactions in
response to stimuli. Such effects range from subtle modu-
lations of the interaction network, e.g. in the case of
autophagy-related proteins when that process was triggered
[133], or the changing composition of Wnt signaling
complexes [134], to extensive disruption of complexes, e.g.
of the Bcr-Abl kinase complex after drug treatment [135].
Accurate quantification is paramount when it comes to
dynamic interactions, and various groups have addressed
this with isotope-labeled reference peptides and absolute
quantification, which also allows estimation of the stoi-
chiometries of interacting proteins [136,137]. The ultimate
challenge in interaction proteomics is to achieve high
throughput and coverage while maintaining very high
quality standards. With the proteomics methods evolving
and quantification being increasingly accurate, the biolog-
ical samples from which the interactions are determined
should also represent the in vivo situation in the best
possible way. For proteineprotein interaction data, one
critical parameter is the expression level of the bait protein.
Ideally, this should be adjusted to near-physiologic levels to
avoid aberrant localization and to ensure that bona fide
interaction partners are present in appropriate amounts
compared to the bait [138]. This can be achieved by tagging
the endogenous locus encoding the bait, which is straight-
forward in lower organisms such as yeasts, but much more
complicated in human cell lines. A recent method based on
bacterial artificial chromosome (BAC) transgenes allevi-
ates these limitations and allows the expression of GFP-
tagged proteins under fully endogenous gene regulatory
control [139]. In addition to providing a subcellular local-
ization tool via the fluorescent tag, this method can easily
be combined with quantitative interaction analysis, for
example to allow the splice isoform-specific interaction
partners of a bait protein to be identified [140]. BACeGFP
interaction data have also been combined with phenotypic
data from RNA interference screens to place genes
involved in mitosis into the context of protein complexes
[141]. This study showed how physical interactions derived
from proteomics integrate beautifully with other omics
data, providing functional relationships of genes or
proteins. Consolidating physical with functional interaction
data will ultimately allow the placing of proteins into
complexes and arranging complexes into dynamic path-
ways and networks.
In this way ever-growing large-scale datasets will
become increasingly useful for biologists and systems
biologists alike (Figure 1.4C). Systems biologists will
better understand the intricate interplay of molecules inside
the cell, while biologists will find new interaction partners
of their protein of interest, and they will be able to place
specific genes into pathways, helping to explain observed
phenotypes.
However, the complete characterization of a mamma-
lian proteineprotein interactome and its integration with
other omics data of the same scale is a vision of the future
and is just coming into reach for the most primitive
organisms [142e144].
LARGE-SCALE DETERMINATION OF POST-
TRANSLATIONAL MODIFICATIONS
Post-translational modifications (PTMs) of proteins are
a key regulatory mechanism in signal transmission that
controls nearly all aspects of cellular function. Tradition-
ally, signaling processes are perceived as discrete linear
pathways that transduce external signals via the post-
translational modification of a few key sites. For example,
a specific phosphorylation event might regulate the func-
tion of a crucial pathway. These pathways have typically
been studied in the conventional, reductionist manner, with
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researchers focusing on the characterization of individual
components and causal interactions in an individual
cascade. However, this biochemical simplicity as usually
visualized fails to account for the systems properties that
are an inherent part of any pathway. It has become
increasingly clear that the specificity of signaleresponse
events, for example for individual receptor pathways, does
not rely on a single protein or gene that is responsible for
signaling specificity. Instead, it has been shown that path-
ways are extensively connected and embedded in signaling
‘networks’ rather than ‘linear pathways’ [145]. Therefore,
the analysis of complex networks as large functional
ensembles may be necessary to infer their behavior. Engi-
neering techniques such as control theory, which were
developed to analyze self-regulating technological systems,
have become popular for describing complex and dynamic
cellular control mechanisms. Among these, a key mecha-
nism is the regulation of the expression levels of proteins
through the gene expression program. However, cells also
extensively use PTMs, which constitute an important class
of molecular switches, for signal propagation to control the
activity, structure, localization and interactions of proteins.
Often a signal to the cell will initially lead to a cascade of
PTM changes, which can happen very rapidly, and later to
a change in the expression of a specific set of proteins. The
specificity as well as the robustness of biological control
mechanisms is largely determined by a combinatorial
system of regulated post-translational modifications, the
resulting proteineprotein interactions, and protein expres-
sion of downstream signaling components along the
temporal and spatial axes. An example illustrating the
specificity of PTM-induced cell decisions is the classic case
of stimulation of ERK activity in PC12 cells: when these
neuronal cells are stimulated for a short time they prolif-
erate, whereas a longer-term activation of the same
pathway leads to their differentiation [146].
As a first step towards understanding the over-
whelmingly complex circuitry of signaling networks, the
PTMs should be identified and quantified in an unbiased
and global manner (Figure 1.5). For this purpose, modern
quantitative mass spectrometry has proved an ideal plat-
form because it is a highly precise yet generic method for
detecting PTMs: MS directly measures the presence of
a PTM by a defined corresponding shift in the mass of the
modified peptide. MS-based mapping and quantification of
PTMs is set to revolutionize signaling research and is
already providing large-scale information on the extent and
diversity of different PTMs in the expressed proteome and
their regulation in response to perturbations [147]. To date,
about 300 different types of protein modifications have
been reported to occur physiologically, and yet more are
being discovered [148]. However, just a few PTMs have
accounted for the majority of classic and MS-based
investigations. Representative examples include
phosphorylation [67,149,150], lysine acetylation [151,152],
glycosylation [153,154], ubiquitylation [155e158] and
methylation [159]. Remarkably, these reports often
expanded the known universe of the PTM under investiga-
tion 10e100-fold compared to the previous non-MS-based
state [147].
Despite this impressive progress in MS-based PTM
proteomics, exhaustive mapping of protein modifications is
challenging for a number of reasons: (i) modified peptides
are present in sub-stoichiometric amounts in complex
mixtures; (ii) the peptides carrying certain PTMs display
more complicated MS/MS fragmentation patterns that can
be difficult to interpret; (iii) the effective database search
space explodes when the search program is allowed to
consider potential PTMs at each modifiable amino acid
residue; and (iv) in addition to identifying the modified
peptide, the PTM needs to be placed with single amino acid
accuracy in the sequence.
To address the sub-stoichiometric amounts of PTMs,
much effort has been put into improving pre-fractionation
and specific enrichment of PTM-carrying peptides. In this
way, more input material is used, leading to higher amounts
of modified peptides and improving their mass-spectro-
metric analysis. At the same time the sample complexity is
reduced, facilitating proteome-wide mapping of modifica-
tions [160] (Figure 1.5A). These methods can be evaluated
by the enrichment factor with respect to the starting peptide
mixture, or the enrichment efficiency, which refers to the
fraction of modified peptides in the enriched population.
For phosphorylation, strong cation exchange chromatog-
raphy or metal affinity complexation allow up to 100-fold
enrichment and often close to 100% efficiency of phos-
phopeptide enrichment [161]. At the other extreme, meth-
ylated peptides are only enriched a few fold, and
enrichment efficiency is about 5% using antibodies directed
towards Lys-acetylated peptides. Analysis of methylation,
acetylation and many others has lagged behind those PTMs
for which very specific tools have been available. Illus-
trating the importance of such reagents, the recent devel-
opment of a monoclonal antibody to profile lysine
ubiquitylation has dramatically boosted our knowledge
about the extent of this PTM [156e158]. This antibody
recognizes peptides containing lysine residues modified by
diglycine, a ubiquitin remnant at the modification site after
trypsin digestion of the sample.
Confident localization of the PTM on modified peptides
requires the presence of the relevant fragment ions in the
MS/MS spectra. Usually, as mentioned above, algorithms
for the analysis of modified peptides provide a PTM
localization score, which indicates how much confidence
should be placed in the site assignment (Figure 1.5B).
Because of the technical challenges in mapping PTMs they
are particularly prone to being undersampled, i.e., to be
missing in certain runs, thereby leading to incomplete
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datasets. In principle, this can be addressed by targeted
methods in which the mass spectrometer is directed to
acquire data for a particular set of modified peptides [162].
Quantification of PTM sites is achieved in the same
ways as for non-modified peptides. However, this becomes
more complicated when a single peptide has multiple
modification sites. By employing quantification at different
time points, kinetic maps of PTM-site dynamics in
response to various perturbations can be obtained
[67,163,164]. PTM-level information can be combined
with information on protein levels, as we have recently
shown in a combined phosphoproteomic and proteomic
analysis of the cell cycle [67]. However, when measuring
early signaling changes, for example downstream of
receptor tyrosine kinase activation, one usually assumes
that proteomic changes will be minimal and that observed
quantitative changes in phosphopeptides can directly be
attributed to changes at the modification site level.
Furthermore, it may be desirable in a systems biology
context to quantify not only the relative change of a modi-
fication site but also the fraction of the protein that is
modified at this site (Figure 1.5C). First reports of the large-
scale determination of phosphorylation stoichiometry have
recently appeared [165,166]. Thus, with ever improving
technology, proteomics can now deliver key parameters
on PTMs that are important for cellular modeling, such
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as PTM site occupancy together with kinetics upon
perturbation.
Even after correctly and comprehensively measuring
the phosphorylation changes upon cellular perturbation, the
question remains which kinase or kinases are responsible
for a given phosphorylation site. A variety of combinations
of quantitative phosphoproteomics and chemical genetics
approaches can answer this question by identifying direct
kinase substrates. For instance, this can involve controlled
inhibition of a genetically engineered cellular kinase by
a small molecule [167]. In an alternative approach, phos-
phorylation patterns in 124 kinase and phosphatase yeast
deletion strains have been measured to globally extract
kinaseesubstrate relationships [168]. To understand the
circuitry that underpins cellular information flow, the
changes in PTM dynamics can additionally be overlaid
with direct proteineprotein interaction datasets such as
those of kinases and phosphatases from yeast [169].
Clearly, it would also be important to understand how the
dynamic kinaseesubstrate interactions vary under different
growth and stress conditions.
From a cellular control perspective, a significant
increase in information content can be achieved if many
proteins are multiply modified, especially if these PTMs
acted combinatorially. In fact, it has become increasingly
clear that a number of cellular processes are regulated by
PTM cross-talk, as exemplified by phosphorylation and
ubiquitylation [170]. Another example is the intimate
interplay of different histone modification marks in the
histone code, which represents one of the most important
epigenetic regulatory mechanisms governing the structure
and function of the genome [171]. To understand such PTM
cross-talk codes that mediate cellular control, MS-based
proteomics is an excellent large-scale method. However,
owing to the fact that correlating PTMs may occur on
different peptides, specialized MS strategies may have to be
used, such as top-down proteomics [172,173].
As described above, MS-based PTM analysis is
uncovering an unexpectedly large extent and diversity of
PTMs that occur on multiple but specific residues on most
proteins. These large-scale PTM studies now serve as an
information-rich resource to the community. For example,
biological researchers can focus on regulatory PTM sites in
high-quality MS data for their proteins or processes of
interest. The data can also be used to investigate basic
characteristics of particular PTMs, such as their evolu-
tionary conservation [154,174,175] and preferential local-
ization across secondary structures of proteins [154,176].
In addition, in vivo maps of many PTMs are beginning
to emerge [150,157,177,178] and a first example of large-
scale PTM quantification in a mouse organ after perturba-
tion has been described [179]. This is now unlocking the
opportunity to study PTM dynamics in tissues to charac-
terize the physiological or pathological responses of
different organs in mammals. With their key roles in
cellular control, MS-enabled PTM signatures also hold
great potential as prognostic and therapeutic biomarkers.
OUTLOOK AND FUTURE CHALLENGES
As detailed in this chapter, MS-based proteomics is
a technology-driven discipline that has made tremendous
progress during recent years. These advances affect the
entire proteomics workflow, starting with sample prepara-
tion and ending with computational proteomics. The advent
of high-resolution high-accuracy MS data, combined with
sophisticated quantification strategies, has been especially
important in obtaining biologically relevant information
from MS-based proteomics. This technology has now
clearly become the method of choice for studying
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endogenous proteins, either at a small scale involving one
or a few different proteins or involving entire cellular
proteomes. It provides a crucial layer of information on the
proteins that previously had to be inferred indirectly from
other measurements, or was absent altogether.
Given the increasingly mature proteomics toolbox, an
ever larger set of cell biological and biomedical problems
can now be tackled. For instance, we expect many more
reports of essentially complete proteome measurements, as
well as highly accurate comparative transcriptome and
proteome studies. It will be interesting to see whether MS-
based proteomics can make inroads into the clinical area,
for instance in classifying cancer patients by their protein
expression patterns.
Despite these promises, major challenges with MS-
based proteomics remain. Foremost among these is the
limited community access to high-accuracy in-depth pro-
teomics. Compared to transcriptomics and the current
massive investments into deep-sequencing based technol-
ogies, the area of MS-based proteomics remains tiny. There
are also entire areas, such as body fluid-based biomarker
discovery, where MS-based proteomics could in principle
make a revolutionary impact but where our current tech-
nology fails woefully to live up to expectations. On the
other hand, this means that MS-based proteomics will offer
exciting opportunities for young researchers for years to
come.
From a systems biology perspective, the ability of
proteomics to detect not only the presence of but to also to
estimate copy numbers of virtually all proteins in a pro-
teome will be crucial in modeling the cellular proteome.
Equally important, proteomics is now poised to deliver
increasingly comprehensive lists of the major PTMs,
including phosphorylation, ubiquitylation, acetylation,
glycosylation and many more. This is a precondition for
determining their function, which will be a monumental
task for the years ahead, and for accurate models of
information processing in the cell. Identification and
quantification of protein isoforms is still a challenge for
MS-based proteomics, but it is becoming increasingly
accessible due to more extensive sequence coverage of the
identified proteins. The direct analysis of undigested
proteins by MS (‘top-down’ proteomics) will also
contribute to this question.
Figure 1.6 summarizes the indispensable role of pro-
teomics in the context of other large-scale methods of
genomics and gene expression analysis. Both genomics and
transcriptomics benefit from the current revolution in next-
generation sequencing methods. We expect deep-
sequencing data to be readily accessible for essentially
every situation of interest in systems biology in the near
future. This includes the genomes of different individuals
as well as differences between normal and cancer genomes
in the same individuals. Likewise, deep sequencing will
contribute tremendously to accurate and comprehensive
mapping of the abundance of mRNA molecules, an early
step in the gene expression program. However, this is still
only half of the story. Proteomics can give us a detailed
picture of the end product of the gene expression cascade,
the mature, active and fully modified protein form. It also
measures regulation directly at the expression level of all
proteins, which cannot be predicted from transcript levels.
In contrast to genomics and transcriptomics, it can char-
acterize gene expression at subcellular resolution, i.e., by
analyzing the proteomes of different cellular compart-
ments. Furthermore, the interactions and dynamics of the
proteome can likewise be studied either at a whole cell level
or in individual subcellular compartments. In conclusion,
despite the technological challenges it faces, MS-based
proteomics is crucial to a systems-level understanding of
cellular function, and is ready to make even more extensive
contributions to the field in the future.
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The aim of my PhD project was to advance interaction proteomics to the next level.
The foundation for this was interaction proteomics work done earlier in our group and
work done in Tony Hyman’s group at theMax Planck Institute of Molecular Cell Biology
and Genetics, Dresden. Ina Poser and Mihail Sarov streamlined the concept of bac-
terial artificial chromosome (BAC) recombineering and set it up in a high-throughput
format [58]. BACs harbour large pieces of a mammalian genome on what is essentially
a large, single-copy bacterial plasmid. With the help of inducible recombinases, BACs
can be easily modified and tags or mutations can be introduced. In particular, N- or
C-terminal green fluorescent protein (GFP) tags can be introduced in 96-well format
with high efficiency. GFP with a long linker with extended functionality is an ideal tag
for protein localization and affinity purification (LAP) [59]. When re-introduced into a
mammalian cell, BAC transgenes look to the cell like additional copies of genetic loci.
The cell therefore expresses GFP-tagged proteins at near-endogenous levels and under
endogenous regulation patterns. Ina Poser in Tony Hyman’s group set out to gener-
ate BAC-GFP HeLa lines in a proteome-wise fashion. Nina Hubner in our group then
combined such cell lines with our expertise on interaction proteomics and developed a
streamlined strategy to delineate protein-protein interactions, called quantitative BAC-
GFP interactomics (QUBIC) [30, 60]. Together with Peter Bandilla, she implemented
most of the wet-lab workflow on a robotics platform and started a high-throughput
pipeline for interactome mapping.
The initial goal of for my PhD work was to carry out QUBIC for a large number of bait
proteins to map human protein-protein interactions globally. In the course of four years
and with a lot of technical help from Bianca Splettstößer, Daniela Vogg, Bhaswati Chat-
terjee, Mario Grötzinger and Susanne Kroiß, we produced more than 10,000 immun-
oprecipitation (IP) samples of thousands of BAG-GFP cell lines. This required careful
logistical planning, a robotics platform, a dedicated mass spectrometer, and sophistic-
ated data management.
A major challenge was the development of appropriate data analysis strategies for large
datasets. The initial approach involved comparing each immunoprecipitation (IP) sample
in three replicates to three negative controls. While this is very straightforward for a
small scale setup, there are certain drawbacks when applying it at a large scale. Since
all interactors emerge by quantitative comparison to the negative control, this becomes
the most important sample of all: If a specific bait IP fails, only data for this bait will be
affected. If the control is not ideal, however, all samples will be compromised. Moreover,
negative control samples would have to be acquired in regular intervals to avoid batch
artifacts. The solution was to develop a strategy that operates without dedicated negative
controls, but uses all appropriate samples as controls for each specific sample. I devised
a strategy that scales favourably to large samples numbers, but also works for smaller
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sample numbers, because specifically enriched cases are automatically excluded from
the control cohort. All bioinformatics procedureswere implemented based on the plugin
architecture for the Perseus data analysis suite, which Jürgen Cox had developed. While
the described bioinformatics workflow constitutes the backbone for the proteome-wide
interactomemapping approach, we included some of the strategies in a joint publication
with Eva Keilhauer, describing a medium-scale interactomics workflow for the budding
yeast.
During the process of acquiring data for the human interactome, it became clear that the
algorithms for label-free quantification in theMaxQuant software, now termedMaxLFQ,
run into performance issues when applied to very large numbers of samples. The rate-
limiting step is called ‘label-free normalization’ and involves the calculation of a global
normalization factor for each sample, which, for ‘single-shot’ runs, accounts mostly for
the amount of sample injected into themass spectrometer. The calculations require pair-
wise comparisons of all sampleswith one another, and therefore computation time grows
quadratically to the point of becoming impracticable for more than 100 samples. Jürgen
Cox and I devised a heuristic approach, which Jürgen implemented as the ‘FastLFQ’
option into MaxQuant, which brings the computational effort back to linear scaling be-
haviour.
Looking at larger and larger interactome datasets while the data were being acquired, I
realized that there was much more insight to be gained than long lists of protein inter-
actions. First, I found that stoichiometry information could be extracted from label-free
quantification (LFQ) intensities of the proteins. As a by-product from switching from
label-based quantification approaches (such as SILAC) to the label-free method, the ‘ab-
solute’ intensities of the proteins, in addition to the relative ratios, now took the centre
stage. With SILAC they had remained largely hidden within the reported protein ra-
tios. Protein intensities, which are calculated as the sum of all peptide intensities for a
given protein, can be used as a proxy for the absolute molar protein amount, when one
accounts for the size of the protein [61]. In the context of protein immunoprecipitation
samples, the stoichiometries of recovery of interacting proteins can be calculated from
their absolute quantities. From a range of well-characterized complexes, it became ap-
parent that core complex members tend to be recovered near 1:1 stoichiometry with the
respective bait, whereas transient interactors are recovered substoichiometrically.
Interaction stoichiometries as observed in immunoprecipitates depend on a number of
factors, including the thermodynamic and kinetic stability of an interaction under assay
conditions. Moreover, the recoverable amount of each interactor is limited by its cellu-
lar abundance. Therefore, knowing the underlying proteome composition is a critical
parameter for data interpretation. Work by Nagarjuna Nagaraj in the group had pion-
eered the acquisition of deep mammalian whole proteome datasets to the point of near-
complete coverage [62]. Naga provided me with a set of deep HeLa proteomes recorded
with the latest generation of sample preparation and mass spectrometry methods.
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The next challenge was to extract absolute protein copy numbers from the HeLa pro-
teome data. Earlier studies relied on exogenous standards, spiked into the samples in
known quantities. These references were critical for scaling the intensity readout accur-
ately. In the course of a discussion among several proteomics groups around potential
scaling errors in existing proteomic datasets based on spike-in standards [63], I realized
that a quick way of cross-checking correct scaling is to compare the sum of all individual
proteinmasses to the expected proteinmass per cell. This idea can be reversed, using the
total protein amount per cell as a scaling factor. Later, my colleague Jacek Wiśniewski
found that absolute scaling is possible even without knowledge of the total cellular pro-
tein mass. This is because the mass of histones is roughly equivalent to the cellular DNA
mass, which can be calculated from the genome size and the ploidy of a cell. We teamed
up to contribute the biochemical and bioinformatics foundation for our ‘proteomic ruler’
method for absolute protein quantification without spike-in standards.
Combining interactome andproteomedata revealed anunprecedented richness of quant-
itative information in three dimensions. The first dimension addresses specific enrich-
ment and served as a filter to discriminate true interactors from background binders.
The second dimension is the stoichiometry of interactors, which I showed to encode the
functional strength of an interaction. Finally, the third dimension describes the cellular
abundances of proteins involved in the interactome network. Taken together, these three
dimensions offer intriguing insights into the structure of the human interactome.
Next to the analysis of the interactome as a whole, each bit of data alone constitutes a
valuable resource for researchers interested in the proteins involved. Therefore, in par-
allel to the human interactome project, I collaborated with a number of colleagues and
external groups on the interactomes of their proteins of interest. This resulted in a num-
ber of collaboration papers on various topics, from the dissection of alternative com-
positions of protein complexes, to the discovery of new, short open reading frames in
cytomegalovirus, to protein complexes with clinical relevance, such as the hereditary
spastic paraplegia proteins, which associate with adaptor protein complex 5.
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QUBIC is a versatile and accurate technology to detect interactions between proteins. Its
defining features are a biological system that recapitulates the in vivo situation as closely
as possible, a streamlinedwet-labworkflowusingmild buffer conditions that retainweak
and transient interactions, and state-of-the-art quantitative proteomic readout in a label-
free format. BAC-GFP cell lines are valuable resources for various applications [58, 64,
65]. Firstly, theGFP signal can be used for live cell imaging of subcellular localization and
dynamics. It is straightforward to introduce mutations in the coding sequence [66]. For
functional studies, this can be used to make the BAC-encoded gene resistant to RNAi-
depletion of the endogenous counterpart. Alternatively, the mouse ortholog of the gene
can be used as a surrogate.
QUBIC was well received in the interaction community. The original papers are highly
cited and other groups have adopted the technology. While QUBIC was optimized for
GFP-tagged proteins expressed in BAC-transgenic cell lines, in principle, any cell extract
containing aGFP-tagged bait protein can be used as inputmaterial. We have successfully
applied the QUBIC strategy to embryonic stem cells expressing GFP tagged proteins
from the endogenous loci or cells transfectedwith cDNAconstructs, toGFP-tagged yeast
strains, organs from GFP-transgenic mice as well as Drosophila larvae and adult flies.
In a series of collaborative papers with different laboratories, my role was to delineate
the interactomes of a number of proteins of interest. The papers published by the time
of initial submission of this thesis can be found in the appendix.
2.1 Functional repurposing revealed by comparing genetic interactions
Frost, A., Elgort, M.G., Brandman, O., Ives, C., Collins, S. R., Miller-Vedam, L., Weibe-
zahn, J., Hein, M. Y., Poser, I., Mann, M., Hyman, A. A. & Weissman, J. S. Functional
repurposing revealed by comparing S. pombe and S. cerevisiae genetic interactions. Cell
149(6), 1339–1352 Jun (2012).
A fruitful collaboration with Jonathan Weissman’s group at the University of Califor-
nia, San Francisco, was initiated in 2010 by Jimena Weibezahn’s stay in our laboratory
as a guest scientist. Her colleague Adam Frost was comparing genetic interaction net-
works of S. cerevisiae with S. pombe. He then looked at deviating patterns of genetic
interactions that pointed him to repurposing of certain proteins to different roles after
separation of the two species. One example of a protein complex that was repurposed
in evolution is the six-membered factor arrest (FAR) complex in S. cerevisiae, respons-
ible for cell-cycle arrest upon mating pheromone signalling [67]. Some of its members
are unique to budding yeast, with no apparent orthologs in S. pombe or metazoa. In
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many aspects, S. pombe is much closer to metazoans. For that reason, genetic interac-
tion data from fission yeast can often be predictive of mammalian biology. In contrast
to budding yeast, FAR complex members of S. pombe interacted genetically with Golgi
proteins and proteins involved cytogenesis and mitosis. Moreover, their orthologs were
found as part of the striatin-interacting phosphatase and kinase (STRIPAK) complex in
mammals [68].
I performed interaction proteomics analyses of GFP-tagged striatin 3 (STRN3). The bait
protein localized to the Golgi and its interactors showed a physical connection between
theGolgi, nuclear envelope proteins and kinase-activating proteins associatedwith centro-
somes, reflecting the genetic interactions found in fission yeast. This suggested that in
budding yeast, the STRIPAK complex was repurposed in light of major evolutionary
differences in cytokinesis and Golgi morphology.
2.2 Decoding human cytomegalovirus
Stern-Ginossar, N., Weisburd, B., Michalski, A., Le, V. T.,Hein, M. Y., Huang, S. X., Ma,
M, Shen, B., Qian, S. B., Hengel, H., Mann, M, Ingolia, N. T. &Weissman, J. S. Decoding
human cytomegalovirus. Science 338(6110), 1088–1093 Nov (2012).
The second collaboration with the Weissman group was with Noam Stern-Ginossar. To
map the complex transcriptomic landscape of human cytomegalovirus (HCMV) and to
characterize its protein coding potential, Noam used ribosome profiling [69] on cells in-
fected with that virus. Ribosome footprints revealed novel open reading frames (ORFs)
in sense or antisense orientation within known ORFs, short ORFs (often upstream of
canonical ones) and ORFs with non-canonical start codons. Annette Michalski in
our group confirmed some of the newly discovered short ORFs on protein level. Noam
cloned selected new ORFs as GFP fusion proteins and we performed interactomics ana-
lyses to screen for interaction partners. Strikingly, a number of GFP-tagged new ORFs
showed distinct subcellular localizations. Their interactome profiles reflected their loc-
alization. For instance, ORF359W-GFP localized to mitochondria and we found it to
interact with the TIMM complex, the transporter of the inner membrane. ORF370W-
GFP localized to the ER and interactedwith the antigen peptide transporter 1 (TAP1) and
HLA-B/C, relevant for the presentation of peptide antigens to immune cells. While the
functional relevance of these short viral proteins remains elusive, distinct localization
and interaction patterns point at critical roles for viral infection.
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Bassik,M. C., Kampmann,M., Lebbink, R. J.,Wang, S.,Hein,M. Y., Poser, I.,Weibezahn,
J., Horlbeck, M.A., Chen, S., Mann, M., Hyman, A. A., Leproust, E.M., McManus, M. T.
& Weissman, J. S. A systematic mammalian genetic interaction map reveals pathways
underlying ricin susceptibility. Cell 152(4), 909–922 Feb (2013).
The third collaboration project with the Weissman group was with Mike Bassik and
Martin Kampmann. Mike and Martin established a methodology to measure genetic
interactions in mammalian cells by shRNA knockdown. In a first step, ultra-complex,
pooled shRNA libraries are transfected into cells and the cells are grown under select-
ive conditions. After some time, the shRNA constructs are quantified in the surviving
population by next generation sequencing. Quantitative comparison to the state before
selection yields a shortlist of genes with knockdown phenotypes. In a second step, ge-
netic interactions are detected by transfecting defined constructs encoding select pairs
of candidate genes with each other or with global knockdown constructs. As the selec-
tion marker, they used the toxin ricin at low concentrations. Ricin is a protein that has a
very complex mode of action. It needs to be taken up by endocytosis, before retrograde
transport to the ER and ‘dislocation’ to the cytosol. There, it depurinates a critical aden-
ine residue in the rRNA of the 60S ribosomal subunits, shutting down all translation in
the cell. This complex pathway offers plenty of possibilities for genetic intervention.
One protein complex whose subunits showed knockdown phenotypes was the vesicle
tethering TRAPP complex. Strikingly, while knockdown of some subunits protected the
cells from ricin toxicity, lack of others rendered the cells sensitized. We solved this puzzle
with the help of interaction proteomics usingGFP-taggedTRAPPCproteins. We showed
that there is a core complex with mutually exclusive binding either to TRAPPC9/10 or
TRAPP8/11/12/13. Most likely, both complex types have opposite roles in ricin transport.
TRAPPC13 was a new subunit, previously called C5orf44, that we proposed based on the
combined genetic and physical interaction data.
Moreover, we identified a novel complex consisting of WDR11 and C17orf75, whose
knockdown sensitized against ricin.
2.4 CCDC22 deficiency blunts proinflammatory NF-κb signaling
Starokadomskyy, P., Gluck, N., Li, H., Chen B., Wallis, M., Maine, G.N., Mao, X., Zaidi,
I.W., Hein M.Y., McDonald, F. J., Lenzner, S., Zecha, A., Ropers, H.H., Kuss, A.W.,
McGaughran, J., Gecz, J. & Burstein, E. CCDC22 deficiency in humans blunts activation
of proinflammatory NF-κb signaling. J Clin Invest 123(5), 2244–2256 May (2013).
X-linked intellectual disability (XLID) is a genetically heterogeneous condition affect-
ing a substantial fraction of men with mental retardation. In a collaboration with Hilger
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Ropers and Andreas Kuss from the Max Planck Institute for Molecular Genetics, Ber-
lin, we included a number of genes implicated in XLID into the QUBIC interactomics
pipeline to study their interactors and possibly the effects of disease-associated muta-
tions on the interaction pattern. CCDC22 is a gene on the X chromosome and several
mutations were found in affected families [70]. While my interaction data of CCDC22
revealed little changes between the wild type protein and mutants, I found CCDC22
to reside in a novel, uncharacterized complex including CCDC93, DSCR3, FAM45A/B,
RANBP1, C16orf62 and several copper metabolism gene MURR1 domain (COMMD)
proteins. These interaction data laid the foundation for a joint collaboration with Ezra
Burstein’s group at the University of Texas, who found evidence for that complex com-
ing from the COMMD side. They gathered additional data suggesting that CCDC22-
COMMD complexes are implicated in NF-κB activation and that CCDC22 mutations
interfere with that process.
2.5 Interaction between AP-5 and hereditary spastic paraplegia proteins
Hirst, J., Borner, G.H., Edgar, J., Hein, M. Y., Mann, M., Buchholz, F., Antrobus, R. &
Robinson, M. S. Interaction between AP-5 and the hereditary spastic paraplegia proteins
SPG11 and SPG15. Mol. Biol. Cell 24(16), 2558–2569 Aug (2013).
My collaborationwithGeorg Borner fromMargaret Robinson’s group in Cambridge was
initiated when Georg stayed as a guest scientist in our laboratory in 2012. The Robin-
son group is interested in vesicle transport, in particular the role of adaptor protein (AP)
complexes. AP complexes sort cargo into vesicles for transport betweenmembrane com-
partments. There are four classical AP complexes AP-1/2/3/4 and the recently discovered
AP-5 [71]. All of them are heterotetramers composed of a two large and two small sub-
units. The large subunit of AP-5 was first identified in a screen for DNA repair pro-
teins and shown to be mutated in patients suffering from hereditary spastic paraplegia,
a characteristic shared with two of its interacting proteins, SPG11 and SPG15 [72]. In our
collaboration paper, we used QUBIC to characterize the composition of the AP-5 com-
plex. For the first time, we implemented absolute quantification to narrow down the
stoichiometry of the subunits and found that the four core subunits as well as SPG11 and
SPG15 are all present in equimolar amounts, forming a relatively stable six-membered
functional complex. This sets this complex apart from other AP complexes, which are
stable tetramers in solution that interact with other proteins primarily onmembranes.
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Key ingredients for a large-scale proteomics study to investigate the human proteome
and interactome are efficient tools for quantifying thousands of proteins accurately across
thousands of samples. In each dataset, there are two inherent dimensions of quantifica-
tion: Relative quantification of a given protein across samples, and ‘absolute’ quantifica-
tion of different proteins in the same sample. Relative quantification of proteins across
samples is conceptually straightforward because one is comparing apples to apples. How-
ever, there are many challenges in the details. ‘Absolute’ quantification is conceptually
more difficult because one has to compare apples to oranges, in this case different pro-
tein species. In its simplest form, the goal is to compare the molar amounts of different
proteins, i. e. their stoichiometry, in a given sample. Often, these quantities should be
lifted to an absolute scale such as copies per cell or femtomoles. The ultimate goal is to
have a quantification scheme that combines all these characteristics. It should produce
a data matrix with values that can be compared in all dimensions: for selected proteins
across samples, for different proteins in one sample, and for different proteins in different
samples.
To come closer to this goal, I worked on two papers together with Jürgen Cox and Jacek
Wiśniewski in our group, introducing methods for label-free relative and absolute pro-
tein quantification.
3.1 MaxLFQ allows accurate proteome-wide label-free quantification
Cox, J.,Hein,M. Y., Luber, C. A., Paron, I., Nagaraj, N. &Mann, M. Accurate Proteome-
wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio
Extraction, Termed MaxLFQ.Mol Cell Proteomics 13(9):2513-26 (2014)
Relative quantification of proteins across conditions was the earliest aim of quantitative
proteomics. All strategies based on stable isotope labels were developed to this end [48–
51]. After incorporation of the label, samples can be mixed and analysed together in
the mass spectrometer. Peptides or proteins then appear in multiplets in single mass
spectrometric runs and their relative quantities can be read off the ratio of the intensities
of the individual peaks making up the multiplets. The number of total ‘plexes’ that can
be combined into a single analysis is limited by the number of available stable isotopes
with amenable chemistry for metabolic or chemical incorporation. Recent advances in
isobaric, MS2-based quantification strategies in combination with the use of labels of
equal nominal masses that can only be distinguished with ultra-high resolution mass
spectrometers allow up to 54-plex analyses [73–75]. However, this comes at considerable
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reagent cost, increased sample complexity and quantification being necessarily coupled
to MS/MS identification.
Arguably the simplest quantification approach is the label-freemethod, where all samples
are measured sequentially and hence there is no principal limitation for the number of
samples to be compared. The actual quantification happens entirely in silico and all pos-
sible biases introduced during sample preparation need to be accounted for at this stage
(Fig. 5).
Figure 5: Strategies for proteomic
quantification.
Two samples (blue and yellow) are to
be compared to each other. The type
of isotope label used (if at all) dictates
the earliest step at which samples can
be mixed. Dashed boxes indicate
parallel sample processing concom-
itant with the potential introduction
of biases. Adapted from [76]
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Jürgen Cox developed a label-free quantification (LFQ) module for MaxQuant as early
as 2009. The trigger was a project carried out by Christian Luber that sought to de-
termine the proteomic differences between two rare subtypes of murine dendritic cells
[77]. Use of the SILAC mouse [78] was not practicable for this project because of the
required number of animals. The idea was therefore to apply the conceptual advantages
of SILAC to the label-free scenario and to compare the intensities of corresponding pep-
tide features across runs. To make the approach compatible with sample fractionation,
normalization factors had to be calculated for each run and MS signals had to be integ-
rated across all fractions. Finally, the software would calculate a matrix of all available
pair-wise peptide ratios. Each peptide ratio alone already serves as a proxy for the pro-
tein ratio and the idea was to calculate profiles of protein intensities across all samples
that best fulfil the constraints imposed by individual peptide ratios.
When I applied the LFQ algorithm on interaction datasets that grew larger and larger
over time, I realized that there were two pitfalls of the current implementation. Firstly,
the computing time for calculating normalization factors for each MS run scaled quad-
ratically with the number of samples. Up to about 40 samples per dataset, the time
MaxQuant spent on these calculations was almost negligible, but in datasets of around
100 samples, it became the rate limiting step. Given that the result of this calculation was
a single factor per raw file, it was obvious that this should be approximable by a heuristic
approach which we termed ‘FastLFQ’. FastLFQ constructs a graph of all pair-wise file
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comparisons and then sequentially removes edges while maintaining overall connectiv-
ity and user-definable minimum and average connectivity parameters for each file. As a
result, label-free normalization now scales linearly with the number of files and I have
successfully used it on datasets containing more than 700 experiments.
The second pitfall affected proteins with very high ratios across samples. This is a com-
mon scenario in interaction proteomics where specific interactors that are present in
high amounts in some samples are virtually absent in other samples. However, we ob-
served cases where ratios were dramatically underestimated, because of high apparent
amounts of interactors in negative control samples. This was the result of a feature of
the algorithm that was designed to produce accurate ratios, but turned out to be error-
prone for proteins with extreme ratios. To generate a robust estimate of protein ratios,
only peptides shared across samples are considered for ratio estimation and the median
of individual ratios was used for further calculations. In the case of proteins with very
high ratios across conditions, not onlywere individual peptide ratios very high, butmany
more peptides were identified in some samples compared to the others. This led to the
paradoxical situation that much of the information content was effectively discarded,
as only shared peptides were taken into account. This was not only against the idea of
extracting the maximal quantitative information. It also made the algorithm sensitive
to outliers as protein ratios could be based on a very small subset of peptide ratios. We
solved this problem by interpolating between two kinds of ratio estimations: the median
of pair-wise peptide ratios as the default, and the ratio of the sum of individual peptide
intensities for extreme cases.
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Accurate Proteome-wide Label-free Quantification
by Delayed Normalization and Maximal Peptide
Ratio Extraction, Termed MaxLFQ*□S
Jürgen Cox‡§, Marco Y. Hein‡, Christian A. Luber‡, Igor Paron‡, Nagarjuna Nagaraj‡,
and Matthias Mann‡§
Protein quantification without isotopic labels has been a
long-standing interest in the proteomics field. However,
accurate and robust proteome-wide quantification with la-
bel-free approaches remains a challenge. We developed a
new intensity determination and normalization procedure
called MaxLFQ that is fully compatible with any peptide or
protein separation prior to LC-MS analysis. Protein abun-
dance profiles are assembled using the maximum possible
information from MS signals, given that the presence of
quantifiable peptides varies from sample to sample. For a
benchmark dataset with two proteomes mixed at known
ratios, we accurately detected the mixing ratio over the
entire protein expression range, with greater precision for
abundant proteins. The significance of individual label-free
quantifications was obtained via a t test approach. For a
second benchmark dataset, we accurately quantify fold
changes over several orders of magnitude, a task that is
challenging with label-based methods. MaxLFQ is a generic
label-free quantification technology that is readily applica-
ble to many biological questions; it is compatible with
standard statistical analysis workflows, and it has been
validated in many and diverse biological projects. Our algo-
rithms can handle very large experiments of 500 samples
in a manageable computing time. It is implemented in the
freely available MaxQuant computational proteomics plat-
form and works completely seamlessly at the click of a
button. Molecular & Cellular Proteomics 13: 10.1074/mcp.
M113.031591, 2513–2526, 2014.
Mass-spectrometry-based proteomics has become an in-
creasingly powerful technology not only for the identification
of large numbers of proteins, but also for their quantification
(1–3). Modern mass spectrometer hardware, in combination
with increasingly sophisticated bioinformatics software for
data analysis, is now ready to tackle the proteome on a global,
comprehensive scale and in a quantitative fashion (4–6).
Stable isotope-based labeling methods are the gold stand-
ard for quantification. However, despite their success, they
inherently entail extra preparation steps, whereas label-free
quantification is by its nature the simplest and most econom-
ical approach. Label-free quantification is in principle appli-
cable to any kind of sample, including materials that cannot
be directly metabolically labeled (for instance, many clinical
samples). In addition, there is no limit on the number of
samples that can be compared, in contrast to the finite num-
ber of “plexes” available for label-based methods (7).
A vast literature on label-free quantification methods, re-
viewed in Ref. 3 and Refs. 8–13, and associated software
projects (14–31) already exist. These computational methods
include simple additive prescriptions to combine peptide in-
tensities (32, 33), reference-peptide-based estimates (34),
and statistical frameworks utilizing additive linear models (35,
36). However, major bottlenecks remain: Most methods re-
quire measurement of samples under uniform conditions with
strict adherence to standard sample-handling procedures,
with minimal fractionation and in tight temporal sequence.
Also, many methods are tailored toward a specific biological
question, such as the detection of protein interactions (37),
and are therefore not suitable as generic tools for quantifica-
tion at a proteome scale. Finally, the modest accuracy of their
quantitative readouts relative to those obtained with stable-
isotope-based methods often prohibits their use for biological
questions that require the detection of small changes, such as
proteome changes upon stimulus.
Metabolic labeling methods such as SILAC1 (38) excel be-
cause of their unparalleled accuracy and robustness, which
are mainly due to stability with regard to variability in sample
processing and analysis steps. When isotope labels are intro-
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duced early in the workflow, samples can be mixed, and any
sample-handling issues equally affect all proteins or peptides.
This allows complex biochemical workflows without loss of
quantitative accuracy. Conversely, any up-front separation of
proteins or peptides potentially poses serious problems in a
label-free approach, because the partitioning into fractions is
prone to change slightly in the analysis of different samples.
Chemical labeling (39–41) is in principle universally applica-
ble, but because the labels are introduced later in the sample
processing, some of the advantages in robustness are lost.
Depending on the label used, it can also be uneconomical for
large studies.
High mass resolution and accuracy and high peptide iden-
tification rates have been key ingredients in the success of
isotope-label-based methods. These factors contribute simi-
larly to the quality of label-free quantification. An increased
identification rate directly improves label-free quantification
because it increases the number of data points and allows
“pairing” of corresponding peptides across runs. Although
high mass accuracy aids in the identification of peptides (42),
it is the high mass resolution that is crucial to accurate quan-
tification. This is because the accurate determination of ex-
tracted ion currents (XICs) of peptides is critical for compari-
son between samples (43). At low mass resolution, XICs of
peptides are often contaminated by nearby peptide signals,
preventing accurate intensity readouts. In the past, this has
led many researchers to use counts of identified MS/MS
spectra as a proxy for the ion intensity or protein abundance
(44). Although the abundance of proteins and the probability
of their peptides being selected for MS/MS sequencing are
correlated to some extent, XIC-based methods should clearly
be superior to spectral counting given sufficient resolution
and optimal algorithms. These advantages are most promi-
nent for low-intensity protein/peptide species, for which a
continuous intensity readout is more information-rich than
discrete counts of spectra. Therefore, we here apply the term
“label-free quantification” strictly to XIC-based approaches
and not to spectral counting.
In this manuscript, we describe the MaxLFQ algorithms,
part of the MaxQuant software suite, that solve two of the
main problems of label-free protein quantification. We intro-
duce “delayed normalization,” which makes label-free quan-
tification fully compatible with any up-front separation. Fur-
thermore, we implemented a novel approach to protein
quantification that extracts the maximum ratio information
from peptide signals in arbitrary numbers of samples to
achieve the highest possible accuracy of quantification.
MaxLFQ is a generic method for label-free quantification
that can be combined with standard statistical tests of quan-
tification accuracy for each of thousands of quantified pro-
teins. MaxLFQ has been available as part of the MaxQuant
software suite for some time and has already been success-
fully applied to a variety of biological questions by us and
other groups. It has delivered excellent performance in bench-
mark comparisons with other software solutions (31).
EXPERIMENTAL PROCEDURES
Proteome Benchmark Dataset—An Escherichia coli K12 strain was
grown in standard LB medium, harvested, washed in PBS, and lysed
in BugBuster (Novagen Merck Chemicals, Schwalbach, Germany)
according to the manufacturer’s protocol. HeLa S3 cells were grown
in standard RPMI 1640 medium supplemented with glutamine, anti-
biotics, and 10% FBS. After being washed with PBS, cells were lysed
in cold modified RIPA buffer (50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 150
mM NaCl, 1% N-octylglycoside, 0.1% sodium deoxycholate, com-
plete protease inhibitor mixture (Roche)) and incubated for 15 min on
ice. Lysates were cleared by centrifugation, and after precipitation
with chloroform/methanol, proteins were resuspended in 6 M urea,
2 M thiourea, 10 mM HEPES, pH 8.0. Prior to in-solution digestion,
60-g protein samples from HeLa S3 lysates were spiked with either
10 g or 30 g of E. coli K12 lysates based on protein amount
(Bradford assay). Both batches were reduced with dithiothreitol and
alkylated with iodoacetamide. Proteins were digested with LysC
(Wako Chemicals, GmbH, Neuss, Germany) for 4 h and then trypsin
digested overnight (Promega, GmbH, Mannheim, Germany). Diges-
tion was stopped by the addition of 2% trifluroacetic acid. Peptides
were separated by isoelectric focusing into 24 fractions on a 3100
OFFGEL Fractionator (Agilent, GmbH, Böblingen, Germany) as de-
scribed in Ref. 45. Each fraction was purified with C18 StageTips (46)
and analyzed via liquid chromatography combined with electrospray
tandem mass spectrometry on an LTQ Orbitrap (Thermo Fisher) with
lock mass calibration (47). All raw files were searched against the
human and E. coli complete proteome sequences obtained from
UniProt (version from January 2013) and a set of commonly observed
contaminants. MS/MS spectra were filtered to contain at most eight
peaks per 100 mass unit intervals. The initial MS mass tolerance was
20 ppm, and MS/MS fragment ions could deviate by up to 0.5 Da (48).
For quantification, intensities can be determined alternatively as the
full peak volume or as the intensity maximum over the retention time
profile, and the latter method was used here as the default. Intensities
of different isotopic peaks in an isotope pattern are always summed
up for further analysis. MaxQuant offers a choice of the degree of
uniqueness required in order for peptides to be included for quanti-
fication: “all peptides,” “only unique peptides,” and “unique plus razor
peptides” (42). Here we chose the latter, because it is a good com-
promise between the two competing interests of using only peptides
that undoubtedly belong to a protein and using as many peptide
signals as possible. The distribution of peptide ions over fractions and
samples is shown in supplemental Fig. S1.
Dynamic Range Benchmark Dataset—The E. coli K12 strain was
grown in standard LB medium, harvested, washed in PBS, and lysed
in 4% SDS, 100 mM Tris, pH 8.5. Lysates were briefly boiled and DNA
sheared using a Sonifier (Branson Model 250). Lysates were cleared
by centrifugation at 15,000  g for 15 min and precipitated with
acetone. Proteins were resuspended in 8 M urea, 25 mM Tris, pH 8.5,
10 mM DTT. After 30 min of incubation, 20 mM iodoacetamide was
added for alkylation. The sample was then diluted 1:3 with 50 mM
ammonium bicarbonate buffer, and the protein concentration was
estimated via tryptophan fluorescence emission assay. After 5 h of
digestion with LysC (Wako Chemicals) at room temperature, the
sample was further diluted 1:3 with ammonium bicarbonate buffer,
and trypsin (Promega) digestion was performed overnight (protein-to-
enzyme ratio of 60:1 in each case). E. coli peptides were then purified
by using a C18 Sep Pak cartridge (Waters, Milford, MA) according to
the manufacturer’s instructions. UPS1 and UPS2 standards (Sigma-
Aldrich) were resuspended in 30 l of 8 M urea, 25 mM Tris, pH 8.5, 10
mM DTT and reduced, alkylated, and digested in an analogous man-
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ner, but with a lower protein-to-enzyme ratio (12:1 for UPS1 and 10:1
for UPS2, both LysC and trypsin). UPS peptides were then purified
using C18 StageTips. E. coli and UPS peptides were quantified based
on absorbance at 280 nm using a NanoDrop spectrophotometer
(Fisher Scientific). For each run, 2 g of E. coli peptides were then
spiked with 0.15 g of either UPS1 or UPS2 peptides, and about 1.6
g of the mix was then analyzed via liquid chromatography combined
with mass spectrometry on a Q Exactive (Thermo Fisher). Data were
analyzed with MaxQuant as described above for the proteome dataset.
All files were searched against the E. coli complete proteome se-
quences plus those of the UPS proteins and common contaminants.
Retention Time Alignment and Identification Transfer—To increase
the number of peptides that can be used for quantification beyond
those that have been sequenced and identified by an MS/MS data-
base search engine, one can transfer peptide identifications to
unsequenced or unidentified peptides by matching their mass and
retention times (“match-between-runs” feature in MaxQuant). A pre-
requisite for this is that retention times between different LC-MS runs
be made comparable via alignment. The order in which LC-MS runs
are aligned is determined by hierarchical clustering, which allows one
to avoid reliance on a single master run. The terminal branches of the
tree from the hierarchical clustering typically connect LC-MS runs of
the same or neighboring fractions or replicate runs, as they are the
most similar. These cases are aligned first. Moving along the tree
structure, increasingly dissimilar runs are integrated. The calibration
functions that are needed to completely align LC-MS runs are usually
time-dependent in a nonlinear way. Every pair-wise alignment step is
performed via two-dimensional Gaussian kernel smoothing of the
mass matches between the two runs. Following the ridge of the
highest density region determines the recalibration function. At each
tree node the resulting recalibration function is applied to one of the
two subtrees, and the other is left unaltered.
Unidentified LC-MS features are then assigned to peptide identifi-
cations in other runs that match based on their accurate masses and
aligned retention times. In complex proteomes, the high mass accu-
racy on current Orbitrap instruments is still insufficient for an unequiv-
ocal peptide identification based on the peptide mass alone. How-
ever, when comparing peptides in similar LC-MS runs, the information
contained in peptide mass and recalibrated retention time is enough
to transfer identifications with a sufficiently low FDR (in the range of
1%), which one can estimate by comparing the density of matches
inside the match time window to the density outside this window (49).
The matching procedure takes into account the up-front separa-
tion, in this case isoelectric focusing of peptides into 24 fractions.
Identifications are only transferred into adjacent fractions. If, for in-
stance, for a given peptide sequenced in fraction 7, isotope patterns
are found to match by mass and retention time in fractions 6, 8, and
17, the matches in fraction 17 are discarded because they have a
much greater probability of being false. The same strategy can be
applied to any other up-front peptide or protein separation (e.g.
one-dimensional gel electrophoresis). All matches with retention time
differences of less than 0.5 min after recalibration are accepted.
Further details on the alignment and matching algorithms, including
how to control the FDR of matching, will be described in a future
manuscript.
Software and Data Availability—The label-free software MaxLFQ is
completely integrated into the MaxQuant software (42) and can be
activated by one additional click. It is freely available to academic and
commercial users as part of MaxQuant and can be downloaded via
the Internet. MaxQuant runs on Windows desktop computers with
Vista or newer operating systems, preferably the 64-bit versions.
There is a large user community at the MaxQuant Google group.
All downstream analysis was done using our in-house developed
Perseus software, which is also freely available from the MaxQuant
website.
The mass spectrometry proteomics data have been deposited
to the ProteomeXchange Consortium (http://proteomecentral.
proteomexchange.org) via the PRIDE partner repository with the
dataset identifier PXD000279.
RESULTS
Proteome-wide Benchmark Dataset—Evaluation of the ac-
curacy of a label-free workflow at a proteome scale requires a
dataset with known ratios. To this end we produced a bench-
mark dataset by mixing whole, distinguishable proteomes in
defined ratios. Combined trypsin-digested lysates of HeLa
cells and E. coli cells were extensively separated via isoelec-
tric focusing into 24 fractions as described (45) and analyzed
via LC-MS/MS in three replicates (“Experimental Proce-
dures”). This was repeated with the same quantity of HeLa,
but admixed with a 3-fold increased amount of E. coli lysate.
In the resulting six samples all human proteins therefore
should have had one-to-one ratios and all E. coli proteins
should have had a ratio of three to one between replicate
groups.
Raw data were processed with MaxQuant (42) and its
built-in Andromeda search engine (50) for feature extraction,
peptide identification, and protein inference. Peptide and pro-
tein FDRs were both set at 1%. MaxQuant identified a total of
789,978 isotope clusters through MS/MS sequencing. Trans-
ferring identifications to other LC-MS runs by matching them
to unidentified features based on their masses and recali-
brated retention times increased the number of quantifiable
isotope patterns more than 2-fold (“match-between-runs,”
“Experimental Procedures”).
A Novel Solution to the Normalization Problem—A major
challenge of label-free quantification with prefractionation is
that separate sample processing inevitably introduces differ-
ences in the fractions to be compared. In principle, correct
normalization of each fraction can eliminate this error. How-
ever, the total peptide ion signals, necessary in order to
perform normalization of the LC MS/MS runs of each fraction,
are spread over several adjacent runs. Therefore one cannot
sum up the peptide ion signals before one knows the normal-
ization coefficients for each fraction.
We solve this dilemma by delaying normalization. After
summing up intensities with normalization factors as free
variables, we determine their quantities via a global optimiza-
tion procedure based on achieving the least overall proteome
variation.
Formally, we want to determine normalization coefficients
Nj, which multiply all intensities in the jth LC-MS run (j runs
from 1 to 144 in our example). The normalization is done
purely from the data obtained and without the addition of
external quantification standards or reliance on a fixed set of
“housekeeping” proteins. Directly adjusting the normalization
coefficients Nj for each of the fractions so that the total signal
Label-free Quantification in MaxQuant
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is equalized leads to errors if the fractionation is slightly irre-
producible or if the mass spectrometric responses in the jth
run are different from average. Therefore, we wish to summa-
rize the peptide ion signals over the fractions in each sample.
This, however, already requires the determination of the run-
specific normalization factors Nj. We exploit the fact that the
majority of the proteome typically does not change between
any two conditions so that the average behavior can be used
as a relative standard. This concept is also applied in label-
based methods (e.g. for the normalization of SILAC ratios in
MaxQuant). After summing the peptide ion signals across
fractions with as-yet unknown Nj factors, we determined
these factors in a nonlinear optimization model that minimized
overall changes for all peptides across all samples (Fig. 1). For
this we defined the total intensity of a peptide ion P in sample
A as
IP, AN  
k
Nrunk XICk, (Eq. 1)
where the index k runs over all isotope patterns for peptide ion
P in sample A. Here, different charge modification states are
treated separately. The sum is understood as a generalized
summation that can be the regular sum or the maximum over
fractions. Also, for the XIC several choices exist, including
total three-dimensional peak volume or area of the cross-
section at the retention time when the maximum intensity is
reached, which was used for this study. The quantity
HN  
Ppeptides

 A,Bsample pairs
log IP, A
IP,B
2 (Eq. 2)
is the sum of all squared logarithmic fold changes between all
samples and summed over all peptide ions (see Fig. 1). We
minimized H(N) numerically with respect to the normalization
coefficients Nj via Levenberg–Marquardt optimization (51) in
order to achieve the least possible amount of differential
regulation for the bulk of the proteins. This procedure is
compatible with any kind of prefractionation and also is in-
sensitive toward irreproducibility in processing. The compu-
tational effort for this procedure grows quadratically with the
number of samples to be compared, which may hamper the
analysis of very large datasets containing hundreds of sam-
ples. In these cases, however, a heuristic may be employed to
estimate normalization coefficients by considering only a sub-
set of possible pair-wise combinations of samples (see sub-
section “Fast Label-free Normalization of Large Datasets”). In
principle, weighting factors can be included in the sum for
H(N) in order to penalize low-intensity ions. Here we refrained
from this in order to keep the parameterization of the model
simple.
Extraction of Maximum Peptide Ratio Information—Another
principal problem in label-free quantification is the selection of
the peptide signals that should contribute to the optimal de-
termination of the protein signal across the samples. A simple
Fraction A B C D E F
:
5 Peptide P:
6
7
8
9
:
IP,A(N) = NA,6XICA,6 + NA,7 XICA,7 + NA,8XICA,8
IP,B(N) = NB,5XICB,5 + NB,6 XICB,6 + NB,7XICB,7 + NB,8XICB,8
IP,C(N) = NC,7XICC,7 + NC,8 XICC,8 + NC,9XICC,9
IP,D(N) = ND,5XICD,5 + ND,6 XICD,6 + ND,7XICD,7
IP,E(N) = NE,6XICE,6 + NE,7XICE,7
IP,F(N) = NF,7XICF,7 + NF,8XICF,8
13
14
15
16
:
Peptide Q:
IQ,A(N) = NA,14XICA,14 + NA,15 XICA,15 + NA,16 XICA,16
IQ,B(N) = NB,13XICB,13 + NB,14 XICB,14 + NB,15 XICB,15 + NB,16 XICB,16
IQ,C(N) = NC,13XICC,13 + NC,14 XICC,14 + NC,15 XICC,15
IQ,D(N) = ND,14XICD,14 + ND,15 XICD,15
IQ,E(N) = NE,14 XICE,14 + NE,15XICE,15 + NE,16XICE,16
IQ,F(N) = NF,14XICF,14 + NF,15 XICF,15
19
20
21
22
Peptide R:
IR,A(N) = NA,21XICA,21 + NA,22 XICA,22
IR,B(N) = NB,19XICB,19 + NB,20 XICB,20 + NB,21 XICB,21
IR,C(N) = NC,20XICC,20 + NC,21 XICC,21 + NC,22 XICC,22
IR,D(N) = ND,20XICD,20 + ND,21 XICD,21
IR,E(N) = NE,19 XICE,19 + NE,20 XICE,20 + NE,21XICE,21
IR F(N) = NF 20 XICF 20 + NF 21XICF 21
(     ) 
(     ) (     ) |          | IP,A(N)IP,B(N)( ) 
:
, , , , ,
log
2
+HP(N) = |     | IP,A(N)IP,C(N)log
2
+ |     | IP,A(N)IP,D(N)log
2
+ other sample pairs 
(     ) (     ) |     | IQ,A(N)IQ,B(N)log
2
+HQ(N) = |     | IQ,A(N)IQ,C(N)log
2
+ |     | IQ,A(N)IQ,D(N)log
2
+ other sample pairs 
(     ) (     ) (     ) |     | IR,A(N)IR,B(N)log
2
+HR(N) = |     | IR,A(N)IR,C(N)log
2
+ |     | IR,A(N)IR,D(N)log
2
+ other sample pairs 
H(N) = HP(N) + HQ(N) + HR(N) + other peptides
FIG. 1. Schematic construction of
the function H(N) to be minimized in
order to determine the normalization
coefficients for each LC-MS/MS run.
Intensity distributions of three peptides
(orange, green, and red) over samples
and fractions are indicated by the sizes
of the circles. H(N) is the sum of the
squared logarithmic changes in all sam-
ples (A, B, C, . . .) for all peptides (P, Q,
R, . . .). When using the fast normaliza-
tion option, only a subset of all possible
pairs of samples will be considered.
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solution to this problem is to add up all peptide signals for
each protein and then compare protein ratios. Alternatively,
peptide intensities may be averaged, or only the top n intense
species may be taken (31). However, these solutions discard
the individual peptide ratios and thus do not extract the max-
imum possible quantification information. Instead, ratios de-
rived from individual peptide signals should be taken into
account, rather than a sum of intensities, because the XIC
ratios for each peptide are already a measurement of the
protein ratio. The very same concept is applied in label-based
methods such as SILAC and contributes to their accuracy.
Due to stochastic MS/MS sequencing and differences in
protein abundances across samples, peptide identifications
are often missing in specific samples. One way to neverthe-
less obtain a signal for each peptide in every sample is to
integrate the missing peptide intensities over the mass reten-
tion time plane using the integration boundaries from the
samples in which the peptide has been identified. In this case,
noise level effectively substitutes for the signal. Care has to be
taken not to under- or overestimate the true ratios in either
of these approaches. Yet another possibility is to restrict
quantification to peptides that have a signal in all samples.
Although this works well when comparing two samples, it
becomes impractical when the number of samples is large—
for example, requiring a peptide signal to be present in all of
100 clinical samples would likely eliminate nearly all peptides
from quantification.
We propose a novel method for protein quantification that
does not suffer from the problems described above (Fig. 2).
We want to use only common peptides for pair-wise ratio
determination without losing scalability for large numbers of
samples. We achieve this for each protein by first calculating
its ratio between any two samples using only peptide species
that are present in both (Figs. 2A and 2B). Then the pair-wise
protein ratio is calculated as follows, taking the pair-wise ratio
of the protein in samples B and C in Fig. 2 as an example: First
the intensities of peptides occurring in both samples are
employed to calculate peptide ratios. In this case, peptide
FIG. 2. Algorithm constructing protein intensity profiles for one protein from its peptide signals. A, an exemplary protein sequence.
Peptides with an XIC-based quantification are indicated in magenta. B, the five peptide sequences give rise to seven peptide species. For this
purpose, a peptide species is a distinct combination of peptide sequence, modification state, and charge, each of which has its own
occurrence pattern over the different samples. C, occurrence matrix of peptide species in the six samples. D, matrix of pair-wise sample protein
ratios calculated from the peptide XIC ratios. Valid/invalid ratios are colored in green/red based on a configurable minimum ratio count cut-off.
If a sample has no valid ratio with any other sample, like sample F, the intensity will be set to zero. E, system of equations that needs to be
solved for the protein abundance profile. F, the resulting protein abundance profile for one protein. The absolute scale is adapted to match the
summed-up raw peptide intensities.
Label-free Quantification in MaxQuant
Molecular & Cellular Proteomics 13.9 2517
46
3.1 Publication: MaxLFQ allows accurate proteome-wide label-free quantification
species P2, P3, and P6 are shared (Fig. 2C). The pair-wise
protein ratio rCB (Fig. 2D) is then defined as the median of
the peptide ratios, to protect against outliers. We then pro-
ceed to determine all pair-wise protein ratios. In the example
in Fig. 2, we require a minimal number of two peptide ratios in
order for a given protein ratio to be considered valid. This
parameter is configurable in the MaxQuant software. Setting a
higher threshold will lead to more accurate quantitative val-
ues, at the expense of more missing values.
At this point we have constructed a triangular matrix contain-
ing all pair-wise protein ratios between any two samples, which
is the maximal possible quantification information. This matrix
corresponds to an overdetermined system of equations for the
underlying protein abundance profile (IA, IB, IC, . . .) across the
samples (Fig. 2E). We perform a least-squares analysis to re-
construct the abundance profile optimally satisfying the individ-
ual protein ratios in the matrix based on the sum of squared
differences

 j,kvalid pairs
log rj,k  log Ij  log Ik2. (Eq. 3)
Then we rescale the whole profile to the cumulative inten-
sity across samples, thereby preserving the total summed
intensity for a protein over all samples (Figs. 2E and 2F). This
procedure is repeated for all proteins, resulting in an accurate
abundance profile for each protein across the samples. The
computational effort grows quadratically with the number of
samples in which a protein is present; however, it is readily
parallelizable at the protein level.
All resulting profiles are written into the MaxQuant output
tables in columns starting with “LFQ intensity.”
Quantification Results for the Proteome Benchmark
Set—To apply the algorithms to the E. coli and HeLa cell
mixture, we required a protein to have non-zero intensity in
two out of the three replicates for each condition. In addition,
protein groups had to be unambiguously assignable to one
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FIG. 3. Quantification results for
the proteome benchmark dataset.
Replicate groups were filtered for two
out of three valid values and averaged,
and the log ratios of the E. coli (orange)/
human (blue) 3:1 versus 1:1 samples
were plotted against the logarithm of
summed peptide intensities from the 1:1
sample as a proxy for absolute protein
abundance. A, quantification using
spectral counts. B, quantification using
summed peptide intensities. C, quantifi-
cation using MaxLFQ. D–F, same as
A–C, but colored using density estima-
tion. G, H, histograms of the ratio distri-
butions of human and E. coli proteins
obtained using the different quantifica-
tion methods.
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species; this was the case for 3453 human and 1556 E. coli
proteins (supplemental Table S1). In Fig. 3, we compare the
performance of MaxLFQ against that of two other frequently
used quantitative metrics: spectral counting and summed
peptide intensities. Both were also extracted by MaxQuant,
so we do not introduce biases due to the search engine and
the set of identified peptides, and only benchmark conceptu-
ally different metrics of quantification. For each case, we
averaged the three replicates of each experimental condition
and plotted the log ratios against the log of the summed
peptide intensity, which can be used as a proxy for absolute
protein abundance (52–54). In all cases, human and E. coli
proteins formed distinct clouds, but with different degrees of
overlap. Spectral count ratio clouds were clearly separated
only for the most abundant proteins (Figs. 3A and 3D). In the
low-intensity region, spectral counts became discrete values,
and their log ratios adopted a very wide distribution with
pronounced overlap of human and E. coli proteins. Further-
more, a systematic distortion was observable that resulted in
a general overestimation of the ratios of low-intensity pro-
teins. Ratios of summed peptide intensities already allowed
almost complete separation of human and E. coli proteins
across the entire abundance range, with some overlap occur-
ring only in the lower half (Figs. 3B and 3E). This demonstrates
a clear advantage of intensity-based approaches. When we
used our MaxLFQ algorithm, the overlap of the populations
was further reduced relative to the summed intensity ap-
proach, and the number of extreme outliers was markedly
reduced (Figs. 3C and 3F). We quantified the widths of the
distributions and the degree of overlap (Figs. 3G–3I), which
demonstrated that MaxLFQ performed best not only by gen-
erating the narrowest distributions, but also by most accu-
rately recapitulating the expected fold change of three be-
tween the population averages.
MaxLFQ has the prerequisite that a majority population of
proteins exists that is not changing between the samples.
How big this population needs to be and what the conse-
quences are if the changing population becomes comparable
in size to the non-changing one can be seen in the benchmark
dataset itself, in which the changing (E. coli) population com-
prised 31% of the proteins measured in total. MaxLFQ still
operated well under these circumstances. The average factor
of three between the changing and non-changing population
was recovered well. The only effect of the large size of the
changing population was a total shift of all log-ratios such that
the non-changing population was centered not exactly at zero
but at slightly negative values. However, this had no effect on
subsequent tests for finding differentially expressed proteins,
as they are all insensitive to global shifts of all values. Regard-
ing samples involving enrichment steps, we refer to our ex-
amples of interaction proteomics studies, in which MaxLFQ
performed very well. In such datasets, enriched proteins may
constitute a large part of the total protein mass (or peak
intensity). Still, we routinely observed a dominant population
of background binding proteins contributing a large number of
peptide features that changed minimally between experimen-
tal conditions (even if their intensities were lower). In large
pulldown datasets, the background population does not have
to be the same over all samples and can be a different one in
each pair-wise sample comparison in MaxLFQ.
Analysis at a population level does not in itself provide
statistically sound information on the regulation state of indi-
vidual proteins. In fact, Fig. 3B shows several human proteins
that appear to be changing by several-fold. In a clinical con-
text these might have been mistaken for biomarkers without
further analysis. We therefore explored different strategies to
retrieve significantly changing proteins based either on simple
fold change or on the variance of their quantitative signals,
ranking the proteins by their highest apparent fold change
(highest ratio of average intensities), by their standard t test p
value, by their Welch modified t test p value, and finally by
their Wilcoxon–Mann–Whitney p value. Because we had full
prior knowledge about which proteins were changing (only the
E. coli ones), we independently knew the FDR and could
construct precision-recall curves for each case to assess
performance (Fig. 4A). This revealed that retrieving proteins by
ratio (corresponding to a fixed fold change cut-off) was the
worst strategy. It had low precision even at small recall values
because of its sensitivity to outlier ratios in individual repli-
cates. When sorting proteins by ratios, we found that the
fourth protein was a false positive (Fig. 4B, arrow). The
Wilcoxon–Mann–Whitney test performed better but also had
problems at low recall. Both versions of the t test performed
significantly better, and the Welch modified t test was slightly
better than the standard t test. At a precision of 0.98, 72% of
the E. coli proteins were recalled. With a precision of 95%,
which is often used in similar circumstances, the vast majority
(88%) of E. coli proteins were retrieved when we used the
Welch modified t test.
In datasets of practical interest, the true proportion of false
positives is not known a priori. As a means to control the FDR
and solve potential multiple hypothesis testing problems in
real biological datasets, we usually apply permutation-based
methods for calculating q-values and global FDRs. These
robust strategies have been successfully applied to high-
throughput biological data for a long time (55). The advantage
of permutation-based methods is that no assumptions need
to be made regarding the parametric distributions of intensi-
ties or ratios. The significance analysis of microarrays (SAM)
method that we apply to most of the biological datasets also
utilizes moderation to ensure the stability of the results.
Whereas in most real applications the stabilization parameter
s0 introduced in Ref. 55 is beneficial, in this particular bench-
mark dataset it did not improve the performance relative to
the original t test statistic. This is presumably because in the
benchmark dataset all true ratios were either 1:1 or 1:3,
whereas in real applications the true ratio distribution has a
dense spectrum of small changes.
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Interestingly, about one-third of the proteome was chang-
ing in the benchmark dataset, which is a large amount, con-
sidering that the normalization was based on the assumption
of a dominating population of non-changing proteins. The
effect of this can be observed in Fig. 3I. The center of the 1:1
population is shifted to slightly negative values. However, the
distance between the means of the 3:1 and 1:1 populations is
near the correct value of log2(3). Such a global shift of all
ratios will not affect statistical testing, as a test such as the t
test is insensitive to such a global shift of all values. If one
insists on having a 1:1 distribution centered exactly at 0, one
can apply another normalization step in which one subtracts
the most frequent value (i.e. the position of the global
maximum).
So far we have assessed the measurability of 3:1 changes
over the whole accessible dynamic range of protein abun-
dances. Another question of interest is how measurable
smaller ratios are. For this purpose we conducted an in silico
experiment in which the results of the actual 3:1 experiment
were rescaled in order to mimic results obtained with lower
mixing ratios. We rescaled the log ratios of all E. coli proteins
in the three samples with the 3-fold increased E. coli abun-
dance by adding the constant
1  S  meanhuman  meanE. coli (Eq. 4)
to all of these values. Here, mean(E. coli) is the average dif-
ference in log intensities between the two replicate groups for
the E. coli proteins, mean(human) is the same quantity calcu-
lated for all human proteins, and s is a scaling factor between
0 and 1. For s  1, the original data are recovered, whereas for
s  0 the mean ratio is 1:1 for all proteins, in particular for the
E. coli proteins. For a given value of s, the corresponding
simulated ratio is r  3s.
Fig. 5A shows precision-recall curves similar to those in Fig.
4A. This time, only the t test was used for determining signif-
icant changes, and we scanned through several values for the
simulated ratio r. As an example, we tolerated a proportion of
false discoveries (Q, the value estimated by the FDR) of 10%
for calling changes significant. Although in that case almost all
truly changing proteins are recovered with a ratio of 3, about
half of them are still obtained at a ratio of 1.6. Going below a
mean ratio change of 1.6 will lead to strong drop in coverage.
The FDR threshold that one wishes to apply depends on the
experimental situation and on the biological or technological
question. There is no a priori given FDR that is applicable to
every case. For instance, if pre-screening is done (e.g. to
explore regulated pathways or biological processes), a 25%
FDR might still be tolerable, whereas in other cases a 5% FDR
might not be stringent enough. To get an idea about the
relationship between protein ratio and coverage achieved for
proteins having this ratio, we plotted this dependence in Fig.
5B for several values of Q. In particular, for low stringency
there is a very rapid drop of coverage around a well-defined
ratio. For instance, the Q  0.25 curve has a steep slope
around a ratio of 1.4 where it achieves half of the coverage.
One could define this “half-coverage point” as the situation for
which it still makes sense to look for ratio changes. In Fig. 5C
we show the ratio at the point of half-coverage as a function
of Q. These ratios can achieve values of far less than 2 for
larger values of Q.
Dynamic Range Benchmark Set—So far, we have demon-
strated that MaxLFQ is able to accurately and robustly
quantify small fold changes on a proteome scale. This is
relevant, for instance, for the analysis of cellular proteome
remodeling upon stimulation. Next, we wanted to test the
performance of the algorithm in the quantification of high
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ratios in the range of several orders of magnitude. Such
ratios typically occur in the context of interaction proteom-
ics experiments (56), where early mixing of isotope-labeled
samples is usually not possible and some of the principal ad-
vantages of metabolic labeling are therefore lost. We have re-
cently shown that both SILAC and MaxLFQ generate similar
ratio distributions (57), indicating that in such cases MaxLFQ is
capable of achieving quantification accuracies comparable to
those obtained with SILAC.
As a benchmark dataset for high protein ratios, we made
use of the universal protein standard (UPS) (Sigma-Aldrich), a
mixture of 48 recombinant human proteins that is available as
an equimolar mixture (UPS1) or mixed at defined ratios span-
ning 5 orders of magnitude (UPS2). This dataset does not
contain fractionation and is used for showing that MaxLFQ
performs well at high dynamic range quantification in general.
We separately digested UPS1 and UPS2 with trypsin and
spiked the peptides into a trypsin-digested E. coli lysate. We
analyzed each condition in four replicates via single-shot LC-
MS/MS. Raw data were processed as described for the pro-
teome benchmark dataset, with some exceptions as outlined
below. MaxQuant identified 232,835 isotope clusters by MS/
MS, and matching between runs increased the number of
quantifiable features by 38%. After protein inference, this
resulted in 2200 non-redundant E. coli protein groups. We
identified all of the 48 human UPS proteins in all samples
containing E. coli with the equimolar UPS1 standard (supple-
mental Table S2). In the sample of E. coli plus UPS2, 15 of the
lower abundant human UPS proteins were never sequenced
by MS/MS, but 10 of them could be identified and quantified
in at least some of the replicates through matching to the
UPS1-containing samples. Applying the same requirement
of two shared peptides for each pair-wise comparison (as
used in the proteome benchmark dataset) expectedly re-
sulted in missing values for samples in which only individual
peptides were found; therefore we lowered this threshold to
one. Extreme ratios typically coincide with very different
peptide populations identified in the samples to be com-
pared: many in the sample with high protein abundance, of
which only a small subset is found in the low-abundance
sample. This can make the protein ratio determination rely
on very few quantification events, which increases the sen-
sitivity to outliers. To address this issue, we implemented an
optional feature called “large ratio stabilization,” which
modifies the ratio determination for pair-wise comparisons
where the number of peptides quantified in the two samples
differs substantially. In a case when fewer than one out of
five peptides is shared between samples, the ratio of the
summed-up peptide intensities is taken for quantification. If
more than two out of five peptides are shared, the median of
pair-wise ratios is used. For intermediate cases, we inter-
polate linearly between these two kinds of ratio determina-
tions. In summary, the protein ratio r is determined by the
median of peptide ratios rm and the ratio of summed-up
peptide intensities rs by the formula
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FIG. 5. Statistical significance of
small protein ratios. A, precision-recall
curves based on a t test on a set of
ratios that were simulated in silico by
shrinking the experimental ratio of three.
B, ratio-coverage plots for these simu-
lated ratios at a set of fixed proportions
of false discoveries among the discov-
eries (Q). One can see a drop in cover-
age around a given ratio, which is par-
ticularly steep for large values of Q. C,
simulated ratio at which one achieves
half-coverage plotted against the value
of Q.
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r   rm if x  2.5rs if x  5
expw log rs  1  w log rm otherwise
(Eq. 5)
where w  (x  2.5)/2.5 and x is the ratio of the number of
peptide features in the sample with the most peptide features to
the number of common peptide features. We found that this
stabilized the general ratio trend and reduced the outlier
sensitivity.
Fig. 6A shows the quantification results for samples contain-
ing UPS2 versus UPS1, plotted in the same way as in Fig. 3.
UPS proteins are clearly separated from the narrow cloud of
E. coli proteins and cluster in groups according to their relative
abundances. For further analysis, we subtracted the median of
the group of UPS proteins present in equal amounts in both
UPS1 and UPS2. In a direct comparison of true ratio versus the
MaxLFQ readout (Fig. 6B), we show that within 2 orders of
magnitude, we obtained quantification results that were ex-
tremely close to the expected values. For ratios of more than
100-fold, we detected increased scatter, but no systematic
error that would lead to an over- or underestimation of the ratio
(Fig. 6F). Summed intensities yielded very similar results within
2 orders of magnitude (Fig. 6C) but a small systematic under-
estimation of very large ratios (Fig. 6G). Spectral counts covered
2 orders of magnitude less than intensity-based methods, be-
cause there were no MS/MS events for all proteins of the lowest
two abundance groups in all UPS2-plus-E. coli samples (Fig.
6D). For proteins covered by MS/MS spectra in both UPS1 and
UPS2 samples, there was a pronounced systematic underesti-
mation of the ratio when calculating the ratio of spectral counts
(Fig. 6H). This clearly shows that spectral counting suffers from
a very narrow dynamic range that is limited by the total number
of identified MS/MS spectra. Of note, all methods unanimously
detected ratios of less than 10 for the comparison of the group
of most abundant proteins in the UPS2 samples. This leads us
to speculate that this was not due to a quantification error, but
rather due to the composition of the UPS2 peptide mixture. It is
possible that the eight most abundant proteins could be slightly
underrepresented because of LC-MS saturation effects or in-
complete digestion.
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FIG. 6. Quantification results for
the dynamic range benchmark data-
set. Replicate groups were filtered for
three out of four valid values and aver-
aged. A, log ratios of the UPS2 versus
UPS1 samples plotted against the log-
arithm of summed peptide intensities
from the UPS1 sample as a proxy for
absolute protein abundance. E. coli pro-
teins are plotted in gray and form a nar-
row population centered on zero. UPS
proteins are color-coded by their abun-
dance groups in the UPS2 sample. B–D,
to compare the ratio readout against the
true ratio, we shifted the population of
UPS proteins that were present in UPS1
and UPS2 in equimolar amounts to 1:1
and plotted the log ratio obtained from
(B) MaxLFQ, (C) summed intensities,
and (D) spectral counts against the log
of the true ratio. E, log intensity ratio
plotted against log MaxLFQ ratios. F–H,
data from B–D plotted as the deviation
from the true ratio. Spectral counts
show a clear underestimation of ratios
across the entire dynamic range and
lose 2 orders of magnitude. Summed
intensities and MaxLFQ show increased
scatter toward ratios of several orders
of magnitude. Summed intensities show
some degree of systematic underesti-
mation of large ratios, which was not
observed for MaxLFQ ratios.
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Fast Label-free Normalization of Large Datasets—In the
analysis of very large datasets, one of the computationally
most expensive steps is the determination of the normaliza-
tion factors for each LC-MS run by minimizing the quantity
H(N) described earlier and depicted in Fig. 1. This quantity
contains a sum running over all pairs of samples that grows
quadratically with the number of samples. (Note that in the
case of pre-fractionation, multiple LC-MS runs contribute to
one sample and do not contribute to a further quadratic
increase of the computational effort.) One approach would be
to do normalization in a more simplistic way and only use the
reconstruction of protein abundances based on paired pep-
tide ratios from MaxLFQ. However, because the normalization
is crucial with fractionated samples, we wanted to find an
algorithm that delivered results very similar to those of the full
MaxLFQ computation, but within a much smaller computation
time.
Because the resulting minimization problem becomes in-
creasingly overdetermined for larger numbers of samples, we
reasoned that a meaningful subset of comparisons would
significantly reduce the computing time while still delivering
correct normalization factors. Even a linear chain of compar-
isons in which every sample occurs exactly once would in
principle be sufficient to determine all normalization factors.
However, this minimal strategy may lead to unstable and
error-prone calculations, as the failure or imprecision of a
single comparison may propagate into the calculation of all
normalization factors. As a compromise considering stability,
correctness, and computational efficiency, a reasonable and
robust subset of pair-wise comparisons needs to be found.
We started by creating a graph with all samples as nodes. A
large overlap of peptides between each pair of nodes was
interpreted as a small distance between them. A subgraph was
then determined in which each node had a minimum number of
three nearest neighbors and the average number of neighbors
over all nodes was six. All edges that were not needed to fulfill
these criteria were removed while making sure that all nodes
remained connected. For the sum in H(N) in Fig. 1, only those
sample pairs were taken into account that had an edge in this
graph, resulting in linear scaling of the computational effort with
the number of samples. This “fast” normalization option can be
optionally activated in MaxQuant, and the parameters for sub-
graph determination are adjustable by the user.
DISCUSSION
We have introduced MaxLFQ as a suite of novel algorithms
for relative protein quantification without stable isotopes. “De-
layed normalization” efficiently solves the problem of how to
compare sample fractions that have been handled in slightly
different ways and analyzed with different MS performance.
Importantly, delayed normalization does not require “house-
hold” proteins, which are assumed to be unchanging in the
experiment. The only prerequisite is a dominant population
of proteins that change minimally between experimental
conditions. The second algorithm allows the retrieval of the
maximum possible information from peptide ratios across
samples, without resorting to arbitrary assignment of the
signal when a peptide signal cannot be detected. Finally, a
profile of “LFQ” intensities is calculated for each protein as
the best estimate satisfying all the pair-wise peptide com-
parisons. Importantly, this intensity profile retains the abso-
lute scale from the original summed-up peptide intensities.
This should readily qualify it as a proxy for absolute protein
abundance. MaxLFQ is a generic approach that works in-
dependently of the experimental question under investiga-
tion, and we have demonstrated equally good performance
for the determination of small and very large ratios. For
assessing the statistical significance of individual protein
ratios, we found that t testing on a dataset with three or
more replicates delivered the best results and was superior
to a simple fold-change cut-off.
Our laboratory has successfully used MaxLFQ in a num-
ber of studies with very diverse biological questions. For
instance, in measurements that spanned more than a year,
we studied the proteomic differences of rare immunological
cell types and found mutually exclusive expressions of pat-
tern recognition receptors (58). We have also followed the
proteome rearrangements during colon cancer develop-
ment and metastasis in the colon mucosa (54). Furthermore,
we have used label-free quantification to study protein–
protein interactions expressed as GFP-tagged constructs
from bacterial artificial chromosomes under endogenous
control (56) and screened for interactors of post-translation-
ally modified histone tails in mouse tissues (57). In that case
we showed that MaxLFQ achieved similar quantification
accuracies as SILAC. Interaction proteomics experiments
typically detect specific interactors with enrichment factors
on the order of several magnitudes. Here, the general ratio
trend is sometimes more important than a very accurate
readout of the actual ratio. Such cases offer a straightfor-
ward remedy for dealing with missing values: they can
simply be imputed as simulated values forming a distribu-
tion around the detection limit of measured intensities and
serve as the basis for judging enrichment factors. This is a
principal advantage over label-based ratio determination,
where dealing with infinite ratios is conceptually more
difficult.
In a very recent study, we used MaxLFQ to study the
secretome of activated immune cells and detected proteins
whose abundance was increased by several orders of mag-
nitude in the culture medium upon stimulation (59).
We have already been making MaxLFQ available as part of
the MaxQuant software for some time, and other groups have
made frequent use of it (60–75). It has also been bench-
marked against other software solutions for label-free quan-
tification (31), independently confirming the excellent per-
formance of our software.
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Recent advances in mass spectrometer hardware (76, 77)
have provided a boost in the depth of standard analyses and
enabled near-complete model proteome quantification in
minimal measuring time (6). Label-free quantification benefits
dramatically from this depth, as it increases the number of
quantifiable features present in a given LC-MS run and allows
averaging over more peptides for protein quantification. Illus-
trating this, in our dynamic-range benchmark dataset we re-
corded one of the largest published E. coli proteomes so far,
resulting in a high sequence coverage and hence a very
narrow cloud of E. coli protein quantifications.
Some challenges for label-free quantification remain: Sam-
ple handling variability needs to be minimized when samples
are to be recorded over the course of many months, on
different machines, or by different laboratories. Standardiza-
tion of instrumentation, simplification of sample preparation
procedures, and automation using multiwell systems or ro-
botics will help to mitigate this issue. Biological studies that
depend on the ultimate accuracy of the ratio readout or on
quantitative information about individual peptides, such as
post-translationally modified ones, will still rely on isotope
labels. In addition, applications that require extreme robust-
ness, such as sample handling in a clinical setting, will likely
benefit from spike-in references that serve as internal stand-
ards. That said, we expect label-free quantification methods in
general and MaxLFQ in particular to gain further momentum in
the proteomics community and become the method of choice
for many applications. The ease of use of MaxLFQ as part of the
MaxQuant software suite should enable our technology to be
widely adopted by nonspecialized labs as well.
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Wiśniewski, J. R.*,Hein,M. Y.*, Cox, J., &Mann,M.A ‘proteomic ruler’ for protein copy
number and concentration estimation without spike-in standards. Mol Cell Proteomics
13(12):3497-506 (2014)
While many proteomics analysis strategies are based on relative protein quantification
across conditions, others require absolute quantities of proteins in ‘hard’ units such as
protein copies per cell. Classically, absolute amounts of individual proteins were determ-
ined by quantification relative to an isotopically labelled reference that was spiked into
the sample in a defined amount (see Fig. 5). This is clearly not practicable for quantifying
large numbers of different proteins.
A challenge for absolute quantifcation without labelled standards is the fact that for in-
dividual peptides, there is no linearity between input amount and signal intensity due
to their different ‘flyabilities’ reflecting their chemical nature. However, taking the top
three best flying peptides of a protein [79] or integrating all peptides and normalizing
for protein length or the number of theoretically expected peptides [61] provides values
with very good correlation to the molar amounts of individual proteins. To bring these
values to absolute levels requires knowledge of a scaling factor that can, for instance,
be calculated by extrapolating from a limited number of ‘anchor’ proteins quantified via
spiked-in standards.
In the course of a discussion following the original description of the intensity-based
absolute quantification (iBAQ) method [61, 63], I proposed a simple sanity check: For
a deep proteome dataset, all protein copy numbers multiplied by their respective mo-
lecular masses should add up to the total protein amount per cell. Reversing this logic,
the total protein amount per cell can serve as the scaling factor without requiring actual
spike-in references. Jacek Wiśniewski in the group had the same idea in the course of a
study on proteomic changes during colon cancer metastasis [80].
To determine the total protein amount per cell, one has to count cells and measure their
protein content. This sounds straightforward, but the accuracy of many protein determ-
ination assays is limited by the reference standards used [81]. Moreover, counting cells in
tissue samples or in non-monodispersed cultures can be difficult. To solve this problem,
Jacek had the idea to use the amount of DNA in the sample as a standard that replaces the
need for cell counting, because the total cellular DNA amount can be calculated from the
ploidy and the genome size or the organism. Going one step further, the mass spectro-
metric signal derived from histones can be used as a ‘proteomic ruler’, because histones
are wrapped aroundDNA in a defined ratio [82]. We teamed upwith the goal to describe
the use of our ‘proteomic ruler’ method and to provide a computational framework to
make its use straightforward for many users.
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3.2 Publication: A ‘proteomic ruler’ for protein copy number and concentration estimation
A “Proteomic Ruler” for Protein Copy Number
and Concentration Estimation without Spike-in
Standards*□S
Jacek R. Wiśniewski‡§¶, Marco Y. Hein‡§, Jürgen Cox‡, and Matthias Mann‡¶
Absolute protein quantification using mass spectrometry
(MS)-based proteomics delivers protein concentrations or
copy numbers per cell. Existing methodologies typically
require a combination of isotope-labeled spike-in refer-
ences, cell counting, and protein concentration measure-
ments. Here we present a novel method that delivers
similar quantitative results directly from deep eukaryotic
proteome datasets without any additional experimental
steps. We show that the MS signal of histones can be
used as a “proteomic ruler” because it is proportional to
the amount of DNA in the sample, which in turn depends
on the number of cells. As a result, our proteomic ruler
approach adds an absolute scale to the MS readout and
allows estimation of the copy numbers of individual pro-
teins per cell. We compare our protein quantifications with
values derived via the use of stable isotope labeling by
amino acids in cell culture and protein epitope signature
tags in a method that combines spike-in protein fragment
standards with precise isotope label quantification. The
proteomic ruler approach yields quantitative readouts that
are in remarkably good agreement with results from the
precision method. We attribute this surprising result to the
fact that the proteomic ruler approach omits error-prone
steps such as cell counting or protein concentration mea-
surements. The proteomic ruler approach is readily appli-
cable to any deep eukaryotic proteome dataset—even in
retrospective analysis—and we demonstrate its usefulness
with a series of mouse organ proteomes. Molecular &
Cellular Proteomics 13: 10.1074/mcp.M113.037309, 3497–
3506, 2014.
Mass spectrometry (MS)1 is now capable of analyzing the
proteome to considerable depth, and more than 10,000 pro-
teins have been reported in single mammalian cell types (1). In
the past decade, MS-based proteomics has gone from sole
identification to the quantification of proteins, which has typ-
ically meant relative quantification between samples (2–4).
Apart from the presence of a protein and its relative fold
changes between different conditions (5), it is often desirable
to estimate absolute quantities such as molar concentrations
or copy numbers per cell, which can be compared for different
proteins (6). For instance, in systems biology, even a rough
estimate of the copy number can help to establish initial
parameters for simulation (7). Likewise, clinical protein mea-
surements are typically done in absolute terms of titers, such
as milligrams per deciliter. For this purpose various ap-
proaches have been utilized, including correlating total MS
signals to visualized structures in the cell (8) and extrapolating
from spiked-in reference protein mixtures (9) or from endog-
enous proteins quantified via accurately characterized, isoto-
pically labeled peptide (10) or protein fragment standards (11).
Absolute quantification is then achieved through quantifica-
tion relative to a known reference. In all cases, results scale
with the amount of input material or amount of spiked-in
standard. Accurate protein concentration measurements are
thus an essential and often limiting factor for overall accuracy.
Commonly used dye-based protein determination methods
rely on the reactivity of few amino acid residues—mainly
tryptophan and tyrosine (12) in the case of the Lowry and BCA
assays, or a hydrophilic/hydrophobic balance of the proteins
in the case of Bradford reagent (13). Systematic errors of up to
a factor of 2 may therefore arise from the selection of a
non-optimal protein standard (14). An additional, often ig-
nored source of errors is the cross-reactivity of the reagents
with non-proteinaceous cell components such as thiols, nu-
cleic acids, and phospholipids.
To convert protein quantities to copies per cell, all methods
require knowledge of the number of cells used for the analy-
sis. This can be obtained directly via cell counting or indirectly
through knowledge of the total protein amount per cell, which
in turn is a function of cell volume and total protein concen-
tration. However, cells are not necessarily uniform; therefore
scaling by cell numbers may be inaccurate, as a 25% variation
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of the diameter of a sphere-shaped cell corresponds to a
2-fold change in cell volume. In tissues, not only are cell sizes
variable, but visual counting of cells is also problematic. For
instance, up to 5-fold differences in calculated cell volumes
have been reported for enterocytes of the intestinal mucosa
(15).
Any deviations in protein determination or cell counts will
inevitably carry over to the final readout, even when very
precise MS methods are used. This limits the overall accu-
racy, without showing up as a decrease in the precision of the
quantification, as measured by standard deviations or coeffi-
cients of variation.
In the course of studying the colon cancer proteome, we
recently devised a method for estimating absolute amounts of
individual proteins or protein classes based on the proportion
of their MS signals to the total MS signal (16). We termed the
method the Total Protein Approach, because we relate this
proportion to a total protein mass. To obtain copy numbers,
we specifically used the total protein mass per cell, which
needs to be determined or estimated separately.
In this study, we expanded the method by a concept we call
the “proteomic ruler” to further allow correct absolute scaling
of the readout without additional steps. We made use of the
defined amount of genetic information in each cell, encoded in
a known amount of DNA. We show that an accurate determi-
nation of the DNA content in a proteomic sample helps to
directly determine the number of cells. We then demonstrate
that the MS signal derived from histones, around which DNA
is wrapped in a defined ratio, can be used as a natural
standard in a whole proteome dataset. It serves as a pro-
teomic ruler that allows the estimation of total protein
amounts per cell. Thereby the quantitative readout can be
absolutely scaled to copies per cell without the need for cell
counting or protein concentration determination.
EXPERIMENTAL PROCEDURES
Plasma Lysate—The author’s blood was capillary-collected via skin
puncture of the middle finger. It was immediately supplemented with
0.05 M EDTA and centrifuged at 5000  g for 1 min to separate blood
cells from plasma. Plasma was diluted 10-fold with lysis buffer con-
taining 0.1 M Tris-HCl, pH 8.0, 0.1 M DTT, and 2% SDS, and the
mixture was incubated at 70 °C for 5 min.
Whole Cell and Tissue Lysates—U87-MG, A549, PC-3, and
Hep-G2 cells were grown in DMEM supplemented with 10% FBS and
1% streptomycin. The cells were harvested at 70% confluence
and dissolved in lysis buffer at 100 °C for 5 min. After being chilled to
room temperature, the lysates were briefly sonicated to reduce the
viscosity of the sample. Frozen mouse tissues (Pel-Freez, Rogers, AR)
were homogenized with T10 basics Ultra-Turrax dispenser in the lysis
buffer at a tissue-to-buffer ratio of 1:10. The homogenates were
incubated at 100 °C for 5 min. Finally, the cell and tissue lysates were
clarified by centrifugation at 16,000  g for 10 min.
Protein Determination—Protein content was determined using a
Cary Eclipse Fluorescence Spectrometer (Varian, Palo Alto, CA) as
described previously (17). Briefly, aliquots of 1 to 3 l of whole cell
lysates were mixed with 2 ml of 8 M urea in 10 mM Tris-HCl, pH 8.5.
The fluorescence was measured at 295 nm for excitation and 350 nm
for emission. The slits were set to 5 nm and 20 nm for excitation and
emission, respectively. Tryptophan was used as a standard. The
protein content was calculated from the following relationship: the
fluorescence of 0.1 g of tryptophan equals 9 g of total protein,
which reflects an average 1.1% weight content of tryptophan in whole
lysates of human cells.
Cell Counting—Tissue cultures were trypsinized at 37 °C for 2 min,
and the released cells were washed with PBS and collected at 1000 
g for 1 min. Then the pellets were suspended in PBS and the cells
were stained with 0.2% Trypan Blue (Invitrogen). Cell counting was
carried out on an automated cell counter (Countess, Invitrogen).
FASP-based Protein Processing—Aliquots of lysates containing
100 g of total protein were processed according to the multi-enzyme
digestion FASP protocol (18). Briefly, protein lysates were depleted
from the detergent using 8 M urea in 0.1 M Tris/HCl, pH 8.5, thiols were
alkylated with iodoacetamide, and proteins were consecutively di-
gested with endoproteinase LysC and trypsin. Digests of plasma
fractions were fractionated using a pipette tip strong anion exchange
method into four and two fractions as described previously (19).
FASP-based Cleavage and Determination of RNA and DNA—After
collection of the peptides released by trypsin, the material remaining
in the filter was washed once with TE buffer (10 mM Tris-HCl, pH 8.0)
and then was digested with 0.5 l (0.5 U) of RiboShredder (Epicenter,
Madison, WI) in 60 l of TE buffer at 37 °C for 1 h to digest RNA. The
released ribonucleotides were collected via centrifugation at
14,000  g. Next the material on filters was washed twice with 80 l
of TE buffer, and then it was cleaved with 6 g of DNAse (DN25,
Sigma, St. Louis, MO) in 60 l of 10 mM Tris-HCl, pH 7.8, containing
2.5 mM MgCl2 and 0.5 mM CaCl2 at 37 °C for 1 h. The obtained
deoxynucleotides were collected via centrifugation. The RNA and
DNA contents were determined by means of UV spectrometry using
extinction coefficients of 0.025 and 0.030 (g/ml)1cm1 at 260 nm,
respectively. The ratio of the spectral densities at 260 nm to 280 nm
was 2, indicating an absence of protein contamination that could
contribute to A260 measurement.
LC-MS/MS and Data Analysis—Peptides were quantified by tryp-
tophan fluorescence as described above, with the exception that the
measurements were performed directly in 0.2 ml of 0.05 M Tris/HCl,
pH 8.5, in 5 mm  5 mm quartz cells. 4-g aliquots of total peptide
were loaded onto C18 reverse phase columns (20 cm long, 75 m
inner diameter, in-house packed with ReproSil-Pur C18-AQ 1.8-m
resin (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany)) with
buffer A (0.5% acetic acid). Peptides were eluted with a linear gradi-
ent of 5% to 30% buffer B (80% acetonitrile and 0.5% acetic acid) at
a flow rate of 250 nl/min over 195 min. This was followed by 10 min
from 30% to 60% buffer B, a washout of 95% buffer B, and re-
equilibration with buffer A. Peptides were electrosprayed and ana-
lyzed on Q Exactive mass spectrometers using a data-dependent
top-10 method with higher energy collisional dissociation fragmenta-
tion. Mouse organ samples were loaded onto a 15-cm reverse-phase
column packed with 3-m resin, separated over 320 min of gradient
time, and analyzed on an LTQ Orbitrap mass spectrometer using
collision-induced dissociation fragmentation. MS data were analyzed
using the MaxQuant software environment (20), version 1.3.10.18,
and its built-in Andromeda search engine (21). Proteins were identi-
fied by searching MS and MS/MS data against the human and mouse
complete proteome sequences from UniProtKB (May 2013 version
containing 88,820 and 50,807 sequences, respectively). Carbami-
domethylation of cysteines was set as a fixed modification. N-terminal
acetylation and oxidation of methionines were set as variable modi-
fications. Up to two missed cleavages were allowed. The initial al-
lowed mass deviation of the precursor ion was up to 6 ppm, and for
the fragment masses it was up to 20 ppm (higher energy collisional
dissociation, Orbitrap readout) and 0.5 Da (collision-induced dissoci-
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ation, ion trap readout). The mass accuracy of the precursor ions was
improved by time-dependent recalibration algorithms of MaxQuant.
The “match between runs” option was enabled to match identifica-
tions across samples within a time window of 30 s of the aligned
retention times. The maximum false peptide and protein discovery
rates were set to 0.01. Protein matching to the reverse database and
proteins identified only with modified peptides were filtered out. Pro-
tein abundances and copy numbers were calculated on the basis of
summed peptide intensities of unique and “razor” peptides as re-
ported by MaxQuant using the Perseus plugin described in this study.
Finally, we removed all protein groups with fewer than two unique
peptides (with the exception of two isoforms of creatine kinase in our
plasma analysis), as they were less likely to yield highly accurate copy
numbers.
Software Availability—The proteomic ruler Perseus plugin is avail-
able as a source code and as compiled binary from the Perseus
website.
RESULTS
The Total Protein Approach Gives Accurate Estimates of
Protein Concentrations—Using our Total Protein Approach,
we previously demonstrated that a protein’s abundance
within the cell as a fraction of the total protein is reflected by
the proportion of its MS signal to the total MS signal (16).
Protein mass
Total protein mass

Protein MS signal
Total MS signal
(Eq. 1)
This proportion can easily be extracted from any MS-based
proteomics measurement, and its accuracy will improve with
the depth of measurement. The value has to be scaled by a
total protein mass, which can conceptually be the entire pro-
tein amount of a cell, the protein amount in a given volume of
body fluid, or even a fixed unit such as 1 g. In that way we
obtain the absolute amount of the protein or protein class per
cell, per unit of volume, or per 1 g of total protein. To show
that this principle is universally applicable, beyond the cell line
and cancer tissue cases that we investigated before (16), we
used it to estimate the concentrations of different diagnosti-
cally relevant proteins or protein classes in blood plasma after
digesting plasma proteins using the FASP method (18). The
total protein concentration in plasma varies around a typical
value of 70 g/l within a narrow margin (22), so we scaled the
MS readout by a total amount of 70 g to obtain grams per liter.
We were able to quantify proteins within their expected phys-
iological ranges over at least 5 orders of magnitude (Fig. 1,
supplemental Table S1).
Nucleic Acid Quantification and Cell Counting via FASP-
based Sample Preparation—In the case of a body fluid such
as plasma, the total protein concentration is a readily acces-
sible scaling parameter, and protein concentrations are
meaningful and relevant. In the case of a cellular proteome,
however, many applications require quantities of copies per
cell, which necessitates cell counting. We wondered whether
cell counting could be replaced by accurate DNA quantifica-
tion when the genome size and ploidy were known. DNA
concentration was shown to be proportional to the cell count
and was successfully used to normalize enzyme activities,
transcript and protein amounts, and metabolome data (23–
25). We hypothesized that DNA quantities could be measured
directly from the proteomic sample, provided that the chro-
matin fraction was retained during sample preparation. In
contrast to in-solution or in-gel approaches, the FASP method
is reactor based (26) and allows sequential processing of the
sample and separation of reaction products. Detergents are
washed out at the beginning of the FASP procedure, and RNA
and DNA, the major components remaining after protease
digestion, can be cleanly released from the filter via RNase or
DNase digestion (Fig. 2A). To test the feasibility of nucleic acid
determination in the FASP format after digestion of proteins
and elution of peptides, we consecutively digested the mate-
rial retained on the filter with RNase and DNase. After each
cleavage we collected the digestion products and determined
their content based on UV absorbance at 260 nm. We ob-
served a linear correlation between the amount of the eluted
nucleotides and the amount of the sample. In parallel, we
processed samples supplemented with defined amounts of
purified calf thymus RNA and DNA. Yields were greater than
95% and were independent of the protein content (Fig. 2B),
indicating that post-FASP digestion of a sample with DNase
and RNase is a suitable method for determination of the RNA
and DNA content in a proteomic sample that does not require
additional preparative steps.
Next, we processed aliquots of total lysates prepared from
counted numbers of four different human cell lines using
two-step LysC/trypsin digestion of the proteins (multi-enzyme
digestion FASP) (27). Both the starting protein amounts and
the generated peptides were quantified. We then quantified
the ribonucleotides and deoxyribonucleotides eluted after
RNase and DNase treatment, respectively. The tryptic and
LysC peptides obtained in the multi-enzyme digestion FASP-
processed cell lysates (above) were analyzed in 4-h LC-
10−5 10−4 10−3 10−2 0.1 1 10 100
Creatine kinase
C−reactive protein
Sex hormone−binding globulin
Thyroxine−binding globulin
Ceruloplasmin
Antitrypsin
Fibrinogen
Transferrin
Albumin
g/l
FIG. 1. Analysis of protein abundances in human plasma using
the Total Protein Approach. Whole plasma was processed using the
multi-enzyme digestion FASP approach with strong anion exchange
peptide fractionation before LC-MS/MS analysis as described in “Ex-
perimental Procedures.” Quantifications of selected target proteins
are indicated as black dots; the reference values (red bars) are from
Refs. 22 and 41. Two isoforms of creatine kinase were identified with
one peptide each, for which we provide annotated MS/MS spectra in
supplemental Fig. S1.
Absolute Protein Quantification without Spike-in References
Molecular & Cellular Proteomics 13.12 3499
59
●
3 Technologies for large-scale relative and absolute protein quantification
MS/MS runs. In triplicate analyses, MaxQuant identified about
7000 proteins in each of the cell lines (supplemental Table S1).
The human genome contains around 3.2  109 base pairs
(28). Multiplying this number by the average mass of a base
pair (615.9 Da) and by the ploidy of the respective cell type
yields an expected amount of cellular DNA. We used a value
of 6.5 pg for a diploid human cell to calculate cell numbers.
Dividing the total amount of protein input by these cell num-
bers, we obtained a protein mass per cell that was very similar
to that obtained by dividing the total protein input amount by
the counted cell numbers (supplemental Table S2).
Histones Serve as a “Proteomic Ruler” for Absolute Scaling
of Proteomic Data—In eukaryotic cells, DNA is packaged in
chromatin by histones, and the mass of the DNA is about
equal to the combined mass of histones (29). We therefore
wondered whether the summed intensity of histones in a
deep, eukaryotic proteome could serve as a proxy for the
amount of DNA and therefore for the cell number. There are
five major histone types, which are expressed in many iso-
forms and variants that are relevant for many aspects of
chromatin biology. For our approach, however, we employed
the summed MS signal of all histone-derived peptides, irre-
spective of which histone they mapped to or how they were
assembled in protein groups. This value reflects the cumula-
tive histone mass. In this way, we used the MS signal of an
entire class of proteins as a proteomic ruler and related it to a
quantity that is not directly amenable to mass spectrometry.
Our hypothesis of the histone proteomic ruler predicts the
following relationship (Fig. 3A):
Histone mass
total protein mass

Histone MS signal
Total MS signal

Cellular DNA mass
Cellular protein mass
(Eq. 2)
In our four-cell-line dataset, the histone MS signal
amounted to 2.07% to 4.03% of the total MS signal. Equating
this fraction with 6.5 pg as the DNA mass of diploid human
cells, we obtained cellular protein masses within a factor of
1.24  0.29 compared with the value obtained via cell count-
ing (Fig. 3B; supplemental Table S2). This is close to the
hypothesized value of 1 and implies that the ratio of histone
MS signal to total MS signal allows the estimation of the total
cellular protein mass without any additional measurements.
The error of the histone MS signal fraction depends on how
accurately the histone MS signal and the total MS signal can
be determined. For histones, a large number of various post-
translational modifications (PTMs) have been identified, lysine
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FIG. 2. A, the proteomic workflow. Cells were counted and lysed in a buffer containing SDS. Protein concentrations in the whole lysates were
determined, and 100-g aliquots of the whole lysates were successively processed in the proteomic reactor (FASP) format. After detergent
removal, proteins were consecutively cleaved with endoproteinase LysC and trypsin. The released LysC and tryptic peptides were subjected
to proteomic analysis. Next, RNA and DNA were digested, and the released ribo- and deoxyribonucleotides were spectrophotometrically
quantified at 260 nm. Protein contents per single cell were calculated from the cell numbers and the protein concentrations. Alternatively,
values of protein mass of single cells were obtained from DNA contents and the protein concentrations. B, determination of the efficiency and
yield of RNase and DNase cleavages. Aliquots of mouse liver lysates were processed with the FASP method, and the residual high-molecular-
weight material was sequentially cleaved with RNase and DNase (labeled “samples digested with DNase and RNase”). The released ribo- and
deoxyribonucleotides were quantified spectrophotometrically at 260 nm. To demonstrate the completeness of digestion over the analyzed
range, samples were supplemented with constant amounts of 2 g of purified DNA or RNA prior to sample processing (labeled “samples 
2 g RNA/DNA digested with DNase/RNase”). To demonstrate the specificity of the initial RNase digestion, samples were supplemented with
DNA and digested with RNase (labeled “samples  2 g DNA digested with RNase”).
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acetylation, serine and threonine phosphorylation, and lysine
methylation being the most frequent. In most standard pro-
teomics workflows, these modifications are not routinely in-
cluded in the database search, and we were wondering
whether this affects the ratio of histone MS signal to total MS
signal, which is critical for our scaling approach. To address
this question, we searched the data again with combinations
of acetylation, phosphorylation, and methylation set as vari-
able modifications. Although individual histones had changes
in their relative abundances, in particular histone H3 (Figs.
4A–4C), the fraction of the cumulative histone to total MS
signal changed only by 5% to 10% (Fig. 4D). This indicates
that, with the exception of histone H3, the fraction of the MS
signal derived from histone peptides that have PTMs is low
and can be neglected in the overall data scaling process.
The accuracy of the total MS signal depends on the depth
of the proteomic analysis. To estimate the required depth for
a robust readout, we ranked all peptides by intensity and
calculated the histone-MS fraction as a function of the num-
ber of identified peptides (Fig. 4E). Because peptide intensi-
ties span many orders of magnitude, the most intense pep-
tides contribute a large part of the total intensity. Within the
first few thousand peptides, the histone fraction is overesti-
mated because histones contribute some of the most intense
peptides. From a depth of around 12,000 or more peptides,
however, the histone fraction stabilizes within tight margins.
This depth of analysis is easily attainable with minimal sample
fractionation and also with single run analyses on latest-
generation machines (30).
For each protein in the measured proteome, we can now
estimate its mass per cell solely from its MS signal as the
product of its MS signal fraction and the cellular protein mass.
This value easily converts to copies per cell.
Protein copies per cell

Protein MS signal
total MS signal

NA
M
 cellular protein mass
(Eq. 3)
 protein MS signal 
NA
M

DNA mass
Histone MS signal
where NA is Avogadro’s constant and M is the molar mass of
the protein.
Ribosomal Proteins as a Proteomic Ruler for Cellular RNA—
Next, we investigated whether the proteomic ruler concept is
also applicable to cellular RNA. Ribosomal RNA typically rep-
resents about 80% of total RNA (31), and in eukaryotic ribo-
somes there is a ratio of about 1:1 between RNA and protein
(32). The summed MS signal for all ribosomal proteins
amounted to values between 3.61% and 5.27% of the total
MS signal across the cell lines. We compared this result by
the biochemical quantification of the total RNA content using
the FASP method in relation to the total protein input (sup-
plemental Table S2). Our results were within a factor of 1.01 
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FIG. 3. Estimation of protein mass
per cell using two biochemical ap-
proaches and the proteomic ruler
method. A, the histone proteomic ruler
concept. The mass of cellular DNA is
approximately equal to the protein mass
of histones. Relating the histone MS sig-
nal to the total MS signal therefore al-
lows one to estimate the protein mass
per cells at a given cell ploidy and ge-
nome size. This method requires neither
cell counting nor the determination of
protein concentration. B, C, comparison
of the values of total protein per cell
obtained based on cell counting, DNA
determination, and the histone pro-
teomic ruler method. D, cell sizes ob-
tained from retrospective analysis of
published proteome datasets of CD4 or
CD8a positive or double negative (DN)
dendritic cell subtypes and plasmacy-
toid dendritic cells (pDCs) (36). All values
represent the mean of two (cell counting)
or three replicates (DNA and histone pro-
teomic ruler quantifications)  S.D.
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0.13 of the biochemical measurements, indicating that the MS
signal of ribosomal proteins can indeed be used as a pro-
teomic ruler to estimate cellular RNA amounts.
Histone Proteomic Ruler Provides Estimates of Cell Sizes in
Tissues—Counting cells in tissue samples is not trivial. How-
ever, determining the DNA and RNA content using our pro-
teomic reactor format is equally straightforward as for cell
lines. We prepared lysates from mouse brain, liver, and thy-
mus; measured protein, RNA, and DNA contents; and per-
formed proteomic analysis. There was excellent agreement
between the total cellular protein mass values derived from
the DNA-based method and our histone proteomic ruler ap-
proach (Fig. 3C; supplemental Table S3). This demonstrates
that the histone proteomic ruler serves as a good proxy for
estimating cellular protein masses in tissues.
The total cellular protein concentration typically lies within a
range of 20% to 30% (w/v) (i.e. 200 to 300 g/l) in many cell
types and organisms (33). This constraint can be used to
convert between cellular protein mass and cell volume. Hepa-
tocytes, the predominant cell type in liver, are roughly cubical
cells with a 15-m edge length (34). Assuming a total protein
concentration of 200 g/l, this translates to 675 pg of protein
per cell. This compares to our estimate of 464  35 pg total
protein per average liver cell, which is reasonable given that
non-hepatocytes contribute the same amount of DNA or his-
tones but less overall protein mass. Thymocytes are at the
other end of the size scale with an average volume of 250 m3
(35). This translates to 50 pg of protein, as compared with our
estimate of 59  31 pg.
To test the applicability of the histone proteomic ruler to the
retrospect analysis of existing datasets, we reevaluated whole-
proteome measurements of murine dendritic cell populations
published by our group in 2010 (36). Samples had been pre-
pared via one-dimensional SDS gel electrophoresis followed by
in-gel digestion, an approach distinct from our FASP-based
method and incompatible with direct DNA quantification from
the proteomic sample. Mature dendritic cells have diameters
between 10 and 15 m (37). We compared these cell sizes to
our proteomic ruler estimates that ranged between 64  14 and
95  25 pg total protein per cell for the different dendritic cell
subtypes (Fig. 3D). These values translated to diameters of 8.5
to 9.7 m for spherical cell shapes, which is expected to be
slightly smaller than observed cell sizes, given the numerous
dendrites projecting from the cell surfaces. Interestingly, our
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FIG. 4. The contribution of PTMs to the estimated total protein content of histones. Comparison of the fractions of the MS signals of
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observed similarities in cell sizes correlate with overall patterns
of proteomic similarity on the level of individual proteins that
were observed in the original study (36).
Label-free Copy Number Estimations Are Strikingly Close to
Precise Spike-in Quantifications—We previously employed
spiked-in protein epitope signature tags (PrESTs) of known
quantities in combination with isotopic labeling, cell counting,
and total protein concentration determination to obtain highly
reliable copy number values of selected proteins (11). To
assess the accuracy of our proteomic-ruler-derived protein
copy numbers, we reanalyzed the same dataset used in the
original PrEST-SILAC study and applied our calculations on
the “heavy” labeled proteome without considering the ratio
information from the “light” PrEST peptides. We recapitulated
not only the correct scaling of the total protein mass, but also
the copy numbers of the individual PrEST-quantified proteins
within an average deviation of 1.5-fold (Fig. 5A; supplemental
Table S4) and comparable precisions judged by the standard
deviations from three replicates. We attribute the surprisingly
good performance of the proteomic ruler quantifications to
the fact that our label-free quantification on average made use
of 19.4 peptides along the entire length of the proteins,
whereas the PrEST-SILAC quantification used 4.7 peptides
on average. This might compensate for some of the principal
limitations of the label-free approach. Looking at the devia-
tions of individual quantifications, we saw that the minority of
larger deviations occurred exclusively with PrEST-SILAC
quantifications based on two or fewer peptides or label-free
quantifications based on 11 or fewer peptides (Fig. 5B). This
observation underlines the benefits of approaches that rely on
multiple independent quantifications instead of single peptide
ratios, as commonly used, for example, with AQUA peptides.
We conclude that for those proteins quantified with more than
a few peptides, the proteomic ruler approach could offer a
surprisingly high level of accuracy, making it an attractive
alternative to label-based methods.
In addition to the comparison with spike-in quantification
data, macromolecular complexes offer another option for val-
idating protein copy numbers. Many obligate protein com-
plexes are well characterized in terms of their composition
and stoichiometry with subunits expressed at equimolar lev-
els. Fig. 5C shows that our histone proteomic-ruler-derived
copy numbers of members of the pyruvate dehydrogenase
complex and the TRiC chaperone closely match the expected
1:1 stoichiometry among subunits.
The Muscle Proteome Is Quantitatively Dominated by Large,
Abundant Proteins—As a practical example of the usefulness
of “easy” absolute protein quantification, we determined cell
sizes and cellular copy numbers of proteins in a panel of other
mouse organs (Fig. 6A). Ovaries consist predominantly of
small follicular cells and showed the least protein per cell (42
pg). Leg muscle cells, in contrast, had around 675 pg of
protein per nucleus. Considering that muscle fibers are syn-
cytial, multi-nucleated cells, the histone proteomic ruler de-
livered protein amounts per nucleus and not per cell in this
particular case. Despite the huge differences in cellular pro-
tein amounts, we observed much less variation in the depend-
ence of the abundance of a protein and its molecular mass,
irrespective of the tissue of origin. This is reflected in the
average molecular mass of a protein, which is calculated as
the ratio of the total protein mass per cell to the total number
of protein molecules (Fig. 6B). This number is rather similar
across tissues, with the notable exception of muscle tissues.
The reason for this becomes apparent when we look at the
distribution of protein sizes across the dynamic range of
the individual proteins (Figs. 6C and 6D). Independent of the
tissue of origin, low-abundant proteins had an average mo-
lecular mass of around 100 kDa, and this value decreased
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with increasing cellular abundance of the proteins to around
40 kDa for the most abundant proteins. This dependence was
observed in earlier studies and is thought to reflect the evo-
lutionary advantage of decreasing the size of abundant pro-
teins for reasons of biosynthetic cost (38). As a consequence
of this trend, the average molecular mass of a protein in a cell
is much smaller than the nominal average of the sizes of all
proteins when their abundances are not taken into account.
Notably, in skeletal muscle cells, filaments and motorproteins
such as titin and myosins are notable exceptions to the trend
of abundant proteins being smaller, as they are both large
(150 kDa) and very abundant (1 million copies per cell) in
this tissue, resulting in a profound increase in the average
molecular protein mass in a muscle cell (Fig. 6C, circles).
Plugin for the Perseus Data Analysis Software for Calcula-
tion of Absolute Protein Abundances—The calculation of the
protein abundances is a simple arithmetic task and can be
performed using commonly available table calculation tools.
To make the proteomic ruler approach easily usable for a wide
community, we have implemented it as a plugin for the Per-
seus data analysis software. Perseus is part of the freely
available MaxQuant suite (20). The proteomic ruler plugin
supports all modes of label-free absolute quantification de-
scribed in this study and takes user-configurable variables
such as the ploidy and the total protein concentration. Op-
tionally, it can incorporate an additional level of protein-spe-
cific correction: our copy number calculation assumes a direct
proportionality between a protein’s cumulative mass in the
proteomic sample and the MS signals summed over all pep-
tides derived from it (see Eq. 3). Hence the protein’s molar
mass serves as a protein-specific normalization factor for
copy number estimation. Because the combination of the
sequence of a protein, the specificity of the protease used for
digestion, and the characteristics of the mass spectrometric
analysis can introduce protein-specific biases (39), our plugin
allows the user to employ alternative normalization factors,
such as the number of theoretically expected peptides that is
used by some methods (9, 40).
In addition, we have implemented auxiliary functionalities.
For instance, molecular weights and numbers of theoretical
peptides can be calculated from protein I.D.s in combination
with the FASTA database. Moreover, the plugin allows the
categorization of proteins according to the expected accu-
racy of absolute quantification: proteins having a high fraction
of theoretical peptides per sequence length and a high num-
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ber of actually identified peptides, most of which are group-
unique, are expected to yield better quantification.
DISCUSSION
In this paper, we propose that accurate absolute quantifi-
cation is possible without the use of spike-in standards
through the use of a concept we call the “proteomic ruler.”
Using the MS signal derived from histones and relating it to
a known amount of DNA per cell provides accurate esti-
mates of the total protein amount per cell that can be used
as scaling factors for calculating cellular copy numbers of
any protein of interest. We note that our approach makes a
number of assumptions that allow us to omit any spike-in
standards. At the same time, it eliminates several experi-
mental steps such as cell counting and absolute protein
concentration determination, which are themselves prone to
errors, in particular stemming from issues with protein de-
termination assays.
We found the quantitative results of our proteomic ruler
approach to be typically within a factor of 2 of precision
measurements or literature values. Importantly, this informa-
tion comes for free, in that it incorporates absolute quantifi-
cation into any kind of in-depth proteome dataset, even in
retrospective analysis. The only prerequisite is a eukaryotic,
whole-cell proteome dataset where the chromatin fraction is
not over- or underrepresented as a result of sample handling.
The latter is a specific requirement for an accurate estimation
of the total protein mass per cell, but all whole proteome
datasets should aim at an unbiased representation of all pro-
tein classes. A reasonable depth of proteomic analysis is
needed to ensure a robust contribution of the histone MS
signal, but the necessary depth should be readily attainable
with many experimental setups. We expect that in the future,
more and more proteomics projects will reach the required
depth of proteome coverage and will be able to incorporate
absolute quantification via the histone proteomic ruler. Addi-
tionally, individual protein copy numbers will become more
accurate with increased peptide coverage in deep datasets.
Furthermore, we envision a generalization of the proteomic
ruler concept beyond using the histone signal to estimate
cellular protein amounts. For instance, using characteristic
protein classes such as membrane or mitochondrial proteins,
it should be possible to infer insights into subcellular archi-
tecture solely from proteomics datasets.
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A crucial part on the way to a high-quality human interactome dataset was the devel-
opment of the strategies to record and extract protein interactions from quantitative MS
datasets. NinaHubner hat largely established the ‘wet lab’ part of theQUBIC interactom-
ics pipeline by the time I joined the project. An issue I addressed was to streamline the
mode in which we carried out biological triplicate experiments in a format that controls
for batch effects, biological variability and performance drifts. The solution was to har-
vest cell pellets for replicates from in several subsequent passages, to perform pulldowns
in batches that contained only one replicate of each cell line, and finally to measure MS
samples in randomized order to avoid artifacts introduced by column carryover or drifts
in machine performance. This setup was largely adopted in the group for the growing
number of projects where is it not practicable to carry out all experiments in parallel.
The interactomics data analysis pipeline required a substantial makeover from the low
throughputmodedescribed in the originalQUBICpublications [30, 60]. The low through-
put mode involved a dedicated negative control in the form of triplicate pulldowns from
the untagged, parental cell line and statistical testing would always be carried out against
this control. In addition, finding interactors required the manual definition of a statist-
ical cut-off specific to each bait protein. Some of the key innovations in this regard were
incorporated into a joint publication with Eva Keilhauer on interactomics in yeast.
4.1 Accurate protein complex retrieval by affinity enrichment MS
Keilhauer, E. C., Hein, M. Y. & Mann, M. Accurate Protein Complex Retrieval by Af-
finity Enrichment Mass Spectrometry (AE-MS) Rather than Affinity Purification Mass
Spectrometry (AP-MS)Mol Cell Proteomicsmcp.M114.041012 (2014)
When Eva Keilhauer joined the group in 2011, the startup project on which we worked
together was to transfer the ideas developed for QUBIC in the mammalian system to
budding yeast, the organism that served as the model system for many large-scale, non-
quantitative interactomics studies in the past [18, 22–24]. A library of strains express-
ing GFP-tagged proteins was available from earlier work in theWeissman laboratory on
protein localization [83]. Therefore, most wet lab protocols could be re-used. New de-
velopments involved an efficient cell lysis protocol and the generation of a control strain
that could be cultured under the same conditions as the non-histidine auxotroph GFP
strains. Eva recorded interactomics data for a number of known protein complexes for
benchmark purposes.
One early finding was that in a typical yeast pulldown sample we identified around 2,000
proteins, which equals half of the expressed proteome. Therefore, we reasoned that the
idea of ‘affinity purification’ has to be re-defined as ‘affinity enrichment’. Moreover this
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emphasized a shift in the role of background binders from a nuisance to an essential part
of the analysis pipeline, as they serve as a means of quality control and as a reference for
normalization. The dataset was of sufficient size to apply strategies I developed for my
human datasets: the use of a reference cohort instead of a dedicated negative control for
statistical testing, superseding the need for the control strain. In addition, once the data-
set becomes sufficiently large, protein profiles across samples start carrying meaningful
information. Profiles of interacting proteins tend to show good correlation; therefore
the correlation coefficient of a candidate interactor to the bait protein serves as an ad-
ditional parameter next to the enrichment factor to de-noise the interaction data in the
borderline area of statistical significance. Eva implemented and tested these strategies
systematically on her datasets.
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Accurate Protein Complex Retrieval by Affinity
Enrichment Mass Spectrometry (AE-MS)
Rather than Affinity Purification Mass
Spectrometry (AP-MS)*□S
Eva C. Keilhauer‡, Marco Y. Hein‡, and Matthias Mann‡§
Protein–protein interactions are fundamental to the under-
standing of biological processes. Affinity purification cou-
pled to mass spectrometry (AP-MS) is one of the most
promising methods for their investigation. Previously, com-
plexes were purified as much as possible, frequently fol-
lowed by identification of individual gel bands. However,
todays mass spectrometers are highly sensitive, and pow-
erful quantitative proteomics strategies are available to dis-
tinguish true interactors from background binders. Here we
describe a high performance affinity enrichment-mass
spectrometry method for investigating protein–protein in-
teractions, in which no attempt at purifying complexes to
homogeneity is made. Instead, we developed analysis
methods that take advantage of specific enrichment of in-
teractors in the context of a large amount of unspecific
background binders. We perform single-step affinity enrich-
ment of endogenously expressed GFP-tagged proteins and
their interactors in budding yeast, followed by single-run,
intensity-based label-free quantitative LC-MS/MS analysis.
Each pull-down contains around 2000 background binders,
which are reinterpreted from troubling contaminants to cru-
cial elements in a novel data analysis strategy. First the
background serves for accurate normalization. Second, in-
teracting proteins are not identified by comparison to a
single untagged control strain, but instead to the other
tagged strains. Third, potential interactors are further vali-
dated by their intensity profiles across all samples. We
demonstrate the power of our AE-MS method using several
well-known and challenging yeast complexes of various
abundances. AE-MS is not only highly efficient and robust,
but also cost effective, broadly applicable, and can be
performed in any laboratory with access to high-resolution
mass spectrometers. Molecular & Cellular Proteomics
14: 10.1074/mcp.M114.041012, 1–16, 2015.
Protein–protein interactions are key to protein-mediated
biological processes and influence all aspects of life. There-
fore, considerable efforts have been dedicated to the map-
ping of protein–protein interactions. A classical experimental
approach consists of co-immunoprecipitation of protein com-
plexes combined with SDS-PAGE followed by Western blot-
ting to identify complex members. More recently, high-
throughput techniques have been introduced; among these
affinity purification-mass spectrometry (AP-MS)1 (1–3) and the
yeast two-hybrid (Y2H) approach (4–6) are the most promi-
nent. AP-MS, in particular, has great potential for detecting
functional interactions under near-physiological conditions,
and has already been employed for interactome mapping in
several organisms (7–15). Various AP-MS approaches have
evolved over time, that differ in expression, tagging, and
affinity purification of the bait protein; fractionation, LC-MS
measurement, and quantification of the sample; and in data
analysis. Recent progress in the AP-MS field has been driven
by two factors: A new generation of mass spectrometers (16)
providing higher sequencing speed, sensitivity, and mass ac-
curacy, and the development of quantitative MS strategies.
In the early days of AP-MS, tagged bait proteins were
mostly overexpressed, enhancing their recovery in the pull-
down. However, overexpression comes at the cost of obscur-
ing the true situation in the cell, potentially leading to the
detection of false interactions (17). Today, increased MS in-
strument power helps in the detection of bait proteins and
interactors expressed at endogenous levels, augmenting the
chances to detect functional interactions. In some simple
organisms like yeast, genes of interest can directly be tagged
in their genetic loci and expressed under their native pro-
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moter. In higher organisms, tagging proteins in their endoge-
nous locus is more challenging, but also for mammalian cells,
methods for close to endogenous expression are available.
For instance, in controlled inducible expression systems, the
concentration of the tagged bait protein can be titrated to
close to endogenous levels (18). A very powerful approach is
BAC transgenomics (19), as used in our QUBIC protocol (20),
where a bacterial artificial chromosome (BAC) containing a
tagged version of the gene of interest including all regulatory
sequences and the natural promoter is stably transfected into
a host cell line.
The affinity purification step has also been subject to sub-
stantial changes over time. Previously, AP has been com-
bined with nonquantitative MS as the readout, meaning all
proteins identified by MS were considered potential interac-
tors. Therefore, to reduce co-purifying “contaminants,” strin-
gent two-step AP protocols using dual affinity tags like the
TAP-tag (21) had to be employed. However, such stringent
and multistep protocols can result in the loss of weak or
transient interactors (3), whereas laborious and partially sub-
jective filtering still has to be applied to clean up the list of
identified proteins. The introduction of quantitative mass
spectrometry (22–25) to the interactomics field about ten
years ago was a paradigm shift, as it offered a proper way of
dealing with unspecific binding and true interactors could be
directly distinguished from background binders (26, 27). Im-
portantly, quantification enables the detection of true interac-
tors even under low-stringent conditions (28). In turn, this
allowed the return to single-step AP protocols, which are
milder and faster, and hence more suitable for detecting weak
and transient interactors.
Despite these advances, nonquantitative methods—often
in combination with the TAP-tagging approach—are still pop-
ular and widely used, presumably because of reagent ex-
penses and labeling protocols used in label-based ap-
proaches. However, there are ways to determine relative
protein abundances in a label-free format. A simple, semi-
quantitative label-free way to estimate protein abundance is
spectral counting (29). Another relative label-free quantifica-
tion strategy is based on peptide intensities (30). In recent
years high resolution MS has become much more widely
accessible and there has been great progress in intensity-
based label-free quantification (LFQ) approaches. Together
with development of sophisticated LFQ algorithms, this has
boosted obtainable accuracy. Intensity-based LFQ now offers
a viable and cost-effective alternative to label-based methods
in most applications (31). The potential of intensity-based LFQ
approaches as tools for investigating protein–protein interac-
tions has already been demonstrated by us (20, 32, 33) and
others (34, 35). We have further refined intensity-based LFQ in
the context of the MaxQuant framework (36) using sophisti-
cated normalization algorithms, achieving excellent accuracy
and robustness of the measured “MaxLFQ” intensities (37).
Another important advance in AP-MS, again enabled by
increased MS instrument power, was the development of
single-shot LC-MS methods with comprehensive coverage.
Instead of extensive fractionation, which was previously
needed to reduce sample complexity, nowadays even entire
model proteomes can be measured in single LC-MS runs (38).
The protein mixture resulting from pull-downs is naturally of
lower complexity compared with the entire proteome. There-
fore, modern MS obviates the need for gel-based (or other)
fractionation and samples can be analyzed in single runs.
Apart from avoiding selection of gel bands by visual exami-
nation, this has many advantages, including decreased sam-
ple preparation and measurement time, increased sensitivity,
and higher quantitative accuracy in a label-free format.
In this work, we build on many of the recent advances in the
field to establish a state of the art LFQ AE-MS method. Based
on our previous QUBIC pipeline (20), we developed an ap-
proach for investigating protein–protein interactions, which
we exemplify in Saccharomyces cerevisiae. We extended the
data analysis pipeline to extract the wealth of information
contained in the LFQ data, by establishing a novel concept
that specifically makes use of the signature of background
binders instead of eliminating them from the data set. The
large amount of unspecific binders detected in our experi-
ments rendered the use of a classic untagged control strain
unnecessary and enabled comparing to a control group con-
sisting of many unrelated pull-downs instead. Our protocol is
generic, practical, and fast, uses low input amounts, and
identifies interactors with high confidence. We propose that
single-step pull-down experiments, especially when coupled
to high-sensitivity MS, should now be regarded as affinity
enrichment rather than affinity purification methods.
EXPERIMENTAL PROCEDURES
Yeast Strains—For all experiments GFP-tagged yeast strains orig-
inating from the Yeast-GFP Clone Collection were used, a library with
4156 GFP-tagged proteins representing about 63% of S. cerevisiae
open reading frames (39). The haploid parental strain of this library,
BY4741 (ATCC 201388), served as an initial control strain and to
construct the strain pHis3-GFP-HIS3kMX6 (short name pHis3-GFP).
To do so, we used the His3 locus in BY4741, which is nonfunctional
because of a deletion of several amino acids in the middle of the
coding sequence. We amplified a cassette containing a GFP gene
without start codon and a His3 gene of Saccharomyces kluyveri under
control of the TEF promoter and terminator out of the vector pFA6a-
GFP(S65T)-HIS3kMX6. This cassette was integrated into the His3
locus of BY4741 directly after the original His3 promoter and start
codon by homologous recombination, replacing the rest of the non-
functional His3 sequence. As a result, our pHis3-GFP strain is able to
synthesize histidine and expresses moderate amounts of cytosolic
GFP just as the tagged library strains.
Culture of Yeast Strains and anti-GFP Immunoprecipitation—
Tagged yeast strains, the parental strain BY4741 and the control
strain pHis3-GFP were first grown on plates (YDP plates for BY4741,
SC-His plates for all other strains) and then in YPD liquid medium at
standard culture conditions. Cell growth was regularly examined by
measuring OD600 nm. Yeast cells were grown until they reached
an OD600 nm of around 1, followed by harvesting culture volumes
High Accuracy Label-free Quantitative AE-MS in Yeast
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equaling 50 ODs. For biochemical triplicates (experimental series 1
(ES1)), three times 50 ODs were harvested out of the same culture and
from then on processed separately. For biological quadruplicates
(experimental series 2 (ES2)), four different colonies were picked on
different days and processed separately from the beginning. Yeast
cell pellets were dissolved in 1.5 ml lysis buffer (150 mM NaCl, 50 mM
Tris HCl pH 7.5, 1 mM MgCl2, 5% glycerol, 1% IGEPAL CA-630
(SIGMA-ALDRICH GmbH, Taufkirchen, Germany), Complete® prote-
ase inhibitors (Roche Diagnostics Deutschland GmbH, Mannheim,
Germany), and 1% benzonase (Merck KGgA, Darmstadt, Germany)),
transferred into FastPrep® tubes (MP Biomedicals GmbH, Es-
chwege, Germany) containing 1 mm silica spheres (lysing matrix C,
MP Biomedicals), frozen in liquid nitrogen and stored at 80 °C until
lysis. The frozen samples were thawed and then lysed in a Fast-
Prep24® instrument (MP Biomedicals) for 6  1 min at maximum
speed. Lysates were cleared by a 10 min centrifugation step at 4 °C
and 4000  g; and 800 l of the clear lysates were transferred into a
deep-well plate for immunoprecipitation. IP of yeast protein com-
plexes was essentially performed as described before for a mamma-
lian cell culture system (20). IPs were performed on a Freedom EVO®
200 robot (Tecan Deutschland GmbH, Crailsheim, Germany)
equipped with a MultiMACS™ M96 separation unit (Miltenyi Biotec
GmbH, Bergisch Gladbach, Germany) that contains a strong perma-
nent magnet. (Miltenyi Biotec also supplies equipment for performing
the same pull-downs in a manual fashion.) The basic steps of the IP
protocol are as follows: First the lysates are mixed with 50 l mag-
netic MACS Anti-GFP MicroBeads (Miltenyi Biotec) and incubated
for 15 min at 4 °C. Because of the favorable kinetics of the mi-
crobeads, tagged proteins are efficiently captured in only 15 min (40).
Then the Multi-96 separation columns are equilibrated with 250 l
equilibration buffer (same as lysis buffer). After that, the lysates are
added to the columns with the magnet turned on, retaining the
magnetic MicroBeads on the column. Once all the liquid has passed
through the columns, they are first washed with 3  800 l ice cold
wash buffer I (0.05% IGEPAL CA-630, 150 mM NaCl, 50 mM Tris HCl
pH 7.5, and 5% glycerol), then with 2  500 l of wash buffer II (150
mM NaCl, 50 mM Tris HCl pH 7.5, and 5% glycerol). Afterward 25 l
of elution buffer I (5 ng/l trypsin, 2 M Urea, 50 mM Tris HCl pH 7.5,
and 1 mM DTT) are added and the columns are incubated for 30 min
at room temperature. In this “in-column digest,” the proteins are
partially digested to allow elution from the columns, and reduced by
DTT. Subsequently the resulting peptides are eluted and alkylated
with 2  50 l elution buffer II (2 M Urea, 50 mM Tris HCl pH 7.5, and
5 mM CAA), and collected in a 96-well plate.
The plate was incubated at room temperature overnight to ensure
a complete tryptic digest. The next morning the digest was stopped
by addition of 1 l Trifluoroacetic acid (TFA) per well. The acidified
peptides were loaded on StageTips (self-made pipette tips containing
two layers of C18) to desalt and purify them according to the standard
protocol (41). Every sample was divided onto two StageTips to give
one “working” StageTip and one “backup” StageTip. The StageTips
were stored at 4 °C until the day of LC-MS/MS measurement.
LC-MS/MS Measurement—Samples were eluted from StageTips
with 2  20 l buffer B (80% ACN and 0.5% acetic acid). The organic
solvent was removed in a SpeedVac concentrator for 20 min, then the
remaining 4 l of peptide mixture were acidified with 1 l of buffer
A*(2% ACN and 0.1% TFA) resulting in 5 l final sample size. 2 l of
each sample were analyzed by nanoflow liquid chromatography on an
EASY-nLC system (Thermo Fisher Scientific, Bremen, Germany) that
was on-line coupled to an LTQ Orbitrap classic (Thermo Fisher Sci-
entific) through a nanoelectrospray ion source (Thermo Fisher Scien-
tific). A 15 cm column with 75 m inner diameter was used for the
chromatography, in-house packed with 3 m reversed-phase silica
beads (ReproSil-Pur C18-AQ, Dr. Maisch GmbH, Germany). Peptides
were separated and directly electrosprayed into the mass spectrom-
eter using a linear gradient from 5.6% to 25.6% acetonitrile in 0.5%
acetic acid over 100 min at a constant flow of 250 nl/min. The linear
gradient was followed by a washout with up to 76% ACN to clean the
column for the next run. The overall gradient length was 134 min. The
LTQ Orbitrap was operated in a data-dependent mode, switching
automatically between one full-scan and subsequent MS/MS scans
of the five most abundant peaks (Top5 method). The instrument was
controlled using Tune Plus 2.0 and Xcalibur 2.0. Full-scans (m/z
300–1650) were acquired in the Orbitrap analyzer with a resolution of
60,000 at 400 m/z. The five most intense ions were sequentially
isolated with a target value of 1000 ions and an isolation width of 2
m/z and fragmented using CID in the linear ion trap with a normalized
collision energy of 40. The activation Q was set to 0.25, the activation
time to 30 ms. Maximum ion accumulation times were set to 500 ms
for full scans and 1000 ms for MS/MS scans. Dynamic exclusion was
enabled; with an exclusion list size of 500 and an exclusion duration
of 180 s. Standard MS parameters were set as follows: 2.2 kV spray
voltage; no sheath and auxiliary gas; 200 °C heated capillary temper-
ature and 110 V tube lens voltage.
Raw Data Processing—All raw files were analyzed together using
the in-house built software MaxQuant (36) (version 1.4.0.6). The de-
rived peak list was searched with the built-in Andromeda search
engine (42) against the reference yeast proteome downloaded from
Uniprot (http://www.uniprot.org/) on 03–20-2013 (6651 sequences)
and a file containing 247 frequently observed contaminants such as
human keratins, bovine serum proteins, and proteases. Strict trypsin
specificity was required with cleavage C-terminal after K or R, allow-
ing up to two missed cleavages. The minimum required peptide
length was set to seven amino acids. Carbamidomethylation of cys-
teine was set as a fixed modification (57.021464 Da) and N-acetyla-
tion of proteins N termini (42.010565 Da) and oxidation of methionine
(15.994915 Da) were set as variable modifications. As no labeling was
performed, multiplicity was set to 1. During the main search, parent
masses were allowed an initial mass deviation of 4.5 ppm and frag-
ment ions were allowed a mass deviation of 0.5 Da. PSM and protein
identifications were filtered using a target-decoy approach at a false
discovery rate (FDR) of 1%. The second peptide feature was enabled.
The match between runs option was also enabled with a match time
window of 0.5 min and an alignment time window of 20 min. Relative,
label-free quantification of proteins was done using the MaxLFQ
algorithm (37) integrated into MaxQuant. The parameters were as
follows: Minimum ratio count was set to 1, the FastLFQ option was
enabled, LFQ minimum number of neighbors was set to 3, and the
LFQ average number of neighbors to 6, as per default. The “protein-
Groups” output file from MaxQuant is available in the supplement
(supplemental Table S1), as well as all spectra for single-peptide-
based protein identifications (supplemental Spectra).
Data Analysis—Further analysis of the MaxQuant-processed data
was performed using the in-house developed Perseus software (ver-
sion 1.4.2.30). The “proteingroups.txt” file produced by MaxQuant
was loaded into Perseus. First, hits to the reverse database, contam-
inants and proteins only identified with modified peptides were elim-
inated. Then the LFQ intensities were logarithmized, and the pull-
downs were divided into ES1 and ES2 and from then on analyzed
separately. Samples were first grouped in triplicates or quadrupli-
cates and identifications were filtered for proteins having at least three
or four valid values in at least one replicate group, respectively. For
every bait a separate grouping was defined, and the data was indi-
vidually filtered for proteins containing at least two (ES1) or three (ES2)
valid values in the specific bait pull-downs. After this, missing values
were imputed with values representing a normal distribution around
the detection limit of the mass spectrometer. To that end, mean and
standard deviation of the distribution of the real intensities were
High Accuracy Label-free Quantitative AE-MS in Yeast
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determined, then a new distribution with a downshift of 1.8 standard
deviations and a width of 0.25 standard deviations was created. The
total matrix was imputed using these values, enabling statistical anal-
ysis. Now a student’s t-tests was performed comparing the bait
pull-down (in replicates) to its individual bait specific control group
(BSCG). This BSCG contained all other pull-downs in the data set
except those of known complex members. This whole procedure of
individual filtering, imputation and t test was repeated for every bait.
The resulting differences between the logarithmized means of the two
groups (“log2(bait/background”) and the negative logarithmized p
values were plotted against each other using R (version 2.15.3) in
“volcano plots.” We introduced two different cutoff lines with the
function y  c/(x - x0), dividing enriched proteins into mildly and
strongly enriched proteins (c  curvature, x0  minimum fold change).
The positions of the cutoff lines were defined for each experimental
series separately by first plotting the distribution of all observed
enrichment factors and deriving the standard deviation of this distri-
bution. The x0 parameter for the inner curve and outer curve was then
set to one and two standard deviations (rounded to one significant
digit), respectively (supplemental Fig. S6B and S6F). The curvature
parameters were obtained by overlaying all plots within one series,
using only pull-downs of functional baits and rather small defined
complexes (ES1: all but CDC73, PUP1, and PUP2; ES2: all but NUP84
and NUP145). The c parameter of the outer line was then adjusted to
optimally separate true interactors from false positives (for more
details see supplemental Fig.S6C, 6D, 6G, and 6H). The curvature of
the inner line was then set to half of the curvature of the outer line.
Cut-off parameters for ES1 were x0  0.9 and c  4 for the inner
curve, and x0  1.8 and c  8 for the outer curve. Cutoff parameters
for ES2 were x0  0.5 and c  4 for the inner curve, and x0  1 and
c  8 for the outer curve. For all enriched proteins outside the inner
cutoff line, we calculated the Pearson correlation of their LFQ
intensity profile across all runs to the LFQ intensity profile of the
corresponding bait. Enriched proteins were assigned to interactor
confidence classes A, B, or C according to their position in the
volcano plot and their correlation value. Cutoffs for the correlation
scores were defined for both series individually by analyzing all
correlations within one series using a quantile–quantile plot (Q–Q
plot), which compares the real distribution of all correlation values
to a theoretical normal distribution (supplemental Fig. S6E and 6F).
The correlation cutoff was 0.55 for experimental series 1and 0.35
for experimental series 2. Note that these cutoff criteria do not
represent absolute fixed values, but rather help to interpret the
individual pull-down result.
RESULTS
Establishing a High Performance AE-MS Method for De-
tecting Interactions in Yeast—First, we set out to develop a
generic and robust, yet high performance affinity enrichment-
mass spectrometry (AE-MS) method for investigating protein–
protein interactions in yeast. This organism is amenable to
genetic and biochemical approaches and has already served
as a model in many of the classical interactome studies. We
chose to work with a GFP-tag system, because this tag is well
tolerated and highly specific antibodies have been generated.
Furthermore, a library of GFP-tagged yeast strains is com-
mercially available, covering about 4000 open reading frames,
and also offering localization data (34). The GFP-tagged bait
proteins in this library are expressed at endogenous levels, a
great advantage for detecting functional interactions. We
chose a subset of 36 strains from this library, containing
tagged bait proteins that are members of characterized com-
plexes from various cellular compartments and cover the
entire abundance range of the yeast proteome (supplemental
Fig. S1).
Next, we wished to construct a control strain that was as
genetically similar to the strains of the library as possible. Be-
cause the parental strain of the GFP-library, BY4741, is histidine
auxotroph and does not express GFP, we reintroduced the
HIS3 selection marker gene and a GFP gene into the dysfunc-
tional HIS3 locus of BY4741 (Experimental Procedures). The
resulting control strain can be grown under the same conditions
as the strains of the GFP library, expresses moderate amounts
of cytosolic GFP and was termed pHIS3-GFP.
An overview of our AE-MS workflow is depicted in Fig. 1.
We combined a mild detergent-based lysis buffer with exten-
sive bead beating to efficiently extract yeast proteins without
disrupting interactions. We investigated the needed input
amounts, and found that a 50 ml yeast culture volume with an
OD600 nm of 1.0 provided ample material for an IP experiment
even with very low expressed baits. Starting from these initial
50 ODs of yeast cells allowed us to save material as backup
at various stages of the sample preparation. The final amount
injected into the mass spectrometer corresponded to only
about 5.3 ODs; a very low amount of starting material, espe-
cially considering that baits were not overexpressed. The
single-step affinity enrichment was performed with highly
specific monoclonal anti-GFP antibodies coupled to magnetic
microbeads in a flow-through column format using mild wash-
ing conditions to preserve weak or transient interactions (Ex-
perimental Procedures). The whole pull-down procedure was
rather short, taking only about 2.5 h from lysis to elution.
Proteins were eluted by in-column predigestion with trypsin,
then digested to completion overnight. For all complexes
tested, we found that the resulting peptides could be analyzed
without any prefractionation in single-shot LC-MS/MS runs on
Orbitrap instrumentation, which considerably shortens overall
experiment time, provides greater reproducibility especially in
a label-free format and higher sensitivity. All experiments were
performed in several replicates; either biochemical triplicates
(experimental series 1, ES1) or biological quadruplicates (ex-
perimental series 2, ES2).
Raw data were analyzed using MaxQuant (36), providing
ppm level mass accuracy, confident identification of proteins
(False Discovery Rate of less than 1%), and accurate intensi-
ty-based label-free quantification, thanks to recently devel-
oped sophisticated normalization and matching algorithms
(37). Remarkably, all our pull-downs resulted in the identifica-
tion of thousands of unspecific binders in addition to the
specific interactors, leading to quantification of about half of
the yeast proteome in every single sample. On the one hand,
this was because of the low stringent single-step protocol in
which we attempt enrichment instead of proper purification of
protein complexes. On the other hand, it resulted from the
high instrument sensitivity of the LTQ Orbitrap instrument,
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and was also promoted by the “match between runs” algo-
rithm in MaxQuant. Matching between runs transfers identifi-
cations from one MS run to another run, where the same
peptide feature was present, but not selected for fragmenta-
tion and hence not identified. High confidence matching is
enabled by the high mass precision of the Orbitrap and
achieved using unique m/z and retention time information of
the features, after the retention times of all runs have been
aligned (43). Processing with matching between runs in-
creased the number of available quantifications in the com-
bined (ES1ES2) unfiltered LFQ matrix of 196 samples times
2304 proteins from 45 to 80%. The very large number of
proteins quantified per IP prompted us to establish novel data
analysis strategies, exploiting the information-rich intensity-
based LFQ data, as described in the following sections.
AE-MS Produces Internal Beadomes for Every Pull-down—
Together, our pull-downs identified a large set of background
binders specific for the affinity matrix and conditions used in
our experiments. As these proteins are usually detected be-
cause they bind to the beads used in the purification, the
totality of them has been called the “bead proteome” or
“beadome” (44, 45). Instead of having to determine this
beadome from separate control experiments, here we detect
it as a byproduct in the specific pull-downs (“internal
beadome”). In total, after standard filtering (Experimental Pro-
cedures) of the data we quantified 2245 different protein
groups in the combined ES1 and ES2 experimental series
(Fig. 2A). Per pull-down, we quantified on average 1860 pro-
teins in ES1 and 1825 proteins in ES2. Only a tiny fraction of
the detected proteins in each pull-down were actual interac-
tors of the corresponding tagged protein. For example, using
MCM2 as bait recovered the six MCM complex members
along with 1891 unspecific background proteins on average.
These six proteins constituted only 0.3% of all identified pro-
teins and only 1.3% of the summed LFQ intensity in the
corresponding pull-downs, although the bait was among the
highest intense proteins.
The unspecific binders identified in our internal beadome
cover the entire abundance range, with only a small bias
toward more highly abundant proteins when compared with
the yeast proteome as a whole (46) (Fig. 2B). GOBP and
GOCC term analysis by category counting of the identified
proteins did not indicate cellular functions or compartments
that are strongly over-or underrepresented (supplemental Fig.
S2A). However, the intensity at which we detect proteins in
the beadome is dependent on two factors: their abundance in
the proteome and their affinity to the beads. Whereas low
abundant proteins are generally not found at high intensities in
the beadome, the intensities of high abundant proteins can
vary from high to low signals (supplemental Fig. S2B and 2C).
Pearson correlation between beadome intensity and pro-
teome copy numbers was 0.53 for both ES1 and ES2. Next,
we performed 2D enrichment analysis (47), in which we com-
pared protein annotations between beadome and proteome in
an intensity-dependent fashion. The major protein classes
that showed higher intensities in the beadome than what
would be expected from their cellular abundance were RNA or
DNA related (e.g. ribosome, spliceosome, nucleolus, and DNA
recombination). This confirms former findings that ribosomal
proteins have a high affinity to the beads. Interestingly, pro-
teins in metabolic categories, which are ubiquitously present
in pull-downs because of their high abundance, tended to be
de-enriched (supplemental Fig. S2D and 2E). We conclude
that the beadome is in essence a scaled down version of the
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proteome, albeit with some preferences related to general
protein binding properties.
The reproducible identification of unspecific binders across
all runs is of course correlated with their intensity; higher
intense background binders are more likely to always be
detected, whereas background binders that are close to the
level of detection may only be identified in some of the runs.
Therefore, the LFQ intensity matrix contains missing values
among the lower intense proteins (marked gray in Fig. 2A). To
enable statistical analysis, such missing values can be “im-
puted.” Therefore, after discarding proteins that are not re-
producibly detected in at least one replicate group, we
imputed the remaining missing values using a normal distri-
bution around the detection limit of the mass spectrometer.
These simulated low intensity values fit well into the profiles of
the low abundant proteins, and because of its randomness,
imputation does not create artifacts in t-tests or in intensity
profile analyses. A comparison of the data set processed with
and without matching identifications between runs, and the
result of imputation are illustrated in supplemental Fig. S3.
Most of the background proteins are characterized by
highly similar intensities in nearly all of the pull-downs within
an experimental series, and we denote these as typical back-
ground binders. Both in ES1 and ES2 for about 90% of all
detected proteins the standard deviation of their intensity
profile was lower than 1.5 log2 LFQ intensity units; and for
about 70% even lower than 1 (Fig. 2C). As expected, this
analysis also confirms that proteins with higher intensity tend
to have more stable background profiles. Next to the typical
background binders, we also found a small number of pro-
teins with irregular profiles. Those atypical background bind-
ers are usually among the lower intense proteins. Both types
of unspecific binders can readily be distinguished from a
specific interactor, whose profile ideally fluctuates mildly
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FIG. 2. The proteomic nature of the background in AE-MS. A, Heatmap of the LFQ intensities of all proteins identified in two experimental
series (ES1 and ES2). Hierarchical row clustering was performed on the logarithmized LFQ intensities of more than 2000 quantified prey
proteins in the 196 pull-downs, without data imputation. B, Histogram of the copy numbers of all proteins quantified in our pull-downs
compared with the entire yeast proteome as in Kulak et al. C, The standard deviation of the LFQ intensity profile for each identified protein was
calculated after imputing missing values. Proteins were then ranked according to the standard deviation of their profile. About 70% of detected
proteins show a profile varying less than 1 log2 LFQ intensity unit and about 90% vary less than 1.5 log2 LFQ intensity units. D, Comparison
of the control strain pHIS3-GFP with the two tagged strains SET1-GFP and PAF1-GFP; all measured in triplicates. The matrix of 36 correlation
plots reveals very high correlations between LFQ intensities within triplicates (Pearson correlation coefficient  0.977 for all strains). The
correlation between different strains is always higher than 0.935. Average correlation of the corresponding nine comparisons were: SET1-GFP
to PAF1-GFP 0.946, SET1-GFP to control strain 0.938, and PAF1-GFP to control strain 0.945. E, Zoom into the SET1-GFP_01 versus
PAF1-GFP_01 correlation plot. The majority of proteins are detected at very similar LFQ intensities in both pull downs. The proteins that differ
the most between the two strains are the members of the two targeted complexes highlighted in color.
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around an average background intensity and only deviates
from that behavior in specific pull-downs, where it is detected
reproducibly and at higher intensities. The relationship of
mean LFQ intensity and standard deviation of the intensity
profile as well as the profiles of some typical and atypical
unspecific binders are further documented in supplemental Fig.
S4. Again, there is a clear trend that the intensity profiles of
higher intense proteins have a smaller standard deviation.
Among the proteins with the highest standard deviation (1.5
log2 LFQ intensity units) many bait proteins and interactors are
found.
A closer look at the heat map in Fig. 2A reveals the back-
ground in ES1 and ES2 to be slightly different. Sample prep-
aration was similar in both experiments; however, ES1 and
ES2 were measured on two different LC-MS systems of the
same type but at different time periods, which introduces
noticeable variation of the corresponding background. The
variation between pull-downs is lower in ES2 because sam-
ples were measured directly after each other in contrast to
ES1 where samples were measured in blocks according to
baits. Because of the slight variations in the background
signature between ES1 and ES2, data analysis was performed
separately for each experimental series. The differences be-
tween ES1 and ES2 allowed us to study the influence of these
workflow parameters.
Exploiting the High Coverage Background for Identifying
Protein Complexes—Evidently, the extremely large number of
unspecific binders detected in addition to the specific inter-
actors in AE-MS represents a completely different experiment
readout than that of classic AP-MS protocols. This large back-
ground needs specialized data analysis, which is; however, not
aimed at removing the unspecific binders, but instead exploits
them for high confidence detection of interactors. We recog-
nized four different ways in which the unspecific binders de-
tected in our pull-downs can be used beneficially.
First, they form the basis for intensity-based LFQ in Max-
Quant. To produce reliable and accurate quantification re-
sults, the normalization procedure performed in MaxQuant
requires a background proteome that is assumed to be un-
changing. This function is provided here by a large number of
unspecific binders identified in all samples. Normalization can
then correct for differences in sample loading and sample
concentration, which is a prerequisite to making the pull-
downs comparable at all and constitutes the basis for further
data analysis.
Second, the unspecific binders can serve as a quality con-
trol. We observed that deviation of the detected background
binders from the standard behavior can indicate insufficient
quality of a specific pull-down, which easily became apparent
by hierarchical clustering of the data matrix. As an example,
see the vertical stripe close to the middle of ES2 in Fig. 2A,
which is a replicate of a pHIS3-GFP pull-down. Close inspec-
tion of the raw data revealed generally low peptide intensities
and polymer contamination in this sample. In another case, a
difference in background signature was not because of sam-
ple quality, but seemed to be because of the nature of the
tagged complex: All six proteasome pull-downs reproducibly
featured a slightly but clearly different background than the
other pull-downs. This can be explained by the fact that
proteasome subunits have high cellular copy numbers and are
part of a very large complex; together this alters conditions on
the beads, “crowding out” some of the normally observed
background binders.
Third, the high number of unspecific binders reproducibly
quantified in all samples resulted in very high correlations
between different pull-downs. In Fig. 2D, these correlations
are plotted for two tagged strains, SET1-GFP and PAF1-GFP,
and the control strain pHIS3-GFP. Within triplicate pull-
downs, the average Pearson correlation coefficients were al-
ways greater than 0.977. Between the different strains, cor-
relation was always higher than 0.935, indicating that the
intensities of the background proteins in the three yeast
strains are highly similar. In fact, the correlation of SET1-GFP
to PAF1-GFP was even higher than the correlation of SET1-
GFP to the control strain pHIS3-GFP (0.945 versus 0.937). The
proteins most changing in intensity between the two pull-
downs were the expected SET1 and PAF1 interactors (Fig.
2E). These findings led us to investigate the possibility of
comparing pull-downs not to an untagged control strain as it
is usually done, but instead to compare them to each other,
which will be further explored in the next section.
Finally, we reasoned that next to the pair-wise correlation of
samples across all protein intensities, pair-wise correlation of
intensity profiles across all samples should contain meaning-
ful information. Specifically, intensity profiles of true interac-
tors across all pull-downs, when compared with the intensity
profile of the corresponding bait, should be correlated. The
characteristic profile of interactors compared with the un-
changing profile of typical background binders or the random
profile of atypical background binders could therefore be
useful in verifying interactor candidates, as we will demon-
strate later on.
Defining Interactors by Comparing Against Other Tagged
Strains—To identify interactors of a specific bait protein in the
presence of the large amount of background binders, we
performed a student’s t test comparing the LFQ intensities of
all proteins identified in replicates of that bait with the LFQ
intensities of all proteins identified in the control (Experimental
Procedures). When the resulting differences between the log2
mean protein intensities between bait and control are plotted
against the negative logarithmized p values in volcano plots,
the unspecific background binders center around zero. The
enriched interactors appear on the right side of the plot,
whereas ideally no proteins should appear on the left side
when comparing to an empty control, as these would represent
proteins depleted by the bait, which is not expected to happen.
The higher the difference between the group means (i.e. the
enrichment) and the p value (i.e. the reproducibility), the more
High Accuracy Label-free Quantitative AE-MS in Yeast
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the interactors move to the top right corner of the plot, which is
the area of highest confidence for a true interaction.
We started by comparing a specific pull-down to an empty
control strain as it is usually done in AP-MS experiments. First
we used BY4741, the parental strain of the GFP library, as
control; however, cross-reactivity of the anti-GFP antibody
could occur in the complete absence of GFP. Therefore, we
had constructed pHIS3-GFP, a control strain highly similar to
the strains of the GFP library, as it could be grown under the
same selective conditions and expressed moderate amounts
of cytosolic GFP (see above). When we compared the pHIS3-
GFP control strain to its parental strain BY4741, we detected
only one yeast protein to be enriched, which was imidazole-
glycerol-phosphate dehydratase, the protein the HIS3 gene
encodes for (Fig. 3A). This illustrates that GFP does not inter-
act with any yeast protein, and furthermore demonstrates that
our AE-MS workflow is sensitive to an extent that it picks up
genetic differences between strains. This confirms the bene-
fits of using a control strain as similar as possible to the actual
bait strain, and supports our hypothesis that other tagged
strains of the GFP-library could present an excellent control,
as they are genetically identical except for the different tagged
protein. When we tested this idea on the example of the SKI
complex we indeed did not observe any differences in the
identified interactors of the bait SKI2, whether we compared
with pHis3-GFP or a tagged strain, e.g. SMC2-GFP (Fig. 3B
and 3C). As the only side-effect the specific interactors of the
other strain now appeared as de-enriched proteins. (We note
that even this could be put to good use in certain cases, as it
in principle enables detection of the interactors of two differ-
ent bait proteins in only one comparison and without employ-
ing a control.)
A larger control group consisting of many control pull-
downs should help to better identify interactors; and we next
tested whether this holds true for our pull-downs. Comparing
a specific pull-down to eight pHis3-GFP pull-downs, consist-
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FIG. 3. Comparing to unrelated tagged strains. All pull-downs in this figure were measured in quadruplicates. Cut-off lines were those of
ES2 (see Experimental Procedures). Red dots represent members of the SKI complex and blue dots represent members of the condensin
complex. A, Comparison of the control strain pHIS3-GFP against its parental strain BY4741. B, Classic comparison of a tagged strain against
an untagged control strain, in this case SKI2-GFP against pHIS3-GFP. C, SKI2-GFP compared with an unrelated tagged strain, SMC2-GFP.
D, SKI2-GFP compared with 8  pHIS3-GFP in quadruplicate ( 32 control pull-downs). E, SKI2-GFP compared with eight unrelated tagged
strains in quadruplicate (APC1-GFP, CAF1-GFP, CCR4-GFP, PAF1-GFP, PEP5-GFP, SMC1-GFP, SMC2-GFP, and SNF4-GFP  32 control
pull-downs). F, SKI2-GFP compared with its bait specific control group (BSCG) consisting of all other pull-downs in the data set except for the
SKI3 quadruplicate ( 116 control pull-downs).
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ing of four biological replicates each, clearly led to better
separation of interactors from the background cloud than just
comparing to one pHIS3-GFP pull-down (compare Fig. 3D to
Fig. 3B). The larger control group provided a less error-prone
average background intensity of every protein, which in turn
resulted in higher p values of the enriched true interacting
proteins. This is particularly beneficial to separate weaker or
transient interactors, which by their nature tend to only be
mildly enriched, from the background cloud, as long as their
low enrichment is highly reproducible. The more control pull-
downs are included into the control group, the better the
results should become. However, performing a large number
of empty control experiments consumes considerable re-
sources. In a human interactome study in 2007 for example,
the authors conducted 202 control experiments (12). We rea-
soned that if we are able to compare tagged strains to each
other, we would naturally obtain a large control group without
any additional efforts. To test this concept, we first compared
the SKI complex pull-downs to eight unrelated tagged strains.
This resulted in the same or better statistical improvement of
the interactors as we had obtained when using the same
number of control strains (Fig. 3E and 3D). We chose the
tagged strains serving as the control group to be unrelated to
the specific bait of interest, in the sense that their tagged
proteins do not reside in a known complex with this bait. To
obtain the largest possible control group, we selected all
unrelated pull-downs in the data set and termed this the “bait
specific control group” (BSCG). If interacting proteins are
included in the BSCG, they can increase the calculated aver-
age background intensity of interactors and therefore artifi-
cially decrease the t test result. For large control groups;
however, wrong assignment would generally not dramatically
change results, as demonstrated by comparing the SKI2 pull-
downs against all other pull-downs in the data set (supple-
mental Fig. S5). Although we here constructed the BSCG from
prior knowledge, it could also be constructed in an iterative
way. In the case of SKI2, the BSCG included all pull-downs
except the replicates of SKI3, resulting in 116 controls. This
led by far to the best separation, placing the SKI complex into
the far upper right corner of the volcano plot (Fig. 3F). There-
fore, we concluded that other pull-downs can serve as excel-
lent controls and in the following determined interactors by
comparing each specific pull-down to its BSCG.
Combining Enrichment Over Background with Intensity Pro-
file Analysis Leads to High Quality Interaction Data—To clas-
sify a protein as an interactor, we needed to introduce a cutoff
that separates enriched proteins from the unchanged cloud of
background binders centered around zero in the volcano
plots. The position of this cutoff is crucial: A stringent cutoff
leads to a low false positive rate, but may miss weaker or
more transient interactors, whereas a permissive cutoff would
include these, but at the cost of increasing false positives. To
preserve information about weak or transient interactors, we
decided to use a two cutoff strategy, which divides interactor
candidates into mildly and strongly enriched proteins (Fig.
4A). To define the position of the two cutoff lines, we plotted
the distribution of all enrichment factors within one series and
placed two minimum fold change cutoffs at one and two
standard deviations, respectively. Interestingly, in the case of
ES2, the series with biological quadruplicates that had been
measured in one block, the standard deviation was much
lower than for ES1. The cutoff lines were placed once for all
pull-downs within an experimental series with curvature pa-
rameters that best separate the outliers from the cumulative
background cloud (for more details see Experimental Proce-
dures and supplemental Fig. S6A–6H).
We then introduced a new criterion to deal with the false
positives among the mildly enriched interactors close to the
cutoff lines. This criterion makes use of the above mentioned
tendency of intensity profiles of true interactors of a bait
protein to be correlated, because interacting proteins should
be enriched whenever one of the complex members is
tagged. Moreover, slight variations across samples because
of background binding should be followed by all complex
subunits. This concept requires a complete LFQ intensity
matrix, produced by imputing missing values from a suitably
chosen random distribution, to not artificially increase or de-
crease the correlation (Experimental Procedures). To evaluate
the similarity of a given profile to the profile of the bait, we
calculated the Pearson correlation of the two profiles; and this
was repeated for every enriched protein (Fig. 4B). Although
strongly enriched proteins generally show medium to high
correlations, mildly enriched proteins generally show lower
correlations, but with a much higher variation from high to
even negative values (supplemental Fig. S7). This indicates
that true interactors exist among those borderline interac-
tors that can be detected with the help of the correlation
analysis. For the example of the MCM4 pull-down in Fig. 4,
five out of the six complex members were highly enriched,
but one (MCM3) only scored a mild enrichment and mod-
erate p value, but a high correlation (0.56), which led to its
correct identification as an interactor of MCM4. In this ex-
emplary pull-down, the detected true interactors showed an
average correlation of 0.68 to the bait, whereas the detected
unspecific binders showed an average correlation of 0.42. In
ES2, the average correlation of detected unspecific binders
was generally even lower. We determined a series specific
correlation cutoff for ES1 and ES2 by evaluating the corre-
lation of all proteins detected in all pull-downs in a Q-Q-plot,
which visualizes the real distribution of all correlation values
compared with a theoretical normal distribution (supple-
mental Fig. S6I and 6J). The point, where actual and theo-
retical distribution sharply deviated was chosen as the cor-
relation cutoff. Correlation analysis worked particularly well
with our data set, as it contains at least two entry points for
every complex.
We then proceeded to group enriched proteins into inter-
actor confidence classes A–C by their enrichment, p value
High Accuracy Label-free Quantitative AE-MS in Yeast
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and correlation to the bait as summarized in Fig. 4C. Class C
proteins are proteins between the two cutoff lines with low
or medium correlation to the bait and are not regarded as
interactors. Class B proteins are proteins between the cutoff
lines with high correlation or proteins outside the outer
cutoff line with medium correlation, and represent lower
confidence interactors. Finally, class A proteins are proteins
outside the outer cutoff line with high correlation and are
considered high confidence interactors. The result of the
classification is shown for the MCM complex in Fig. 4C, and
the same color scheme is used in all volcano plots throughout
the supplemental Material ES1/ES2. Although we found the
above classification scheme to be very efficient, it should not be
seen as absolute, but rather as a help in interpreting the pull-
downs results.
How the intensity profile analysis can recognize false-pos-
itives is illustrated by the profiles of SFC1 and SDH3 in Fig.
4B. They represent atypical background binders (see above)
fluctuating from low to high intensities across pull-downs.
Because they appeared by chance in all of the replicates of
the specific pull-down they scored both a good enrichment
factor and p value. However, because of the fluctuations in
their profiles, the correlation to the bait intensity profile is
poor, which reclassifies SFC1 as lower confidence interactor
and SDH3 as noninteractor. Without the correlation analysis,
SFC1 would have been considered a high confidence inter-
actor. Conversely, proteins that are only minimally but repro-
ducibly enriched are likely to still be true interactors if they
show good correlation (See MCM3 in Fig. 4B). Using the
data set-dependent cutoff definition, the average complex
coverage per pull-down (calculated as true positives/(true
positives  false negatives), with true complex members de-
rived from UniProt) was 74% for ES1 and even 83% for ES2.
Among the 82 and 79 class A interactors, the false-positive
rates (calculated as false positives/(true positives  false
positives) were only 6 and 0% for ES1 and ES2 respectively.
Among the 32 class B interactors in ES1, the false-positive
rate was 53%; however, 15 out of these 17 false positives
were downgraded from class A and therefore rightfully clas-
sified as lower confidence interactors. Among the 15 class B
interactors in ES2, the false positive rate was 20%. False-
negative rates in class C (calculated as true complex mem-
bers falsely classified as class C/all proteins in class C) were
very low with 3% (4 out of 133) for ES1 and 6% (2 out of 35)
for ES2. For all the aforementioned calculations, the two
large complexes (NPC and proteasome) as well as the com-
plexes were no classification could be performed (APC2,
CDC73, and TEF1) were excluded.
Defining Complexes of Various Sizes, Abundances, and
Cellular Localizations—The bait proteins in our study had
been selected to represent a wide range of cellular abun-
dances (supplemental Fig. S1), localizations (e.g. cytosolic,
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nuclear, and membrane bound), and functions (e.g. cell cycle,
transcription, translation-elongation, and transport). For each
of the pull-downs, the volcano plot containing the results of
our analysis is depicted in supplemental Material ES1 and/or
supplemental Material ES2. All bait proteins and the page
number of the corresponding volcano plot within the supple-
mental Material ES1/ES2 are summarized in a table on the
first page of both files. Given the diversity of these complexes,
they serve to illustrate different aspects of our method.
When we used very low abundant proteins as baits, we
were still able to identify interactors with a surprisingly high
complex coverage, especially considering that our system
uses endogenous expression and relatively little input mate-
rial. For instance the members of the anaphase promoting
complex, which has a key regulatory role in the cell cycle, are
expressed at an estimated average of about 70 copies per cell
in unsynchronized yeast cells (46). Using APC1 (about 30
copies/cell) as the entry point to the APC, our standard pull-
down protocol already identified 11 out of 13 APC members.
The two missing complex members (APC9 and APC11) are
potentially even lower abundant in unsynchronized cells as
they were also not detected in a deep yeast proteome (46).
Similarly, pull-down of the SET1/COMPASS histone methyl-
transferase complex by its SET1 (135 copies/cell) and SWD3
(74 copies/cell) subunits revealed all eight complex members
as clear outliers in the volcano plots.
Conversely, we were also able to detect interactors of very
high abundant proteins. Here the challenge is that these pro-
teins often have very high background intensities – ranging in
our workflow to a log2 intensity of up to about 36 – over which
they can hardly be further enriched. For the elongation factor
CAM1 (49,500 copies/cell, average log2 background intensity
29.9) we identified CAM1 itself and its direct interactor EFB1
with a moderate but clear enrichment but an extremely sig-
nificant p value (p  1025). However, TEF1 (630,000 copies/
cell, average log2 background intensity of 34.8), another elon-
gation factor 1 complex member, did not register as an
interactor as its background intensity is so high that it cannot
be significantly further enriched. Even when we tagged TEF1,
this bait was not an outlier, although all three interactors
CAM1, EFB1, and TEF4 were significantly enriched. We also
targeted another very high abundant complex, the ribosome-
associated complex (RAC) through its components SSZ1
(59,450 copies/cell, average log2 background intensity of
32.2) and ZUO1 (45,188 copies/cell, average log2 background
intensity of 31.4). Although SSZ1 only retrieved itself as out-
lier, when we tagged ZUO, we could indeed detect SSZ1 with
mild enrichment but with a very good p value (p  1022).
Although the above examples serve as positive controls,
illustrating aspects of our affinity enrichment workflow, we
also we detected some interactors that are not part of the
stable, known core complexes. The MCM complex presents
the core of the replicative DNA helicase in yeast and forms a
double hexameric ring around the DNA (48). We identified
TOF1 (Topoisomerase 1-associated factor 1) which is not part
of the core helicase but which has been shown to interact and
regulate it (49). TOF1 is an example of an interactor that was
promoted to likely interactor status (class B), because of its
high correlation with complex members.
The yeast proteasome consists of a 20S core particle com-
posed of 28  and -subunits assembled into four rings, and
a 19S regulatory particle on both sides of the core composed
of 19 proteins. As the proteasome is a highly dynamic holo-
complex, its purification is not trivial (50). Using two 20S
members, PUP1 ( subunit) and PUP2 ( subunit), retrieved
the complete 20S complex and most of the 19S members.
Additionally, we found a number of transient interactors, such
as the proteasome activator BLM10, the proteasome stabiliz-
ing component ECM29, the proteasome chaperone PBA1 and
the uncharacterized protein YCR076C. The latter has already
been reported to interact with proteasome core particle sub-
units (51), an association that we now confirm. Other enriched
proteins found in the PUP1/PUP2 pull-downs that are not
reported to interact with the complex could be proteasome
substrates.
The nuclear pore complex (NPC) represents an example of
a very large complex (about 30 different proteins in multiple
copies) that is embedded in the nuclear membrane (52). Per-
forming pull-downs with two of the subunits (NUP84 and
NUP145), we found many components of the NPC (19 and 16
respectively), which, remarkably, is more than what was iden-
tified for these two baits in a dedicated membrane interac-
tome (53). Additionally, we identified proteins that are not only
components of the NPC but also of the spindle pole body
(SPB), namely CDC31 (54, 55) and NDC1 (56). Consequently,
other components of the SPB including SPC110 and SPC42
were among the outliers. We also identified the inner nuclear
membrane protein HEH2, which has been proposed to be
important for a proper distribution of nuclear pores across the
nuclear envelope (57).
Two further examples are PAF1 (RNA polymerase II-asso-
ciated protein 1), pull-down of which resulted in all five core
complex members as well as RPO21. This protein is a subunit
of the RNA polymerase II. Likewise pull-down of PEP5, a
member of the HOPS complex, retrieved all its members, and
furthermore VPS8, a component of the CORVET complex
sharing four subunits (PEP3,PEP5,VPS16, and VPS33) with
the HOPS complex (58).
Apart from core and transient, proteins can also be mutually
exclusive complex members. As an example, the SNF1 pro-
tein kinase complex is a hetero-trimeric complex consisting of
the alpha subunit SNF1, the gamma subunit SNF4, and one of
three alternative beta subunits SIP1, SIP2, or GAL83 (Fig. 5A)
(59). This complex proved to be a good case to investigate the
effects of mutually exclusive complex members on the inten-
sity profile analysis. We used SNF4 and GAL83 as baits,
hence SIP1 and SIP2 were only identified in the SNF4 pull-
down, as expected (Fig. 5B and 5C). Nevertheless they
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showed a correlation of 0.37 and 0.45, respectively, to the bait
SNF4 (Fig. 5D), which was higher than the correlation cutoff
(0.35 for ES2). This demonstrates the usefulness of correlation
analysis for associating even alternative members with the
core complex. This complex also illustrates the need for sev-
eral entry points per complex to recapitulate more compli-
cated complex arrangements such as alternative cellular sub-
complexes. Using SNF4 as bait, we additionally identified the
protein SAK1, which is an upstream kinase that activates
SNF1 (60).
DISCUSSION
For about two decades, AP-MS techniques have been used
as tools for investigating protein complexes, and they have
been improved greatly during this time. Previously, protein
complexes were extensively purified, to reduce the amount of
copurifying unspecific binders as much as possible. However,
such stringent purification becomes unnecessary as soon as
AP is coupled to high resolution, quantitative MS. Quantifica-
tion can distinguish the true interactors from contaminants.
Therefore, protocols can be less stringent, preserving weaker
SNF4
GAL83
SNF1
SNF4
SIP1
SNF1
SNF4
SIP2
SNF1
SNF4 (c=1)
SNF1 (c=0.75)
GAL83 (c=0.72)
SIP1 (c=0.37)
SIP2 (c=0.45)
A
P
C
1
A
P
C
2
B
Y
47
41
C
A
F
1
C
A
M
1
C
C
R
4
G
A
L8
3
N
U
P
14
5
N
U
P
84
PA
F
1
P
E
P
3
P
E
P
5
P
H
IS
3_
1
P
H
IS
3_
2
P
H
IS
3_
3
P
H
IS
3_
4
P
H
IS
3_
5
P
H
IS
3_
6
P
H
IS
3_
7
P
H
IS
3_
8 
R
T
F
1
S
K
I2
S
K
I3
S
M
C
1
S
M
C
2
S
M
C
3
S
M
C
4
S
N
F
4
S
S
Z
1
T
E
F
1
Z
U
O
1
lo
g2
 L
FQ
 in
te
ns
ity
log2(bait/background)
−l
og
10
 p
-v
al
ue
log2(bait/background)
−l
og
10
 p
-v
al
ue
SNF1
SNF4
GAL83
SNF1
SNF4
SIP1
SIP2
SAK1
GAL83
Bait=GAL83
Bait=SNF4
20
30
20
30
20
30
20
30
20
30
−10 −5 0 5 10
0
5
10
15
20
25
−10 −5 0 5
0
5
10
15
20
25
10
A
C D
B
FIG. 5. Correlation analysis and mutually exclusive binding. A, Schematic representation of the three alternate SNF1 protein kinase
complexes. B, Volcano plot of GAL83 compared with its bait-specific control group (BSCG). C, Volcano plot of SNF4 compared with its BSCG.
D, Intensity profiles of the gamma subunit SNF4, the alpha subunit SNF1, and the three alternate beta subunits GAL83, SIP1, and SIP2 as well
as their correlation to the bait SNF4.
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interactions, while resulting in a higher background. In this
work, we have taken this concept to its logical conclusion by
employing low stringent single-step enrichment of protein
complexes followed by label-free quantitative MS analysis in
which we co-purify a very large number of unspecific binders
representing about half of the yeast proteome. Complexes
can still be confidently identified because of their enrichment
in specific bait pull-downs versus all other pull-downs. As we
do not aim to purify but only to enrich, we suggest terming
such methods AE-MS. Our methodology is solely based on
intensity-based label-free quantification, which has advanced
considerably and for pull-downs is now comparable with la-
bel-based quantification approaches like SILAC (20, 33).
Identification of a large number of background binders is
unavoidable with modern MS instrumentation. Perhaps coun-
terintuitively, our results demonstrate that these unspecific
proteins can actually be beneficial, elevating them from a
nuisance to an essential part of the analysis. Apart from their
essential use in normalization, they are indicators of the re-
producibility within a specific workflow and serving as quality
control. As unchanging background binders greatly outnum-
ber changing interactors, pull-downs are highly similar to each
other, which in turn obviates the need for a dedicated control
strain. Finally, we have shown that reproducible detection of
unspecific binders allows further characterization of interactor
candidates by correlating their intensity profiles to the profile
of the bait. Using our pipeline, we identified interactors of a
diverse set of endogenously expressed bait proteins with high
confidence, starting from minimal input amounts of unlabeled
yeast, and requiring modest measuring times despite repli-
cate analysis. In medium or large-scale projects, our workflow
automatically provides a large control group, without actually
performing any control pull-downs. However, as illustrated
with the SKI complex, using only one tagged strain as control
(or an empty stain) already correctly identified all complex
members, demonstrating the feasibility of AE-MS also for
small scale projects.
Although a large improvement, our AE-MS workflow does
not solve all issues in MS-based interaction studies. Mem-
brane complexes always present a challenge because of their
hydrophobic nature. However, our protocol yielded excellent
results for the HOPS vacuolar membrane complex and the
nuclear pore complex without adapting it in any way. For the
SPOTS complex, we only retrieved two out of the six complex
members. Adapting the type of detergent or the detergent
concentration in the lysis buffer may help to better identify
membrane complexes (53). To further verify interactors, we
have introduced intensity profile analysis, which proved to be
very helpful for upgrading weaker interactors and uncovering
false positives. As this method relies on correlation to the bait
profile, it could; however, not be used in three cases where we
did not detect the bait as an outlier (in ES1: APC2 and CDC73;
in ES2: TEF1). In the case of CDC73, the bait was incorrectly
tagged in the strain we used, as we subsequently found by a
control PCR. For APC2 the very low copy number was pre-
sumably the reason, as even in ES2 where we found APC2, it
was only identified with two peptides. Finally, as already men-
tioned, for TEF1 the background intensity was so high that it
did not form a useful profile. However, the intensity profiling
only serves as additional information, and in all these cases
the correct interacting proteins were still identified through
their enrichment. A final potential caveat for the intensity
profile analysis are newly identified proteins interacting with
several baits, which decreases their correlation score. How-
ever, provided their enrichment is high, they would still be
considered (class B) interactors. Examination of the actual
intensity profile of such promiscuous interactors could also
help in judging whether weak correlation to the bait is caused
by strong fluctuation between all samples, making the protein
a false positive, or caused by strong fluctuation between
several replicate groups, making it a potential link between
several complexes.
The two largest yeast interactomes published in 2006 by
Gavin et al. and Krogan et al. both employed TAP-tagging
coupled to nonquantitative MS and among other frequency
filtering of detected proteins to remove unspecific binders (9,
10). This can be problematic in the case of atypical back-
ground binders that appear spontaneously at high intensity in
only some pull-downs. In our AE-MS approach, pull-downs
are performed in replicates, hence such proteins are rarely
scored as interactors. Even if an atypical background binder is
by chance detected in all replicates, the intensity profile anal-
ysis can still uncover it. With very few exceptions, all of the
proteins listed as contaminant in the above studies were also
found in our data set. However, they did not appear as inter-
actors in any of our pull-downs other than where expected.
The data sets of Gavin et al. and Krogan et al. only share
about one quarter of detected interactions (61) and did not
contain 1/3 or 1/2 of the baits that we had tagged here,
respectively. For each of the pull-downs that we could com-
pare between all three studies (APC2, BRE2, CCR4, NUP84,
NUP145, POP2, RTF1, SET1, SKI2, SMC1, SSZ1, and SWD3)
the complex coverage was equal or better using the AE-MS
method. In one case, we only retrieved EFB1 as interactors of
CAM1 whereas Gavin et al. also found TEF1 and TEF2. Al-
though these proteins were also found in a mock TAP-tag
purification and therefore included in the contaminant list, we
reason that more stringent purification could be helpful for
detecting interactors of extremely high expressed proteins
such as CAM1.
Recent interaction proteomics efforts typically at least em-
ploy semiquantitative approaches; however, removal of con-
taminants can still be problematic. There is an ongoing col-
laborative effort to establish a “contaminant repository for
affinity purification,” the “CRAPome,” containing control pull-
downs from various laboratories performed under various
experimental conditions (62). In the case of yeast 17 control
pull-downs are currently available, of which 12 have been
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performed using GFP-tagged proteins and nano-magnetic
beads. However, a larger number of controls may be neces-
sary to comprehensively cover all nonspecific binders and
thereby avoid incorrectly classifying a nonspecific binder as
an interactor. Our AE-MS method sidesteps this problem, as
the samples themselves are the controls. The minor but clear
differences between our two experimental series (Fig. 2A)
demonstrate that minor changes in the workflow like using a
different machine of the same type can already alter the
detected low abundant background binders, making the no-
tion of a universal CRAPome problematic.
From the differences between the two experimental series
we also conclude that for the most optimal output, AE-MS
experiments should be executed in a reproducible manner
from sample preparation to MS measurement, which should
ideally be conducted on one machine and in one batch as in
ES2. However, the MaxLFQ normalization algorithm success-
fully corrected for most of the variability in the ES1 series in
general and in the proteasome pull-downs in particular, re-
sulting in excellent results even for ES1.
To perform the AE-MS workflow described here, only three
elements were needed: tagged proteins of interest, a high
resolution LC-MS system, and sophisticated software to
quantify proteins and analyze the data. Here we used the LTQ
Orbitrap classic, which—although not being the latest Or-
bitrap technology—proved to be sufficient for identifying even
very low abundant protein complexes. Such technology is
now widely accessible, as is the MaxQuant software for per-
forming accurate intensity-based label-free quantification and
the Perseus program for statistical analysis of the data. Our
AE-MS protocol is equally suited to investigate a small, me-
dium or large number of samples. For a smaller set of sam-
ples, SILAC labeling could easily be implemented, which
might provide even more accurate ratios in the case of
borderline enrichment. More and more AP-MS workflows al-
ready use single-step protocols and employ high resolution MS,
and therefore rather represent AE-MS methods. The shift in the
conceptual framework from AP-MS to AE-MS and the develop-
ment of sophisticated analysis tools for AE-MS experiments
should contribute to higher quality interaction data, thereby
making studies more comparable, and helping to solve open
challenges in the interactomics field.
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5 A quantitative map of the human interactome
Mymain project combinesmany aspects introduced in the publications discussed earlier
in this thesis: Quantitative BAC-GFP interactomics as the conceptual foundation, label-
free quantification as an essential tool to allow for a project of the given scale, and new
strategies for extracting high-confidence interactors as the statistics back-end.
Novel aspects that are unique to my main manuscript are the scale, encompassing more
than 1,000 bait proteins or around one year of net MSmeasurement time. Furthermore,
I introduced a concept that uses three dimensions of quantification. The first dimension
serves as a specificity filter, for which I additionally introduced a false discovery rate
(FDR)-controlled method for defining cut-offs. The second dimension applied absolute
quantification on the interactors relative to the bait, yielding the stoichiometries of inter-
actions. The third dimension requires the incorporation of whole proteome data for the
biological system in which interactions are being detected, in this case the HeLa cell line.
Absolute quantification of protein copy numbers inHeLa enables the analysis of the rela-
tionship of the interactome to its underlying proteome. These three dimensions allowed
me to carry out quantitative analyses that were not even conceptually applicable to pre-
vious interactomics studies. In particular, I showed that the interaction stoichiometries
are a proxy for the functional strength of an interaction, which carries over to the topo-
logical properties of that interaction in the global interactome network. An unexpected
finding was that the wealth of weak interactions appear to be most critical for overall
network structure and form the glue that holds the network ‘hairball’ together.
5.1 The human interactome in three quantitative dimensions
Hein,M. Y., Hubner, N. C., Poser, I., Cox, J., Nagaraj, N., Toyoda, Y., Gak, I.,Weisswange,
I., Mansfeld, J., Buchholz, F., Hyman, A. A. &Mann,M. The human interactome in three
quantitative dimensions. Under review (2014).
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The organisation of a cell emerges from the interactions in protein networks. The inter-
actome is critically dependent on the strengths of interactions and the cellular abundances
of interactors, both of which span orders of magnitude. However, these two aspects have not
yet been analysed globally. Here, we have generated a library of HeLa cell lines expressing
1,125 distinct GFP-tagged proteins under endogenous control, which we used as input for a
next-generation interaction proteomic survey. Three quantitative dimensions measure spe-
cificity, interaction stoichiometry, and cellular abundances. Our analyses demonstrate that
the interactions in protein networks are dominated by weak, substoichiometric interactions
that play a pivotal role in defining network topology. The minority of stable complexes can
be identified by their unique stoichiometry signature. This study provides a rich interaction
dataset connecting more than 5,400 proteins with more than 28,000 statistically significant
interactions, and introduces a novel framework for quantitative network analysis.
Proteins are the protagonists of life at the mo-
lecular level. They interact with each other for
structural, regulatory and catalytic purposes,
forming macromolecular structures as well as
stable or transient multi-protein complexes.
Accordingly, protein interactions vary greatly
in their thermodynamic and kinetic proper-
ties and protein abundances range from just a
few to millions of copies per cell. The inter-
actome is therefore the product of two factors:
binary affinities between protein interfaces1–3
as well as the cellular proteome, which it-
self is characterized by subcellular localiza-
tion, post-translational modifications and pro-
tein concentrations4,5. Mapping the protein in-
teractome landscape has been a long-standing
goal of modern biology and a variety of meth-
ods have been developed to this end6. Af-
finity purification followed by mass spectro-
metry (AP-MS) can determine the members of
protein complexes in their cellular context in
an unbiased manner7 and has enabled large-
scale protein interaction studies of yeast8–11,
fruit fly12 and human13,14. Nanoscale liquid
chromatography (LC) coupled to sensitive and
fast mass spectrometers has boosted interac-
tion proteomics technology, increasing proteo-
mic coverage and minimizing false negative
rates. It has also enabled a paradigm shift from
identification to quantification of interacting
proteins15. Instead of employingmultiple strin-
gent washing steps, quantitative approaches
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Figure 1 | Quantitative BAC-GFP interactomics (QUBIC).
aBAC recombineering workflow for generating transgenic HeLa lines. bSingle-step affinity-purification,
single-run LC-MS/MS workflow. c Three dimensions of proteomic quantification are used to detect
specific interactors via co-enrichment and profile correlation and to estimate binding stoichiometries of
interacting proteins and their cellular abundances. d Proteome coverage and abundance distribution
of the bait proteins and their interactors.
permit the use of mild immunoprecipitation
(IP) protocols, because specific binders stand
out from a very large background of identified
proteins by their quantitative enrichment16.
Additionally, MS-based proteomics is now able
to characterize entire cellular proteomes with
increasingly complete coverage4,17, providing
abundances and copy number estimates of the
expressed proteins. In principle, this now al-
lows studying the quantitative interactome as
a function of the underlying proteome. To
generate model systems that closely recapit-
ulate the in vivo condition, we have previ-
ously developed bacterial artificial chromo-
some (BAC) transgeneomics: Green fluores-
cent protein (GFP)-tagged proteins are ex-
pressed in mammalian cell lines from BAC
transgenes with near-endogenous expression
patterns18. Combining these cell lines with
the quantitative proteomics workflow resulted
in a versatile and highly specific method that
we termed quantitative BAC-GFP interactom-
ics (QUBIC)19. Here, we applied QUBIC in
a proteome-wide manner, assembling a large-
scale map of the human interactome with an
unprecedented wealth of information. We ad-
dress the strengths of interactions by a novel
quantification strategy in three dimensions.
Our approach directly reveals stable complexes
via their characteristic stoichiometry signa-
ture among a large majority of weak, substoi-
chiometric interactions. This study establishes
a new concept for quantitative interactome
studies.
Quantitative BAC-GFP interactomics
Collections of strains or cell lines express-
ing tagged proteins are indispensable tools for
many systems biology approaches20,21. Ex-
pressing tagged proteins from engineered BAC
transgenes maintains the endogenous pro-
moters, intron-exon-structures and regulatory
elements, ensuring near-endogenous expres-
sion levels and patterns18,22. We have previ-
ously used this system to study chromosome
segregation and the function of motor pro-
teins23,24. To map the human protein inter-
actome globally, we built on our previous work
and generated a resource of 1,330 stable BAC-
GFP HeLa cell lines (Fig. 1a and Supplement-
ary Table 1). Mouse BACs are excellent sur-
rogates for their human counterparts and of-
fer additional options, such as resistance to
RNAi against the endogenous counterparts25,
allowing verification of the functionality of the
tagged proteins23,24. In 615 cell lines, we used
mouse BACs with a median sequence identity
of 94% with their respective human orthologs
(Extended Data Fig. 1 a). Overall, this human-
centric collection encompasses 1,125 distinct
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bait proteins, across all protein classes (Exten-
ded Data Fig. 1 b-d) some of which are present
as both mouse and human forms, or individu-
ally tagged on both termini. For all cell lines,
we performed QUBIC in three biological rep-
licate experiments, resulting in 3,990 LC-MS
runs recorded on an Orbitrap mass spectro-
meter in a net measurement time of around
one year (Fig. 1 b). To define specific inter-
actors, we employed MaxLFQ, the label-free
quantification (LFQ)module of theMaxQuant
software26,27. Bait proteins and their inter-
actors are characterized by quantitative co-
enrichment when tracing their intensity pro-
files across many samples (Fig. 1 b–c). Select-
ing threshold criteria for accepting a given can-
didate as interactor is a critical step during
data analysis. Whereas previous studies of-
ten used empirical cut-offs28 or relied on data
randomization29,30 or reference datasets31, we
developed an entirely data-driven and false dis-
covery rate (FDR)-controlled approach, har-
nessing asymmetries in the outlier distribu-
tions of enrichment factors (Extended Data
Fig. 1 e–f).
In addition to local co-enrichment, we found
the intensity profiles of interacting proteins to
be closely correlated globally (Online Meth-
ods). Such profile correlations alone can
indicate protein interactions when proteome
samples are subjected to extensive native
fractionation32,33. Here we employed them
as additional classifiers of our interactions16.
The combination of enrichment FDRs and pro-
file correlation coefficients defines the con-
fidence class of each interaction (Extended
Data Fig. 1 g). Because this approach does
not require gold standards of known interac-
tions or non-interactions34, nor subtracts pre-
sumed contaminant proteins35, it allows us to
retain weak and commonly blacklisted inter-
actors, such as chaperones and cytoskeletal or
ribosomal proteins. Our analysis resulted in
28,504 unique and statistically significant inter-
actions involving 5,462 distinct proteins (Sup-
plementary Table 2).
Interaction stoichiometries and protein
abundances
A second dimension of quantification can
be applied to determine the stoichiometries
of proteins within complexes36,37. These
can be computationally extracted from label-
free affinity purification data with remarkable
accuracy38. If a stable protein complex con-
tained one copy of each subunit, they should all
be retrieved in equimolar amounts after IP39,40.
However, measured stoichiometries between
preys and baits span orders of magnitude in
practice. Limited kinetic and thermodynamic
stability can result in substoichiometric recov-
ery of interacting proteins. Proteins may reside
in many different molecular assemblies with
fractions of their cellular pools. Finally, the cel-
lular abundance of an interactor can be a limit-
ing factor for howmuch is recoverable after IP;
therefore, cellular copy numbers must be de-
termined as a third quantitative dimension in
a separate experiment.
For each pair of interacting proteins, we first
quantified their stoichiometry in the immun-
oprecipitates using a label-free strategy that
combines the MaxLFQ algorithm with a nor-
malization step accounting for the varying
detectabilities of different proteins41 (Online
Methods). To determine the precision of our
method, we systematically compared label-free
interaction stoichiometries from experiments
where the same bait proteins were tagged on
different termini, or where we had data from
both human and mouse bait orthologs (Exten-
ded Data Fig. 2 a–e). The results showed a high
degree of reliability (r ≈ 0.8) and a precision
within a factor of three. Importantly, there
were no systematic biases introduced by the
position of the tag or the BAC species. This
validates our approach and demonstrates re-
markable conservation of protein interactions
across species. Next, we performed a deep
proteomic sequencing experiment on the par-
ental HeLa cell line that all our BAC-transgenic
lines are derived from. In one day of measure-
ment time per replicate, we reached a depth of
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about 9,000 proteins. To estimate cellular pro-
tein abundances, we applied a similar label-free
approach and scaled the values to copies per
cell42,43 (OnlineMethods). The proteomedata-
set provided cellular copy numbers for 5,305
proteins from the interactome dataset, cover-
ing 97% of all interactors (Fig. 1 d). Only a
small minority of proteins were found as inter-
actors, but escaped detection in our proteome
data, which we attribute mostly to low cellu-
lar abundance. The abundances of interacting
proteins closely follow the distribution of bait
abundances, covering the entire dynamic range
of the proteome. This demonstrates that our
BAC-based system closely recapitulates the in
vivo situation, enabling us to probe the inter-
actome as a function of the endogenous cellu-
lar proteome.
Quantifying the interactome in three dimen-
sions
The combination of interaction stoichiomet-
ries and relative cellular abundances of inter-
actors paint a unique picture of the interactome
that remained unexplored in previous studies.
This stoichiometry plot (Fig. 2 a) is a power-
ful tool to organize long lists of interactors,
because each region reflects a different scen-
ario (Fig. 2 b): Stable, one-to-one and fully re-
covered complexes in which the partners have
equal cellular abundance appear around the
origin of the plot (case 1 in Fig. 2 b). Super-
stoichiometry, the recovery of more prey than
bait, is only expected for stable complexes con-
taining more prey than bait copies. Indeed, we
find few substantially superstoichiometric in-
teractions. If interactions are weak and com-
plexes dissociate partially during IP, or if inter-
actions involve only part of the bait pool, inter-
actors are recovered at substoichiometric levels
(case 2), reflecting lower occupancy of interac-
tion interfaces of the bait. A vast predomin-
ance of sub- over superstoichiometry confirms
that stability and occupancy are the main de-
terminants for most interactions. Many stable
interactions featured abundance stoichiomet-
ries greater than one (case 3). This reflects 1:1
binding of a more abundant prey, such as the
interaction of the abundant GTP-binding pro-
tein RAN with its guanine-nucleotide releas-
ing factor RCC1 or that of α-tubulin with the
NEK9 kinase (see Supplementary Table 2). The
reciprocal interaction stoichiometry readouts
are necessarily smaller than one, because any
higher abundant bait can maximally recover
the entire pool of its lower abundant prey
(case 4). This would also be the default case
for overexpressed baits. Substoichiometric
interactions are retrieved over an estimated
five orders of magnitude; for example, NEK9
is recovered at 6 ⋅ 10−6× the amount of α-
tubulin. The proteome-interactome relation-
ship – which implies that there should be few
points below the diagonal – together with the
dynamic range limit, results in a characteristic
triangular shape of the ‘cloud’ of interactions
(Fig. 2 a).
About 10% of our interactions connected
members of well-characterized complexes an-
notated in the CORUM database44. They pop-
ulate a confined area characterized by a sig-
nature of balanced stoichiometries (case 1 in
Fig. 2b). These findings suggest that subunits
of prototypical complexes are mostly part of
one predominant, stable complex type in the
cell and that their abundances are regulated
to avoid an excess of unbound members. Ex-
trapolating from the signature of know com-
plexes, we reasoned that inference of stable
complexes should be possible solely from the
stoichiometry signature of individual baits as
opposed to analysis of the entire network45,46.
We filtered our data for those featuring the
core stoichiometry signature (dashed circle
in Fig. 2 c), yielding a larger cluster connect-
ing several molecular assemblies such as ma-
jor cytoskeletal proteins, the nuclear pore
complex and the ribosome as well as 194
isolated putative core complexes (Fig. 2 d).
These recapitulated the majority of CORUM-
annotated complexes that involve our bait pro-
teins (Fig. 2 e).
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Figure 2 | The stoichiometry plot.
a Overlay of all interaction and abundance stoichiometry data for all interactions. The characteristic
triangular shape is a consequence of the dynamic range limits in the interactome (left border), in the
proteome (top border) and the stoichiometry limit imposed by the relative cellular protein abundances
(diagonal). b Schematic interaction scenarios: (1) Equal cellular abundance, stable interaction. (2)
Equal cellular abundance, weak interaction. (3) Stable interaction where cellar abundance of the prey
is higher than that of the bait. (4) Reciprocal case where a stable interaction retrieves the entire
pool of the less abundant prey. c Stoichiometry plot of interactions between proteins annotated as
CORUM complex members. The area of highest density can be approximated by a circle containing
58 % of those interactions (dashed circle, centre: 0, –0.5; radius: 1). d Sub-networks of interactions
matching the CORUM-characteristic stoichiometry signature. Known interactions annotated in UniProt
or CORUM are displayed in red. e Quantification of the CORUM overlap. 125 isolated networks
remain unannotated; 70 networks are annotated with 548 partially redundant CORUM terms; 286
terms assigned to our baits were not recovered as interactions. f Size distribution of annotated vs.
unannotated networks.
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We confirmed the known tendency of large
complexes to be well annotated33, while smal-
ler assemblies lacked previous description
(Fig. 2 f). The largest of our 125 networks with
no database annotation was the recently dis-
covered COMMD/CCDC22/CCDC93 (CCC)
complex47. The stoichiometry plot offers a
unique opportunity for comparing the over-
lap of our dataset with published data (Exten-
ded Data Fig. 3 a–c). For instance, the intersec-
tionwith a recent co-fractionation interactome
study33 closely recapitulated the core-complex
signature. Conversely, the overlap with iRef-
Web, a portal of consolidated protein interac-
tions from different sources48, reached much
further into the substoichiometric region. Fi-
nally, the modest overlap with recent large-
scale yeast-two-hybrid data3 was mostly lim-
ited to cases characterized by quantitative prey
recovery to the extent permitted by cellular
abundance. Moreover, the stoichiometry plot
quantitatively confirmed the intuitive notion
that high-stoichiometry interactions are easier
to detect as they are enriched in the 1 % FDR
compared to the 5% FDR cohort (Extended
Data Fig. 3 d–e). This is also reflected in the
agreement of gene ontology (GO) annotations
in pairs of interacting proteins (Extended Data
Fig. 3 f).
Interactions explain phenotypes and genetic
associations
Our dataset provides an extensive resource that
can be mined for poorly characterized protein
interactions to gain insight into biological pro-
cesses. In the following, we investigate cases of
both new stable core complexes and substoi-
chiometric assemblies. Our dataset suggested
a novel stable complex involving SUCO and
TAPT1, two integral membrane proteins of the
endoplasmic reticulum (Fig. 3 a–c). Mutants
of their murine orthologs exhibit severe de-
fects during skeletal development: Truncation
of TAPT1 causes transformations in the axial
skeleton and perinatal lethality49, whereas loss
of the SUN domain-containing ossification
factor SUCO (also known as OPT) impairs
postnatal bone formation, causing fractures
and neonatal death50. The latter study linked
the phenotype to impaired rough ER expan-
sion and consequent failure of osteoblasts to
secrete collagen required for bone formation.
Knockdown of human SUCO increased the
cells’ resistance against ricin, whose toxicity
depends on endocytosis and retrograde traf-
ficking to the ER51. Similarly, the yeast ortho-
log of TAPT1, EMP65 (YER140W), is involved
in protein folding in the ER and shows buf-
fering genetic and physical interactions with
the SUNdomain protein SLP1 (YOR154W)52,53.
We used our interactionmethodology onGFP-
tagged strains to confirm this complex in
yeast. Although EMP65 consists almost en-
tirely of transmembrane segments, we found
clear evidence for their interaction irrespect-
ive of which served as bait (Extended Data
Fig. 4 a–b). Similarly, we validated the recip-
rocal interaction in the mammalian system us-
ing TAPT1 as bait (Extended Data Fig. 4 c). To-
gether, these data and our findings establish
TAPT1–SUCO as the higher eukaryote ortho-
log of SLP1–EMP65: a novel, low abundant ER
membrane complex (Extended Data Fig. 4 d),
which is required for skeletal development.
Going beyond stable complexes, we discovered
an interaction between the anaphase promot-
ing complex or cyclosome (APC/C) and the
uncharacterized protein KIAA1430. The stoi-
chiometry plot indicated that KIAA1430 is of
lower cellular abundance and not an oblig-
ate member of the APC/C, as the partners
were recovered substoichiometrically at ∼1 %
of the respective baits in reciprocal experi-
ments (Fig. 3 d–e). In interphase, a fraction of
GFP-tagged KIAA1430 localized to the centro-
somes, in particular the centrioles, and was
largely excluded from the nucleus (Fig. 3 f),
while theAPC/C is predominantly nuclear19,54.
During mitosis, after nuclear envelope break-
down (NEBD), APC/C accumulates onmitotic
spindles, centromeres and centrosomes54,55,
reflecting a partially common localization with
KIAA1430.
91
●
5 A quantitative map of the human interactome
Consistently, we confirmed the APC/C–
KIAA1430 interaction in mitotically arrested,
but not in interphase cells (Fig. 3 g). To func-
tionally investigate the mitotic interaction, we
used time-lapse microscopy to determine the
time cells require from NEBD to the onset
of anaphase as a function of APC/C activ-
ity. KIAA1430 knockdown resulted in a mild
delay that was sensitive to reversine, a small
molecule inhibitor of the mitotic checkpoint
kinase MPS1 (Fig. 3h–i, ref. 56). These findings
suggest that the depletion of KIAA1430 activ-
ates the spindle assembly checkpoint, thereby
postponing the activation of the APC/C. Re-
cent reports identified the ciliary protein hem-
ingway (HMW) as the Drosophila ortholog of
KIAA1430 (ref. 57) and implicated the APC/C
in regulating ciliary length and polarity58,59.
Given that centrioles are common features of
cilia and centrosomes, our data suggest that in
human cells, KIAA1430 recruits a sub-fraction
of the APC/C to the centrosome to facilitate
mitotic progression.
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Figure 3 | The TAPT1–SUCO complex and the KIAA1430–APC/C interaction.
a Volcano plot of SUCO interactors. b Stoichiometry plot indicates that TAPT1 and SUCO form a core
complex. c Immunofluorescence imaging of C-terminally GFP-tagged TAPT1 and SUCO in HeLa shows
ER localizations. d Stoichiometry plot of APC/C interactors (bait: CDC23) identifies KIAA1430 (red) as
substoichiometric binder. e Stoichiometry plot of KIAA1430 interactors shows APC/C subunits (blue)
as substoichiometric interactors. f Maximum intensity projections of living interphase and mitotic cells
expressing KIAA1430-GFP and histone 3.1-iRFP indicate that KIAA1430 localizes to centrioles. gWestern
blot analysis of ANAPC3 IPs from interphase and mitotically arrested cells expressing KIAA1430-LAP.
hWestern analyses showing the extent of KIAA1430 depletion before and after the time-lapse analyses
presented in panel i. i Time KIAA1430-depleted cells require to proceed from NEBD to anaphase,
compared to control cells (n=300 each). Adding 0.5 µM reversine rescues the delay (n=200 each). Red
lines: mean. Significance according to two-tailed Mann-Whitney test. Scale bars: 10 µM.
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These examples illustrate how the combina-
tion of three quantitative dimensions offers a
unique view on the interactions of individual
proteins and facilitates their functional invest-
igation. We have compiled this information
into an easily usable resource, provided as Sup-
plementary Data and available via the IntAct
database upon publication: For each of the
1,330 tagged cell lines, we present a concise,
one-page summary outlining the abundance of
the bait protein, the co-enrichment and con-
fidence classification of candidate interactors
along with the stoichiometry plot and the pre-
dictions of the core complexes. A reading guide
is presented in Extended Data Fig. 5.
The relevance of weak, substoichiometric in-
teractions
Our study revealed that interactions within ob-
ligate complexes constitute only a small minor-
ity of the interactome. We reasoned that the
majority of remaining interactions, which we
refer to as ‘weak’, should be of a function-
ally and conceptually different nature, as indic-
ated by our example of the KIAA1430–APC/C
interaction. To directly investigate the in-
terplay of strong and weak interactions on a
biologically relevant example, we interrogated
the chaperonin TRiC (also called CCT) that
is known to act on a large number of client
proteins60. Its coremachinery of eight subunits
was clearly identified as an abundant obligate
complex (Fig. 4 a), and represents a promin-
ent hub in our interactome dataset. Virtually
all interactors co-enriched with tagged TRiC
core subunits were co-chaperones, regulatory
proteins or proteins containing known sub-
strate motifs61 (Extended Data Table 1). Char-
acteristic of all was lower cellular abundance
than TRiC (except for some cytoskeletal pro-
teins) and substoichiometric recovery, classify-
ing these interactors as distinct from the core
subunits. We consistently found the unchar-
acterized protein FAM203A/B as a weak inter-
actor. Its ortholog in C. elegans shows a cyto-
skeletal knockdown phenotype62, which we
found to be reminiscent of phosducin proteins.
TRiC requires these to fold actin and tubulin63
and we therefore speculate that FAM203A/B
might have a similar function.
In reciprocal experiments, TRiC core complex
members were co-enriched by 5% of all bait
proteins (Fig. 4 b, Extended Data Table 2). This
is in line with estimates of TRiC being in-
volved in folding of 5–10% of the proteome60.
However, only some of these baits were also
found in TRiC IPs. This asymmetry can be
explained with knowledge of the underlying
proteome: At 1.3 million copies of the hexade-
cameric complex, TRiC is much more abund-
ant than most substrates, of which only a frac-
tion will be in the process of folding at any
given time (Supplementary Table 3). Con-
sequently, only a minute fraction of the TRiC
pool will be acting on each substrate and its
recovery will be ‘diluted’ to substoichiomet-
ric levels. In the reciprocal case, however,
TRiC occupies a significant fraction of the cli-
ent protein population – the fraction in the
state of folding – rendering the interaction
more readily detectable within the dynamic
range (Fig. 4 b). The stoichiometry of TRiC
recovery in the substrate IPs ranges from less
than 10−3 to above 10−1 (Fig. 4 b). As TRiC
substrates are thought to comprise 5–10% of
all protein molecules60, which we estimate at
6 ⋅ 109 protein molecules per HeLa cell, our
stoichiometry data imply that on average 0.2–
0.4% of them are bound to the chaperone at
any time. While the stoichiometry readout
classified these interactions as ‘weak’, they fulfil
an important function as they connect a very
diverse set of protein classes. Moreover, our
data suggest that a proteome–interactome re-
lationship balances the amount of TRiC with
the cumulative amount of its substrates.
Extrapolating from our chaperone example,
we wondered whether the differences between
‘strong’ and ‘weak’ interactions, as judged by
their stoichiometry readout, carry over to
other characteristics. First, we investigated
whether interaction stoichiometry is indic-
ative of co-expression across tissues or cell
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Figure 4 | The TRiC interactome is defined by weak links.
a Stoichiometry plot of N-terminally tagged CCT3 interactors as a representative TRiC subunit. b Re-
ciprocal stoichiometry plot of the averaged positions of the TRiC subunits from all bait pull-downs
that co-enrich at least three TRiC subunits. Symbol shapes and colours indicate the category of the
interactors; symbol size is scaled according to profile correlation.
types. To this end, we extracted protein
abundance correlation profiles across many
tissues from a recent human proteome draft
dataset64. While co-expression coefficients
scattered widely, there was a notable relation-
ship with interaction stoichiometry (Extended
Data Fig Fig. 6 a): strong, stoichiometric in-
teractors were more likely to be coherently
expressed. This is in agreement with earlier
findings in yeast showing that members of
stable complexes are enriched in co-regulated
modules65. Conversely, ‘weak’ interactions in-
volve proteins that are not necessarily tightly
co-regulated across conditions.
Next, we tested how strong and weak interac-
tions behave with regard to their role in net-
work topology and analysed a sub-network of
interactors surrounding RNA polymerases I, II
and III. Our data recapitulated shared subunits
and interactions with other complexes, such
as general transcription factor complexes, the
negative elongation factor (NELF) complex,
the mediator complex and the polymerase-
associated factor (PAF) (Fig. 5 a). Sequen-
tial removal of substoichiometric interactions
from the network led to fragmentation events,
in which the individual complexes gradually
lose their interconnections and emerge as in-
dividual modules (Fig. 5 b). Finally, the three
polymerases remain internally connected via
their shared subunits.
Taking this approach to a global level, we then
probed the response of our entire network to
the in silico removal of edges according to their
stoichiometry characteristics. Seminal studies
on the topology of networks have used sim-
ilar approaches, showing that scale-free net-
works are resilient to random removal of edges,
but sensitive to targeted attacks66. Specific-
ally, removal of the topologically most critical
edges led to rapid fragmentation of the net-
work. We targeted edges for removal agnostic
to their global network properties, but solely
by their local stoichiometry readout, compar-
ing preferential removal of strong vs. weak
interactions with random removal. This re-
vealed vastly different network characteristics
of weak and strong interactions. The weakest
interactions turned out to be most critical for
network topology: Their preferential removal
led to a rapid increase of the number of isol-
ated network fragments, whereas removing the
strongest 50% of edges hardly resulted in any
network fragmentation (Fig. 5c). The largest
connected component, which causes the typ-
ical ‘hairball’ appearance of large-scale net-
work, shrunk about linearly with removal of
weak interactions (Fig. 5d) and also left more
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Figure 5 | Strong and weak interactions have different global properties.
a Sub-network of complexes surrounding RNA polymerases I/II/III. Proteins are colour-coded by known
complex memberships, edges are color-coded by protein correlation coefficient, edge widths rep-
resent interaction stoichiometries. b Effect of removal of weak, substoichiometric interactors on the
polymerase network. The grey area visualizes how the network size changes with sequential removal of
substoichiometric interactions. Points where removal of an edge fragments the network into separate
networks are indicated. The sizes of individual networks are then separated by white lines. c Global
network effect of random or targeted removal of interactions on the total number of isolated sub-
networks. d Effect on the number of proteins present in the largest entirely connected sub-network.
e Effect on the fraction of total connected proteins that are part of this largest sub-network until a
minimum is reached.
proteins entirely unconnected (Extended Data
Fig. 5 a).
Conversely, preferential removal of strong in-
teractions led to a network response that in-
creased its small-world characteristics: the
largest network encompasses the vast majority
of connected proteins (Fig. 5e), fewer proteins
are left without connections (Extended Data
Fig. 5b) and isolated network fragments are
smaller (Extended Data Fig. 5 c).
Together, these analyses indicate that interac-
tion stoichiometries, which are ‘local’ proper-
ties extracted from single interaction experi-
ments, predict the ‘global’ behaviour of the pro-
teins involved: Strong interactions are indic-
ative of proteins that are co-regulated across
cell types. In the network, they form modules
of high interconnectivity, rendering the net-
work topologically resilient to their removal.
Weak interactions, on the other hand, domin-
ate the network both in numbers and by their
topologically critical role as long-range inter-
actions between more diverse sets of proteins.
As a consequence of this investigation, inter-
action networks can be fragmented into indi-
vidual, definedmodules, by identifying and re-
moving weak links. In summary, availability
of interaction stoichiometries on a global scale
effectively allows us to ‘comb’ the interactome
hairball, to identifymodules and visualize their
interconnectedness.
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Discussion
Here we have introduced a novel concept of
interactome analysis. Using an efficient, low-
stringent IP protocol, accurate label-free quan-
tification of both the IPs and the complete pro-
teome, we extracted three quantitative dimen-
sions, all of which proved critical for charac-
terizing protein interactions. While the first
dimension identifies statistically significant in-
teractions, the second and third dimension
define their stoichiometric contexts. Earlier
large-scale studies did not address these addi-
tional dimensions, in part because of the chal-
lenges involved in extracting accurate quant-
itative values. Moreover, past studies often
employed overexpression of bait proteins, pre-
cluding meaningful stoichiometry readout22,
and near-complete proteome coverage was
not attainable. Finding stable protein com-
plexes is usually a major goal of interactom-
ics studies14,33. We showed that obligate pro-
tein complexes feature a unique signature of
balanced stoichiometries – an infrequent oc-
currence among the multitude of interactions
documented here. Such a signature led us to
discover TAPT1-SUCO, a low abundant integ-
ral membrane complex of the ER. This com-
plex elegantly ties together a body of available
evidences, including knockout phenotypes of
both TAPT1 and SUCO and genetic interac-
tions of their yeast orthologs. This mani-
festation of genotype as phenotype may ap-
ply to many of the complexes and interactions
provided here67.
As a representative of the majority of weaker,
non-obligate interactions, we characterized the
binding of KIAA1430 to the APC/C, suggest-
ing that low interaction stoichiometries are
the result of an interaction that is limited to
centrioles in mitotic cells. We provided func-
tional data pointing at a role of KIAA1430
in recruitment of APC/C to centrioles, failure
of which delays cell cycle progression. Our
stoichiometry-based classification subdivided
the interactome of the TRiC chaperonin into
obligate core subunits, regulatory interactors
and a large number of substrates. We find that
lack of reciprocal verification can be indicative
of an inherently asymmetric nature of true and
biologically relevant interactions, particularly
outside obligate core complexes. This example
also illustrates how the observed interactome is
shaped by protein abundances and, conversely,
implies overall regulation of protein abund-
ances by protein interactions. Therefore, the
interactome always has to be interpreted as a
function of the underlying proteome.
Substoichiometric interactions have frequently
gone undetected in interactome studies and
may be thought to be less important; never-
theless they have been suggested to be cru-
cial features of all networks68. Our study dir-
ectly and quantitatively demonstrates the pre-
dominance of ‘weak’ interactions in the pro-
tein interactome. MS-based methods cover
more than four orders of magnitude of interac-
tion stoichiometry28, and our low-stringency
biochemical workflow ideally harnesses this
sensitivity. However, substoichiometric in-
teractions involving low abundance preys can
still be challenging to detect (Extended Data
Fig. 3 d–e). Therefore, the prevalence of weak
interactions is likely to be even more pro-
nounced and their relevance vastly underap-
preciated. Previous studies typically recor-
ded all interactions as equal, except for statist-
ical scores. Therefore, the roles of individual
interactions had to be predicted from prior
knowledge or from global network properties.
Highly connected proteins were described as
interaction hubs, regions of high clustering
coefficients withmany shared pathway annota-
tions were characterized as complexes45,46, and
weak interactions were inferred from weaker
connectivity patterns14. However, this is prob-
lematic because of the limited coverage of ex-
isting datasets. For the first time, we have
showndirectly that local stoichiometry data re-
flect global network topological properties of
interactions, setting the stage for quantitative
network analysis from the ground up. Weak
links form the ‘glue’ that holds the cellular net-
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work together – as we have shown specific-
ally for the RNApolymerase network and glob-
ally for the entire network – and are hence
much more important for network structure.
This property, which may seem counterintuit-
ive at first glance, has been shown for mobile
communication networks before69, indicating
that it is a feature of networks in general. If
weak links are removed, networks collapse into
defined modules that are tightly interconnec-
ted by strong links. Translated into biological
terms, stable complexes would remain in isol-
ation, but without weak links, they would not
be able to connect to each other or to transient,
dynamic regulators.
A major contribution of this study lies in the
characterization of the interactomes surround-
ing more than 1,100 different baits, which to-
gether cover a large part of the expressed pro-
teome with more than 28,000 high confidence
interactions. We present our results in an ac-
cessible format that can be easilymined and in-
terpreted by non-specialists. Our resource of
mammalian cell lines expressing GFP-tagged
proteins under endogenous control can also
be employed for other studies, for example fo-
cusing on subcellular localization or functional
characterization of individual proteins. The in-
teraction data validate these cell lines for such
uses. We approach saturation with respect to
the number of coverable proteins (Extended
Data Fig. 7 a), but observe only part of the en-
tire interactome directly, which we predict to
encompass between 80,000 and 180,000 de-
tectable interactions in HeLa (Extended Data
Fig. 7 b). Our additional quantitative dimen-
sions may prove helpful for increasing inter-
actome coverage in silico, for example by se-
lective matrix expansion6. Given its useful-
ness in interpreting interaction data, the stoi-
chiometry readout developed here can become
a general basis for future interactome studies
and for the analysis of interactome dynamics,
whichwillmanifest foremost as quantitative al-
teration of occupancies rather than qualitative
gain or loss of interactors.
Methods
Cell culture
HeLa Kyoto cell lines expressing N- or C-
terminally GFP tagged proteins from BAC
transgenes were generated and cultured as pre-
viously described18. For APC3 immunoprecip-
itations, cells were arrested in mitosis with
330 nM nocodazole (Sigma) using a double
thymidine block and release protocol70. His-
tone 3.1-iRFP expressing cells were created by
gene targeting as described earlier71. All BAC
cell lines and exact tag sequences are listed in
Supplementary Table 1 along with proteome
and interactomemetadata on the bait proteins.
For interaction experiments, cells were grown
to near-confluency on two 15 cm cell culture
dishes per experiment, detached with accutase
(PAA) and snap frozen. Replicates samples
were harvested in at least two different pas-
sages. Immunofluorescence imaging was per-
formed as described23.
Affinity-purification–mass spectrometry
Cell pellets were lysed and subjected to affin-
ity purification on a robotic system and sub-
sequent single-shot mass spectrometric ana-
lysis on an Orbitrap instrument as previously
described19. We processed triplicates separ-
ately on different days and carried out MS-
analyses in randomized order over the course
of weeks to months, to minimize any influence
of column carryover and drifts in instrument
performance.
Whole proteome measurements
HeLa cells were lysed in guanidinium chlor-
ide lysis buffer and digested sequentially with
LysC and trypsin as described72. Peptides
were desalted on stacked C18 reverse phase
(Waters Sep-pak) and strong cation exchange
cartridges and eluted using 70% acetonitrile.
Pooled eluates were separated into six fractions
on strong anion exchange (SAX) StageTips73.
MS measurements were performed in three
replicates on a quadrupoleOrbitrapmass spec-
trometer as described72.
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Data processing
Raw files were processed with MaxQuant26
(version 1.3.9.10) in seven sets, each contain-
ing ∼600 AP-MS runs and the HeLa pro-
teome fractions. MS/MS spectra were searched
against a modified version of the November
2012 release of the UniProt complete human
proteome sequence database. For each bait
protein expressed from a mouse BAC locus,
the human sequence in the fasta file was con-
catenated with the mouse sequence (unless
identical), to enable the identification of pep-
tides unique to the mouse sequence. For all
steps of protein quantification, we employed
MaxLFQ,MaxQuant’s label-free quantification
(LFQ) algorithm27. This algorithm compares
the intensities of individual peptides across
runs and calculates an LFQ intensity profile for
each protein group, while retaining the abso-
lute component of the sum of peptide intensit-
ies. Thereby they also serve as a proxy for abso-
lute molar protein abundance, when normal-
ized by the number of theoretical tryptic pep-
tides expected for each protein41. We required
one ratio count for each pair-wise comparison
step and activated the FastLFQ settingwith two
minimum and two average comparisons to en-
able the normalization of large datasets inman-
ageable computing time (one week per set on a
desktop workstation).
Detection of protein interactions
Protein identifications were filtered, removing
hits to the reverse decoy database as well as
proteins only identified by modified peptides.
We required that each protein be quantified
in all replicates from the AP-MS samples of at
least one cell line. Protein LFQ intensities were
logarithmized and missing values imputed by
values simulating noise around the detection
limit. For each protein, a non-parametric
method was used to select a subset of samples
that provide a distribution of background in-
tensities for this protein (SupplementaryMeth-
ods). This subset was used first to normalize all
protein intensities to represent relative enrich-
ment, and then to serve as the control group
for a two-tailed Welch’s t test. Specific out-
liers in the volcanoplots of logarithmized p val-
ues against enrichments were determined by
an approach making use of the asymmetry in
the outlier population (Extended Data Fig. 1 e–
f). We used two cut-offs of different stringen-
cies, representing 1 and 5% of enrichment false
discovery rate (FDR), respectively. Correlation
coefficients between the intensity profiles of in-
teracting proteins were calculated as additional
quality parameters16. Enrichment FDR (classes
A, B and C) and profile correlation (modifier +
or –) define the confidence class of an interac-
tion (Extended Data Fig. 2 g).
Estimation of binding stoichiometries and
cellular copy numbers
Estimating stoichiometries requires the com-
parison of the amounts of different proteins re-
lative to each other in one IP. To this end, we
first subtracted the median intensity across all
samples to account for the proportion due to
unspecific binding. We then divided LFQ in-
tensities by the number of theoretically observ-
able peptides for this protein, as in the iBAQ
method41. This corrects for biases introduced
by different lengths of the protein sequences
and the frequency and distribution of proteo-
lytic cleavage sites. Finally, we expressed stoi-
chiometries relative to the bait protein. Cellu-
lar copy numbers and abundances were calcu-
lated using a similar approach43 on the whole
proteome data and brought to absolute scale
by normalization to a total protein amount of
200 pg in a cell volume of 1 pl for aHeLa cell.
Network analyses
Network analyses were performed based on
the data listed in Supplementary Table 2 using
custom-made plugins in the Perseus environ-
ment that is part of MaxQuant. For the pur-
pose of counting unique interactions and for
the histogram of the numbers of interactors,
we regarded interactions as non-directional,
flattened multiple protein groups mapping to
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the same gene name and to the most abund-
ant isoform and considered interactions found
multiple times only once. For network per-
turbation analyses, we selected all non-self-
interactions of confidence classes A+, A, B+,
and assembled them into graphs. We then re-
moved edges sequentially according to their
interaction stoichiometry readout. Prey-bait
combinations discovered multiple times were
treated as separate edges. Once a protein had
lost all its edges, it was removed. As control,
we deleted edges randomly and represented the
median of 100 random repetitions, and repres-
ent the scatter as the first or third quartile ±1.5
interquartile ranges.
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Hein et al. Extended Data Figure 1
Extended Data Figure 1 | a Amino acid sequence identities for the BAC-GFP lines expressing tagged
proteins from the mouse locus. Median sequence identity is 94 %, and 90 % of all mouse BAC lines show
sequence identities greater 75 %. b-d Test for biases of the selection of baits as well as interacting and
non-interacting proteins compared to the HeLa proteome by Gene Ontology (GO) Slim annotations.
We calculated the percentages of all annotations that apply to >1 % of all proteins. The red solid
line indicates no bias. Dashed lines indicate two-fold over- or underrepresentation. b The selection
of bait proteins shows a slight enrichment of annotated, well-studied proteins. Metabolic enzymes,
mitochondrial and extracellular proteins are slightly underrepresented, whereas known complex
members or proteins involved in processes we studied earlier23,24 are overrepresented. Membrane
proteins are represented according to their fraction in the proteome. c Interacting proteins show
no biases beyond those of the bait selection and no bias of more than two-fold. d Comparison of
annotations of proteins found in the interactome vs. never found as interactors showed similar trends.
Moreover, it revealed an overrepresentation of nuclear proteins and the term ‘‘organelle organization’’
(which includes cytoskeletal proteins), highlighting the relevance of protein interactions in these
compartments. e ‘Hawaii’ plot: overlay of all volcano plots of protein enrichments in specific over
control IPs plotted against corresponding p values. Two cut-off lines were placed graphically according
to the given formula, defining confidence classes A and B. Confidence class C is defined by enrichment
>2 standard deviations without crossing the threshold for classes A or B. f Definition of the cut-off curve
parameters x0 (minimum enrichment) and c (curvature). The point cloud is largely symmetric to the
y-axis, while meaningful outliers are only expected on the right side (enrichment), but not on the left
side (depletion). Any axially symmetric cut-off curve will result in a number of left-sided outliers (false
hits) and right-sided outliers (potentially true hits). Conceptually related to the target-decoy approach
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for peptide and protein identification, the fraction of the left-sided outliers to the total number of
outliers serves as an FDR estimate. For a given FDR (shaded areas), a combination of x0 and c can be
selected that maximizes the number of right-sided outliers (red lines). Our cut-offs of 1 % and 5 % FDR
are indicated by dashed lines. g We combined the enrichment FDR with protein profile correlation
coefficients across IPs16 to define confidence classes. Classes C and C+ represent cases that did not
cross the FDR threshold, but showed enrichments >2 fold and correlation coefficients >0.4 and 0.5,
respectively. Numbers in brackets represent the numbers of hits for a given confidence class. Note that
the number of unique interactions is lower as bait proteins also represent hits and some interactions
may be found several times or involving several isoforms.
Extended Data Figure 2 (opposite page) | a Correlation of interaction stoichiometries values derived
from cell lines using human and mouse ortholog bait sequences (n=103). b Correlation of interaction
stoichiometries values derived from cell lines using N- and C-terminal tags on the same bait sequence
(n=50). c No systematic biases between human/mouse and N/C-terminal tags and a precision of
stoichiometries within a factor of three. d 50 representative examples for mouse vs. human. e 40
representative examples for N- vs. C-terminal tag.
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Hein et al. Extended Data Figure 3
Extended Data Figure 3 | a Overlap of our data with published interaction data obtained by protein
correlation profiling33. bOverlap with relevant interactions in iRefWeb (human; physical; experimental;
pairwise or multi-subunit interactions). c Overlap with the ‘‘HI-II-1’’ Y2H dataset3. Red contour lines
separate areas in steps of 1.5-fold increased point density. d Stoichiometry plot of all interactions
with FDRs <1 %. e Stoichiometry plot of all interactions with FDRs between 1 and 5 %. f Overlap of
GO-annotations between pairs of well-annotated proteins (> annotated terms each).
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Hein et al. Extended Data Figure 4
Extended Data Figure 4 | a SLP1-GFP pull-down using a strain from the S. cerevisiae GFP library21.
b EMP65-GFP pull-down. c Reciprocal confirmation of the TAPT1-SUCO interaction in HeLa. d Cellular
abundance plot showing copy numbers of TAPT1 and SUCO in the HeLa proteome. In all plots, bait
proteins are marked in red and relevant interactors in blue.
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Extended Data Figure 5 | Reading guide for the Supplementary Data. a Cell line metadata.
b Volcano plot of protein enrichment factors vs. negative logarithmized p values as well as threshold
lines for different interaction confidence classes. c Cellular abundance plot showing the abundance
of the bait in the HeLa proteome. d Stoichiometry plot of interaction and abundance stoichiometries
relative to the bait protein.
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Extended Data Figure 6 | a Protein co-expression correlation coefficients (from ref. 64) as a function
of interaction stoichiometries. b Effect of the random or targeted removal of interactions on the total
number of connected proteins (proteins with ⩾ 1 interactions). c Effect on the average size of networks
isolated from the largest network.
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ExtendedData Figure 7 | aNumber of distinct interactors as a function of the number of BAC-GFP line
analysed. Solid lines represent the median of 100 trajectories in randomized order; the scatter indicates
the standard deviation from bootstrapping with 100 repetitions. Dashed lines are projections based
on a linear model n = nmax((1− e)−bx
c
) that was fit to the data in the range between cell lines #500 and
#1330. The model predicts 6240 and 6420 proteins, respectively, to be coverable. b Number of distinct
interactions as a function of the number of BAC-GFP lines analysed, with projections representing an
analogous fit of an exponential model. The model predicts 84,400 and 183,500 as the asymptotic
numbers of distinct interactions that can be covered with the highest or with all confidence classes,
respectively.
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Extended Data Table 1 | Proteins co-enriched with GFP-tagged TRiC subunits. Listed are all prey
proteins that scored as interactors in at least two sets of TRiC pull-downs. Numeric values represent
medians of all evidences.
Hein et al., Extended Data Table 2 
 
Bait Type 
Corre-
lation 
# of 
TRiC 
sub-
units 
log10
interaction 
stoichio-
metry 
log10
abundance
stoichio-
metry 
CCT7 
TRiC core 
0.788 8 0.243 0.166
CCT4 0.720 8 -0.002 0.020 
CCT3 0.692 8 -0.005 -0.084 
CCT8 0.813 8 -0.025 0.142 
CCT4 0.790 8 -0.059 0.027 
CCT2 0.742 8 -0.149 -0.115 
TUBA3
cyto-
skeleton 
0.233 8 0.190 NA 
TUBA3 0.226 8 -0.181 NA 
TUBG1 0.310 8 -0.609 0.836 
TUBG1 0.310 8 -0.733 0.836 
TUBG1 0.310 8 -0.873 0.836 
TUBG1 0.185 8 -0.934 0.855 
TUBA1 0.371 8 -1.759 -0.577 
TUBE1 0.081 6 -2.193 2.121 
ACTR1 0.099 7 -2.636 2.218 
TUBE1 0.096 3 -2.912 2.226 
ACTB 0.084 4 -3.585 -0.880 
ACTR2 0.285 8 -1.843 0.583 
PPP4C 
phospha-
tases 
0.173 8 0.074 1.275 
PPP2C 0.280 8 -0.794 0.437 
PPP2C 0.133 8 -0.822 0.315 
PPP2C 0.182 8 -0.906 0.323 
PPP6C 0.362 8 -1.012 1.230 
IGBP1 0.274 8 -1.406 1.378 
WDR61 
WD 
domain 
protein 
0.103 8 1.085 0.675 
WDR48 0.106 8 0.010 1.414 
GNB1 0.244 8 -0.248 0.679 
RFWD3 0.155 8 -0.308 2.650 
NSMAF 0.194 8 -0.361 2.513 
DDB2 0.129 8 -0.866 1.552 
STRN3 0.258 8 -1.486 1.740 
DTL 0.103 8 -1.501 3.123 
STRN3 0.258 8 -1.522 1.740 
NEDD1 0.119 8 -1.930 2.142 
KIF21B 0.114 7 -2.090 2.929 
KIF21A 0.047 8 -2.109 1.566 
WRAP5 0.056 8 -2.156 1.717 
CDC20 0.203 7 -2.222 2.013 
STRN 0.322 8 -2.224 1.345 
PRPF4 0.138 8 -2.473 1.106 
SEH1L 0.107 4 -2.792 1.028 
NEDD1 0.413 8 -2.656 2.098 
NEDD1 0.413 8 -1.053 2.098 
BUB3 0.105 3 -3.766 1.026 
SAMM5
other 
0.134 8 -0.401 1.288 
NIPSN 0.136 8 -0.832 1.172 
PDK3 0.140 8 -1.022 2.989 
HDAC1 0.182 8 -1.276 0.614 
ARMC6 0.144 8 -1.647 1.622 
JAK3 0.103 4 -1.941 4.128 
XRCC3 -0.009 4 -2.331 3.967 
ILK 0.107 7 -2.636 1.545 
CDK1 0.219 4 -3.655 0.337 
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ExtendedData Table 2 | Proteins co-enriching TRiC. Listed are all bait proteins in whose pull-downs
at least three TRiC core subunits were scored as interactors. Numeric values represent medians of all
TRiC subunit values.
Hein et al., Extended Data Table 2 
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phospha-
tases 
0.173 8 0.074 1.275 
PPP2C 0.280 8 -0.794 0.437 
PPP2C 0.133 8 -0.822 0.315 
PPP2C 0.182 8 -0.906 0.323 
PPP6C 0.362 8 -1.012 1.230 
IGBP1 0.274 8 -1.406 1.378 
WDR61 
WD 
domain 
protein 
0.103 8 1.085 0.675 
WDR48 0.106 8 0.010 1.414 
GNB1 0.244 8 -0.248 0.679 
RFWD3 0.155 8 -0.308 2.650 
NSMAF 0.194 8 -0.361 2.513 
DDB2 0.129 8 -0.866 1.552 
STRN3 0.258 8 -1.486 1.740 
DTL 0.103 8 -1.501 3.123 
STRN3 0.258 8 -1.522 1.740 
NEDD1 0.119 8 -1.930 2.142 
KIF21B 0.114 7 -2.090 2.929 
KIF21A 0.047 8 -2.109 1.566 
WRAP5 0.056 8 -2.156 1.717 
CDC20 0.203 7 -2.222 2.013 
STRN 0.322 8 -2.224 1.345 
PRPF4 0.138 8 -2.473 1.106 
SEH1L 0.107 4 -2.792 1.028 
NEDD1 0.413 8 -2.656 2.098 
NEDD1 0.413 8 -1.053 2.098 
BUB3 0.105 3 -3.766 1.026 
SAMM5
other 
0.134 8 -0.401 1.288 
NIPSN 0.136 8 -0.832 1.172 
PDK3 0.140 8 -1.022 2.989 
HDAC1 0.182 8 -1.276 0.614 
ARMC6 0.144 8 -1.647 1.622 
JAK3 0.103 4 -1.941 4.128 
XRCC3 -0.009 4 -2.331 3.967 
ILK 0.107 7 -2.636 1.545 
CDK1 0.219 4 -3.655 0.337 
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In this thesis, I presented an interactomics dataset that covers a large part of the human
protein interactome. I developed methods for proteomic quantification in both the re-
lative and the absolute dimensions. Combining both enabled a unique analysis of the
strengths of protein interactions, the discovery of novel protein complexes and a better
understanding of the nature and topology of the interactome network.
6.1 The future of proteomic quantification
Label-free quantification is rapidly gainingmomentum in our group (which ironically is
most renowned for the invention of SILAC [49]). SILAC still remains powerful in some
areas that rely on labelled spike-in references. For instance, protein correlation profiling
methods result in fractions of very different composition [84]. The assumption underly-
ing the label-free normalization procedures is overall similarity of sample composition,
which is not the case here. A SILAC standard accounts for this by providing a ‘local’ ref-
erence. Moreover, super-SILAC spike-ins [85] have their merits for applications where
samples are to be measured on different machines, in different laboratories or over long
periods of time. Local normalization by SILAC references accounts for such biases. For
virtually all other research applications, label-free strategies are superseding SILAC –
even in areas such as phosphoproteomics.
Work presented here contributes to this development by providing a framework for rel-
ative and absolute proteomic quantification. The MaxLFQ algorithms for relative label-
free quantification have proven very mature in a large number of diverse projects in
our group. A critical ingredient is the ease of use of MaxLFQ at the click of a button in
MaxQuant, doing awaywith computational obstacles that non-specialist users otherwise
have to face.
A challenge that needs to be addressed in the future is the accuracy of label-free absolute
quantification, which currently only provides estimates. Proper quantification schemes
acquire one quantitative piece of evidence per peptide and become very accurate by av-
eraging over many of them. In contrast, label-free absolute estimation approaches such
as ‘top three’ or iBAQ rely on the empirical observation that peptide-specific behaviour
can be neglected if one integrates over many peptides derived from one protein. There-
fore, the combination of the protein sequence and the protease used for digestion may
introduce a quantification bias [86]. This bias is more prominent for proteins with only
few peptides and conceptually difficult to control for.
Even with this limitation in mind, our ‘proteomic ruler’ already provides a very con-
venient and straightforward way for many proteomics projects to implement absolute
quantification into the data analysis workflow. The proteomic ruler method should be a
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welcome tool for the proteomics community and widen the perspective of scientists that
have so far only looked at ratios of protein amounts between conditions and neglected
absolute abundances.
Quantification in multiple dimensions clearly appears to be the way into the future for
proteomics. Irrespective of the actual quantification methodology, the computational
back-end should integrate all available label-based and label-free quantification events
and transform the quantitative readout into the following format: A comprehensive
– ideally complete – matrix of identified proteins and their absolute quantities in all
samples. All values should be properly normalized so that quantitative comparisons can
be made both across samples and across proteins (Fig. 6).
Figure 6: Future of proteomic quantification.
The ideal protomics quantification strategy should result
in a comprehensive matrix of absolute protein abund-
ances that can be compared quantitatively both across
samples and across proteins.
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6.2 The future of interaction proteomics
The interactomics work presented here built on ‘wet lab’ and MS procedures that have
matured into a very robust tool for cell biology. I have applied this tool in focused collab-
oration projects in diverse biological areas. Moreover, in a joint effort with TonyHyman’s
group and with the help of a team of technicians, we have shown that we are are able to
investigate the human interactome globally.
Our interactomics platform is gradually adopted by the life science community, but
some misconceptions remain. First and foremost, many life scientists still see AP-MS
as conceptually different from classical immunoprecipitation followed by western blot-
ting, which it is not. We just replace the western blot with a mass spectrometric readout.
They also assume our technology to be less sensitive and noisier. Given the five orders
of dynamic range seen in the human interactome dataset, this is clearly not the case. To-
gether with Eva Keilhauer, I have shown that our affinity enrichment workflow is at least
as easy, if not easier than conventional methods and any laboratory with access to high
resolution mass spectrometry could and should adopt it.
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One major area of improvement presented here is the data analysis side. The workflow
consisting of generic label-free quantification inMaxQuant, and standardized statistical
testing in Perseus, combined with FDR-controlled threshold definition provide a prin-
cipled approach for the analysis of any kind of protein interactions. The quantitative
protein profile correlations across samples serve as additional criteria to narrow down
borderline interactors and cases of alternative complex compositions, mutually exclus-
ive binding or protein moonlighting. Moreover, the signature of background binding
proteins provides a built-in quality control metric that comes entirely ‘for free’ and that
western blot-based approaches lack in principle. A novel concept for the analysis of
the human interactome was to apply multiple dimensions of relative absolute proteo-
mic quantification. This has the potential to become a new standard for analysing and
visualizing protein interaction data.
The ‘wet lab’ side of the workflow is largely based on protocols borrowed from classical
protein biochemistry, with the exception of improvements such as the shift from 1D gel
electrophoresis to on-bead or in-column digestion. While individual interactomics ex-
periments are now straightforward to perform, a global interactomics study requires
considerable amounts of input material and MS measurement time: Data acquisition
for our human interactome dataset took almost four years and a substantial amount of
molecular biology and cell culture work. This poses obstacles for continued exploration
of the interactome, for instance if one seeks to study the human interactome dynamically
or to extend the work to other species.
In light of improvements in mass spectrometer speeds as well as laboratory automation
and miniaturization, it would now be logical to implement radical changes also on the
‘wet lab’ side. The goal is a substantial decrease in the sample requirements and a dra-
matic increase in throughput, without compromising on data quality. In this regard, a
major challenge will be to maintain the dynamic range of interactome detection while
scaling down the amount of input material. Given the dynamic range of interaction
strengths, the weakest interactors will be the first ones lost when one reduces measure-
ment time or input material. Recent studies have introduced an orthogonal method for
protein interaction detection, based on protein correlation profiling across extensively
fractionated cell extracts [87, 88]. Thismethod provides a straightforward shortcut to the
core set of protein complexes. What distinguishes our approach, however, is the ability
to capture a wealth of weak interactions in a quantitative fashion, in addition to stable
core complexes.
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6.3 The nature of the interactome
My analysis into the stoichiometric nature of obligate, stable protein complexes revealed
that these are a small minority in the interactome dataset. Looking at the entire inter-
actome space, it is conceivable that the distribution of interaction strengths follows a
power law, similar to the distribution of the degree of connectivity in the network: Most
proteins will have very low affinities to most proteins, whereas only few proteins engage
in strong interactions with few select other proteins. The dynamic range of interaction
strengths will likely be much wider than the dynamic range of protein concentrations
in the cell, rendering most weak interactions functionally irrelevant. However, bioin-
formatic analyses suggest that weak, non-specific interactions are a driving force for the
evolution of the proteome [89]. In this sense, protein concentrations are maintained at
theminimum levels that allow for specific interactions, keeping deleterious, non-specific
interactions to a minimum. This concept also sheds additional light on the increasing
specialization of cell types and compartmentalization inside the cell in higher organisms,
because increasing complexity in one compartment hampers specific interactions while
boosting non-specific ones. Weak, non-specific interactions are also a playground for
evolution to form functionally relevant links.
An important consequence of the dynamic range of interaction strengths is that weak
interactions form the ‘glue’ of the network by interconnecting virtually all proteins in
the cell. This poses a challenge for the visualization of large networks, as they inevit-
ably grow into impenetrable ‘hairballs’ with size [43]. On a personal note, I initially felt
that hairballness or small-worldness of a network was a sign of bad data quality and a
high fraction of false positives. However, I learnt that small-worldness is the very nature
of networks in general and the protein interactome in particular. The predominance of
weak interactions is also likely to be an underappreciated cause for the minimal overlap
between different large-scale datasets. Strong interactions are easy to detect and there-
fore reproducible, but they constitute only the minority of all interactions. Weak inter-
actions are by their nature more difficult to detect, making them less reproducible.
One aspect of the interactome that I highlighted in my thesis is its tight interconnec-
tion with the underlying proteome. Protein abundances are critical determinants of the
outcome of an interaction experiment: Interactors may be missed if the bait is much
more abundant in the cell, while they may be recoverable easily in the reciprocal experi-
ment. At first glance, this can be seen as just a feature of the immunoprecipitation assay.
However, it is more than that, as it is indicative of an inherent asymmetry of the interac-
tion. The majority of the pool of the less abundant partner might be bound to the higher
abundant partner, which in turn only finds a fraction of its pool engaged in this interac-
tion. This asymmetry that is the consequence of the intertwined proteome-interactome
relationship is likely to extend to other tiers in the omics space (see Fig. 3). Genetic
interaction phenotypes may be asymmetric because of the abundances of the products
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of the interacting genes, and because of the asymmetries in their corresponding phys-
ical interactions. Establishing systematic, fully quantitative, cross-omics approaches will
become strong tools for the future of systems biology.
With global, sophisticated, quantitative, sensitive and increasingly fast interactomics
methods at hand, one might ask the question of whether we will ever be able to draft a
reference human interactome or to map the complete interactome? This question takes
us back to the definition of the interactome itself. As a metaphor, one could equate the
sequencing of the human genome to drawing a topographicalmap of an island, sayGreat
Britain. Initially, there are blank areas on the map, but over time the map will become
more refined and exact. Calculating the landmass area will be relatively accurate once
all regions have been explored at least once and all further mapping will only lead to
incremental improvements. At a certain point, one will come up with a reference map.
This map would be the equivalent to the human genome, which serves as anchor point
for many follow-up studies. In this analogy, mapping the human proteome is like the at-
tempt to measure the length of the coastline. The length of the line depends on the scale
of measurement due to its fractal properties [90]: The smaller the scale, the longer the
measurement. On an infinitesimally small scale, the coastline becomes arbitrarily long.
This illustrates the meaninglessness of the concept itself: There is no one human pro-
teome or a reference thereof. The more one measures, the deeper one will get, but one
will never achieve completion. In this sense, drafting a reference human interactome
is the equivalent of measuring the 3D surface area of Britain. It depends on the scale
of measurement and changes constantly, both of which make it an equally impossible
task. However, we will gain enormous insight from trying to get deeper and deeper if we
redefine our goal as the process itself.
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SUMMARY
We present a genetic interaction map of pairwise
measures including 40% of nonessential S. pombe
genes. By comparing interaction maps for fission
and budding yeast, we confirmed widespread con-
servation of genetic relationships within and between
complexes and pathways. However, we identified an
important subset of orthologous complexes that
have undergone functional ‘‘repurposing’’: the evolu-
tion of divergent functions and partnerships. We
validated three functional repurposing events in
S. pombe and mammalian cells and discovered that
(1) two lumenal sensors of misfolded ER proteins,
the kinase/nuclease Ire1 and the glucosyltransferase
Gpt1, act together to mount an ER stress response;
(2) ESCRT factors regulate spindle-pole-body dupli-
cation; and (3) a membrane-protein phosphatase
and kinase complex, the STRIPAK complex, bridges
the cis-Golgi, the centrosome, and the outer nuclear
membrane to direct mitotic progression. Each
discovery opens new areas of inquiry and—
together—have implications for model organism-
based research and the evolution of genetic systems.
INTRODUCTION
Understanding the relationships between gene products is
fundamental to biology. Measuring genetic interactions (GIs),
the extent to which the function of one gene depends on a
second, is an unbiased way of determining functional relation-
ships and has proven to be a powerful technique for discovering
gene function, grouping genes into complexes, and organizing
them into pathways (Tong et al., 2004; Schuldiner et al., 2005;
Ooi et al., 2006; Roguev et al., 2008; Costanzo et al., 2010;
Horn et al., 2011). The development of high-density, quantitative
assays for GI mapping in the budding yeast S. cerevisiae (Sc)
led to numerous findings. For example, maps of endoplasmic
reticulum (ER) and mitochondrial genes led to the discovery of
the complex responsible for very-long-chain fatty-acid biosyn-
thesis (Denic and Weissman, 2007), identification of the GET
complex and other factors responsible for tail-anchored mem-
brane protein insertion (Schuldiner et al., 2008, 2005; Costanzo
et al., 2010; Jonikas et al., 2009), discovery of the SPOTS
complex as a regulator of sphingolipid homeostasis (Breslow
et al., 2010), and identification ofMitOS as a determinant of mito-
chondrial morphology (Hoppins et al., 2011). GI maps of other
pathways have led to a range of insights, including discovery
of novel mechanisms of epigenetic control (Collins et al., 2007;
Costanzo et al., 2010; Dai et al., 2008).
These discoveries speak to the power of GI analysis to group
genes into complexes and to chart connections between path-
ways independently of a priori knowledge. But how plastic are
genetic pathways over the course of evolution? In addition to
searching for novel factors and pathways in the fission yeast
Schizosaccharomyces pombe (Sp), we sought to determine
systematically the extent to which conserved genes have
adapted to serve in different roles with different partners. It is
a fundamental consequence of evolution that conserved genes
encode macromolecules with conserved biochemical proper-
ties. Yet gene-to-phenotype relationships are not as predictable.
For example, hypoxanthine-guanine phosphoribosyltransferase
(HGPRT) catalyzes purine monophosphate generation in every
organism, but mutations in yeast lead to abnormal mitochondrial
genome maintenance and cisplatin resistance (Kowalski et al.,
2008), whereas mutations in humans lead to the neuropsychi-
atric signs of Lesch-Nyhan syndrome. Developmental biologists
have noted that orthologous genes have been repurposed to
control the morphologies of distinct body parts in highly diver-
gent organisms (Niwa et al., 2010). Furthermore, point mutations
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in the active sites of metabolic enzymes can change substrate
specificity or electron transfer steps with profound phenotypic
consequences (e.g., IDH1/2, Dang et al., 2009). Finally, genetic
relationships have been reported to changemarkedly when cells
are challenged with a stress like DNA damage (Bandyopadhyay
et al., 2010).
Efforts to study functional repurposing have been limited by
a lack of global comparisons. Work in Sp nowmakes large-scale
comparisons to Sc possible. Fission yeasts diverged from
budding yeasts 500 million years ago, and their genomes
show no synteny (Rhind et al., 2011). Efforts to curate the
genomes of Sp and Sc have identified a shared subset of
4,450 apparent orthologs (Wood, 2006). In light of extensive
GI data generated in Sc, availability of a Sp deletion collection
(Kim, et al., 2010), high-throughput methods for generating Sp
double mutants (Roguev et al., 2007; Dixon et al., 2008), and
annotation of orthologous genes in these organisms, we saw a
unique opportunity to assess how often conserved genes
acquire new functions and partners over the course of evolution.
In addition to an evolutionary analysis, functional mapping in
Sp is valuable for discovering new cell biology. Investigators
from many disciplines have reported that certain aspects of Sp
are better models of metazoan biology. For example, they
possess (1) an RNAi pathway, (2) repetitive centromeres, (3)
G2/M cell-cycle control, (4) contractile ring-driven cytokinesis,
and (5) complex heterochromatin and splicing regulation (Saba-
tinos and Forsburg, 2010; Rhind et al., 2011). Some of these
processes have been studied extensively, whereas others have
received limited attention. We intended to characterize func-
Figure 1. Data Set Overview and Reproduc-
ibility Benchmarks
(A) Functional classification of genes in the map.
(B) Scatter plot comparing scores from reciprocal
crosses.
(C) Scatter plot of correlation coefficients between
genetic interaction (GI) profiles for query versus
array pairs of strains.
See Figures S1 and S2 for additional information
about how we generated our Sp GI map.
tional repurposing through evolution
and to identify processes in which Sp
genetics can predict the properties of
mammalian cells.
We report that many genes displayed
conserved patterns of GI, and that core
complexes or modules displayed highly
correlated patterns of GI (Roguev et al.,
2008; Dixon et al., 2008). However, an
important subset of conserved genes
manifested divergent genetic relation-
ships. By comparing the functional pro-
files of annotated orthologs, we identified
genes that had acquired new partners
or were participating in different or addi-
tional pathways in Sp versus Sc. We
chose three disparate cases of diver-
gence for detailed investigation. Our findings reveal organelle
homeostasis mechanisms and mitosis control factors. Consid-
ered together, our findings suggest applications for model
organism-based research and impact our view of evolution.
RESULTS AND DISCUSSION
S. pombe Genetic Interaction Map
We evaluated pairwise GIs for 1,297 alleles in G418-marked
‘‘array’’ strains crossed against 597 nourseothricin (NAT)-
marked ‘‘query’’ strains (Figure S1 available online). Strains
harboring 1,503 unique gene deletions and 64 unique hypomor-
phic (Degron-DAmP; Schuldiner et al., 2005; Breslow et al.,
2008) alleles of essential genes were used to generate 774,309
double mutants (expanding by 8-fold the number of GIs
measured in Sp; Figure 1A). Interaction scores were determined
by comparing the observed fitness of the double mutants with
the typical fitness determined empirically from the expected
penalty associated with each mutation (Figure S2) (Collins
et al., 2010). Our map consists of a matrix of GIs for 40% of
the nonessential genome. Each row and column corresponds
to the GI profile for one allele and is a phenotypic signature.
We sorted the rows and columns of the matrix using hierarchical
clustering such that neighbors have similar functional profiles.
The resulting map is modular: correlated genes cluster together
as a result of their shared GIs (Figure S3).
Multiple metrics for evaluating the data set argued for its
quality. First, biological triplicate measurements revealed that
the scores are reproducible (overall correlation of 0.78).
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Second, the same triplicate sets measured 6–12 months later
remained highly correlated (0.72). We also assessed the
reproducibility of scores identified for reciprocal crosses: two
scores that derived from independent measurements in which
the antibiotic-resistance marker and the mating type of each
strain were swapped (query A 3 array B versus query B 3 array
A). Query strains and array strains have different histories and are
subjected to different storage and growth conditions during the
assay and consequently may have differences in fitness. Despite
these differences, the correlation of 0.65 for scores derived from
reciprocal crosses is comparable to the highest quality Sc
studies (Figure 1B) (Baryshnikova et al., 2010; Collins et al.,
2010; Hoppins et al., 2011). From the scorematrix, we computed
pairwise correlations for all pairs of alleles from cells of the same
mating type background and the reproducibility of the correla-
tions observed between profiles (Figure 1C). Irreproducible
correlations between profiles do occur as the majority of scores
are between unrelated genes, but the diagonal is enriched with
gene-to-gene correlations that are reproducible whether the
strains being compared are h or h+ pairs.
Our Sp map identified > 700 high-confidence gene-to-gene
correlations indicative of genes with related functions. Many of
these are internal validations because they are known to be
related (Figures 2A and S3). Among the most notable clusters
of genes, our analysis identified correctly the relationships
between factors involved in the contractile ring, glycosylation,
autophagy, retromer and ESCRT pathways, protein folding
and quality control, the peroxisome, the G2/M transition,
spindle and kinetochore assembly, lipid biosynthesis, hypoxia
responses, clathrin adaptors and SNARE complexes, prefoldin,
ubiquitin ligases and substrate adapters, mannosyltransferase
and N-acetyltransferase complexes, mitochondria import and
export, G protein-coupled receptor signaling, the Elongator
complex, mRNA splicing, histone deacetylases, and the relation-
ship between the alternative translocon and ER membrane
protein complex (Data S1 and S2; Figures 2A and S3).
How reliable are such pairwise correlations for identifying
bona fide functional partners? In addition to the reproducibility
within a single data set as shown in Figure 1C, the adoption of
high-throughput GI assays by multiple groups makes it possible
to compare inter-lab reproducibility. We compared the Sc
gene-to-gene correlations reported by Costanzo et al. with those
reported by Hoppins et al. from a shared subset of interactions
that overlapped partially with orthologous interactions sampled
in our Sp study (500 interaction scores per profile). Gene-to-
gene correlations that exceed 0.4 between labs or within a
data set (Figure 1C versus Figure 2B) are highly likely to be repro-
ducible, true positives that are robust to differences in data
collection or analysis.
Functional Conservation versus Functional
Repurposing
Using this same subset of orthologous interactions, we com-
pared the gene-to-gene correlations observed in our Sp data
set with those observed in Sc (Figure 2C). As reported (Roguev
et al., 2008; Dixon et al., 2008), there is widespread functional
conservation of gene-to-gene relationships. This is true espe-
cially for known complexes and pathways that appear to have
descended from the last common ancestor unmodified (green,
Table S1). However, our systematic view also revealed subsets
of genes whose correlations in Sc were not observed in Sp
and another subset whose correlations in Sp were not observed
inSc (Figures 2B–2D; Table S1).We considered these to be plau-
sible cases of functional repurposing: the adaption of conserved
factors to serve additional or different roles in one organism
versus the other (Figure 2E). We computed amino acid sequence
comparison-based statistics for each case of highly correlated
pairwise relationships conserved between Sp and Sc (green),
versus relationships that are correlated in Sc but not Sp (cyan)
or Sp but not Sc (red). Lower amino acid similarity did not corre-
late with repurposing (Figure 2D, left), but lower percentage
coverage (i.e., additional motifs or domains present in only one
of the orthologs) did correlate with apparent repurposing (Fig-
ure 2D, right). At the same time, these genes appear to be unique
descendants of the same ancestral gene and to have adapted
within the system of one organism versus the other to serve
alternative functions.
Another explanation for some cases of divergent genetic rela-
tionships is the relative degree of redundancy within a pathway.
For example, inSp there are only two genes of theGOLD-domain
family of COP-II coat components (SPAC17A5.08 and
SPBC16E9.09). InSc, there are three homologs of SPAC17A5.08
(ERP2, ERP3, and ERP4) and two homologs of SPBC16E9.09
(ERP5 and ERP6). SPAC17A5.08 and SPBC16E9.09 share
virtually all of the same interactions in Sp, whereas none of the
pairwise comparisons of ERP2/3/4 versus ERP5/6 profiles
shared significant overlap in Sc (Figure 2C). This is expected
but also highlights the value of Sp as a model eukaryote: it
contains few paralogs, and thus there is an increased probability
of detecting relationships between nonredundant factors (Aslett
and Wood, 2006). A third explanation for divergent genetic
correlations is simply that these organisms have different depen-
dencies on a given process under the conditions of the assay
(‘‘organismal emphasis’’). For example, autophagy genes were
identified in Sc, but this analysis derived from growth on rich
media where autophagy genes display few robust interactions
in Sc. In Sp, autophagy pathway genes displayed strong interac-
tions under the conditions used in our protocol (Data S1 and S2).
As we were interested in functional repurposing, we selected
three disparate cases of divergence that we could not explain
by environmental dependencies or redundancy (Figure 2D; Table
S1). The divergence was evident when comparing correlations
from the subset of interactions used for Figure 2 and was clear
when comparing the entire data sets. Each case represents
a distinct pathway: the unfolded protein response (UPR),
spindle-pole-body (SPB) duplication, and mitosis. The genes
involved have strong GIs and robust—but different—correlated
partners in Sc versus Sp. Validation assays in all cases indicated
that these genes have evolved different genetic relationships and
serve in new or additional roles in fission versus budding yeast.
The UPR Requires Gpt1 and Ire1
Ire1 is a conserved transmembrane kinase and nuclease that
serves as the central sensor for misfolding stress in the ER. In
Sc, Ire1 senses ER stress via its lumenal domains, leading to
oligomerization and activation of Ire1’s nuclease to catalyze
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the unconventional splicing and activation of Ire1’s direct
and only substrate —the transcription factor Hac1. Active
Hac1 then induces the UPR transcriptional program (Walter
and Ron, 2011). This pathway is conserved, though in meta-
zoans, the IRE1 ortholog has additional outputs and substrates.
For example, in addition to splicing the Hac1 ortholog XBP1,
metazoan IRE1 degrades ER-localized mRNAs (Hollien and
Weissman, 2006; Hollien et al., 2009) thereby decreasing the
ER-folding burden in a pathway termed regulated Ire1-depen-
dent decay (RIDD). Conservation of the UPR in fission yeast
remains unclear: Sp possesses Ire1 but does not possess an
apparent Hac1/XBP1 ortholog.
Figure 2. Functional Conservation versus Functional Repurposing
(A) Distribution of correlation coefficients between GI profiles, with extreme cases of pairwise correlation and anticorrelation annotated as gene a - gene b.
(B) Scatter plot of correlation coefficients comparing Sc data reported by Hoppins et al. versus those of Costanzo et al. See Table S1 for a list of highly correlated
profiles and highly reproducible (green) correlation relationships.
(C) Scatter plot of correlation coefficients comparingGI profiles for Sp versus Sc. Highlighted examples of pairwise relationships that are correlated in Sp but not
Sc are listed below the scatter plot. Bold indicates functional relationships explored in this study. See Table S1 for additional examples of correlated pairwise
relationships conserved between Sp and Sc (green) and pairwise relationships that are correlated in Sc but not Sp (cyan) or Sp but not Sc (red).
(D) Amino acid sequence comparison-based statistics for Sp versus Sc orthologs highlighted in (B) and (C). Horizontal bars = median values. See Table S1 for
BLAST scores, E VALUEs, percent identities, and overlap.
(E) Functional repurposing: the functions of ancestral genes are unknown, but for the factors studied here, the apparent gene-to-gene and gene-to-phenotype
relationships in Sp are divergent from those in Sc.
For a global view of the Sp genetic interaction map, see Figure S3.
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In Sc, the functional relationship between IRE1 and HAC1 is
among the most compelling cases of an unbranched, linear
pathway. Accordingly, the GI profiles for IRE1 and HAC1 are
highly correlated (Figure 3B). The correlation between these
genes in Sc reflects their shared aggravating interactions with
genes involved in lipid biosynthesis, protein folding, glycosyla-
tion, and quality control—indicating that budding yeast are
dependent equally on both genes to survive ER stress
Figure 3. The UPR Depends on Gpt1/Cnx1 and Ire1
(A and B) Distribution of correlation coefficients for Sp Dire1 (A) compared with distribution of correlation coefficients for Sc DIRE1 (B) (when different, names for
Sc orthologs in gray text).
(C) Three-dimensional (3D) scatter plot forSp scores comparingDire1withDgpt1 on the x and y axes, respectively, and the calnexin ortholog cnx1-degron-DAmP
color-coded according to the inset scale.
(D) 3D scatter plot for Sc scores comparing DIRE1 with DHAC1 on the x and y axes, respectively, and the nonessential calnexin ortholog DCNE1 color-coded
according to the inset scale.
(E) Fold induction of normalized bip1 mRNA levels by qPCR in ER stress-inducing conditions. Each bar is the mean of three biological and three technical
replicates per strain per condition.
(F) Fold induction of GFP/RFP ratios in cells harboring a reporter system in which a Hac1p-responsive promoter drives green fluorescent protein corrected for
nonspecific expression changes by comparing GFP to coexpressed RFP from a constitutive (TEF2) promoter (Jonikas et al., 2009). Error bars represent standard
deviation (SD).
(G) Growth sensitivity of the indicated Sp strains to 20 mM DTT or 2.5 mg/ml tunicamycin.
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(Figure 3D). The profile for ire1 in Sp revealed many of the same
aggravating interactions (Figure 3C). Consistent with these GIs
and ire1’s presumed role in inducing the UPR, Dire1 cells are
sensitive to the ER protein-folding stressors DTT and tunicamy-
cin (Figures 3C, 3E, and 3G). However, instead of a transcription
factor like Hac1, ire1’s most highly correlated partners in Sp
were the UDP-glucose-glycoprotein glucosyltransferase (UGT)
(gpt1) and a calnexin ortholog (cnx1) (Figures 3A and 3C).
This is a remarkable and unexpected finding, as in Sp and
mammalian cells, Gpt1 and Cnx1 are core components of a
lectin-chaperone system for glycoprotein folding (Ellgaard and
Helenius, 2003). Misfolded proteins are recognized by Gpt1,
which then appends terminal glucose residues to the core oligo-
saccaharide. The calnexin ortholog Cnx1 recognizes the terminal
glucose modification made by Gpt1 and binds to glucosylated
substrates to facilitate folding (Sousa and Parodi, 1995;
Fanchiotti et al., 1998). The strength and reproducibility of the
correlations between ire1, gpt1, and cnx1 were among the
most robust relationships in the entire Sp data set (Figures 2A
and 3A). In Sc, the putative UGT is the essential enzyme KRE5.
TheGI profiles for temperature-sensitive and -constitutive hypo-
morphic alleles of this enzyme are consistent with its enzymatic
role—including significant correlations with CWH41 and the
calnexin ortholog CNE1—but neither its profile nor CNE1’s
show strong similarity to the profiles for IRE1 or HAC1.
The correlations between gpt1, cnx1, and ire1 in Sp imply a
fundamental functional connection between these distinct
sensors of misfolding—a connection that despite extensive
studies was not apparent in Sc. We probed this putative
functional connection by challenging Dire1, Dgpt1, cnx1-
Degron-DAmP single- and double-mutant cells with DTT and
tunicamycin, drugs that specifically disrupt ER protein folding.
As predicted by their overlapping genetic signatures, Dire1 and
Dgpt1 cells have the same sensitivities and transcriptional UPR
defects, whereas the double-mutant phenotypes are no stronger
than the single-mutant phenotypes (Figures 3E and 3G). By
contrast, budding yeast DCNE1 cells display robust Ire1-depen-
dent activation of Hac1 (Figure 3F). Moreover, KRE5 hypomor-
phic cells are insensitive to DTT and tunicamycin (Breslow
et al., 2008). Finally, KRE5 hypomorphs display no GI with
IRE1 or HAC1 (Costanzo et al., 2010). These results imply that,
in comparison with Sc, the conserved enzymes Gpt1 and Ire1
have been repurposed. The unanticipated connection between
these stress sensors raises many questions about how mis-
folded proteins are sensed and how stress signals are trans-
duced into differential outputs (e.g., transcription factor splicing
or RIDD) in fission yeast and mammalian cells.
ESCRT-III and Vps4 Proteins Regulate SPB Duplication
Studies in Sc led to the discovery and characterization of the
endosomal sorting complex required for transport (ESCRT)
genes in endosomal maturation (Hurley and Emr, 2006). Subse-
quent work in mammals confirmed the role of ESCRTs in multi-
vesicular body formation but also revealed that ESCRTs act as
membrane fission factors during enveloped virus budding (Rai-
borg and Stenmark, 2009; von Schwedler et al., 2003). Further
work in archaea (Samson et al., 2008; Lindås et al., 2008) and
in mammalian cells demonstrated that ESCRTs mediate the final
abscission step of cytokinesis (Carlton and Martin-Serrano,
2007; Morita et al., 2007). Finally, depletion of ESCRT-III and
VPS4 proteins was reported to producemultipolar spindles, sug-
gesting that these factors are required for centrosome dynamics
(Morita et al., 2010). The centrosomal defects in cells depleted of
ESCRT-III/VPS4 were profound: up to 80% of depleted HeLa
cells exhibit five or more centrosomes during the first mitosis
after siRNA treatment. Thus ESCRT genes serve in a diversity
of cellular pathways, but this diversity was not apparent in
pioneering Sc studies.
TheGI profiles between ESCRTs and the rest of the endolyso-
somal system were among the most robust in our study. In
addition to the expected interactions, vps32, vps24, and vps4
also displayed significant albeit weaker degrees of correlation
with two nuclear membrane proteins, apq12 and brr6, which
are determinants of SPB duplication (Figure 4A) (Tamm et al.,
2011). In fungi, the SPB has a bulky cytoplasmic microtubule-
organizing center (MTOC) that is separated from the nuclear
MTOC by the nuclear envelope (NE). Duplication of the cyto-
plasmic MTOC precedes insertion of the structure into the
nuclear membrane (Jaspersen and Winey, 2004). Brr6 and
Apq12 are recruited to SPBs and are required for SPB insertion
and NE integrity during SPB insertion (Tamm et al., 2011). In Sp,
apq12 and brr6 are most correlated with each other. In addition,
they display moderate correlations with components of the
TACC/TOG complex (alp7/alp14), which regulates spindle
formation (Sato and Toda, 2007), the NIMA kinase (fin1), which
regulates SPB duplication (Grallert et al., 2004), core SPB
components (cut11 and cut12) (West et al., 1998; Tallada
et al., 2009), and—unlike Sc—the ESCRTs vps4, vps32, and
vps24 (Figures 4A and 4B).
The correlation between brr6/apq12 and late ESCRTs reflects
their shared aggravating interactions with nuclear membrane
proteins implicated in SPB duplication, nuclear morphology,
and pore biogenesis (SPAC23C4.05c, pom34, nup97, ima1,
nem1/spo7 complex, Figure 4C). These genes also share
moderate aggravating interactions with regulators of mitosis,
spindle formation, and kintechore components (mis17, mis15,
mde4, rad26, and cut8, Figure 4C). By contrast, APQ12 and
VPS4 are uncorrelated in Sc (Figures 4B and 4D). The few shared
synthetic sick interactions include the Swr1 nucleosome-remod-
eling complex, which shows synthetic interactions with many
functionally unrelated genes (Figure 4D). With the exception of
POM152, interactions with genes implicated in the SPB, nuclear
pore, spindle, or kinetochorewere not observed inSc (Figure 4D).
These GI profiles suggested that, despite the extensive differ-
ences between yeast SPBs and mammalian centrosomes,
ESCRTs in Sp serve in an analogous role during the duplication
of MTOCs (Morita et al., 2010). This possibility is also suggested
by the report that deletion of the Sp ESCRT-II subunit dot2 leads
to overamplification of SPBs inmeiosis (Jin et al., 2005).We used
an integrated, constitutive marker of the SPB, Cut12-CFP, to
examine mitotic SPB phenotypes directly in ESCRT mutants
(Toya et al., 2007). As predicted, both Dvps4 and Dvps32 cells
displayed an overamplification of Cut12-CFP-labeled structures
(Figure 4E). Of these,Dvps4 led to themore penetrant phenotype
and was associated with large cytoplasmic bodies (Figure 4E).
We also noted that for both Dvps4 and Dvps32, the severity
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and penetrance of the phenotype decreased over time, perhaps
explaining why this phenotype was only observed in Ddot2 cells
during meiotic divisions.
We next explored in detail the possibility that ESCRT factors
regulate SPB dynamics in Sc. We examined four different SPB
proteins: the core component Spc42p, outer plaque (Cnm67p-
GFP) and inner plaque (Spc110p-GFP) components, and
gamma-tubulin (Tub4p-GFP) (Figures 4F and S4); however, we
were unable to observe any indication of SPB duplication or
fragmentation errors. Thus, both the global GI analysis and
focused studies indicate that the role of the ESCRTs in regulating
SPB duplication represents a novel activity not seen in Sc. In
addition to identifying another example of functional repurpos-
ing, these studies indicate that fission yeast will become an
important model for further study of ESCRT factors and their
role at centrosomes.
Figure 4. ESCRT-III Proteins and Vps4 Regulate SPB Duplication
(A and B) Distribution of correlation coefficients for Sp apq12 (A) compared with distribution of correlation coefficients for Sc APQ12 (B) (when different, names for
Sc orthologs shown in gray text).
(C) Scatter plot of mean scores for Sp apq12 and brr6 versus mean scores for vps32, vps24, and vps4. The following Sc orthologs have different names:
SPAC23C4.05c = MSC1, mik1 = SWE1, rad26 = LCD1, mis15 = CHL4, mde4 = LRS4, cut8 = STS1, kap111 = KAP122, nup97 = NIC96, and mph1 = MPS1.
(D) Scatter plot of mean scores for Sc APQ12 versus VPS4.
(E and F) DIC and fluorescence micrographs of the indicated cells expressing constitutive SPB markers (Cut12-CFP in Sp, Spc42p-GFP in Sc). For the frag-
mentation/duplication phenotypes observed in Sp, the percent penetrance ± SD is noted. In addition to Spc42p, outer plaque (Cnm67p-GFP), inner plaque
(Spc110p-GFP), and gamma-tubulin (Tub4p-GFP) marked strains were scored (see Figure S4).
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The FAR Complex Regulates Mitosis in Fission Yeast
In Sc, mating pheromones initiate signaling cascades that lead
to cell-cycle arrest (Elion, 2000). Multiple genes implicated in
this phenomenon have been named FAR (factor arrest) genes,
including a six-member complex composed of FAR3, FAR7,
FAR8, FAR9/VPS64, FAR10, and FAR11. Initial characterizations
indicated that mutation of this complex did not prevent phero-
mone-induced cell-cycle arrest but rather premature resumption
of budding (Kemp and Sprague, 2003). Sc studies have found
that the functional profiles of the FAR complex correlate with
one another and other factors (Figure 5B) (Hoppins et al., 2011;
Costanzo et al., 2010). Among the most salient, a moderate
degree of correlation between the FAR complex and protein
phosphatase type 2A (PP2A, PPG1 subunit) and notable anticor-
relation with a well-characterized factor arrest gene, FAR1,were
observed (Figure 5B). The shared interactions between compo-
nents of the FAR complex include the TORC2 kinase complex,
lipid synthesis, and ERMES complex genes (Figure 5D). These
finding are consistent with the idea that the FAR complex regu-
lates PP2A but suggest it has pleiotropic roles.
The FAR complex is an intriguing candidate for functional re-
purposing in that some of its constituents are unique to budding
yeast. FAR3 and FAR7 are only found in a restricted set of
budding yeasts (Figure S5) with no apparent orthologs in meta-
zoa orSp.Recently, an immunoprecipitation/mass spectrometry
(IP-MS) study of human PP2A complexes identified a homolo-
gous complex: the striatin-interacting phosphatase and kinase
(STRIPAK) complex (Goudreault et al., 2009). STRIPAK contains
the PP2A catalytic (PP2Ac) and scaffolding (PP2A A) subunits,
the striatins (FAR8 homologs that possess PP2A regulatory B00 0
domains), the transmembrane striatin-interacting proteins
(STRIP1 and STRIP2, FAR11 homologs), and the tail-anchored
membrane protein sarcolemmal membrane-associated protein
(SLMAP, a FAR10 homolog).
In addition to the above, STRIPAK contains a homolog of the
yeast protein Mob1 (Moreno et al., 2001; Goudreault et al.,
2009)—named MOBKL3 in human cells—that is a critical
component of the septation initiation network (SIN) in fission
yeast (McCollum and Gould, 2001). Multiple Mob1 homologs
exist in mammals, and their function as kinase activators
appears to be conserved (Hergovich et al., 2006). STRIPAK
assemblies also contain Ste20-family kinases (Goudreault
et al., 2009). The absence of FAR3 and FAR7 from Sp and
metazoa and the presence of additional proteins not found in
the Sc complex suggest that the cellular roles of STRIPAK
complexes have ramified. Recent studies have identified
STRIPAK as a regulator of the Hippo pathway (Ribeiro et al.,
2010), as a modulator of Ras-MAPK signaling (Horn et al.,
2011), and as a regulator of SIN in Sp (Singh et al., 2011).
The GI profiles for Sp far8 (SPBC1773.01), far10
(SPBC3H7.13), and far11 (SPBC27B12.04c) are correlated with
each other and—in contrast to Sc—with multiple genes involved
in cytokinesis and mitosis, including components of the actomy-
osin contractile ring (rlc1, cam2, fic1, rga8, imp2, ccd15, pxl1,
rga7, myp2), the CDC14 ortholog clp1, the kinase pck1, and
Golgi proteins zrg17, cis4, and SPCC613.03 (Figure 5A). This
pattern suggested that the FAR complex plays a role in mitosis
control in Sp. The correlations between FAR complex genes in
Sp reflect strong aggravating interactions with a PP2A regulatory
subunit (par1) and aggravating interactions with the mitotic exit
phosphatase (clp1 /CDC14), core components of the contractile
ring, and the catalytic PP2Asubunit (SPAC22H10.04) (Figure 5C).
Shared alleviating interactions include interactions between
different FAR subunits, a spindle attachment factor (mad1),
and a phosphatase (stp1) implicated in the G2/M transition
(Figure 5C).
These relationships suggest that the FAR complex regulates
PP2A-mediated mitotic transitions. Moreover, the strong aggra-
vating interaction between FAR complex genes and par1
suggests that the regulatory specificity conferred on PP2A by
the FAR complex can be compensated for in Sp by this alterna-
tive B subunit. Single mutants of far8, far10, and far11 do not
have striking phenotypes, as assayed by flow cytometry for
size and DNA content or by DIC imaging (Figure 5E). However,
as predicted by theirGIs, double mutants of FAR complex genes
with genes functioning in mitotic signaling, cytokinesis, or
abscission have profound phenotypes. Double mutations with
the type II myosin heavy chain myp2, an AAA ATPase we have
named ATPase-like fidgetin-1 (alf1), and the CDC14-related
protein phosphatase clp1 have abnormal morphologies and
enhanced ploidy as measured by flow cytometry and DIC
microscopy (Figure 5E). The aggravating interactions seen in
Sp were not observed in Sc. DFAR8 and DFAR10 cells do not
have cell-cycle defects, and double mutants with a ts allele of
CDC14 have the same maximum permissive temperature as
the single mutant CDC14-3 (32C). After 2 hr at 32C, single-
mutant CDC14-3 cells manifest clear shifts in ploidy and
bud hyperelongation. Double-mutant DFAR8/CDC14-3 and
DFAR10/CDC14-3 cells are indistinguishable from CDC14-3
single mutants (Figure 5E). Thus, as indicated by the systematic
GI data, the role of the FAR complex in directing late mitotic
events is not found in Sc.
STRIPAK Signaling Complexes Bridge the Golgi, the
Centrosome, and the Nuclear Membrane
We sought to determine whether the gene-to-phenotype rela-
tionships observed for the Sp FAR complex were predictive of
human STRIPAK complexes. The mitocheck consortium re-
ported that silencing of STRN (Far8) resulted in binuclear cells
and cell death (Neumann et al., 2010). We found that siRNA-
mediated depletions of core STRIPAK components, including
STRN3 (Far8) and STRIP1 (Far11), in HeLa cells resulted in
strong shifts from 2C to 4C DNA content (Figure 6A). Microscopy
of silenced cells corroborated the increase in DNA content and
revealed a range from binuclear to horseshoe- and torus-shaped
nuclei or fragmented nuclear remnants. Most remarkable, we
often observed that centrosomes and intact Golgi stacks were
found within the cavity of horseshoe- or torus-shaped nuclei
(Figures 6C, S6B, and S6C).
Given that STRIPs (Far11) and SLMAP (Far10) are membrane
proteins and depletion of STRN3 or STRIP1 led to Golgi ribbons
surrounded by dysmorphic nuclei, we sought to determine in
which organelle this complex resides. We generated HeLa lines
expressing STRN3-eGFP and STRIP1-eGFP from single-copy
bacterial artificial chromosomes (Poser et al., 2008) under
control of native promoters and untranslated sequences.
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Figure 5. the FAR Complex Regulates the Cell Cycle in Fission Yeast
(A and B) Distribution of correlation coefficients for Sp far8 (A) compared with distribution of correlation coefficients for Sc FAR8 (B) (when different, names for Sc
orthologs shown in gray text).
(C and D) Distribution of aggravating and alleviating GIs shared by the FAR complex genes in (C) Sp and (D) Sc.
(E) Flow cytometry analysis showing forward scatter (FSC, top panel) and DNA content histograms (PI, bottom panel) for wild-type (black) and mutant cells (red).
Traces represent mean values from triplicate experiments next to corresponding DIC images of representative cells. Bars, 3 mm. See Figure S5 for phylogenetic
analysis of Far3p and Far7p.
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Colocalization microscopy indicated that these proteins exist in
the Golgi (Figure 6D). To evaluate the functionality of the tagged
proteins, we purified them for analysis by mass spectrometry
and recovered the STRIPAK constituents reported previously,
including SLMAP, indicating that the Golgi-localized GFP fusion
proteins form functional complexes (Figure 6E).
Despite the copurification of SLMAP with striatin and STRIP
proteins, siRNA deletion of SLMAP produced a different pheno-
type, and SLMAP did not localize to the Golgi (Figures 7 and S6).
Depletion of SLMAP produced a subtle increase in 4C DNA and
S phase cells, whereas microscopy revealed a significant
increase in the number of pericentrin foci observed in interphase
cells (Figures 7A and 7C). This suggests that SLMAP serves as
a physical and signaling connection between the Golgi and
centrosomes and is important for SPB duplication or spindle
assembly. Early studies of SLMAP truncations revealed that it
Figure 6. STRIPs and Striatins Form a Golgi Complex that Regulates Mitosis
(A and B) Flow cytometry analysis showing DNA content histograms of HeLa cells treated with control siRNA targeting luciferase (black) or siRNAs to deplete
STRIPAK complex subunits (red). HeLa cell depletions reveal multinucleate cells and fragmented nuclei.
(C) HeLa cell depleted of STRIP1 (Far11) for 48 hr. Fluorescence staining shows centrosomes (red), Golgi (green), and nuclei (blue).
(D) HeLa cells harboring bacterial artificial chromosomes for eGFP-tagged STRN3 (Far8) or STRIP1 (Far11), demonstrating Golgi-like morphology and coloc-
alization with the Golgi-resident protein GIANTIN (red). See Figure S6 for additional colocalizations after siRNA depletion.
(E) Volcano plot representation of STRN3-interacting proteins. For each protein identified by IP-MS, the ratio of the intensities in the STRN3 IPs over the control
was calculated and plotted against the p value of a t test calculated from triplicates. The red curve is a cutoff calculated from false discovery rate estimation.
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can localize to centrosomes via the FHA domain, and that over-
expression of SLMAP truncations induces mitotic arrest (Guzzo
et al., 2004). C-terminal truncations of SLMAP localized to
centrosomes—however, the tail-anchored and full-length
membrane protein tagged at the N terminus localized to the
outer NE during interphase (Figure 7D). During mitosis, full-
length SLMAP localized clearly to centrosomes and the
membranous material surrounding the mitotic spindle after NE
breakdown (Figure 7E).
The presence of the striatins and STRIPs in theGolgi, the pres-
ence of SLMAP in the outer NE, the association between SLMAP
and centrosomes, and the copurification of MOBKL3 and
PP2A with the complex are important clues to one function of
the STRIPAK complex in human cells. Mob1-like proteins acti-
vate mitotic kinases after being recruited to the spindle poles
(Wurzenberger and Gerlich, 2011). Disruption of these signals
results in mitotic failures in yeast. Accordingly, when we
depleted MOBKL3 in HeLa cells, we observed nearly universal
spindle failures followed by cell death (Figures 7B and S6D). Inte-
grating these observations, we propose that human STRIPAK
complexes serve to direct mitotic signaling events (Figure 7G).
STRIPAK complexes appear positioned to regulate the activity
Figure 7. STRIPAK Signaling Complexes Bridge the NE, Centrosomes, and Golgi
(A and B) Flow cytometry analysis showing DNA content histograms of HeLa cells treated with control siRNA targeting luciferase (black) or siRNAs to deplete
SLMAP (Far10) or MOBKL3 (Mob1). HeLa cells were depleted of the designated proteins and labled for immunofluorescence. See Figure S6 for additional images
of siMOBKL3 phenotypes.
(C) Fraction of interphase cells with abnormal numbers of pericentrin foci following siRNA treatment. Errors bars represent standard error of the mean (SEM).
(D and E) HeLa cells transiently expressing mCherry-SLMAP and labeled for immunofluorescence. See Figure S6 for the lack of colocalization betweenmCherry-
SLMAP and the Golgi.
(F) Domain architecture of the FAR/STRIPAK components.
(G) STRIPAK model: striatin and STRIPs reside at the Golgi. Striatins serve as regulatory B00 0 subunits of a PP2A trimer. Striatin/STRIP recruit MOBKL3. STRIPs
interact with SLMAP in the outer nuclear membrane, bridging the Golgi, the centrosome, and the NE. These interactions are likely restricted to specific cell-cycle
phases, and the interaction between SLMAP and centrosomes predominates during mitosis. Disruption of STRIPAK leads to diverse failures during mitosis:
including centrosome duplication errors, spindle assembly errors, and cytokinesis failure. For related data, see Figure S6.
Cell 149, 1339–1352, June 8, 2012 ª2012 Elsevier Inc. 1349
133
●
Appendix
of Mob/kinase complexes and to form a unique PP2A holoen-
zyme directed toward mitotic substrates. Furthermore, the fact
that two components of this complex reside in the Golgi and
a third resides in the outer NE suggests that STRIPAK complexes
participate in the tethering of centrosomes to the Golgi, centro-
some duplication signaling, Golgi fragmentation at the G2/M
transition, or targeting Golgi fragments to spindle poles during
mitosis (Figure 7G). Given the increasing evidence that the Golgi
and spindles have functional interactions throughout the cell
cycle (Sütterlin and Colanzi, 2010), our observations suggest
that the STRIPAK complex mediates communication between
these organelles. The functional repurposing of the STRIPAK
complex in Sc, in contrast to the distinctly different complex
formed in Sp and mammals, correlates with the evolution of
major differences between these organisms in cytokinesis,
cell-cycle phasing, and Golgi morphology.
Perpsective
JacquesMonod’s expression of biological unity, ‘‘Anything found
to be true of E. coli must also be true of elephants,’’ can be
answered with a nuanced view in light of the dramatic increase
in functional genomic information.Weanalyzedgenesconserved
in budding yeast, fission yeast, and mammals with a focus on
functional divergence. In an important subset of genes, we found
evidence of functional repurposing: the use of conserved
machines in different pathways with different inputs or outputs.
Monod’s reductionist view describes the depth of conservation
between structure and function: folds and key residues confer
durable properties through evolution. Protein complexes tend
to be conserved but not as deeply as structure, whereas connec-
tions between complexes or pathways can be quite plastic.
The unique opportunity to conduct a functional comparison
between two divergent eukaryotes with comprehensive ortholog
mapping provided us with an unparalleled view of repurposing.
Having this view enabled us to document an unanticipated
degree of malleability in function and functional connections.
Our Spmap led to several mechanistic insights that are relevant
to understandingmammalian cells. It also yielded a rich resource
for other investigators as we have described only a fraction of the
connections in our data. To aid these efforts, we have appended
two files (Data S1 and S2) and created a website for the commu-
nity to navigate this data set (http://yeastquantitativegenetics.
ucsf.edu:8000/DataBrowser.html). Future studies will enhance
our understanding of which components and connections are
invariant across evolution versus those that are adaptable.
Moreover, it should be possible to connect repurposing events
to changes in cellular physiology (e.g., switching from fission to
budding cell division). Such insights may prove to be useful in
medicine in that malignancy and infection are both problems
of rapid evolution. Our ability to design ‘‘conditionally lethal’’
therapies will also depend on understanding which functional
relationships can be repurposed.
EXPERIMENTAL PROCEDURES
Strains and Genetic Crosses
Array G418-resistant haploid single-deletion mutants were isogenic to SP286
(h+ ade6-M210;ura4-D18;leu1-32) selected from the BIONEER collection
(Kim et al., 2010). The nourseothricin-resistant h query strains were made
in the PEM2 strain (Roguev et al., 2007). Targeting cassettes were built using
a two-step, fusion PCR protocol in which long (3 kb) cassettes were ampli-
fied after annealing mediated by nonpalindromic and unique GC-rich overlap-
ping sequences (Figure S1). Integration of the resistance markers into the
target locus was verified by PCR. Query strains harboring constitutive hypo-
morphic Degron-DAmP alleles were made via the same strategy, except a
degron sequence (Ravid and Hochstrasser, 2008) was fused in place of the
stop codon, followed by a selectable maker in place of the 30 untranslated
region (UTR). Mating, selection, and propagation of the double mutants
were carried on a Singer RoToR pinning robot using the PEM2 procedure
(Roguev et al., 2008, 2007). For directed assays in Sc, single and double muta-
tions were generated in W303 diploids followed by sporulation and tetrad
dissection.
Genetic Interaction Score Acquisition and Analysis
Double-mutant plates were scanned on a flat-bed scanner (EPSON PhotoPer-
fection 350, Figure S2), and integrated colony intensities were extracted using
a custom algorithm (scripts available upon request) executed in MATLAB (The
Mathworks, Natcik, MA, USA). Fitness analysis was performed by a strategy
modified from Collins et al. (2010), including normalization of plate-surface
artifacts, row/column normalization artifacts, and batch artifacts. Linkage
biases due to the reduced frequency of recombination between linked loci
(manifested by a reduced number of spores and a spurious negative score)
were used to identify contaminated or misannotated strains (Figure S2D).
See the Extended Experimental Procedures for a full description of the
materials and methods.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, one table, and two data sets and can be found with this article online
at doi:10.1016/j.cell.2012.04.028.
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Decoding Human Cytomegalovirus
Noam Stern-Ginossar,1 Ben Weisburd,1 Annette Michalski,2* Vu Thuy Khanh Le,3 Marco Y. Hein,2
Sheng-Xiong Huang,4 Ming Ma,4 Ben Shen,4,5,6 Shu-Bing Qian,7 Hartmut Hengel,3
Matthias Mann,2 Nicholas T. Ingolia,1† Jonathan S. Weissman1*
The human cytomegalovirus (HCMV) genome was sequenced 20 years ago. However, like those
of other complex viruses, our understanding of its protein coding potential is far from complete.
We used ribosome profiling and transcript analysis to experimentally define the HCMV translation
products and follow their temporal expression. We identified hundreds of previously unidentified
open reading frames and confirmed a fraction by means of mass spectrometry. We found
that regulated use of alternative transcript start sites plays a broad role in enabling tight temporal
control of HCMV protein expression and allowing multiple distinct polypeptides to be generated
from a single genomic locus. Our results reveal an unanticipated complexity to the HCMV coding capacity
and illustrate the role of regulated changes in transcript start sites in generating this complexity.
The herpesvirus human cytomegalovirus(HCMV) infects the majority of human-ity, leading to severe disease in newborns
and immunocompromised adults (1). The HCMV
genome is ~240 kbwith estimates of between 165
and 252 open reading frames (ORFs) (2, 3). These
annotations likely do not capture the complex-
ity of the HCMV proteome (4) because HCMV
has a complex transcriptome (5, 6), and genomic
regions studied in detail reveal noncanonical trans-
lational events, including regulatory (7) and over-
lapping ORFs (8–11). Defining the full set of
translation products—both stable and unstable,
the latter with potential regulatory/antigenic func-
tion (12)—is critical for understanding HCMV.
To identify the range of HCMV-translated
ORFs and monitor their temporal expression, we
infected human foreskin fibroblasts (HFFs) with
the clinical HCMV strain Merlin and harvested
cells at 5, 24, and 72 hours after infection using
four approaches to generate libraries of ribosome-
protectedmRNA fragments (Fig. 1A and table S1).
The first two measured the overall in vivo distri-
bution of ribosomes on a givenmessage; infected
cells were either pretreated with the translation
elongation inhibitor cycloheximide or, to exclude
drug artifacts, lysed without drug pretreatment
(no-drug). Additionally, cells were pretreated with
harringtonine or lactimidomycin (LTM), two drugs
with distinct mechanisms, which lead to strong
accumulation of ribosomes at translation initia-
tion sites and depletion of ribosomes over the
body of the message (Fig. 1A) (13–15). A modi-
fied RNA sequencing protocol allowed quanti-
fication of RNA levels as well as identification
of 5′ transcript ends by generating a strong over-
representation of fragments that start at the 5′ end
of messages (fig. S1) (16).
The ability of these approaches to provide a
comprehensive view of gene organization is il-
lustrated for the UL25 ORF: A single transcript
start site is found upstream of the ORF (Fig. 1A,
mRNA panel). Harringtonine and LTM mark a
single translation initiation site at the first AUG
downstream of the transcript start (Fig. 1A, Harr
and LTM). Ribosome density accumulates over
the ORF body ending at the first in-frame stop
codon (Fig. 1A, CHX and no-drug). In the no-
drug sample, excess ribosome density accumu-
lates at the stop codon (Fig. 1A, no-drug) (14).
Examination of the full range of HCMV
translation products, as reflected by the ribo-
some footprints, revealed many putative previ-
ously unidentified ORFs: internal ORFs lying
within existing ORFs either in-frame, resulting in
N-terminally truncated translation products (Fig.
1B), or out of frame, resulting in entirely previous-
ly unknown polypeptides (Fig. 1C); short uORFs
(upstream ORFs) lying upstream of canonical
ORFs (Fig. 2A); ORFs within transcripts anti-
sense to canonical ORFs (Fig. 2B); and previ-
ously unidentified short ORFs encoded by distinct
transcripts (Fig. 2C). For all of these categories,
we also observed ORFs starting at near-cognate
codons (codons differing from AUG by one nu-
cleotide), especially CUG (Fig. 2D).
HCMVexpresses several long RNAs lacking
canonical ORFs, including b2.7, an abundant
RNA, which inhibits apoptosis (17). In agree-
ment with b2.7’s observed polysome associa-
tion (18), multiple short ORFs are translated
from this RNA (Fig. 2E and fig. S2), and the
corresponding proteins for two of these ORFs
were detected by means of high-resolution MS
(Fig. 2E). Although the translation efficiency
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of these ORFs is low, four of them are highly
conserved across HCMV strains (table S2). We
found three similar polycistronic coding RNAs
(including RNA1.2 and RNA4.9), and two
short proteins encoded by these RNAs were
confirmed with MS (fig. S3).
To define systematically the HCMV-translated
ORFs using the ribosome profiling data, we first
annotated HCMV splice junctions, identifying
88 splice sites (table S3). We then exploited the
harringtonine-induced accumulation of ribo-
somes at translation start sites so as to identify
ORFs using a support vector machine (SVM)–
based machine learning strategy (14, 19). We
observed a strong enrichment for AUG (33-fold)
and near cognate codons in the translation initia-
tion sites identified with this analysis (Fig. 3A).
Visual inspection of the ribosome profiling data
confirmed the SVM-identified ORFs and sug-
gested an additional 53 putative ORFs (table S4).
The large majority (86%) of the SVM-identified
ORFs, and all of the manually identified ones,
were identified by means of SVM analysis of
an independent biological replicate (table S5 and
fig. S4). The observed initiation sites were not
caused by harringtonine because LTM treatment
also induced ribosome accumulation at the vast
majority (>98%) of these positions (Fig. 3B).
In total, we identified 751 translated ORFs
that were supported by both the LTM and
harringtonine data (tables S5 and S6 and file S1).
The footprint density measurements for these
ORFs were reproducible between biological rep-
licates (figs. S5 and S6). Of these ORFs, 147were
previously suggested to be coding (Fig. 3C). We
did not find strong evidence of translation for 24
previously annotated ORFs (table S7), although
these proteins may well be expressed under dif-
ferent conditions.
Many newly identified ORFs are very short
(245 ORFs ≤ 20 codons) (Fig. 3C) and are found
upstream of longer ORFs. We also identified 239
short ORFs (21 to 80 codons) (Fig. 3D). Last,
we identified 120 ORFs that are longer than 80
amino acids. These are primarily ORFs that con-
tain splice junctions or alternative 5′ ends of
previous annotations.
Several lines of evidence support the valid-
ity of the ORFs we identified. First, as seen for
the previously annotated ORFs, newly iden-
tified ORFs showed a significant [P < 10−70;
Kolmogorov-Smirnov (K-S) test] excess of ri-
bosome footprints at the predicted stop codon
(Fig. 1A and fig. S7). Because our ORF predictions
Fig. 1. Ribosome profiling of HCMV-infected cells. (A) Ribosome occupancies
after various treatments (illustrated to left); cycloheximide (CHX), no-drug,
harringtonine (Harr), and LTM together with mRNA profiles of the UL25 gene
at 72 hours after infection. An arrow marks the mRNA start. (B and C) Ribo-
some occupancy profiles for (B) UL38 and (C) UL10 genes that contain internal
initiations. The gray area symbolizes a low-complexity region.
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were based on translation initiation sites found
in the harringtonine and LTM samples, the ob-
servation that these accurately predicted down-
stream stop codons in an untreated sample
provides independent support for our approach.
Second, ribosome-protected footprints displayed
a 3-nucleotide (nt) periodicity that was in phase
with the predicted start site both globally (Fig.
3E) and in specific ORFs that contain internal
Fig. 2. Many ribosome footprints do not correspond to previously annotated
ORFs. (A) Ribosome occupancy profiles for the leader region of UL139 gene.
(B) Ribosome occupancy profiles of plus and minus strands (red and blue,
respectively) for the UL91 gene. (C) mRNA and ribosome occupancy profiles
for a previously unidentified short ORF. (D) Ribosome occupancies around a
short ORF that initiates at a CUG codon. (E) Ribosome occupancy profiles for
RNA b2.7. (Top) The annotated MS/MS spectra of two distinct peptides orig-
inating from ORFL6C and ORFL7C.
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out-of-frame ORFs (fig. S8). Third, brief inhi-
bition of translation initiation using an eIF4A
inhibitor Pateamine A (20) led to depletion of ri-
bosome density from the body of the large ma-
jority of the predicted ORFs (fig. S9), indicating
that the ribosomes were engaged in active elon-
gation. The newly identified ORFs also exhibited
a distribution of expression levels similar to that
of previously annotated canonical ORFs (fig. S10).
Last, many of the newly identified ORFs are
conserved in other HCMV strains (table S2).
High-resolution tandem mass spectrometric
measurements on virally infected cells by using
stringent criteria and manual validation (files S2
and S3) (16, 21) unambiguously detected 53 pre-
viously unidentified proteins out of the 96 ge-
nomic loci that are not overlapping with annotated
ORFs and contain at least one specific previously
unidentified protein that is longer than 55 amino
acids (table S8). For classes of new ORFs that
were difficult to monitor withMS (truncated forms
of longer proteins or short proteins), we used a
tagging approach. For two N-terminally trun-
cated proteins (derived fromUL16 andUL38), we
confirmed the appearance of alternative shorter
transcripts and detected the expected full length
and truncated tagged protein products (fig. S11).
The truncated protein derived from UL16 was
also observed in the context of the native virus
(fig. S12), and we confirmed a splice variant of
UL138 by using an antibody (fig. S12). For five
short ORFs (including two initiated at near cog-
nate start sites), we fused the ORFs in frame to a
green fluorescent protein (GFP)–coding region
in their otherwise native transcript context. We
identified protein products of the expected sizes
and confirmed that we correctly identified the
translation start sites (fig. S13). We also showed
that one of these short proteins (US33A-57aa),
which was not identified with MS but was re-
cently predicted by means of transcript analysis
to be coding (6), is expressed in the context of
the native virus (Fig. 3F and fig. S12). Addition-
ally, we focused on the very short, near cognate
driven uORFs that lie directly upstream of UL119
and US9, whose inclusion changes during infec-
tion as a result of changes in the 5′ end of the
transcripts. We found that these uORFs modu-
lated the translation efficiency of a downstream
reporter gene (fig. S14).
Last, we examined the subcellular localiza-
tion for 18 newly identified ORFs (11 of which
were detected by means of mass spectrometry)
(table S9) using transient expression of GFP-
tagged proteins. We detected 15 proteins, 10 of
which showed specific subcellular localization
patterns: six in mitochondria, three in the endo-
plasmic reticulum (ER), and one in the nucleus
(Fig. 3G and fig. S15). Immunoprecipation and
MS experiments on two of these GFP-tagged
proteins, ORF359W (ER localized) and US33A
(mitochondrially localized), identified a few spe-
cific interacting proteins. Western blot analysis
confirmed the interactions with TAP1 (ORF359W)
and the mitochondrial inner membrane transport
TIM machinery (US33A) (fig. S16).
HCMV genes are expressed in a temporally
regulated cascade. Our data provides an oppor-
tunity to monitor viral protein translation through-
out infection. Most of the viral genes, including
newly identified ORFs, showed tight temporal
regulation of protein synthesis levels; 82% of
ORFs varied by at least fivefold. Hierarchical
clustering of viral coding regions by their foot-
print densities during infection (a measure of
the relative translation rates) revealed several dis-
tinct temporal expression patterns (fig. S17).
As was seen previously for a limited number
of genomic loci (8–11, 22), examination of viral
transcripts during infection revealed a pervasive
use of alternative 5′ ends that is critical to the
Fig. 3. Annotating the HCMV-translated ORFs. (A) Fold
enrichment of AUG and near-cognate codons at pre-
dicted sites of translation initiation compared with their
genomic distribution. (B) The ribosome footprints occu-
pancy after LTM treatment at each start codon (relative
to the median density across the gene) is depicted for
the previously annotated ORFs (blue) and newly iden-
tified ORFs (red; empty red for ORFs that were removed).
The occupancy at a codon five positions downstream of
the start codon is depicted as a control (green). (C) Venn
diagram summarizing the HCMV-translated ORFs. Fifty-
three ORFs were initially identified through manual in-
spection. (D) The lengths distribution of newly identified
ORFs (red) and previously annotated ORFs (blue). (E) Po-
sition of 30-nt ribosome footprints relative to the reading
frame in the newly identified ORFs (red) and previous-
ly annotated ORFs (blue). (F) MRC-5 cells were mock-
treated or infected with TB40-US33A-hemagglutinin
(HA), and protein lysates were analyzed with Western
blotting with indicated antibodies. (G) HeLa cells were
transfected with GFP fusion proteins together with an ER marker (KDEL-mCherry) or stained with MitoTracker Red (Invitrogen, Grand Island) and
imaged by means of confocal microscopy.
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tight temporal regulation of viral genes expres-
sion and production of alternate protein products
during infection. For example, at the US18-US20
locus, 5 hours after infection there is one main
transcript starting just upstream ofUS20 enabling
US20 translation. At 24 hours after infection, a
shorter version of the transcript is detected starting
immediately upstream of US18, enabling its trans-
lation. A third previously unknown transcript
isoform starting within the US18 coding sequence
emerges at 72 hours after infection, resulting
in translation of a truncated version of US18
(ORFS346C.1) at this time point (Fig. 4, A and B).
Another example is detailed in fig. S18, and we
identified reproducible temporal regulation of
5′ ends in 61 viral loci (encompassing ~350 ORFs)
(figs. S19 and S20 and table S10), six of which
we confirmedwithNorthern blot analysis (Fig. 4B
and figs. S11 and S21). Thus, our studies reveal a
pervasive mode of viral gene regulation in which
dynamic changes in 5′ ends of transcripts con-
trol protein expression from overlapping coding
regions. Just as alternative splicing (a process in
which a single gene codes for multiple proteins)
expands protein diversity, alternative transcript
start sites may provide a broadly usedmechanism
for generating complex proteomes.
The genomic era began with the sequencing
of the bacterial DNAvirus, phi X, in 1977 (23)
and the mammalian DNAvirus, Simian virus 40
(24), the following year. Since then, extraordinary
advances in sequencing technology have enabled
the determination of a vast array of viral genomes.
Deciphering their protein coding potential, how-
ever, remains challenging. Here, we present an
experimentally based analysis of translation of
a complex DNA virus, HCMV, by using both
next-generation sequencing and high-resolution
proteomics. It is possible that many of the short
ORFs we have identified are rapidly degraded
and do not act as functional polypeptides. None-
theless, these could still have regulatory function
or be an important part of the immunological
repertoire of the virus as major histocompatibility
complex (MHC) class I bound peptides are
Fig. 4. A major source of ORFs’ diversity during infection originates from
alternative transcripts starts. (A) The mRNA and ribosome occupancy profiles
around US18 to US20 loci at different infection times (marked left). Small
arrows denote the different mRNA starts, and (top) the corresponding mRNAs
are illustrated. (Bottom) An expanded view of the US18 locus at 72 hours after
infection and includes the harringtonine and LTM profiles (asterisks indicate
the internal initiation). (B) Total RNA extracted at different time points during
infection was subjected to Northern blotting for ORFS346C.1.
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SUMMARY
Genetic interaction (GI) maps, comprising pairwise
measures of how strongly the function of one gene
depends on the presence of a second, have enabled
the systematic exploration of gene function in micro-
organisms. Here, we present a two-stage strategy to
construct high-density GI maps in mammalian cells.
First, we use ultracomplex pooled shRNA libraries
(25 shRNAs/gene) to identify high-confidence hit
genes for a given phenotype and effective shRNAs.
We then construct double-shRNA libraries from
these to systematically measure GIs between hits.
A GI map focused on ricin susceptibility broadly
recapitulates known pathways and provides many
unexpected insights. These include a noncanonical
role for COPI, a previously uncharacterized protein
complex affecting toxin clearance, a specialized
role for the ribosomal protein RPS25, and func-
tionally distinct mammalian TRAPP complexes. The
ability to rapidly generate mammalian GI maps
provides a potentially transformative tool for defining
gene function and designing combination therapies
based on synergistic pairs.
INTRODUCTION
Analysis of mammalian genomic sequences provides a parts list
of the proteins that comprise a cell. The remaining challenge is to
define functions for these parts and understand how they act
together. Work in model organisms, especially budding yeast,
has demonstrated the broad utility of comprehensive genetic
interaction (GI) maps in defining gene function in a systematic
and unbiased manner (Collins et al., 2009; Dixon et al., 2009).
GIs, which measure the extent to which the phenotype of a first
mutation is modified by the presence of a second, reveal func-
tional relationships between genes. Additionally, the pattern of
GIs of a gene provides an information-rich description of its
phenotype, which can be used to detect functional similarities
between genes and reveal pathways without prior assumptions
about cellular functions.
Systematic quantitative analysis of GIs in yeast has allowed
rapid identification of new functional complexes, predicted
roles for uncharacterized genes, revealed network rewiring in
response to environmental changes, and demonstrated func-
tional repurposing of complexes and interactions during evolu-
tion (Bandyopadhyay et al., 2010; Collins et al., 2009; Dixon
et al., 2009; Frost et al., 2012). More recently, GI maps have
also been used with great success in Gram-negative bacteria,
fission yeast, and cultured cells from fruit flies (Butland et al.,
2008; Frost et al., 2012; Horn et al., 2011; Ryan et al., 2012;
Typas et al., 2008).
In mammalian cells, an approach for systematic mapping of
GIs could have broad utility for unbiased functional annotation
of the human genome as well as for targeted investigation of
mammalian-specific pathways. More generally, a better under-
standing of the structure of GIs may clarify the complex herita-
bility of common traits (Zuk et al., 2012). Furthermore, GIs are
important in both the pathogenesis and treatment of a number
of human diseases, such as cancer (Ashworth et al., 2011). For
example, pairs of genes that exhibit synthetic lethality in cancer
cells, but not healthy cells, are ideal targets for combination
therapies aimed at limiting the emergence of drug resistance in
rapidly evolving cells.
A number of challenges confront any effort to systematically
quantify GIs. First, high-precision phenotypic measurements
are needed to accurately determine GIs, which are quantified
as the deviation of an observed double-mutant phenotype
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from that expected from two individual mutants. Second, GIs are
typically rare (Collins et al., 2009; Dixon et al., 2009), and
therefore a scalable high-throughput approach is required to
generate large, high-density GI maps. At the same time, the large
number of possible pairwise interactions in the human genome
(4 3 108) makes it necessary to focus on a subset of genes
with common biological functions to create a sufficiently dense
GI map to reveal meaningful insights.
Recent developments in screening technologies have laid the
groundwork for systematic forward genetics in mammalian cells.
Both short-hairpin RNA (shRNA)-based RNA interference (RNAi)
and haploid insertion approaches lend themselves to pooled
screening, which, when combined with deep-sequencing-based
readouts (Bassik et al., 2009; Carette et al., 2011; Silva et al.,
2008), allows massive multiplexing and provides a controlled,
identical environment for all cells. Nevertheless, the extraction
of robust biological information from genome-wide screening
data is challenging (Kaelin, 2012); for RNAi-based screens in
particular, the problems of false-positive hits caused by off-
target effects and false-negative hits caused by ineffective
RNAi agents can limit reliability. Despite these challenges,
screens for modifiers of single genes have demonstrated the
value of investigating GIs by RNAi (Barbie et al., 2009; Luo
et al., 2009).
We have developed a scalable, high-precision pooled
shRNA-based approach for robustly conducting RNAi-based
screens and measuring GIs in high throughput in mammalian
cells. We used our method to examine genetic modifiers of
cellular susceptibility to ricin. Ricin is a member of a broad class
of AB-type protein toxins that includes major human pathogens.
Similar to many viral pathogens, these toxins enter cells by
endocytosis and hijack intracellular trafficking pathways.
Though medically important in their own right, these agents
have also been used with great success to probe various
aspects of cell biology (Johannes and Popoff, 2008; Spooner
and Lord, 2012). Because the general biology of ricin has
been extensively studied, it is well suited to evaluate screening
approaches. Indeed, several recent screens have been con-
ducted to identify factors whose depletion protects against
AB-toxins (Carette et al., 2009; Guimaraes et al., 2011; Moreau
et al., 2011; Pawar et al., 2011). Nonetheless, a comprehensive
understanding of the pathways exploited by ricin is missing,
and little is known about factors whose loss enhances ricin
toxicity.
In a primary genome-wide screen for modifiers of ricin suscep-
tibility, we found 200 known and previously uncharacterized
factors that either sensitized or protected cells against ricin
intoxication; with some interesting exceptions, these factors
were remarkably well focused on the retrograde transport
pathway. We then defined functional relationships among these
genes in a GI map. We could broadly recapitulate existing
complexes and pathways, functionally dissect multiprotein com-
plexes, identify new complexes with uncharacterized compo-
nents, and provide unexpected insights into the functions of
well-characterized genes. More broadly, this work establishes
a strategy that integrates a robust method for RNAi screening
with scalable, systematic analysis of GIs, which should be appli-
cable to diverse biological problems.
RESULTS AND DISCUSSION
Strategy for Primary Screens Using Ultracomplex
shRNA Libraries
The first step in our strategy is to conduct a genome-wide screen
to identify genes that function within a biological pathway of
interest and effective shRNAs that target them, using ultracom-
plex shRNA libraries. Ultracomplex libraries increase the likeli-
hood of targeting each gene with several effective shRNAs, thus
reducing the false-negative rate. Additionally, requiring several
active shRNAs to identify a hit gene reduces the rate of false
positives, as it is unlikely that several shRNAs targeting a non-
hit gene have off-target effects relevant to the phenotype of
interest. Two key technical developments enable ultrahigh-
coverage screening: the ability to construct ultracomplex libraries
using massively parallel oligonucleotide synthesis (Cleary et al.,
2004; Silva et al., 2005) and the capacity of deep sequencing to
monitor screening results (Bassik et al., 2009; Silva et al., 2008).
To determine the best design for a genome-wide ultracomplex
shRNA library, we conducted a pilot screen with a limited library
targeting 1,000 genes with 50 shRNAs each. We chose ricin as
a selective agent for our screen because it efficiently kills cells
and relies on numerous host cell factors for its toxicity. In our pilot
library,we includedshRNAs targetinganumberofgenes thatwere
previously reported to affect ricin sensitivity. In addition, we
included more than 1,000 negative control shRNAs that had the
same overall base composition as the other shRNAs in the library
but that did not match the sequence of any human transcript.
We infected K562 human myelogenous leukemia cells with
these libraries and subjected one half of the population to four
pulses of ricin treatment while the other half was grown
in the absence of ricin. After 12 days, genomic DNA was
isolated from cells of the treated and untreated populations,
the shRNA-encoding cassettes were PCR amplified, and their
frequencies were quantified by deep sequencing (Figure 1A).
Comparison of the frequency of each shRNA in the treated and
untreated populations yielded an enrichment ratio. To enable
direct comparisons between different experiments, we defined
a metric r for ricin resistance, which quantifies the differential
effect that an shRNA has on cell growth in the presence versus
absence of ricin (see Extended Experimental Procedures avail-
able online and M.K., M.C.B., and J.S.W., unpublished data).
An shRNA without effect on ricin sensitivity has a r of 0; shRNAs
conferring ricin resistance have positive r values; and shRNAs
sensitizing cells to ricin have negative r values. The criterion
for hit genes was based on a p value, which reports on the prob-
ability that the distribution of rs for all shRNAs targeting a given
gene was significantly different from the distribution for negative
control shRNAs (reflecting both random noise and off-target
effects), as determined by the Mann-Whitney U test (Figure 1B).
The robustness of this approach is supported by the agreement
of hit genes obtained when we constructed and screened two
independent shRNA libraries targeting the same genes but using
different shRNA designs and target sites (Figure S1A).
To identify an appropriate complexity for a genome-wide
library, we examined how the number of shRNAs targeting
each gene affects the confidence of hit detection. Specifically,
we calculated p values based on random subsets of shRNAs
910 Cell 152, 909–922, February 14, 2013 ª2013 Elsevier Inc.
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for each gene and determined the effect of subset size on the
p value for three example genes: the strong hit gene RAB1A,
the weaker hit gene STX16, and the non-hit gene CRYAB (Fig-
ure 1C). In our experimental system, the ability to confidently
resolve STX16 from background began at 15 shRNAs per
gene and increased steadily as more shRNAs were included.
These examples are representative of the entire spectrum of
genes (Figure 1D): increasing the coverage of shRNAs per
gene improved the signal for hits without spuriously increasing
p values for non-hits. Based on these results, we chose
a coverage of 25 shRNAs per gene for a genome-wide library.
Reproducibility and Performance of Ultracomplex
Libraries in a Pilot Ricin Screen
To test the ability of our screening approach to identify effective
shRNAs targeting hit genes, we carried out the ricin resistance
pilot screen in duplicate. The quantitative phenotypes of shRNAs
targeting hit genes correlated reasonably well between repli-
cates (Figure S1B). A main source of noise in pooled screens is
thought to be Poisson sampling error, originating from repeated
passaging of cells through a population bottleneck (Pierce et al.,
2007). Indeed, conducting a batch retest of shRNAs chosen
based on primary screen results with a coverage of 50,000
cells per shRNA species, as compared with 1,000 cells per
shRNA during the primary screen, strongly suppressed the level
of observed variability (Figure S1C). In future screens, a small-
scale (2 l) bioreactor should allow one to conduct an entire
primary genome-wide screen in a single batch of suspension
cells with 4,000-fold coverage of cells per shRNA.
We validated phenotypes for single shRNAs individually (Fig-
ure S1D) and in a pooled batch retest or individual competitive
growth assays. These two quantitative assays gave highly corre-
lated results (Figure S1E). Generally, the phenotypic strength of
shRNAs targetingagivenhitgenealsocorrelatedwellwith theeffi-
ciency of target mRNA knockdown (Figure S1F), suggesting that
shRNAs were predominantly acting through the intended target.
A Genome-wide, High-Coverage shRNA Screen for
Modifiers of Ricin Toxicity Yields Diverse Hits Focused
on Key Pathways
We next designed a library targeting each annotated human
protein-coding gene with 25 independent shRNAs on average,
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Figure 1. Pooled High-Coverage RNAi
Screen for Ricin Resistance and Sensiti-
zation
(A) Experimental strategy: A population of K562
cells was infected with a pooled high-cover-
age shRNA library and split into two subpopu-
lations, one of which was treated with ricin.
The frequency of shRNA-encoding constructs in
each subpopulation was determined by deep
sequencing.
(B) Based on the frequency in the treated and
untreated subpopulations, a quantitative resis-
tance phenotype r was calculated for each
shRNA. Comparing the distribution of rs for
shRNAs targeting a gene of interest to the r
distribution for negative control shRNAs using the
Mann-Whitney U test yielded a p value for the
gene. RAB1B knockdown protects cells from ricin
(p = 6.9 3 108), whereas knockdown of COPA
sensitizes cells to ricin (p = 2.4 3 108).
(C and D) Increasing the coverage of the shRNA
library improves the detection of hit genes above
background. p values for each gene in a test library
were calculated on the basis of random subsets
of the data; the number of shRNAs included per
gene was varied. Random subsampling was
repeated 100 times; means of –log10 P values are
shown. Gray dotted lines indicated a coverage of
25 shRNAs per gene, which we chose for our
genome-wide library.
(C) Means of –log10 p values ± SD for three
example genes: a strong hit (RAB1A), a moderate
hit (STX16), and a non-hit (CRYAB).
(D) Means of –log10 p values for all 1,079 genes
targeted by the library (left) and for the top 50 hits
based on the p value calculated from 45 shRNAs
(right).
See also Figure S1.
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as well as at least 500 negative control shRNAs per experiment.
The shRNAswere grouped in nine sublibraries of 55,000 shRNAs
each, based on annotated biological functions (Extended
Experimental Procedures).
For our first application of the genome-wide screening
approach, we also used ricin, as it should give access to the
rich biology of host pathways exploited by this toxin (Lord
et al., 2005; Sandvig et al., 2010; Spooner and Lord, 2012).
Specifically, ricin is internalized by endocytosis and traffics retro-
gradely through the secretory pathway to the ER, where its A and
B subunits are dissociated. The catalytic A subunit is then retro-
translocated to the cytoplasm, where it depurinates a single
base in the 28S rRNA, shutting down translation and leading to
apoptosis (Figure 2A).
We defined a set of hit genes based on false discovery rate
(FDR; Storey and Tibshirani, 2003); this set contained the 73
strongest protective hits (FDR <0.05) and the 83 strongest sensi-
tizing hits (FDR <0.02) (Table S1). These hits were strongly
enriched for genes related to trafficking along the secretory
pathway (Figure 2B). Figure 2C displays the top hits in their
A B
C
p value
p value :
Figure 2. Hits from a Genome-wide Screen
Recapitulate Known Ricin Biology
(A) Overview of ricin intoxication of mammalian
cells. Ricin is taken up by endocytosis and traffics
retrogradely to the ER, where ricin A and B chains
dissociate. The A chain retrotranslocates to the
cytoplasm and cleaves ribosomal RNA, thereby
inhibiting protein synthesis and ultimately trig-
gering apoptosis.
(B) GO-term enrichment analysis for top hits. Top
hits were defined as the set of 73 protective genes
with an FDR <0.05 and 83 sensitizing genes with
an FDR <0.02. Nonredundant GO terms with an
FDR <0.05 are shown. (Black bars) biological
process; (gray bars) cellular component.
(C) Visualization of top hits in cellular pathways as
blue circles (protective hits) and red circles (sen-
sitizing hits); circle area is proportional to –log10
p value. Selected hits below the top hit cutoff were
included (pink and light blue circles) if they were
part of a known physical complex containing a top
hit or if they were part of the GI map presented in
Figure 5. Gray ovals indicate known physical
complexes, and the asterisk identifies theWDR11/
C17orf75 complex identified in this study.
See also Figure S2 and Table S1.
canonical cellular context (see also Fig-
ure S2). A large fraction of characterized
hits included genes either acting in the
secretory pathway or otherwise expected
based on known ricin biology. In addition,
we tagged several poorly characterized
hit genes with GFP, expressed them
from their native chromosomal context
in BACs (Poser et al., 2008), and con-
firmed that they were localized to secre-
tory pathway organelles (Figure S3). We
found that many of the top hits in the
screen are also known to exist in physical complexes with
each other, with strong protection upon knockdown of compo-
nents of COPII, TRAPP, and GARP and strong sensitization
upon knockdown of components of COPI, the ribosome, and
the proteasome. Taken together, the above results illustrate
the specificity and robustness of the hits identified by our
approach.
Consistent with results from previous ricin screens and indi-
vidual gene studies, we found that the early endocytic factors
clathrin and Rab5 (Moreau et al., 2011) were required for ricin
toxicity, as well as STX16, a snare protein involved in vesicle
fusion at the TGN (Amessou et al., 2007). Among the most
strongly enriched were components of the GARP complex
known to be required for tethering endosome-derived vesicles
to the Golgi (Bonifacino and Hierro, 2011). Knockdowns of
several (but not all, see below) components of the vesicle-
tethering TRAPP complex were among the most strongly
protective.
Surprisingly, a large number of components of the COPII
machinery required for anterograde vesicle budding from the
912 Cell 152, 909–922, February 14, 2013 ª2013 Elsevier Inc.
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ER were strongly protective against ricin when knocked down,
which has not been previously observed. It is likely that shut-
down of ER-Golgi trafficking (and consequent Golgi collapse)
prevents ER delivery of ricin.
Depletion of ribosomal components and ribosome biogenesis
factors sensitized cells to the toxin, as expected given that ricin
targets the ribosome. A notable exception was RPS25, whose
knockdown was strongly protective against ricin, as discussed
below.
Identification of Atorvastatin as a Small-Molecule
Inhibitor of Ricin Transport to the ER
One goal of RNAi-based forward genetic screens is to identify
therapeutically valuable targets for small-molecule inhibitors.
Consistent with previous studies (Grimmer et al., 2000), our
primary screen identified components of the cholesterol biosyn-
thesis pathway, including HMG-CoA reductase (HMGCR). We
observed a dose-dependent protection of ricin-treated cells by
the HMGCR inhibitor atorvastatin (Figure 3A), confirming the
role of HMGCR in modulating the toxicity of ricin and demon-
strating that our primary screen could identify effective pharma-
cological targets.
To assess whether inhibition of HMGCR by atorvastatin
affected delivery of ricin to the ER, we expressed an ER-targeted
SNAP protein (Geiger et al., 2011) in cells and added benzylgua-
nine (BG)-coupled ricin to measure ricin flux into the ER. Upon
delivery of toxin to the ER, an irreversible bond can form between
ricin-BG and ER-SNAP, which we could quantify as an increase
in molecular weight by western blot (Figure 3B). The fraction
of SNAP that is present in ricin conjugates was reduced
by 80% upon treatment with atorvastatin (Figures 3B and
3C), suggesting that toxin traffic to the ER was blocked upon
HMGCR inhibition.
A Paradoxical Role for COPI in Diverting Ricin from
the ER
One of the more surprising results from the primary screen was
a profound sensitization to ricin upon depletion of COPI compo-
nents (Figure 2C and Table S1), which are normally involved in
retrograde endosome-Golgi and Golgi-ER transport (Popoff
et al., 2011). Several groups have observed a lack of requirement
for retrograde COPI components in trafficking of ricin or Shiga
toxin (Chen et al., 2002; Girod et al., 1999; Llorente et al.,
2003). However, sensitization by COPI depletion or inactivation
has not been described previously.
Primary hits from the ricin screen were retested in batch in
a second cell type (Raji B) for their effects on sensitivity to both
ricin and Shiga toxin, a similar AB toxin (data not shown). Again,
we observed sensitization to ricin upon COPI knockdown but
strong protection against Shiga toxin, revealing an unexpected
difference between the trafficking pathways of these two well-
studied toxins. Individual shRNAs targeting COPI components
ARCN1 or COPZ1 confirmed this finding (Figure 3D). This diver-
gent set of requirements was the exception rather than the rule:
ARF1 is a representative factor whose knockdown protected
against both toxins (Figure 3D). COPI depletion enhanced
delivery of toxin to the ER based on the SNAP assay (Figure 3E).
It may be that COPI knockdown upregulates a compensatory
alternative pathway or that it normally functions in transport
steps that divert ricin from the ER.
A Strategy for Generating High-Density GI Maps Based
on Double-shRNA Screens
Though our screen accurately identified genes that are important
for ricin pathology, the large number of hits makes individual vali-
dation and characterization challenging. Indeed, the difficulty in
pinpointing promising hits for in-depth follow up represents
DC
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Figure 3. Characterization of Hit Genes
from the Primary Screen
(A) K562 cells were treated with ricin in the pres-
ence or absence of atorvastatin for 24 hr and were
then allowed to recover in the continued presence
of atorvastatin. The mean percentage of viable
cells in triplicate measurements ± SD was quan-
tified using flow cytometry.
(B) Cells expressing ER-localized SNAP were
intoxicated with benzylguanine-labeled ricin, and
covalent ricin-SNAP complexes were detected by
anti-SNAP western blot.
(C) Quantification of ricin-modified fraction of ER-
SNAP (mean of triplicate experiments ± SD).
(D) Raji B cells were infected with shRNAs target-
ing the indicated genes, and a competitive growth
assaywas performed in the presence of either ricin
or shiga toxin (Stx). Mean of triplicate ricin resis-
tance (r) measurements ± SD is shown.
(E) COPZ1 knockdown increases levels of ER-
localized ricin (mean of triplicate experiments ±
SD), as measured by the SNAP assay.
Error bars represent SD. See also Figure S3.
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Figure 4. Effects of Combinatorial Gene Knockdowns by Double-shRNAs
(A) Experimental strategy: Active shRNAs targeting hit genes from the primary screen were individually cloned, and barcodes were added upstream and
downstream of the miR30 context. Pooled ligation yielded a library of all pairwise combinations of shRNAs. Ricin resistance phenotypes of double-shRNAs were
determined as for the primary screen; double-shRNAs were identified by sequencing the combinatorial barcode (red arrow).
(B) Reproducibility between phenotypes of individual shRNAs in a batch retest (mean of two experiments ± spread) and the same shRNAs paired with negative
control shRNAs in a double-shRNA screen (mean ± SD for combinations with 12 different negative control shRNAs).
(C) Reproducibility between two permutations of double-shRNA constructs representing (negative control + targeted) or (targeted + negative control), mean ±SD
for combinations with 12 different negative control shRNAs.
(legend continued on next page)
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a general bottleneck for the interpretation of RNAi screens.
To address this issue, we developed a strategy to systematically
determine GIs between the hits based on double-knockdown
phenotypes. For this purpose, we created a double-shRNA
library based on effective shRNAs identified from the primary
screen. shRNA-encoding cassettes were individually barcoded,
pooled, and ligated to obtain all pairwise combinations (Figures
4A and S4). This double-shRNA library was introduced into cells
and subjected to a ricin resistance screen under the same condi-
tions as those in the primary screen to quantify double-shRNA
phenotypes.
In order to obtain single-shRNA phenotypes from the same
screen, we included 12 negative control shRNAs in the double-
shRNA library pool. Importantly, phenotypes of single shRNAs
as quantified by batch retest were in excellent agreement with
phenotypes of double shRNAs combining the same shRNAs
with negative control shRNAs (Figure 4B). Moreover, the pres-
ence of a second shRNA and the order of shRNAs within the
double-shRNA construct had minimal impact on the measured
phenotypes (Figure 4C) or knockdown efficiency (Figures S5,
S6D, and S6E).
We found that the typical phenotype of a given double shRNA
could be reliably predicted by a linear relationship of the pheno-
types of the two individual shRNAs (Figure 4D). GIs were thus
quantified as deviations from the linear fit of this typical
double-mutant phenotype. Deviations toward the phenotype of
WT cells were defined as buffering GIs, and deviations away
from WT were defined as synergistic GIs. As expected, two
shRNAs targeting the same gene typically showed buffering
GIs (e.g., SEC23B in Figure 4D), whereas synergistic GIs could
be observed for some shRNAs targeting genes acting in parallel
(e.g., shRNAs targeting SEC23A and SEC23B, two isoforms with
partially distinct functions; Fromme et al., 2008; Schwarz et al.,
2009; Figure 4D). GIs observed in the pooled double-shRNA
screen could also be reproduced in individual validation experi-
ments. For example, SEC23A and SEC23B knockdown (whose
specificity was validated by rescue experiments; Figures S6A–
S6C) synergized to create highly ricin-resistant cells, as moni-
tored by the competitive growth assay (Figure 4E). A similar
synergistic effect was seen when the amount of ricin reaching
the ER was assessed by ER-SNAP assay (Figures 4F and S6F).
Construction and Benchmarking of a Ricin GI Map
A major motivation for systematic GI mapping beyond the direct
analysis of pairwise interactions between genes is the possibility
of analyzing the correlation of global GI patterns between
different genes. Genes with highly correlated GI patterns tend
to be functionally related (Collins et al., 2009; Dixon et al., 2009).
Correlations between shRNA GI patterns derived from our
double-shRNA screens were highly reproducible between inde-
pendent experimental replicates (Figure 5A). As expected,
shRNAs targeting the same gene had more correlated GI
patterns than other shRNAs (Figure 5B), indicating that their
phenotypes were mostly due to on-target knockdown. Similarly,
shRNA pairs targeting different members of the same protein
complex had highly correlated GI patterns, which were clearly
distinct from the bulk of shRNA pairs. This result demonstrates
the ability of our approach to broadly identify genes encoding
members of the same physical complex. Interestingly, shRNAs
targeting a small set of genes produced GI patterns that were
anticorrelated with those targeting other components of the
same physical complex (Figure 5B), causing an overall bimodal
distribution of intracomplex GIs. These genes also had the oppo-
site phenotype in the primary screen: TRAPPC9 (anticorrelated
with other members of the TRAPP complex), SEC23A (anticorre-
lated with other COPII components), and RPS25 (uncorrelated
with ribosomal proteins of the large subunit). The unusual
behavior of these three genes is robustly observed for all three
shRNAs targeting each of them and is therefore likely to reflect
the functional differences. These findings illustrate that our
genetic results can functionally dissect known physical com-
plexes, which we explore below in more detail for RPS25 and
the TRAPP complex.
A possible source of noise in an RNAi-based GI map is the fact
that an effective on-target shRNA can have partial off-target
effects, which can confound its GI pattern. To minimize this
effect, we required each gene in the GI map to be targeted by
at least two (and typically three) shRNAs whose GI patterns
were sufficiently correlated (Extended Experimental Procedures;
M.K., M.C.B., and J.S.W., unpublished data) and averaged the
GIs of these highly correlated shRNAs for each gene. Using
these stringent criteria, the resulting GI map (Figure 5C) encom-
passed pairwise interactions between 60 genes, each repre-
sented by three shRNAs on average, and was based on the
pooled measurement of >36,000 double-shRNA phenotypes.
The main limitation for increasing the scale of GI maps is the
availability of highly validated shRNAs, as a single bioreactor
run can measure >500,000 shRNA pairs.
Functional Predictions from the Ricin GI Map
Hierarchical clustering of genes based on the correlation of their
GIs was remarkably successful at recapitulating a number of
well-characterized complexes, including the COPI and COPII
vesicle coats, clathrin, GARP, and the ribosome, as well as
complexes with unknown roles in ricin biology, such as the cohe-
sins (Figure 5C). In addition, the map demonstrated clustering of
functionally interacting proteins, such as the small GTPase ARF1
and its guanine nucleotide exchange factor GBF1.
The GI map also led to numerous functional predictions, three
of which are highlighted below.
(D) Genetic interactions are calculated as deviations from the typical double-mutant phenotype. The relationship between single shRNA phenotypes and double-
shRNA phenotypes in combination with an shRNA of interest (in this example, SEC23B_i) is typically linear (red line). Deviations from this line are defined as
genetic interactions. Buffering interactions (yellow) are closer to WT phenotype than expected, as in this case found for double-shRNAs targeting SEC23B twice.
Synergistic interactions (blue) are further away fromWT than expected, as in this case found for double-shRNAs targeting both isoforms of SEC23, SEC23A, and
SEC23B.
(E) Phenotypes for individual and combinatorial SEC23A, SEC23B knockdown measured in competitive growth assay (mean of triplicate experiments ± SD).
(F) Quantification of ER localization of ricin measured by the SNAP assay in different knockdown strains (mean of triplicate experiments ± SD).
See also Figures S4, S5, and S6.
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Figure 5. A GI Map Reveals Functionally and Physically Interacting Genes
(A and B) Correlations of GI patterns between shRNA pairs: shRNAs targeting the same gene in orange, shRNAs targeting different genes in previously known
physical complexes in purple, and other pairs of shRNAs in gray.
(A) Reproducibility of GI correlations between shRNA pairs in two experimental replicates.
(B) High intragene and intracomplex correlation of GIs. Distributions of correlation coefficients between shRNA pairs are shown for the three classes of shRNA
pairs. The anticorrelated part of the bimodal distribution of intracomplex shRNA pairs is fully accounted for by pairs including shRNAs targeting TRAPPC9,
SEC23A, and RPS25.
(C) GIs for all gene pairs were calculated (shown as a yellow-cyan heatmap), and genes were clustered hierarchically based on the correlation of their GIs.
Individual phenotypes are indicated by sidebars using a red-blue heatmap. Genes marked with asterisks were imported from a separate double-shRNA screen
that we conducted with a partially overlapping gene set. Gene pairs for which no GIs were measures are indicated in gray. Known physically or functionally
interacting groups of genes are labeled by vertical lines; diamonds mark interactions defined in this study.
916 Cell 152, 909–922, February 14, 2013 ª2013 Elsevier Inc.
149
●
Appendix
An Unexpected Role for Ribosomal Protein RPS25
Remarkably, we found that RPS25 knockdown conferred ricin
resistance. By contrast, all other ribosomal hits sensitized cells
to ricin, as expected given that ribosome inactivation is the basis
for ricin cytotoxicity. The GI map provided a clue to the divergent
role of RPS25: RPS25 formed a cluster with ILF2 and ILF3 (Fig-
ure 5C). ILF2/3 encode heterodimeric nucleic-acid-binding
proteins with roles in transcription, mRNA stability, and transla-
tional control (Barber, 2009). ILF2/3 knockdown protected
against ricin, and we confirmed that the shRNAs against
RPS25 and ILF2/3 acted through their intended target genes
(Figure S7). As expected for proteins in a physical complex,
shRNAs targeting ILF2 showed buffering GIs with shRNAs
targeting ILF3 (Figures 6A and 6B). Surprisingly, we also
observed very strong buffering interactions between ILF2/3
and RPS25, which was consistent for all combinations of the
nine shRNAs targeting ILF2, ILF3, and RPS25 (Figure 6B).
Previous literature has implicated both RPS25 and ILF2/3 in
translational control: RPS25 has been shown to be required for
translation of IRES-containing mRNAs in cricket paralysis virus
(Landry et al., 2009), whereas ILF2/3 can bind viral IRES and
control translation (Merrill and Gromeier, 2006). Therefore, it is
tempting to speculate that ILF2/3 and RPS25may work together
to control translation of certain transcripts that affect ricin sensi-
tivity, possibly under particular stress conditions.
Identification of the WDR11/C17orf75 Complex
One unexpected prediction was the interaction betweenWDR11
and C17orf75, two poorly characterized genes. Both sensitized
cells to ricin when depleted, exhibited highly correlated profiles
in the GI map, and showed buffering interactions with each
other, which is often a signature for genes encoding proteins in
the same pathway or physical complex. Indeed, we found that
the encoded proteins interacted in reciprocal immunoprecipita-
tion experiments (Figures 6C and 6D).
Previously, WDR11was suggested to interact with a transcrip-
tion factor (Kim et al., 2010), as well as to impact flux through the
autophagy pathway (Behrends et al., 2010). Consistent with the
latter observation, we found that GFP-tagged WDR11 partially
colocalized with the autophagosome marker LC3 (Figure 6E).
This suggests a potential role for WDR11 in toxin degradation.
Indeed, depletion of WDR11 or BECN1, a regulator of auto-
phagy, caused an increase in total cellular ricin (Figure 6F). By
contrast, other genes that sensitized (COPZ1) or protected
(TRAPPC8) cells against ricin had an insignificant effect on total
toxin levels (although they do affect toxin delivery to the ER; Fig-
ure 6G). When degradation pathways are inhibited, more ricin
can enter the productive intoxication pathway (Figure 6H), which
provides a potential explanation for the observed increase in
delivery of toxin to the ER upon depletion ofWDR11 (Figure 6G).
Nonetheless, further study will be required to define the precise
role of this complex.
Functional Dissection of the Mammalian TRAPP
Complex
Two of themost strongly protective hits from our primary screen,
C4orf41 and KIAA1012, were poorly characterized at the onset
of our studies. In our GI map, these genes formed a highly corre-
lated cluster connected by buffering GIs with another poorly
characterized gene, C5orf44, and with TRAPPC1, a member of
the TRAPP complex, a highly conserved multisubunit complex
involved in ER-Golgi, endosome-Golgi, and autophagosome
transport (Barrowman et al., 2010). Based on this pattern, we
predicted that C4orf41, KIAA1012, and C5orf44 function as
TRAPP complex components. To test this, we GFP tagged and
immunoprecipitated these components (Figures 7A and 7B).
We could identify most TRAPP components described to date,
as well as C5orf44, in both immunoprecipitations. C4orf41 and
KIAA1012 were previously identified as TRAPP3 interactors in
a high-throughput immunoprecipitation study (Gavin et al.,
2002) and, concurrent with our studies, were independently
identified as TRAPP components and designated TRAPPC8
and TRAPPC11, respectively (Scrivens et al., 2011). Additionally,
C5orf44 was recently shown to exhibit homology to yeast Trs65
and to physically interact with other TRAPP components (Choi
et al., 2011). Based on these observations, we designate
C5orf44 as TRAPPC13.
In yeast, several TRAPP complexes have been identified
(Barrowman et al., 2010) with distinct roles in ER-Golgi traffic
(TRAPPI), intra-Golgi and endosome-Golgi traffic (TRAPPII),
and autophagy (TRAPPIII). In mammalian cells, TRAPP has
been suggested to form a single large complex (Scrivens et al.,
2011), and it has been unclear whether this complex is respon-
sible for all observed TRAPP activities.
Our data revealed a clear functional distinction between
different TRAPP components. We found only a subset of TRAPP
components as strongly protective hits, whereas other com-
ponents had either no phenotype or, in the case of TRAPPC9,
were mildly sensitizing (Table S1; Figure S7E). Moreover, the
genetic interaction pattern of TRAPPC9 showed a striking anti-
correlation with other TRAPP components (Figures 7C and
5C), suggesting that complexes containing these proteins are
distinct and have opposing roles in ricin trafficking. Indeed, we
found that immunoprecipitation of either TRAPPC8 or
TRAPPC11 pulled down the COPII components SEC31A and
SEC23IP as well as the other known TRAPP components, with
the prominent exception of TRAPPC9 and TRAPPC10 (Fig-
ure 7D). Similarly, previous immunoprecipitation experiments
found that TRAPPC9 did not recover TRAPPC8 (Zong et al.,
2011). Conversely, we found that immunoprecipitation of
TRAPPC10 pulled down core TRAPP components, but not
TRAPPC8/11/12/13, SEC31, or SEC23IP (Figure 7D). Based on
this, we examined the migration properties of the various TRAPP
components by size exclusion chromatography. These studies
directly established the existence of two physically distinct
complexes: a larger complex containing TRAPPC8 and
TRAPPC11 and a smaller one containing TRAPPC10 (Figure 7E).
To further define mammalian TRAPP complexes, we exam-
ined their interactions with COPII components. The yeast
TRAPPI complex is a COPII-vesicle-tethering factor (Sacher
et al., 2001), and COPII and TRAPPC3 interact in yeast and
mammalian cells (Cai et al., 2007). Consistent with this, GFP-
labeled TRAPPC8 and TRAPPC11 colocalized with SEC31A
(Figure S7F). Our finding that TRAPPC8 and TRAPPC11, but
not TRAPPC10, coimmunoprecipitated the COPII component
SEC31A (Figure 7F) suggests that differential interaction with
COPII may functionally distinguish the two mammalian TRAPP
complexes. Indeed, knockdown of TRAPC11 or TRAPC12, but
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Figure 6. Interactions Predicted from the GI Map: RPS25/ILF2/3 and WDR11/C17orf75
(A) Buffering genetic interactions between shRNAs targeting ILF3, the ribosomal subunit RPS25, and ILF2/ILF3.
(B) Correlation and buffering genetic interactions between shRNAs targeting ILF2, ILF3, and RPS25 in an shRNA-based genetic interaction map.
(C and D) The poorly characterized, genetically correlated proteins WDR11 and C17orf75 interact physically, as shown by reciprocal coimmunoprecipitation
and MS.
(E) GFP-WDR11 partially colocalizes with the autophagosome/lysosome marker mCherry-LC3 in HeLa cells.
(F) Total cellular ricin levels after intoxication, as quantified by western blotting, are increased upon knockdown of degradation-related genes andWDR11 (which
sensitizes to ricin);meanof triplicate experiments±SD. Theasterisk indicates statistically significant differences (p<0.05,Student’s t test). Error bars represent SD.
(legend continued on next page)
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not TRAPPC9, disrupted the interaction of TRAPPC8 with
SEC31A (Figure 7F). Thus, the two distinct mammalian TRAPP
complexes, defined by the presence of TRAPPC9/10 or
TRAPPC8/11/12/13, differentially interact with COPII (Figure 7H);
we refer to these as mTRAPPII and mTRAPPIII, respectively.
The two TRAPP complexes seem to have opposing roles in
ricin transport. Because we observe protection against ricin
with COPII or mTRAPPIII knockdowns and these components
interact physically, it is tempting to speculate that this complex
functions similarly to yeast TRAPPI in COPII vesicle tethering.
Additionally, TRAPPC8 knockdown has been reported to impact
flux through the autophagy pathway (Behrends et al., 2010), and
we observed a mild enhancement of toxin degradation upon
TRAPPC8 knockdown (Figure 6H), raising the possibility that
mTRAPPIII functions in both COPII-mediated trafficking and
autophagy. By contrast, TRAPPC9/10 was previously reported
to interact with COPI components (Yamasaki et al., 2009). More-
over, we find that both COPI and TRAPPC9 knockdown sensitize
cells to ricin, suggesting that mTRAPPII may function in tethering
of COPI vesicles. More generally, our findings establish that
there are functionally distinct mammalian TRAPP complexes
and lay the groundwork for a mechanistic understanding of their
specialized functions.
Perspective
Building on previous pooled shRNA strategies (e.g., Moffat et al.,
2006; Silva et al., 2005), we have developed an integrated plat-
form to functionally dissect complex biological processes in
mammalian cells using high-density genetic interaction maps.
Our strategy opens mammalian cell biology to the types of
systematic genetic analyses that have been highly successful
in microorganisms (Collins et al., 2009; Dixon et al., 2009).
Our first application of the platform elucidated key cellular
pathways and revealed how they modulate ricin susceptibility.
Our analysis of the TRAPP complex, in particular, illustrates
how genetic and physical interactions provide complementary
approaches to understand the functions of multiprotein com-
plexes, as our studies revealed two functionally distinct mamma-
lian TRAPP complexes.
A key aspect of our primary screening platform is the ability to
identify hit genes based on the likelihood that shRNAs act
through the intended target gene rather than solely the strength
and reproducibility of observed shRNA phenotypes. This is facil-
itated by the use of ultracomplex shRNA libraries that include
a large number of negative controls. Our approach also provides
a principled way to benchmark shRNA library design and
screening systems based not only on the strength of on-target
mRNA knockdown, but also by the ability to distinguish true
hits from background (e.g., off-target effects or statistical noise).
Using this criterion, we are currently exploring modifications to
the experimental strategy and shRNA design of our ultracomplex
libraries. Another important feature of ultracomplex libraries is
that they target each gene with a wide spectrum of shRNAs
with different knockdown strengths, effectively creating an allelic
series. This will facilitate the study of essential genes, as well as
gene dosage effects. Though our genetic interaction maps are
currently based on shRNAs identified in a primary screen, our
growing library of validated shRNAs will soon enable the
mapping of interactions between genes that do not have an
individual phenotype and the detection of synergistic genetic
interactions between them. Ongoing efforts by several groups
to identify effective shRNAs (Cheung et al., 2011; Fellmann
et al., 2011; Marcotte et al., 2012) will greatly facilitate the
construction of larger GI maps.
Our approach should be broadly applicable to the study of
complex biological systems. Although we present a pooled
screening strategy based on cell growth and viability, other
phenotypic readouts that physically separate cell populations
can be used, such as fluorescence-activated cell sorting or
migration assays. In addition, the ability to rapidly generate
and screen a double-shRNA library will allow one to explore
conservation and rewiring of genetic interactions in diverse cell
types and under different conditions (Bandyopadhyay et al.,
2010; M.K., M.C.B., and J.S.W., unpublished data).
The systematic exploration of genetic interactions in human
cells also has broad medical relevance, especially for cancer
biology and therapy. Functional surveys of genes in cancer cells
can distinguish oncogenic drivers from mere passengers.
Genetic interactions are thought to be crucial determinants of
properties of individual cancer cells (Ashworth et al., 2011),
such as their resistance to therapeutic agents. A better under-
standing of resistance pathways in specific genetic back-
grounds could pave the way for personalized combination
therapies that preemptively block the cancer’s escape routes.
More generally, as demonstrated for HIV, combination therapy
is a promising strategy to counter the problem of rapidly evolving
drug resistance in tumors. The ability to identify rare synthetic
lethal interactions between huge numbers of gene pairs maxi-
mizes the opportunity to identify pairs of drugs that synergisti-
cally target a disease state.
EXPERIMENTAL PROCEDURES
shRNA Libraries
To express shRNAs from a Pol II promoter in a miR30-derived context, we
adapted strategies developed by the Hannon and Elledge groups (Paddison
et al., 2004; Silva et al., 2005). Construction of pooled libraries was conducted
essentially as previously described (Bassik et al., 2009). The genome-wide
library was divided into nine sublibraries with 55,000 shRNA each and
targeted each human protein-coding gene with 25 independent shRNAs.
Each sublibrary also contained 500 or more negative control shRNAs, which
were designed to match the base composition of targeted shRNAs within
the same sublibrary without targeting any transcript in the human genome.
Table S2 contains the sequences of all primers used in this study, and Table
S3 includes target sequences of all active shRNAs used for follow-up
experiments.
(G) WDR11 and COPZ1 knockdown increase levels of ER-localized ricin as measured by the SNAP assay, whereas TRAPPC8 knockdown decreases levels of
ER-localized ricin; mean of triplicate experiments ± SD. The asterisks indicate statistically significant differences (**p < 0.01; ***p < 0.001; Student’s t test). Error
bars represent SD.
(H) Model: Ricin partitions between degradation and productive intoxication pathways; inhibition of degradation increases productive intoxication.
See also Figure S7.
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Ricin Resistance Screening
For pooled screens, cells were seeded at 0.5 3 106/ml at a representation of
1,000 cells/library element and were treated with 0.5 ng/ml ricin (Vector
labs), which reduced cell number by 50% compared with untreated cells
due to a combination of cell death and reduced growth rate. This selective
pressure represents a compromise between stronger selection, which can
increase the dynamic range of observed phenotypes, and weaker selection,
which reduces population bottlenecks and thus reduces Poisson sampling
noise. After 24 hr, ricin was washed out. Each day during the screen, cells
were diluted to 0.5 3 106/ml. After 2–3 days of recovery when treated cells
were again doubling at WT rate, a new cycle of ricin treatment was initiated
(total of four pulses). For competitive growth assays, cells were infected with
D
A B C
E
GF
H
p 
va
lu
e
Figure 7. Functional Dissection of the TRAPP Complex
(A and B) All TRAPP complex members (other than TRAPPC9/10) specifically coimmunoprecipitate with TRAPPC11 (A) and TRAPPC8 (B), as quantified by mass
spectrometry.
(C) Correlation of genetic interactions with TRAPPC11 and buffering genetic interaction with TRAPPC11 are shown for each gene included in the genetic
interaction map. TRAPP complex members are shown in blue. TRAPPC9 (red) shows a strongly anticorrelated genetic interaction pattern when compared to
other TRAPP complex members.
(D) Abundance (quantified as LFQ) of each TRAPP subunit in the immunoprecipitation is indicated by color scale.
(E) Extracts from K562 cells were fractionated by size exclusion chromatography on a Superose 6 column. Western blot could detect comigration of TRAPPC8
and TRAPPC11, which were larger in size than TRAPPC10. The core component TRAPPC3 migrated with both components. EXT, unfractionated extract.
(F) Immunoprecipitation of TRAPPC8 or TRAPPC10 tagged with GFP showed specific association of TRAPPC8 with SEC31A.
(G) Association of GFP-TRAPPC8 with SEC31A was assessed by immunoprecipitation in extracts from cells stably expressing shRNAs targeting the indicated
TRAPP components.
(H) Hypothetical model for mammalian TRAPP complexes. We propose that at least two complexes exist, which contain a core set of proteins (yellow) and unique
subunits, either TRAPPC9/10 (mTRAPPII) or TRAPPC8/11/12/13 (mTRAPPIII), which associate with COPI or COPII vesicles, respectively.
920 Cell 152, 909–922, February 14, 2013 ª2013 Elsevier Inc.
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lentivirus-encoding individual shRNAs. After 3 days, cells were seeded in 24-
well plates at 0.5 3 106/ml and treated with 0.5 ng/ml ricin. After 24 hr, ricin
was washed out, and cells were adjusted to 0.5 3 106/ml. Percentages of
mCherry-positive cells were assessed by FACS 24–48 hr later.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, three
tables, and seven figures and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2013.01.030.
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ABSTRACT The AP-5 complex is a recently identified but evolutionarily ancient member of 
the family of heterotetrameric adaptor proteins (AP complexes). It is associated with two 
proteins that are mutated in patients with hereditary spastic paraplegia, SPG11 and SPG15. 
Here we show that the four AP-5 subunits can be coimmunoprecipitated with SPG11 and 
SPG15, both from cytosol and from detergent-extracted membranes, with a stoichiometry of 
∼1:1:1:1:1:1. Knockdowns of SPG11 or SPG15 phenocopy knockdowns of AP-5 subunits: all 
six knockdowns cause the cation-independent mannose 6-phosphate receptor to become 
trapped in clusters of early endosomes. In addition, AP-5, SPG11, and SPG15 colocalize on a 
late endosomal/lysosomal compartment. Both SPG11 and SPG15 have predicted secondary 
structures containing α-solenoids related to those of clathrin heavy chain and COPI subunits. 
SPG11 also has an N-terminal, β-propeller–like domain, which interacts in vitro with AP-5. We 
propose that AP-5, SPG15, and SPG11 form a coat-like complex, with AP-5 involved in pro-
tein sorting, SPG15 facilitating the docking of the coat onto membranes by interacting with 
PI3P via its FYVE domain, and SPG11 (possibly together with SPG15) forming a scaffold.
INTRODUCTION
AP-5 is the most recently identified and the least well characterized 
of the heterotetrameric adaptor protein (AP) complexes (Hirst et al., 
2011). Its subunits share so little sequence identity with the subunits 
of the other AP complexes that they cannot be found using stan-
dard bioinformatics tools such as BLAST, and so for many years the 
existence of a fifth AP complex was unsuspected. However, struc-
tural prediction programs indicate that the subunits of AP-5 adopt 
similar folds to their counterparts in APs 1–4, and so their nomencla-
ture follows the same convention: ζ and β5 for the two large sub-
units, μ5 for the medium subunit, and σ5 for the small subunit, en-
coded by the genes AP5Z1, AP5B1, AP5M1, and AP5S1, respectively. 
Like all of the AP complexes, AP-5 is evolutionarily ancient (Hirst 
et al., 2011) and ubiquitously expressed (http://biogps.org/, www 
.ncbi.nlm.nih.gov/UniGene/), although its expression profile in de-
veloping chick embryos (Hirst et al., 2013) suggests that it may be 
particularly important in neurons.
Characterization of AP-5 has been somewhat hampered by its 
low abundance (Hirst et al., 2013) and absence from a number of 
model organisms (Hirst et al., 2011). However, an important insight 
into its function came from the discovery by Słabicki et al. (2010) that 
AP-5 subunits could be coimmunoprecipitated with two proteins 
mutated in patients with hereditary spastic paraplegia (HSP), SPG11 
and SPG15 (also known as spatacsin and spastizin/ZFYVE26/FYVE-
CENT, respectively). HSP is a group of genetic disorders character-
ized by progressive spasticity in the lower limbs. Mutations in SPG11 
and SPG15 are the major causes of HSP accompanied by thin cor-
pus callosum and mental impairment (Boukhris et al., 2008), and 
patients with mutations in these two genes present with the same 
clinical features. In addition, morpholino knockdowns of SPG11 and 
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SPG15 in zebrafish produce very similar phenotypes, affecting the 
development of motor neurons (Martin et al., 2012). Both observa-
tions are consistent with the two proteins acting together in the 
same pathway. Furthermore, Słabicki et al. (2010) discovered that 
mutations in AP5Z1 are also associated with HSP, although in this 
case the patients had a later onset of the disease.
Both SPG11 and SPG15 are large proteins (>250 kDa), and 
SPG15 has a FYVE domain that binds in vitro to phosphatidylinositol 
3-phosphate (PI3P; Sagona et al., 2010). Little is known about the 
precise functions of the two proteins or how they associate with AP-
5. In addition, there is some controversy over the localization of 
SPG11 and SPG15, with labeling reported in many different loca-
tions, including endoplasmic reticulum, endosomes, microtubules, 
mitochondria, nuclei, and the midbody of dividing cells (Hanein 
et al., 2008; Sagona et al., 2010; Murmu et al., 2011). In the present 
study, we use a combination of biochemistry and microscopy to be-
gin to dissect the structural and functional relationship between AP-
5, SPG11, and SPG15.
RESULTS
Stable association of SPG11/SPG15 with AP-5
We previously generated a HeLa cell line expressing green fluores-
cent protein (GFP)–tagged σ5 and showed by Western blotting that 
when cytosol from these cells is immunoprecipitated with anti-GFP, 
other AP-5 subunits coprecipitate (Hirst et al., 2011). To identify ad-
ditional AP-5–associated proteins, we have analyzed our σ5-GFP 
immunoprecipitates by mass spectrometry and also carried out im-
munoprecipitations on cells expressing GFP-tagged ζ, SPG15, and 
SPG11.
In the σ5-GFP immunoprecipitates, we identified >50 proteins, 
but only 6 of these were specifically brought down in cells express-
ing σ5-GFP and not in control cells, and these were the ζ, β5, μ5, 
and σ5 subunits of AP-5, together with SPG11 and SPG15 (Supple-
mental Table S1). To investigate the interaction further, we used the 
Quantitative BAC InteraCtomics (QUBIC) method, which allows the 
sensitive and unbiased detection of protein–protein interactions 
(Hubner et al., 2010). Triplicate immunoprecipitations were per-
formed on three BAC transgenic cell lines expressing GFP-tagged 
SPG11, SPG15, or AP-5 ζ from their endogenous promoters. Pre-
cipitated proteins were identified by mass spectrometry and com-
pared with immunoprecipitations performed on a control cell line, 
using label-free quantification. Proteins specifically associated with 
the bait were thus readily distinguished from nonspecific back-
ground proteins (Figure 1A). The only proteins that were consistently 
and specifically coprecipitated with all three baits were the four 
AP-5 subunits, SPG11, and SPG15.
We also used the proteomic data to estimate the relative abun-
dance of the precipitated proteins (Figure 1B). Our data indicate 
that all six proteins are present in equal copy numbers. In turn, this 
suggests that AP-5 is part of a stable hexameric complex consisting 
of one AP-5 tetramer and one copy each of SPG11 and SGP15.
The identification of AP-5 subunits in the SPG15-GFP immuno-
precipitate was confirmed by Western blotting, which also showed 
that these interactions occur in cytosol, as well as on membranes 
(Figure 2A). The coprecipitation of SPG11 and SPG15 with cytosolic 
AP-5 indicates a very stable association because under the same 
conditions, clathrin does not coimmunoprecipitate with AP-1 or 
AP-2 (Figure 2B).
SPG11 or SPG15 knockdown phenocopies AP-5 knockdown
If SPG11 and SPG15 are associated with AP-5, they might be ex-
pected to have similar knockdown phenotypes. We previously 
showed by immunofluorescence that knockdown of any of the AP-5 
subunits results in perturbed trafficking of the cation-independent 
mannose 6-phosphate receptor (CIMPR), causing it to become 
trapped in clusters of endosomes that are positive for EEA1 and the 
retromer subunit Vps26 (Hirst et al., 2011; Figure 3). Knocking down 
either SPG11 or SPG15 produces a similar phenotype (Figure 3A), 
which we quantified by automated microscopy (Figure 3B; see Sup-
plemental Figure S1 for Western blots of the knockdowns). In all 
three knockdowns, labeled structures appeared larger, brighter, and 
fewer, most likely due to endosomal clustering (Hirst et al., 2011). 
This phenotype could be observed not only with the small interfer-
ing RNA (siRNA) pool but also with single, nonoverlapping siRNAs 
(Supplemental Figure S2) and was slightly more pronounced for 
SPG15 than for SPG11. Knockdown of SPG15 (but not SPG11) also 
resulted in the tubulation of EEA1-positive endosomes (Supplemen-
tal Figure S2). Although the significance of the tubulation pheno-
type is unclear, knocking down another HSP protein, strumpellin, 
also causes endosomes to tubulate (Harbour et al., 2010).
Localization of SPG11 and SPG15
In our previous study on AP-5, we carried out immunolocalization 
studies on cells expressing either μ5-GFP or σ5-GFP and saw punc-
tate labeling that partially overlapped with the late endosomal/
lysosomal marker LAMP1. We also saw nuclear labeling for σ5-GFP 
but not for μ5-GFP. This is most likely due to excess nonassembled 
σ5-GFP, which is sufficiently small (<50 kDa) to diffuse freely into 
the nucleus (Hirst et al., 2011; Figure 4A). We found that GFP-
tagged SPG15 and SPG11 had a similar pattern but without the 
nuclear background, including overlap with LAMP1 (Figure 4A and 
Supplemental Figure S3). There have been conflicting reports 
about the localization of SPG11 and SPG15, however, and there is 
always the danger that tagged constructs may be mislocalized. 
Therefore, we made monoclonal antibodies against both SPG11 
and the AP-5 ζ subunit to investigate the distribution of the endog-
enous proteins. Antibodies against both proteins labeled puncta 
distributed throughout the cytoplasm in human fibroblasts and in 
SPG15-GFP–expressing HeLa cells (Figure 4, B and C, and Supple-
mental Figure S4), and double labeling for endogenous SPG11 
and LAMP1 again showed substantial overlap (Figure 4B). This 
punctate labeling pattern was lost when the proteins were de-
pleted using siRNA (Supplemental Figure S4), confirming the spec-
ificity of the antibodies. There was also substantial colocalization 
between SPG15-GFP and endogenous ζ and SPG11 (Figure 4C). 
To investigate whether there is any overlap with some of the other 
structures that have been reported to colocalize with SPG15 and/
or SPG11, we labeled our cells expressing the tagged constructs 
with markers for early endosomes, centrosomes, and endoplasmic 
reticulum exit sites but did not see coincident labeling (Supple-
mental Figure S5).
We also carried out live-cell imaging on the SPG15-GFP–
expressing cells and found that the puncta were dynamic in nature, 
with long-range as well as short-range movements (Figure 5A and 
Supplemental Movie S1). When the cells were incubated with either 
Lysotracker Red or Magic Red Cathepsin B (Figure 5B and Supple-
mental Movies S2 and S3), we found almost complete overlap with 
SPG15-GFP. This indicates that the SPG15 compartment is acidic 
and contains active hydrolases. In addition, localization of SPG15-
GFP by immunogold electron microscopy (EM) showed labeling of 
structures that often contained membrane whorls (Figure 5C). To-
gether, these data show that AP-5, SPG11, and SPG15 localize to 
organelles that can be morphologically, enzymatically, and bio-
chemically defined as late endosomes/lysosomes.
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Dependence of AP-5 on SPG11 and 
SPG15
To investigate whether AP-5, SPG11, and 
SPG15 are dependent on each other for 
their localization and/or stability, we 
knocked down one protein and then looked 
for effects on the others by immunofluores-
cence microscopy. Knockdown of either 
SPG11 or SPG15 resulted in a dramatic loss 
of σ5-GFP punctate labeling, comparable 
to the loss of σ5-GFP labeling when other 
subunits of AP-5 are knocked down 
(Figure 6A). Western blotting indicated that 
AP-5 subunits may be destabilized when 
SPG15 is depleted (Supplemental Figure 
S1), so the loss of punctate AP-5 labeling 
could result from effects on stability, recruit-
ment, or both. In contrast, knocking down 
AP-5 subunits produced little or no effect 
on the localization of GFP-tagged SPG15 or 
SPG11. We also observed that AP-5 ζ label-
ing was brighter in cells expressing SPG15-
GFP (Figure 4C), suggesting that increasing 
the expression of SPG15 increases the 
membrane localization of AP-5. Thus AP-5 
appears to depend on SPG11/SPG15 for its 
localization and/or stability but not vice 
versa.
A number of vesicle coat proteins, in-
cluding AP-1, AP-3, and AP-4, require the 
small GTPase ARF1 to localize to mem-
branes, and become cytosolic when cells 
are treated with the drug brefeldin A, which 
inhibits guanine nucleotide exchange fac-
tors for ARF1. Neither AP-5 nor SPG15 is 
affected by brefeldin A (Hirst et al., 2011; 
Figure 6B), however, indicating that their 
localization to membranes is ARF1 inde-
pendent. The plasma membrane adaptor 
AP-2 is also ARF1 independent, but it re-
quires a specific phosphoinositide for its 
FIGURE 1: Stable association of SPG11 and SPG15 with AP-5. (A) QUBIC interaction proteomic 
analysis. GFP-tagged AP-5 ζ, SPG11, and SPG15 were stably expressed under the control of 
their endogenous promoters. Immunoprecipitations were performed with an anti-GFP antibody 
and compared by label-free quantitative mass spectrometry with immunoprecipitations (IPs) 
performed on a control cell line with no GFP bait protein. Every experiment was performed in 
triplicate. Data were analyzed with a t test to determine significant interactions (Hubner et al., 
2010) and visualized in a “volcano plot.” For each identified protein, plots show the fold 
difference in abundance (bait IP vs. control IP; x-axis, log2 scale), as well as a p-value indicating 
robustness of the observed difference (y-axis, –log10 scale). Specific interactors have high fold 
differences and low p values (top right quadrant of the plot). The “volcano” lines indicate the 
significance cut-off that separates specific interactors from background. With every bait, all four 
AP-5 subunits, SPG11, and SPG15 are specifically coimmunoprecipitated. The SPG11 bait also 
coIPs a number of abundant cytoskeletal proteins, but since these proteins were not identified 
in the other two QUBIC experiments, it seems unlikely that these interactions are physiologically 
relevant. Furthermore, the SPG11 pull down has a greater scatter of background proteins 
than the AP-5 ζ and SGP15 pull downs, suggesting that it may be slightly less specific. 
(B) Stoichiometry analysis. Normalized peptide intensities were used to estimate the relative 
abundance of specific interactors identified in A (iBAQ method; Schwanhäusser et al., 2011). 
For each protein, the values from all triplicate repeats were plotted. Only coimmunoprecipitated 
proteins were included, since the bait protein 
tends to be overrepresented in 
immunoprecipitation experiments. The 
relative abundances of proteins were 
normalized to the median abundance of all 
proteins across each experiment (i.e., median 
set to 1.0). The data show that regardless of 
the bait protein, roughly equal molar 
amounts of AP-5 subunits, SPG11, and 
SPG15 are coprecipitated, which supports 
the existence of an equimolar hexameric 
complex consisting of AP-5, SPG11, and 
SPG15. The only exception is a substantially 
higher proportion of AP-5 σ precipitated 
with AP-5 ζ (top). Based on structural 
information on other AP complexes (Page 
and Robinson, 1995; Collins et al., 2002), 
these two subunits may form a stable 
subcomplex, and expression of tagged AP-5 
ζ may thus stabilize and increase the 
recovery of AP-5 σ.
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FIGURE 2: Western blots of immunoprecipitates. (A) Immunoprecipitations were carried out on 
either control HeLa cells or HeLa cells expressing SPG15-GFP using anti-GFP, and the blots were 
probed using antibodies against AP-5 subunits. AP-5 coprecipitates with SPG15-GFP in both a 
high-speed supernatant of homogenized cells (SUP) and a Triton X-100 extract of a high-speed 
pellet (PEL), indicating that the association occurs both in cytosol and on membranes. The 
lower–molecular weight band in the immunoprecipitates probed with anti-β5 appears to be 
nonspecific. (B) A cytosol fraction from SPG15-GFP–expressing cells was immunoprecipitated 
with the antibodies indicated at the top, and Western blots were probed with the antibodies 
indicated at the side. Although AP-5 coimmunoprecipitates with SPG15-GFP, AP-1 and AP-2 do 
not coimmunoprecipitate with clathrin heavy chain (CHC). The input is 2.5% relative to the IP for 
SPG15-GFP and 5% for CHC, AP-1, and AP-2.
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localization, phosphatidylinositol 4,5-bisphosphate, which is mainly 
generated on the plasma membrane (Beck and Keen, 1991; Honing 
et al., 2005). SPG15 has been shown to bind in vitro to another 
phosphoinositide, PI3P (Sagona et al., 2010), which is found mainly 
on endosomes. To investigate the importance of this interaction in 
vivo, we treated cells with the phosphoinositide (PI) 3-kinase inhibi-
tor wortmannin. The punctate patterns of both SPG15-GFP and 
σ5-GFP were lost under these conditions (Figure 6B), indicating 
that PI3P is required for the recruitment of both SPG15 and AP-5, 
most likely by interacting with the FYVE domain of SPG15.
AP-5 interacts with the N-terminal domain of SPG11
We previously showed that AP-5 does not colocalize with clathrin 
and cannot be detected in clathrin-coated vesicle-enriched fractions 
(Hirst et al., 2011), indicating that if it is a component of a vesicle 
coat, it must use some other type of scaffold. It is intriguing that 
both SPG11 and SPG15 are predicted to contain α-helical solenoids, 
similar to those of clathrin heavy chain, the α and β′ subunits of the 
COPI coat, and the Sec31 subunit of the COPII coat (Devos et al., 
2004). In clathrin, COPI, and COPII, the α-solenoid is preceded by a 
β-propeller, and SPG11 also has a predicted N-terminal, β-propeller–
like fold. In addition, HHpred (Söding et al., 2005) identifies clathrin 
heavy chain, α-COP, and β′-COP as matches for both the α-solenoid 
and the β-propeller regions (Figure 7, A and B).
The β-propeller of clathrin heavy chain is a major hub for protein–
protein interactions (Lemmon and Traub, 2012), with binding part-
ners including AP-1, AP-2, and several “alternative adaptors.” To 
determine whether the β-propeller–like domain of SPG11 also acts 
as a binding platform, we carried out a glutathione S-transferase 
(GST) pull down on HeLa cell cytosol, using residues 1–500 of SPG11 
as bait. We were able to detect the ζ subunit of AP-5 by Western 
blotting (Figure 7C), indicating that a similar type of interaction at-
taches AP-5 to SPG11. As controls, we probed for the γ subunit of 
AP-1 and the α subunit of AP-2. Even though AP-1 and AP-2 are 
∼30- and ∼70-fold more abundant in HeLa 
cells than AP-5 (Hirst et al., 2013), respec-
tively, they could not be detected in the pull 
down.
DISCUSSION
By analogy with other AP complexes, it 
seems likely that the role of AP-5 is to act as 
a cargo adaptor for a novel type of coat. 
Other components of the coat may include 
proteins that form a docking site to facilitate 
recruitment onto membranes and proteins 
that can assemble into some sort of scaf-
fold. We propose that SPG15 and SPG11 
function as a docking site and scaffold, 
respectively.
The interaction between AP-5 and 
SPG11/SPG15 was initially demonstrated 
by immunoprecipitation. We extended 
these observations to determine whether 
the proteins are associated with each other 
in cytosol as well as on membranes, deter-
mine their stoichiometry, and look for other 
binding partners. We found that the four 
AP-5 subunits, SPG11, and SPG15 invari-
ably coimmunoprecipitate with each other, 
without pulling down any other proteins, 
and can be coimmunoprecipitated from cy-
tosol, as well as from membrane extracts. This is in contrast to AP-1/
AP-2 and clathrin, which only interact on membranes and do not 
efficiently coimmunoprecipitate even from membrane extracts. 
Thus AP-5 and SPG11/SPG15 are more like the COPI coat in this 
respect, where there is a relatively stable complex, called the 
coatomer, which can be dissociated into two subcomplexes (Pavel 
et al., 1998). SPG11 and SPG15 appear to be in an equimolar ratio 
with the four AP-5 subunits, which again is reminiscent of coatomer, 
where all seven subunits are stoichiometric with each other.
In addition to coimmunoprecipitating with AP-5, SPG11 and 
SPG15 have similar knockdown phenotypes to the AP-5 subunits. In 
every case, the CIMPR becomes trapped in membrane clusters that 
are positive for EEA1 and Vps26, indicating that they are early endo-
somal compartments. AP-5, SPG11, and SPG15 also have very simi-
lar subcellular distributions, localizing to a late endosomal/lysosomal 
compartment. This pattern can be seen with antibodies against en-
dogenous proteins, as well as with tagged constructs, and it is 
strongly reduced when the proteins are depleted with siRNA, dem-
onstrating that the labeling is specific. The identity of the compart-
ment is based on several lines of evidence: the label shows substan-
tial overlap with LAMP1; it colocalizes with both Lysotracker Red, a 
vital stain for acidic organelles, and Magic Red Cathepsin B, a vital 
stain for organelles containing active hydrolases; and by immuno-
gold EM it is associated with structures containing membrane 
whorls. Thus, although knocking down the proteins produces 
changes in an early endosomal compartment, the proteins them-
selves localize (at least primarily) to a later compartment.
The connection between SPG11/SPG15/AP-5 and HSP indicates 
that a loss of these proteins is particularly deleterious to neurons with 
long axons because these are the cells that are primarily affected. Late 
endosomes and lysosomes are found mostly in the neuronal cell body, 
but some are present in axons, where they are transported mainly in 
the retrograde direction (Tsukita and Ishikawa, 1980; Cai et al., 2010). 
Whether mutations in AP-5, SPG11, or SPG15 affect axonal trafficking 
159
●
Appendix
2562 | J. Hirst et al. Molecular Biology of the Cell
FIGURE 3: Knockdown of SPG11 and SPG15 phenocopies AP-5 knockdown. (A) HeLa cells were treated with siRNAs as 
indicated and double labeled for the CIMPR and the retromer protein Vps26. In the siRNA-treated cells, the CIMPR 
clusters in Vps26-positive endosomes. There also appears to be increased colocalization of CIMPR and Vps26 in these 
cells. All of the images of siRNA-treated cells were taken at half the exposure time of the controls because of the 
increased brightness. Scale bar, 20 μm. (B) The knockdown phenotypes were quantified using an ArrayScan VTI 
microscope and Spot Detector V4 algorithm application for automated image collection and analysis. Means of CIMPR 
labeling in control and knockdown cells were compared using repeated-measures analysis of variance and the post hoc 
Tukey–Kramer significance test (*p < 0.05, **p < 0.01, ***p < 0.001). More than 1500 cells were scored per knockdown 
condition (two independent repeats). In every knockdown, there is an increase in the area and intensity of spots and a 
concomitant decrease in the number of spots (although the decrease in spot number could be a result of increased 
clustering rather than fewer structures).
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FIGURE 4: Immunofluorescence labeling of AP-5, SPG15, and SPG11. (A) Cells stably expressing either σ5-GFP or 
SPG15-GFP were fixed and double labeled with antibodies against GFP (to enhance the signal) and the late endosomal/
lysosomal protein LAMP1. Cytosolic σ5-GFP was washed out by saponin before fixation, leaving nuclear staining (this 
construct is likely to diffuse freely in and out of the nucleus). The punctate GFP labeling throughout the cytoplasm is 
partially coincident with LAMP1. (B) Primary human fibroblasts were double labeled for endogenous SPG11 and LAMP1. 
The two antibodies show good colocalization. (C) Cells expressing SPG15-GFP were fixed and double labeled with 
anti-GFP and monoclonal antibodies against either SPG11 or ζ subunit of AP-5. The labeling patterns for tagged SPG15 
and endogenous ζ or SPG11 are largely coincident. Scale bars, 20 μm.
of these organelles or cause HSP for some other reason (e.g., by im-
pairing axonal maintenance) remains to be determined.
The PI 3-kinase inhibitor wortmannin causes AP-5, SPG11, and 
SPG15 to appear cytosolic rather than membrane associated, indi-
cating that the phosphoinositide PI3P acts as a membrane identity 
marker, most likely by binding to the FYVE domain of SPG15. 
Although PI3P is usually regarded as marker for an early endosomal 
compartment, there is at least one other protein, sorting nexin 16 
(Snx16), that binds to PI3P (via a PX domain) but localizes to a late 
endosomal compartment (Brankatschk et al., 2011). In the case of 
Snx16, another domain also contributes to localization (Hanson and 
Hong, 2003), and it seems likely that additional interactions will be 
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FIGURE 5: SPG15 localization. (A) Stills from a movie (Supplemental Movie S1) showing cells expressing SPG15-GFP. 
Cells were imaged every 10 s over 15 min. Motile structures can be seen moving over short (arrows) and long distances 
(circle). Scale bar, 20 μm. (See Supplemental Movie S1.) (B) Cells expressing SPG15-GFP were either incubated with 
Lysotracker Red, a vital stain for acidic organelles, and imaged immediately, or incubated with Magic Red Cathepsin B 
substrate, a vital stain for active lysosomal hydrolases, for 30 min and then imaged. SPG15-GFP colocalizes with both 
markers. Scale bar: 20 μm. (See Supplemental Movies S2 and S3.) (C) Immunogold labeling of SPG15-GFP–expressing 
cells. Because of the low abundance of the protein, labeling was sparse, but there was very little background. Gold 
particles can be seen associated with organelles containing membrane whorls, characteristic of late endosomes/
lysosomes, but we did not find any label associated with budding profiles. Scale bar, 200 nm.
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SPG11 or SPG15. Most organisms have either both AP-5 and 
SPG11/SPG15 or neither, but there are a few exceptions, including 
Drosophila, that have SPG11/SPG15 but not AP-5 (Hirst et al., 2011). 
Thus it is possible that SPG11/SPG15 may be able to function in the 
absence of AP-5. The observation that patients with mutations in 
found to facilitate the binding of SPG11/SPG15 to late endosomes, 
similar to the “coincidence detection” mechanism used to recruit 
AP-2 onto membranes (Haucke, 2005).
Although knockdown of SPG11 or SPG15 affects the localization 
of AP-5, knocking down AP-5 does not affect the localization of 
FIGURE 6: Localization of AP-5 depends on SPG11/SPG15 and is sensitive to wortmannin. (A) Cells stably expressing 
σ5-GFP, SPG15-GFP, or SPG11-GFP were treated with siRNAs and then labeled with anti-GFP. The σ5-GFP–expressing 
cells were treated with saponin before fixation to wash out cytosolic proteins. The punctate labeling of σ5-GFP is lost 
when ζ, SPG11, or SPG15 is depleted. In contrast, the punctate labeling of SPG15-GFP or SPG11-GFP is not lost when 
ζ is depleted. SPG15 labeling becomes diffuse when SPG11 is depleted, however, and SPG11 labeling becomes diffuse 
when SPG15 is depleted. In both cases, siRNAs targeting the construct itself (plus the endogenous version of the 
protein) strongly reduce the total fluorescence. (B) Cells stably expressing either SPG15-GFP or σ5-GFP were treated 
with 5 μg/ml brefeldin A (BFA) for 5 min or 100 nM wortmannin for 1 h and then fixed. The σ5-GFP–expressing cells 
were treated with saponin to wash out cytosolic proteins before fixation. The punctate labeling of both proteins is 
insensitive to brefeldin A but is lost upon treatment with wortmannin. Scale bars, 20 μm.
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FIGURE 7: Domain organization of SPG15 and SPG11. (A) The domain organization of SPG15 was predicted by 
DOMpred, and then homology searching with each domain was carried out using HHpred (http://toolkit.tuebingen 
.mpg.de/hhpred). More information about the HHpred hits is available in Supplemental Table S2. PSIpred was used to 
carry out a secondary structure prediction for each residue. The α-helices are in magenta and β-strands in cyan. The 
height of each colored vertical line is proportional to the confidence of the secondary structure prediction (McGuffin 
et al., 2000). (B) A similar analysis was carried out on SPG11. (C) GST alone or the N-terminal domain of SPG11 coupled 
to GST was incubated with HeLa cell cytosol, and bound AP-5 ζ was detected by Western blotting. The N-terminal 
domain of SPG11 (GST-SPG11N) pulls down AP-5 ζ from cytosol. We estimate, however, that no more than ∼10% of the 
total AP-5 ζ was pulled down by the SPG11 construct, probably because most of the AP-5 already has SPG11 stably 
associated with it, so the pull down only captures “unoccupied” AP-5. As controls, blots of the cytosol and pull downs 
were also probed with antibodies against the AP-1 γ and AP-2 α subunits. Although both of these proteins are much 
more abundant in cytosol than AP-5 ζ, neither was detected in the GST-SPG11N pull down.
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(Carlsbad, CA). Monoclonal antibodies were raised against peptides 
from AP5Z1 (1H1) and SPG11 (4C10, 4L15, 3I13) by Abmart (Shang-
hai, China). Sixteen peptide immunogens for either SPG11 or ζ were 
overexpressed in Escherichia coli, purified by Ni-affinity chromatog-
raphy, and injected into BALB/C mice. Spleen cells were fused with 
SP2/0 myeloma cells, and selected clonal cell lines were used to 
produce ascites fluid, from which antibodies were purified by pro-
tein A/G affinity chromatography. Where known, the epitope is indi-
cated: 3I13 (KDHAKTSDPG), 4L15 (PVQNYKTKEG), and 4C10 
(PQELQGSKQE). The isotypes of the mouse monoclonal antibodies 
made for this study are immunoglobulin G2b (IgG2b; 1H1 and 
4C10), IgG2a (4L15), and IgG3 (3I13). The mouse monoclonals 
against EEA1, C-NAP1, and LAMP1 are all IgG1, and the mouse 
anti-GFP is IgG2a.
For pull-down experiments, a cDNA encoding residues 1–500 of 
SPG11 was cloned into pGEX4T-1 for expression of GST-SPG11N, 
and the resulting fusion protein (which was partially insoluble and 
degraded) was purified using glutathione-Sepharose, as specified 
by the manufacturer (GE Healthcare, Piscataway, NJ).
RNA interference
Knockdowns were performed using the following On-Target Plus 
siRNA reagents from Dharmacon, Lafayette, CO) or a nontargeting 
SMARTpool siRNA (D-001810-10) as a control. The siRNAs were as 
follows: μ5 (C14orf108), J-015523-09, J-015523-10; ζ (KIAA0415), 
L-025284-01; SPG11 (FLJ21439), L-017138-00; SPG15 (ZFYVE26), 
J-031136-09, J-031136-10, J-031136-11, J-031136-12; all used at a 
concentration of 25 nM. Knockdowns were performed with a single-
hit 72-h protocol using Oligofectamine (Invitrogen) and Opti-Mem 
(Invitrogen) following the manufacturer’s instructions.
Tissue culture
HeLaM cells (Tiwari et al., 1987) were grown in DMEM (Sigma-Al-
drich) supplemented with 10% (vol/vol) fetal calf serum (Sigma-Al-
drich), 2 mM l-glutamine, 50 U/ml penicillin, and 50 μg/ml strepto-
mycin. A stable clonal cell line expressing σ5-GFP (Hirst et al., 2011) 
was derived by G418 selection. HeLa cells stably expressing GFP-
tagged SPG11, SPG15, and KIAA0415 (ζ) have been previously de-
scribed (Słabicki et al., 2010). Because of loss of expression over 
time in culture, the cells were sorted by flow cytometry for medium 
to high expression of GFP and maintained in G418-containing 
medium.
Fluorescence microscopy
For immunofluorescence microscopy, cells were plated into glass-
bottom dishes (MatTek, Ashland, MA) and treated where indicated 
with 5 μg/ml brefeldin A for 5 min, 100 nM wortmannin for 1 h, or 
0.05% (wt/vol) saponin in phosphate-buffered saline (PBS) for 1 min. 
The cells were then fixed with 3% formaldehyde, permeabilized with 
0.1% Triton X-100, and labeled as indicated. The cells were imaged 
with a Zeiss Axiovert 200 inverted microscope (Carl Zeiss, Jena, Ger-
many) using a Zeiss Plan Achromat 63× oil immersion objective (nu-
merical aperture 1.4), an OCRA-ER2 camera (Hamamatsu, Hama-
matsu, Japan), and Improvision Openlab software (PerkinElmer, 
Waltham, MA).
For live-cell microscopy, cells were plated into glass-bottom 
dishes (MatTek) and incubated in CO2-independent media with 50 nM 
Lysotracker Red DND-99 (Invitrogen) or Magic Red Cathepsin B 
substrate (AbD Serotec, Raleigh, NC), following manufacturer’s 
instructions. The cells were imaged on a Zeiss LSM710 confocal 
microscope with Zeiss ZEN software. Movie images were captured 
every 10 s for a period of up to 15 min.
AP-5 ζ/AP5Z1 have a later onset of HSP than patients with muta-
tions in SPG11 or SPG15 (Słabicki et al., 2010) is consistent with this 
possibility. However, only two AP5Z1-deficient patients from a single 
family have been identified, so more examples will be needed be-
fore firm conclusions can be drawn. Fifty-two different loci associ-
ated with HSP have been identified, but the causative genes have 
been found for only 31 of these (Finsterer et al., 2012), and there are 
likely to be other, as-yet-unidentified loci. Whole-genome or whole-
exome sequencing may be the most efficient way of identifying ad-
ditional HPS-causing mutations (Züchner, 2010; Bettencourt et al., 
2013; Gonzalez et al., 2013). AP5B1, AP5M1, and AP5S1 are prom-
ising candidates for some of the other HPS causative genes, espe-
cially since mutations in all four of the AP-4 subunit genes have been 
shown to cause a form of “complex” HSP (reviewed in Hirst et al., 
2013).
Unlike SPG15, SPG11 does not have any obvious functional do-
mains; however, its predicted secondary structure, consisting of a 
β-propeller–like N-terminal domain followed by an α-solenoid, to-
gether with its homology to other coat components, including clath-
rin, suggests that it may form some sort of scaffold. Clathrin uses its 
N-terminal β-propeller domain to interact with AP complexes, and 
our pull-down experiments suggest that the same is true for the in-
teraction between SPG11 and AP-5. It is interesting that this domain 
is missing in SPG11 from insects, which also lack AP-5. The α-
solenoids of SPG11 and SPG15 may interact with each other to form 
a scaffold, similar to the clathrin, COPI, and COPII coats. It is not 
clear, however, what the morphology of such a scaffold might be 
because the labeling we observe for tagged SPG15 does not ap-
pear to be associated with budding profiles, suggesting that the 
AP-5/SPG11/SPG15 complex may be more analogous to the flat, 
bilayered clathrin/ESCRT-0 coats on early endosomes (Raiborg 
et al., 2002), which are believed to hold cargo proteins in place 
rather than package them into vesicles.
If AP-5 is indeed involved in cargo selection, what cargo proteins 
does it sort? We had hoped to find candidates in our immunopre-
cipitates, but the only proteins that were clearly being brought down 
specifically were AP-5 subunits, SPG11, and SPG15. This result is 
not entirely unexpected because coat–cargo interactions are very 
transient and often difficult to capture. We have recently been able 
to use the “knocksideways” technique for rapid protein inactivation, 
followed by subcellular fractionation and comparative proteomics, 
to identify >50 cargo proteins that are dependent on AP-1 and/or 
GGA2 for efficient packaging into CCVs (Hirst et al., 2012). By using 
a similar approach on AP-5, SPG11, and SPG15, we hope to be able 
to establish the precise functions of each of these proteins.
MATERIALS AND METHODS
Antibodies and constructs
Antibodies used in this study include in-house antibodies against 
clathrin and AP-1 (Simpson et al., 1996) and commercial antibodies 
against EEA1 (E41120; BD Transduction Labs, Lexington, KY), 
LAMP1 (sc18821; Santa Cruz Biotechnology, Santa Cruz, CA), GFP 
(ab6556; Abcam, Cambridge, MA), CIMPR (ab2733; Abcam), C-
NAP1 (BD611375; BD Biosciences, San Diego, CA), AP-2 α (610502; 
BD Biosciences), and AP5Z1 (KIAA0415; sc139260; Santa Cruz Bio-
technology). Rabbit anti-GFP and sheep anti-SEC16A were kind 
gifts from Matthew Seaman (Cambridge Institute for Medical Re-
search, Cambridge, United Kingdom) and David Stephens (Univer-
sity of Bristol, Bristol, United Kingdom), respectively. Horseradish 
peroxidase–labeled secondary antibodies were purchased from 
Sigma-Aldrich (St. Louis, MO) and fluorescently labeled secondary 
antibodies (species and/or isotype specific) from Invitrogen 
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control cell lines reveals proteins specifically associated with the 
bait. QUBIC was performed essentially as described by Hubner 
et al. (2010). Anti-GFP immunoprecipitations of BAC and control cell 
lines were performed in triplicate. The precipitated proteins were 
analyzed by mass spectrometry and compared using label-free 
quantification. The following cell lines were analyzed. BAC cell lines: 
SGP11-GFP, AP-5 ζ-GFP (Słabicki et al., 2010), SPG15-GFP (origi-
nally established by Słabicki et al., 2010; we selected a clonal cell 
line from this); control cell line: derived from the SPG15-GFP cell 
line; we selected cells that had lost expression of the SPG15-GFP 
bait (as determined by immunofluorescence microscopy and West-
ern blotting). This control cell line therefore closely corresponds to 
the parental HeLa cells used to generate all of the BAC cell lines.
To gauge the stoichiometry of identified proteins, we used in-
tensity-based absolute quantification (iBAQ) estimation of protein 
abundance (Schwanhäusser et al., 2011; implemented in the Max-
Quant package by Cox and Mann, 2008). iBAQ sums the intensi-
ties of all identified peptides for each protein and normalizes the 
total intensity to the number of theoretically obtainable tryptic 
peptides of the protein. Unlike the original publication, we omitted 
a spike-in standard and assumed proportionality between the 
iBAQ intensity and protein molarity. iBAQ can be used to estimate 
the relative abundance of subunits in a protein complex (Arike 
et al., 2012). Although the accuracy of the method is limited, it can 
clearly distinguish between stoichiometric (1:1) and substoichio-
metric (<<1:1) interactions. For each individual pull down, iBAQ 
values of coimmunoprecipitated proteins were first normalized to 
the iBAQ value of the bait protein. Data from pull downs with the 
same bait (triplicate repeats) were then combined and iBAQ values 
normalized to the median iBAQ value of the set (excluding the bait 
protein). Values were then log-transformed and plotted 
(Figure 1B).
To quantify knockdown phenotypes, we used an automated 
ArrayScan VTI microscope (Cellomics/Thermo Fisher, Pittsburgh, 
PA) and the SpotDetector V4 assay algorithm. Cells were plated 
onto 96-well PerkinElmer microplates and stained with anti-CIMPR, 
followed by Alexa Fluor 488–donkey anti-mouse IgG and whole-cell 
stain (Invitrogen). The cells were imaged with a modified Zeiss Axio-
vert 200M inverted microscope, a Zeiss 40×/0.5 Achroplan objec-
tive, and a Hamamatsu OCRA-ER camera, and >1500 cells quanti-
fied for each condition using ARRAYSCAN software.
Electron microscopy
For immunogold electron microscopy, a clonal line of cells express-
ing SPG15-GFP was derived, permeabilized by immersion in liquid 
N2, and fixed by adding an equal volume of freshly prepared 8% 
paraformaldehyde/0.2% gluteraldehyde in 0.1 M phosphate buffer, 
pH 7.4. After 5 min the solution was removed and cells were post-
fixed in 4% paraformaldehyde/0.1% glutaraldehyde in 0.1 M phos-
phate buffer, pH 7.4, for 1 h at room temperature and further pro-
cessed as previously described (Hirst et al., 2009). Ultrathin sections 
were labeled with the commercial GFP antibody (see previous de-
scription), followed by protein A conjugated to colloidal gold 
(Utrecht University, Utrecht, Netherlands), and viewed using a Phil-
lips CM 100 transmission electron microscope (Philips Electron 
Optics, Cambridge, United Kingdom) at an operating voltage of 
80 kV.
Immunoprecipitation and GST pull-down experiments
For immunoprecipitations from whole-cell lysates, cells stably ex-
pressing σ5-GFP or SPG15-GFP were solubilized in PBS containing 
1% Triton X-100 and insoluble material removed before incubation 
with GFP-Trap (ChromoTek, Martinsried, Germany), according to 
the manufacturer’s instructions. For analysis by mass spectrometry, 
proteins were processed by filter-aided sample preparation solution 
digest (Wiśniewski et al., 2009), and the sample was analyzed by 
liquid chromatography–tandem mass spectrometry in an Orbitrap 
mass spectrometer (Thermo Scientific; Waltham, MA; Antrobus and 
Borner, 2011). For immunoprecipitations from cytosol and mem-
brane fractions, cells stably expressing SPG15-GFP were scraped in 
PBS and lysed by six passages through a 21-gauge needle/5-ml sy-
ringe. Nuclei and unbroken cells were removed by centrifugation at 
4000 × g for 5 min, and then membranes were recovered at 50,000 
× g for 1 h. The membrane pellet was solubilized in PBS containing 
1% Triton X-100 and clarified by centrifugation. Triton X-100 was 
also added to the supernatant to a concentration of 1%, and then 
both samples were incubated with GFP-Trap (ChromoTek) accord-
ing to the manufacturer’s instructions.
For GST pull-down experiments, cells were solubilized in PBS 
containing 1% NP40, and insoluble material was removed by cen-
trifugation at 20,000 × g for 30 min. Samples containing 5 mg of 
starting lysate were precleared with 50 μg/ml GST, followed by glu-
tathione–Sepharose. The lysates were then incubated with 50 μg/ml 
GST-SPG11N, followed by glutathione–Sepharose, and washed 
with PBS containing 1% NP40, followed by PBS. Bound proteins 
were eluted with SDS–PAGE loading buffer.
Several cell lines were analyzed by QUBIC. QUBIC is a recent 
proteomics method for unbiased and sensitive identification of pro-
tein–protein interactions (Hubner and Mann, 2011). It is based on 
the generation of stable cell lines that express a GFP-tagged, full-
length bait protein under control of its endogenous promoter. The 
tagged bait protein is expressed at near-physiological levels and 
can be immunoprecipitated with an anti-GFP antibody. Quantitative 
mass spectrometric analysis of immunoprecipitates from bait and 
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NF-κB is a master regulator of inflammation and has been implicated in the pathogenesis of immune dis-
orders and cancer. Its regulation involves a variety of steps, including the controlled degradation of inhibi-
tory IκB proteins. In addition, the inactivation of DNA-bound NF-κB is essential for its regulation. This step 
requires a factor known as copper metabolism Murr1 domain–containing 1 (COMMD1), the prototype mem-
ber of a conserved gene family. While COMMD proteins have been linked to the ubiquitination pathway, little 
else is known about other family members. Here we demonstrate that all COMMD proteins bind to CCDC22, 
a factor recently implicated in X-linked intellectual disability (XLID). We showed that an XLID-associated 
CCDC22 mutation decreased CCDC22 protein expression and impaired its binding to COMMD proteins. 
Moreover, some affected individuals displayed ectodermal dysplasia, a congenital condition that can result 
from developmental NF-κB blockade. Indeed, patient-derived cells demonstrated impaired NF-κB activation 
due to decreased IκB ubiquitination and degradation. In addition, we found that COMMD8 acted in conjunc-
tion with CCDC22 to direct the degradation of IκB proteins. Taken together, our results indicate that CCDC22 
participates in NF-κB activation and that its deficiency leads to decreased IκB turnover in humans, highlight-
ing an important regulatory component of this pathway.
Introduction
Copper metabolism Murr1 domain–containing (COMMD) pro-
teins are a group of 10 evolutionarily conserved factors present 
in a wide range of organisms, including plants, protozoa, worms, 
insects, and vertebrates (1). COMMD1, the prototype member of 
the family, has been linked to a number of physiologic processes, 
including copper homeostasis (2–4), sodium balance (5–8), and 
adaptation to hypoxia (9, 10). COMMD1 has also been found to 
inhibit NF-κB (11, 12), a proinflammatory transcription factor 
that regulates close to 400 target genes that play essential roles in 
immune responses, immune system development, and cell survival 
and proliferation (13–15).
The underlying mechanism for the diverse functions of 
COMMD1 has not been fully elucidated, but in several instances, 
COMMD1 has been shown to promote the ubiquitination of spe-
cific cellular proteins (12). Recently, it was shown that COMMD1 
and other COMMD family members interact with and regulate 
the activation of a class of ubiquitin ligases known as Cullin-RING 
ligases (CRLs) (16). CRLs are multiprotein complexes containing 
a Cullin family member as the main scaffold protein (Cul1, Cul2, 
Cul3, Cul4a, Cul4b, Cul5, and Cul7 in humans). To form the active 
ligase, each Cullin associates with a RING finger protein (Rbx1 or 
Rbx2) and any of various substrate binding partner proteins specif-
ic to each Cullin. This prolific group of enzymes accounts for more 
than 25% of all ubiquitin ligases in mammals and regulate diverse 
cellular processes, including cell cycle progression, DNA repair, and 
many signal transduction pathways, including NF-κB (17).
Activation of NF-κB is controlled by various ubiquitination 
events, including the critically important degradation of IκB, a 
constitutive inhibitor of this pathway (18). This step is mediated 
by Cul1 in association with β-transducin repeat–containing pro-
tein (βTrCP), which form the complex CRL1-βTrCP (also known 
as SCFβTrCP) (19–21). Under basal conditions, so-called “classical” 
IκB proteins (IκB-α, IκB-β, or IκB-ε) bind to NF-κB dimers and 
mask their nuclear localization sequence, keeping them inac-
tive in the cytosol (22). IκB phosphorylation by the IκB kinase 
complex (IKK) generates a phospho-serine motif at the amino 
termini of classical IκB proteins. This motif is recognized by the 
F-box proteins βTrCP1 or βTrCP2, the substrate binding subunit 
of the CRL1-βTrCP ligase, leading to rapid ubiquitination and 
degradation of IκB (23).
Another CRL-regulated step in the NF-κB pathway is the degra-
dation of chromatin-associated NF-κB subunits such as RelA (also 
known as p65), which plays an essential role in limiting gene expres-
sion (11, 12). This event is triggered by IKK-dependent phosphor-
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ylation of RelA (24, 25) and is mediated by a CRL2 complex that 
depends on COMMD1 for its activation (12, 16). Interestingly, while 
certain COMMD proteins, such as COMMD8 and COMMD10, 
bind to Cul1 (16), it was not previously known whether these factors 
promote the ubiquitination of CRL1 targets such as IκB.
In this study, we demonstrated that coiled-coil domain–con-
taining protein 22 (CCDC22), a highly conserved protein recently 
implicated in X-linked intellectual disability (XLID) (26), is an asso-
ciated factor that binds to all COMMD family members. CCDC22 
was required for the ubiquitination and subsequent turnover of 
IκB proteins. Individuals with a hypomorphic mutation in CCDC22 
demonstrated IκB stabilization and a blunted NF-κB response. 
These findings highlight a novel aspect in the activation of IκB 
ubiquitination and the control of NF-κB through CCDC22.
Results
COMMD proteins associate with CCDC22, a broadly expressed gene. We 
hypothesized that, given their structural homology, COMMD 
proteins might assemble similar molecular complexes in vivo and 
that the identification and characterization of potential protein 
partners might provide insights into the mechanism of action 
of COMMD family members in general. In order to accomplish 
our goal, we began to systematically characterize protein com-
plexes associated with COMMD proteins in vivo using tandem 
affinity purification (TAP). In these screens, 3 COMMD protein 
baits were used: COMMD1, COMMD9, and COMMD10. Con-
sistent with the known ability of COMMD proteins to interact 
with each other (1), the TAP screens identified other endogenous 
COMMD proteins. Interestingly, these baits interacted with a spe-
cific and unique combination of COMMD partners: COMMD1 
brought down COMMD3, COMMD4, and COMMD6, whereas 
COMMD9 and COMMD10 interacted with each other as well as 
with COMMD5 and COMMD6 (Figure 1A).
In addition, in all 3 screens, mass spectrometry analysis iden-
tified peptides that matched with high confidence to a protein 
of previously unknown function, termed CCDC22 (Figure 1A). 
Using deposited data available from BioGPS (27), we found that 
CCDC22 is broadly expressed in human tissues (Supplemental 
Figure 1A; supplemental material available online with this article; 
doi:10.1172/JCI66466DS1). Moreover, we examined the pattern of 
expression for the Ccdc22 ortholog in mouse tissues and confirmed 
similar findings at the mRNA level by quantitative real-time RT-PCR 
(qRT-PCR) and at the protein level by Western blot analysis (Sup-
plemental Figure 1, B and C).
CCDC22-COMMD interactions were readily validated in endog-
enous coimmunoprecipitations using 2 antisera raised against 
CCDC22, which coprecipitated endogenous COMMD1 (Figure 1B). 
Reciprocal precipitations using antisera against COMMD1, 
COMMD6, COMMD9, and COMMD10 also coprecipitated endog-
enous CCDC22 (Figure 1C). Consistent with prior reports (1, 28), 
COMMD1 and COMMD6 were present in the same complex 
(Figure 1C). The interaction of CCDC22 with 4 COMMD fam-
ily members suggested the possibility that other COMMD proteins 
might also interact with this factor. Given the paucity of characterized 
antibodies to other COMMD family members, we expressed COMMD 
proteins fused to glutathione S-transferase (GST) in mammalian cells 
and subsequently precipitated these proteins from cell lysates. All 10 
COMMD proteins were able to coprecipitate endogenous CCDC22 
to a similar extent (Figure 1D). Finally, a quantitative BAC-GFP 
interactomics experiment (29) using GFP-tagged CCDC22 as bait 
was also performed. For these experiments, CCDC22 was stably 
expressed in HeLa cells through the introduction of a BAC encoding 
GFP-tagged CCDC22 from its native locus (30). Again, all COMMD 
proteins were identified with high confidence as interacting partners 
of CCDC22 using 2 distinct affinity tag combinations (Figure 1E 
and Supplemental Figure 2), which confirmed that this protein is an 
associated factor of all COMMD family members.
CCDC22 regulates the cellular localization of COMMD proteins. Next, 
we examined the cellular distribution of CCDC22. Using a yellow 
fluorescent protein (YFP) fusion protein, we found CCDC22 to 
be localized primarily in the cytosol, with a punctate perinuclear 
distribution, and with minor presence in the nucleus (Supplemen-
tal Figure 1D), in agreement with what is reported for the endog-
enous protein by the Protein Atlas project (31). Since the cellular 
distribution of CCDC22 was similar to the pattern displayed by 
several COMMD proteins (16), we also analyzed whether CCDC22 
and COMMD1 could colocalize. Using GFP- and DsRed2-tagged 
versions of CCDC22 and COMMD1, respectively, we identified 
clear colocalization, while at the same time, some fraction of these 
proteins displayed exclusive cellular localization (Figure 2A). This 
colocalization is in agreement with the protein-protein interaction 
identified biochemically.
In order to clarify the role of CCDC22 binding to all COMMD 
proteins, we examined whether CCDC22 regulates the ability of 
COMMD proteins to interact with each other. After CCDC22 
silencing, the amount of COMMD1 or COMMD10 bound to 
endogenous COMMD6 was unaffected (Figure 2B), which suggests 
that these key protein-protein interactions are not controlled by 
CCDC22. Next, we evaluated whether CCDC22 plays a role in the 
cellular distribution of COMMD proteins. Silencing of CCDC22 
dramatically changed the cellular localization of fluorescently 
tagged COMMD family members, inducing redistribution to large 
perinuclear punctate foci (Figure 2C). Quantitatively, CCDC22 defi-
ciency led to a nearly 5-fold higher number of cells with YFP-tagged 
COMMD1 or COMMD10 aggregates (Figure 2D). These data indi-
cate that CCDC22 regulates the cellular distribution of COMMD 
proteins, but is not required for COMMD-COMMD interactions.
The amino terminus of CCDC22 and the COMM domain are necessary 
and sufficient for interaction. Homology analysis using the Conserved 
Domain Database (32) indicates that CCDC22 is highly conserved 
and a single ortholog is present in plants, protozoa, worms, 
insects, and vertebrates, a range of organisms similar to that in 
which COMMD genes are found. Notably, CCDC22 and COMMD 
orthologs are not evident in yeast or bacteria. The areas of highest 
homology among CCDC22 orthologs (Figure 3A) are their extreme 
amino termini (first ∼150 amino acids) and their carboxyl termini 
(∼350 amino acids). This latter region corresponds to a coil-coiled 
domain and bears similarity to structural maintenance of chro-
mosomes (SMC) proteins, factors that bind to chromatin and are 
involved in meiosis and DNA repair (33). Further characterization 
of the CCDC22-COMMD1 interaction showed that COMMD1 
bound to the amino terminus of CCDC22 (Figure 3B). In addition, 
the COMM domain of COMMD1, a carboxyterminal homology 
domain present in all COMMD proteins, was necessary and suf-
ficient for CCDC22 binding (Figure 3C), in agreement with the 
binding of all COMM domain–containing proteins to CCDC22.
An XLID-associated CCDC22 mutation impairs COMMD binding. 
Recently, a mutation in CCDC22 was identified in a family with 
XLID (OMIM 300859) and other developmental abnormalities 
(26). Affected members carry a single point mutation in CCDC22 
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(c.49A>G/p.T17A) that changes codon 17 from Thr to Ala, a high-
ly conserved residue among vertebrates. It has been shown that 
this T17A mutation, by virtue of its close proximity to a splice 
site, results in abnormal splicing and diminished mRNA levels 
(26). Indeed, we found that EBV-immortalized B lymphocytes 
(lymphoblastoid cell lines; LCLs) from affected individuals had 
reduced CCDC22 transcript levels, whereas expression of fork-
head box P3 (FOXP3), a gene in close proximity to CCDC22, was 
not affected (Supplemental Figure 3, A and B). Interestingly, the 
corresponding reduction in CCDC22 protein levels was relatively 
modest in LCLs (Figure 3D, input), and we therefore speculated 
that the T17A mutation may also result in functional alterations 
of the CCDC22 protein. Indeed, endogenous T17A was unable 
to bind to COMMD1 in lymphoid cells from affected individu-
als, a finding that was disproportionate to the small decrement 
in CCDC22 expression noted in these cells (Figure 3D). Similarly, 
T17A expressed in HEK 293 cells was defective in its ability to bind 
to endogenous COMMD1, even when both the WT and mutant 
CCDC22 proteins were expressed at comparable levels (Figure 3E).
Several other rare variants of CCDC22 were identified in additional 
families (Figure 3A). Although some of them, such as the E239K vari-
ant, have subsequently been found at a low frequency in the NHLBI 
Figure 1
Identification of CCDC22 as a COMMD associated factor. (A) TAP screen identification of CCDC22. CCDC22 peptides identified with high con-
fidence in TAP screens using 3 different COMMD protein baits are indicated by blue shading. The specific COMMD proteins identified with each 
bait are shown at right. (B and C) Endogenous CCDC22 coimmunoprecipitated with endogenous COMMD proteins. (B) Endogenous CCDC22 
was immunoprecipitated (IP) from HEK 293 cell lysates using 2 anti-CCDC22 antisera, and the recovered material was immunoblotted for 
COMMD1. Preimmune serum (PIS) or beads only were used as negative controls. (C) COMMD1, COMMD6, COMMD9, and COMMD10 were 
pulled down with polyclonal immune sera, and the precipitated material was immunoblotted for CCDC22. Some input lanes corresponded to 
different exposures of the same film. (D) CCDC22 associated with all COMMD family members. COMMD proteins fused to GST were expressed 
in HEK 293 cells and precipitated from Triton X-100 lysates. The recovered material was immunoblotted for endogenous CCDC22. PD, pulldown; 
NS, nonspecific band. (E) COMMD proteins were the main interaction partners of CCDC22. Volcano plot representation of CCDC22-interacting 
proteins. LAP-tagged CCDC22 was immunoprecipitated using an antibody directed against the tag. Nontransfected parental HeLa cells served 
as control. For each protein identified by mass spectrometry, the ratio of the intensities in the CCDC22 IPs over the control was calculated and 
plotted against the P value (2-tailed t test) calculated from triplicate experiments, both on a logarithmic scale. Dashed curves represent the cutoff, 
calculated based on a false discovery rate estimation. Specific interactors (top right) are indicated.
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exome sequencing project (12 of 8,627 genomes), the other variants 
appear to be unique to the XLID kindred. Therefore, we examined 
how these CCDC22 variants bind to COMMD1 using a coimmu-
noprecipitation approach. None of these variants seemed to affect 
COMMD1 binding when tested in LCLs or after expression in 
HEK 293 cells (Figure 3, F and G). Similarly, quantitative BAC-GFP 
interactomics experiments with T30A, R128Q, E239K, and R321W 
failed to disclose any changes in their binding to COMMD proteins 
(data not shown). However, 2 of the variants, R128Q and R321W, 
displayed substantial changes in their cellular localization patterns, 
demonstrating a fine speckled distribution in the cell that was dif-
ferent from the coarse dots noted when expressing the WT protein 
(Figure 3, H and I). Thus, independent of their binding to COMMD 
proteins, these 2 mutants demonstrated a functional impairment.
The T17A mutation or CCDC22 deficiency leads to blunted NF-κB acti-
vation. Given the role of COMMD1 in the regulation of NF-κB, we 
turned our attention to a possible role for CCDC22 in this path-
way. Careful examination of the XLID kindred carrying the T17A 
mutation revealed that some affected individuals had aplasia cutis 
and markedly abnormal dentition (Figure 4A), 2 manifestations 
of ectodermal dysplasia. This congenital change can be found 
in individuals with hypomorphic mutations in NEMO (34, 35), 
which encodes an essential scaffold protein in the IKK complex. 
Ectodermal dysplasia can be similarly observed as a result of IκB-α 
mutations that alter its degradation (36), or in individuals with 
mutations in the ectodysplasin (EDA) pathway, a TNF-related sig-
naling cascade that is involved in ectodermal development (37). 
Therefore, this clinical phenotype suggested a potential blockade 
of NF-κB activation during development (38).
Consistent with this, primary fibroblasts from 2 probands dem-
onstrated decreased TNF-dependent activation of NF-κB target 
genes, such as IL8 and TNF-α–induced protein 3 (TNFAIP3; also 
known as A20), when compared with their heterozygous carrier 
mother (Figure 4B). Moreover, NF-κB–dependent gene expression 
in response to CD40 ligand (CD40L) stimulation was impaired 
in an LCL from an individual with the T17A mutation compared 
with a normal control LCL (Figure 4C). Similar to the effect of the 
T17A mutation, CCDC22 silencing led to impaired activation of 
NF-κB target genes in the control LCL (Figure 4D and Supple-
mental Figure 4). Finally, to exclude the possibility of an off-target 
effect of the siRNA experiments, these were repeated using 2 sepa-
rate siRNA duplexes in HEK 293 cells. Again, in both instances, 
CCDC22 silencing led to decreased TNF-induced activation of 
NF-κB–dependent genes (Figure 4E and Supplemental Figure 5A). 
Conversely, CCDC22 overexpression led to greater IL8 activation 
in this system (Supplemental Figure 5B).
Given these effects on NF-κB activity, we examined whether 
CCDC22 was itself regulated by NF-κB in any way. We found 
that CCDC22 expression was not inducible by NF-κB activation, 
and its binding to COMMD1 was constitutive and not induced 
Figure 2
CCDC22 is required for proper cellular 
distribution of COMMD family proteins. (A) 
Colocalization of CCDC22 with COMMD1. 
GFP-tagged CCDC22 and DsRed2-
tagged COMMD1 were overexpressed 
in U2OS cells. Cells were counter-
stained with Hoechst and imaged by 
confocal microscopy. Scale bars: 10 μm. 
The merged view is also shown 
enlarged (merged and zoom; enlarged 
×3-fold). (B) CCDC22 was not required 
for COMMD-COMMD interaction. HEK 
293 cells were transfected with an 
siRNA targeting CCDC22 (siCCDC22) 
or a control duplex. After 48 hours, 
endogenous COMMD6 was immuno-
precipitated, and the recovered mate-
rial was immunoblotted for endogenous 
COMMD1 and COMMD10. (C and D) 
CCDC22 deficiency led to COMMD 
mislocalization. U2OS cells were trans-
fected with YFP-tagged COMMD1 or 
COMMD10 together with siRNA against 
CCDC22 or a control duplex (siCon-
trol). (C) Nuclear counterstaining with 
Hoechst was performed just prior to 
confocal imaging. Scale bars: 10 μm. 
(D) The proportion of cells with a large 
perinuclear punctate pattern was deter-
mined by examining more than 100 cells 
per dish in a blinded manner.
Downloaded on May 18, 2014.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/66466
171
●
Appendix
research article
2248 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 5   May 2013
Figure 3
CCDC22-COMMD interactions and the effects of XLID-associated variants. (A) Schematic representation of CCDC22. Conserved regions and the 
location of nonrecurrent sequence variants identified in XLID patients are displayed. (B and C) The amino terminus of CCDC22 and the COMM 
domain of COMMD1 were necessary and sufficient for binding. (B) Full-length (F.L.) and indicated domains of CCDC22 were expressed fused to 
GST, and their binding to endogenous COMMD1 was examined by coprecipitation. (C) Similar experiments were performed to detect coprecipita-
tion of endogenous CCDC22 with full-length COMMD1 or its aminoterminal (N-term; amino acids 1–118) or carboxyterminal (C-term; amino acids 
119–190) domains. (D and E) The XLID-associated mutation CCDC22 T17A impaired COMMD1 binding. (D) Coimmunoprecipitation between 
endogenous CCDC22 and COMMD1 was examined in LCLs derived from the kindred with the T17A mutation and a healthy control subject (WT). 
(E) Endogenous COMMD1 was similarly immunoprecipitated from HEK 293 cells expressing CCDC22 T17A or the WT. (F and G) Interaction of 
COMMD1 with other XLID-associated variants of CCDC22. (F) The ability of endogenous COMMD1 and CCDC22 E239K to interact was exam-
ined using available LCLs. (G) Interactions were examined by expressing HA-tagged CCDC22 proteins in HEK 293 cells. Immunoprecipitation of 
endogenous COMMD1 was followed by immunoblotting for HA-tagged CCDC22. (H and I) Abnormal cellular distribution of CCDC22 variants. (H) 
Distribution of YFP-tagged CCDC22 variants, determined by confocal microscopy. Scale bars: 10 μm. (I) Cellular distribution after examination of 
more than 100 cells per group in a blinded manner.
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by TNF stimulation (Supplemental Figure 6, A and B). Together, 
these data indicated that CCDC22 deficiency, or a hypomorphic 
mutation in this gene that impairs the interaction with COMMD 
proteins, leads to blunted activation of NF-κB.
CCDC22 is required for IκB turnover. The positive role that CCDC22 
plays in NF-κB activation stands in contrast with the inhibitory 
function of COMMD1 in this pathway (1, 11, 12). Nevertheless, 
consistent with the interaction between these 2 proteins, we found 
that CCDC22 was present in a complex containing both Cul2 
and COMMD1 (Supplemental Figure 7A), and, like COMMD1, 
CCDC22 could be inducibly bound to the NF-κB–responsive pro-
moter of baculoviral IAP repeat containing 3 (BIRC3; also known 
as c-IAP2; Supplemental Figure 7B). Although these findings were 
consistent with the interaction between CCDC22 and COMMD1, 
they failed to explain CCDC22’s inhibitory role on NF-κB. There-
fore, we hypothesized that this factor must have an additional site 
of action that is COMMD1 independent.
To test this possibility, we examined the effects of CCDC22 
silencing on NF-κB nuclear accumulation. CCDC22 silencing led 
to a reduction in nuclear translocation of NF-κB after cell stimula-
Figure 4
CCDC22 is required for NF-κB activation. (A) Aplasia cutis (left, arrows) and examples of abnormal dentition (right) in patients with the T17A 
mutation. (B) Fibroblasts from XLID patients displayed blunted activation of NF-κB–dependent genes. Primary dermal fibroblasts from patients 
demonstrated decreased TNF-induced activation of IL8 and RELB compared with their mother, a heterozygote mutation carrier (HET). (C) 
Response of NF-κB genes to CD40L activation was decreased in a LCL derived from an XLID patient. LCLs derived from an XLID patient or a 
healthy control were stimulated with CD40L. (D) CCDC22 deficiency phenocopied the T17A mutation. LCLs derived from the healthy control in 
C were transfected with the indicated siRNA oligonucleotides and subsequently stimulated with CD40L. (E) CCDC22 was required for activation 
of NF-κB–responsive genes in HEK 293 cells. 2 siRNA oligonucleotides targeting CCDC22 were used, and cells were subsequently stimulated 
with TNF. (B–E) Gene induction was evaluated in triplicate experiments by qRT-PCR; data represent mean and SEM.
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tion, as shown by DNA-protein coprecipitation using oligonucle-
otides containing tandem κB sites or by direct Western blotting 
of nuclear extracts (Figure 5A). This finding suggested a possible 
blockade in IκB degradation, akin to that observed in hypomorph-
ic NEMO mutations (35). This possibility was examined in a vari-
ety of systems. First, primary dermal fibroblasts from individuals 
with the T17A mutation displayed markedly delayed or absent 
IκB degradation compared with cells derived from their mother, 
a heterozygous carrier (Figure 5B). All 3 classical IκB proteins 
were affected, and the basal level of IκB-α was also notably ele-
vated. In addition, CCDC22 protein levels were more significantly 
reduced in mutant fibroblasts than in LCLs (compare Figure 3D 
and Figure 5B), highlighting the variable effect of the mutation 
on mRNA splicing and gene expression (26). Experiments using 
siRNA in HEK 293 cells demonstrated a similar result, although 
in these cells, the effects were most dramatic for IκB-β and IκB-ε 
(Figure 5C). Moreover, the changes in IκB-β turnover proved to 
result from altered protein stability, not from alterations in mRNA 
expression. Using cycloheximide (CHX) to block new protein 
synthesis, we found that TNF-induced degradation of IκB-β was 
Figure 5
CCDC22 is required for RelA nuclear transport and IκB degradation. (A) CCDC22 deficiency resulted in depressed nuclear accumulation of 
active NF-κB. HEK 293 cells were transfected with the indicated siRNAs and stimulated with TNF. The presence of active NF-κB complexes in 
nuclear extracts was assessed by a DNA-protein coprecipitation assay (top) or by direct immunoblotting (input, bottom). RNA polymerase II 
(Pol II) served as a loading control. (B) TNF-induced degradation of classical IκB proteins was impaired in primary fibroblasts bearing the T17A 
mutation. Primary dermal fibroblasts from 2 patients demonstrate decreased TNF-induced degradation of IκB-α, IκB-β, and IκB-ε compared with 
fibroblasts from their mother, a heterozygote mutation carrier. (C) CCDC22 deficiency impaired TNF-induced IκB degradation. HEK 293 cells 
were transfected with the indicated siRNA oligonucleotides and treated with TNF. IκB degradation was determined by Western blot analysis. (D) 
CCDC22 deficiency affected IκB-β stability. Cells transfected with the indicated siRNA were subsequently treated with cycloheximide (CHX) to 
inhibit new protein synthesis. IκB-β stability after TNF stimulation was examined by immunoblotting. (E) IκB-α degradation was impaired in XLID-
derived LCLs. LCLs derived from a healthy control subject and an XLID patient with the T17A mutation were stimulated with PMA, and IκB-α 
degradation was examined by immunoblotting. (F) IκB-α phosphorylation was not affected in XLID-derived LCLs. LCLs derived from a healthy 
control and an XLID patient were stimulated with PMA for indicated times. Phosphorylation of IκB-α at serines 32 and 36 was determined by 
immunoblotting using a phosphospecific antibody.
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Figure 6
CCDC22 is required for IκB ubiquitination. (A) IκB-α ubiquitination is reduced in lymphoid cells bearing the T17A mutation. LCLs derived from a 
healthy control subject and an XLID patient with the T17A mutation were stimulated with PMA. The protease inhibitor MG-132 was concurrently 
administered. Ubiquitinated phospho–IκB-α levels were determined by immunoprecipitating NF-κB complexes with a RelA antibody, followed 
by phospho–IκB-α immunoblotting. (B) CCDC22 interacted with various CRL1-βTrCP components. FLAG-tagged Cul1, βTrCP1, or SKP1 were 
expressed along with CCDC22 in HEK 293 cells. CRL components were immunoprecipitated using a FLAG antibody, and CCDC22 was detected 
in the recovered material by immunoblotting. (C) Endogenous CCDC22 interacted with Cul1, Cul2, and Cul3. CCDC22 was immunoprecipitated, 
and the recovered material was immunoblotted for endogenous Cul1, Cul2, and Cul3. Some input lanes corresponded to different exposures 
of the same film. (D) Cul1 and Cul2 were not required for CCDC22-COMMD interaction. HEK 293 cells were treated with siRNA against Cul1, 
Cul2, or an irrelevant control. Endogenous CCDC22 was subsequently immunoprecipitated, and the recovered material was immunoblotted for 
endogenous COMMD1 and COMMD10. (E) CCDC22 was not required for Cullin-COMMD interaction. HEK 293 cells were transfected with GST, 
GST-COMMD1, or GST-COMMD8 along with control or anti-CCDC22 siRNA. After 48 hours, cell lysates were purified on GST-agarose, and the 
recovered material was immunoblotted for endogenous Cul1, Cul2, Cul3, and COMMD1.
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nous IκB-α ubiquitination after PMA stimulation (Figure 6A). IκB 
ubiquitination in response to this signal is carried out by CRL1-
βTrCP, a Cul1-containing complex. As noted previously, certain 
COMMD proteins — most notably COMMD8 and COMMD10 
(16) — can bind to Cul1, which suggests the possibility that 
CCDC22 might interact with this complex as well. Indeed, 
CCDC22 coprecipitated various components of this multimeric 
ligase when expressed in HEK 293 cells (Figure 6B). Moreover, pre-
cipitation of endogenous CCDC22 led to the recovery of endog-
enous Cul1, Cul2, and Cul3 (Figure 6C). Finally, CCDC22 was 
able to interact with other Cullin family members (Supplemental 
Figure 9A), in line with similar observations for COMMD family 
members (16). Together, these data demonstrated that CCDC22 
interacts with the ligase that targets IκB proteins for degradation 
and is required for its ability to ubiquitinate this substrate in vivo.
The ability of both CCDC22 and COMMD family members to 
interact with CRLs led us to examine whether CRLs play a role in 
the interactions between CCDC22 and COMMD proteins. Silencing 
markedly delayed by RNAi against CCDC22 (Figure 5D). Finally, 
LCLs from individuals with the T17A mutation also displayed 
reduced degradation of IκB-α after PMA or CD40L stimulation 
(Figure 5E and Supplemental Figure 8A). Less dramatic changes 
in IκB-β degradation at later time points were also evident in this 
LCL model (Supplemental Figure 8B).
In all instances, the impaired degradation of IκB-α was not associ-
ated with reduced IκB-α phosphorylation (Figure 5F and Supple-
mental Figure 8C), which indicates that the blockade in degradation 
was not caused by impaired IKK function. In fact, phospho–IκB-α 
levels were higher in mutant cells, which indicates that the reduced 
IκB degradation is caused by an event that occurs after phosphoryla-
tion. Thus, these data suggest that impaired CCDC22 activity leads 
to decreased degradation of phosphorylated IκB.
CCDC22 is required for IκB ubiquitination. Based on the above find-
ings, we reasoned that the ubiquitination of phosphorylated IκB 
proteins might be regulated by CCDC22. Indeed, in an LCL from 
a T17A-affected patient, we noted marked reductions in endoge-
Figure 7
COMMD8, a partner of CCDC22, is also required for IκB degradation. (A and B) COMMD8 deficiency impaired TNF-induced IκB-α degradation. 
(A) HEK 293 cells were transfected with the indicated siRNA oligonucleotides, and the effectiveness of the silencing was determined by qRT-PCR. 
(B) In parallel, cells were stimulated with TNF, and IκB-α degradation was examined by immunoblotting. (C and D) COMMD8 was required for 
NF-κB–responsive gene expression. (C) HEK 293 cells were transfected with the indicated siRNA oligonucleotides and subsequently treated with 
TNF. Induction of several NF-κB–responsive genes was examined. (D) The findings in C were recapitulated using 2 distinct siRNA oligonucle-
otides against COMMD8. (A, C, and D) Gene induction was evaluated in triplicate experiments by qRT-PCR; data represent mean and SEM.
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on previously published studies indicating that 
COMMD proteins form dimers (1, 39) and on 
our mass spectrometry data demonstrating that 
only certain COMMD combinations were pres-
ent in vivo (Figure 1A). Thus, based on the avail-
able data, we conclude that CCDC22 plays a criti-
cal role in controlling the cellular distribution 
of these complexes (Figure 2), and in so doing, it 
seems to be necessary for their normal function. 
We postulate that the specific composition of 
COMMD proteins present in any given CCDC22-
COMMD complex, as well as the specific CRLs 
to which they bind, ultimately determine their 
unique functions. In addition, we speculate that 
CCDC22 and COMMD proteins work in con-
cert to regulate these ligases, probably acting as 
a complex to displace the CRL inhibitor CAND1, 
as recently reported in the case of COMMD1 (16).
Since CRLs are involved in a vast array of cel-
lular processes, we anticipate that CCDC22 will 
have pleiotropic effects in multiple pathways besides the effects on 
NF-κB transcription observed here. Indeed, the complex pheno-
type noted in individuals carrying the hypomorphic T17A muta-
tion indicates that CCDC22 plays an important developmental role 
in the nervous system and beyond. In this regard, it is noteworthy 
that Cul4b has been similarly linked to XLID, and CCDC22 may 
therefore also be involved in the regulation of CRL4B targets that 
are important for neuronal biology (40). Other rare variants in this 
gene were also noted in families with XLID; in the case of 2 of these 
variants, R128Q and R321W, we demonstrated a clear functional 
alteration of the mutant proteins, which were mislocalized in the 
cell. The mechanism for this abnormal localization was not medi-
ated by altered COMMD binding, but may involve other protein-
protein interactions that remain to be elucidated. With regard to 
the T30A and E239K variants, no functional effects were identified 
by our studies; with respect to E239K, we speculate that this may 
be a rare but functionally normal protein, since it can be found in 
the NHLBI exome database. Ultimately, we anticipate that addi-
tional mutations in this gene will be uncovered in the context of 
XLID and other X-linked developmental disorders.
Our data suggested that in the NF-κB pathway, a CCDC22-
COMMD8 complex plays an important role in IκB turnover 
and NF-κB activation through its interaction with Cul1, the 
ligase that targets IκB (21). However, we conversely found that 
CCDC22-COMMD1 complexes bound preferentially to Cul2, 
a ligase involved in NF-κB/RelA ubiquitination and removal of 
chromatin-bound NF-κB (12, 25). With these dual functions, 
CCDC22 deficiency or mutation would impair the activity of both 
COMMD1 and COMMD8 complexes, but the lack of IκB degra-
dation, an upstream and initial step in this pathway, had a domi-
nant role and was responsible for the impaired NF-κB activation 
described herein (Figure 8). The role of CCDC22 in IκB degrada-
tion is supported by ample analysis of cells derived from individu-
als with the hypomorphic T17A mutation. Moreover, our concor-
dant findings after RNAi-induced silencing of CCDC22 confirmed 
the role of this factor in NF-κB activation. In agreement with these 
observations, some of the individuals with XLID affected by the 
T17A mutation displayed ectodermal dysplasia, a congenital 
change that can result from blunted NF-κB activation down-
stream of EDAR, a member of the TNF receptor superfamily (37). 
of Cul1 or Cul2 did not affect CCDC22-COMMD1 or CCDC22-
COMMD10 interactions in coimmunoprecipitation experiments 
(Figure 6D and Supplemental Figure 9B). Conversely, we next evalu-
ated whether CCDC22 could play a role in the interaction between 
COMMD proteins and CRLs. The binding between COMMD1 or 
COMMD8 and their respective preferential Cullin partners was not 
substantially affected by CCDC22 silencing (Figure 6E and Supple-
mental Figure 9C). This experiment also served as a further dem-
onstration that COMMD1 binds preferentially to Cul2, whereas 
COMMD8 binds better to Cul1 and Cul3. Thus, these data sug-
gested that despite the ability of COMMDs, CCDC22, and Cullin 
to form a triple complex, none of them seems to play a scaffold role.
COMMD8 is also required for IκB turnover and NF-κB activation. Our 
results indicated that CCDC22 promotes IκB ubiquitination and 
degradation, and we reasoned that this effect might be mediated by 
CCDC22’s interaction with another COMMD family member or 
might be COMMD independent. To identify a possible COMMD 
protein that might be similarly involved in the degradation of IκB, 
we focused our attention on COMMD family members that inter-
act with Cul1 (the central subunit in the CRL1-βTrCP complex), 
such as COMMD8 and COMMD10 (16). COMMD8 repression led 
to decreased IκB-α degradation, an effect not seen after COMMD1 
or COMMD10 RNAi (Figure 7, A and B). Similarly, COMMD8 or 
CCDC22 silencing led to decreased activation of several NF-κB tar-
get genes, while an opposite effect was seen after COMMD1 RNAi 
(Figure 7C). These observations were recapitulated using 2 inde-
pendent RNAi duplexes targeting COMMD8 (Figure 7D), which 
indicates that this is unlikely to be an off-target effect. Together, 
these data suggested that a CCDC22-COMMD8 complex partici-
pates in the activation of CRL1-βTrCP and is required for optimal 
IκB degradation and subsequent activation of NF-κB target genes.
Discussion
In this study, we identified CCDC22 as a novel interacting protein 
that binds avidly to COMMD family members. Our data indicate 
that each COMMD protein, from COMMD1 to COMMD10, 
interacts with CCDC22. However, it is unlikely that this occurs in 
a single complex containing CCDC22 and all 10 COMMD family 
members at the same time. Rather, we postulate that different and 
distinct CCDC22-COMMD complexes exist in vivo. This is based 
Figure 8
Role of CCDC22-COMMD complexes in NF-κB pathway regulation.
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the corresponding pEBB-FLAG vectors. All other plasmids used were 
described previously (1, 3, 16, 25, 28, 46–48). See Supplemental Table 1 
for target sequences of the siRNA duplexes used.
Cell culture and transfection. HEK 293, HeLa, and U2OS cell lines were 
obtained from ATCC and cultured in DMEM supplemented with 10% 
FBS and l-glutamine. A standard calcium phosphate transfection proto-
col was used to transfect plasmids and siRNA in HEK 293 cells (48); the 
Fugene transfection system (Invitrogen) was used for HeLa and U2OS 
cells. Patient-derived cells were obtained after IRB approval and informed 
consent. LCLs were generated by immortalization of peripheral lympho-
cytes with EBNA as previously described (49). Primary human fibroblasts 
of XLID patients and their mother, a heterozygote carrier of the CCDC22 
mutation, were obtained from skin punch biopsies. LCLs and primary 
fibroblasts were cultured in RPMI 1640 (Cellgro, 10-040-CM) supplement-
ed with 10% FBS. For siRNA transfection of LCLs, electroporation was 
performed using the Neon Transfection System (Invitrogen) following the 
manufacturer’s recommendations. Briefly, 1 × 108 cells in 10 ml RPMI 1640 
supplemented with 10% FBS and l-glutamine were pulsed 2 times (pulse 
voltage, 1,100 V; pulse width, 30 ms each). In certain experiments, TNF 
(1,000 U/ml; Roche), cycloheximide (60 μg/ml; BioVision), PMA (250 nM; 
Fisher BioReagents), CD40L (50 ng/ml; Enzo Life Science), and/or MG-132 
(40 μM; Boston Biochem) were applied to the growth media.
qRT-PCR. Total RNA was extracted from cells using the RNeasy proce-
dure (Qiagen) according to the manufacturer’s instructions. An RT reac-
tion with 5 μg total RNA in 20 μl was performed, using random hexamers 
and reverse transcription reagents according to the manufacturer’s instruc-
tions (Invitrogen). This was followed by qRT-PCR performed using a Mas-
tercycler ep realplex2 system (Eppendorf). Oligonucleotides and internal 
probes for NFKBIA, CUL1, and IL8 transcripts were obtained from Applied 
Biosystems, and a Taqman PCR Master Mix with GAPDH mRNA quantita-
tion was duplexed in the same well as an internal control. See Supplemen-
tal Table 2 for primers used for Sybr green–based qRT-PCR of other genes.
Immunoblotting and precipitation. Whole cell lysates were prepared by add-
ing Triton lysis buffer (25 mM HEPES, 100 mM NaCl, 10 mM DTT, 1 mM 
EDTA, 10% glycerol, 1% Triton X-100) or RIPA buffer (PBS, 1% NP-40, 
0.5% sodium deoxycholate, 0.1% SDS, 10 mM DTT) supplemented with 
1 mM sodium orthovanadate and protease inhibitors (Roche), as indi-
cated in each experiment. Cytosolic and nuclear extracts were prepared 
as previously described (1). Native immunoprecipitation, denatured 
immunoprecipitation, GSH precipitation, and immunoblotting were 
performed as previously described (1, 3, 50). Antiserum to COMMD1 
has been previously described (1). Antisera against human CCDC22, 
COMMD6, COMMD9, and COMMD10 were generated by serial immu-
nization of rabbits with purified full-length recombinant proteins pre-
pared in E. coli. These antibodies were validated by Western blot for their 
ability to detect overexpressed protein after transient transfection, as well 
as the loss of a specific band of the correct molecular weight after RNAi 
(silencing confirmed by qRT-PCR). Antiserum to Cul3 was provided by M. 
Peter (ETH Zurich, Zurich, Switzerland). See Supplemental Table 3 for all 
commercial antibodies used.
TAP and bimolecular affinity purification. TAP screening for COMMD1 
has been previously reported (1). TAP screening for COMMD9 and 
COMMD10 were performed by sequential purification through HA bind-
ing resin (Roche) and streptavidin agarose (Pierce). Briefly, 10 plates of 
seeded HEK 293 cells (15 cm each) were transfected with pEBB-2×HA-
COMMD9-TB or pEBB-2×HA-COMMD10-TB. 2 days later, nuclear and 
cytosolic extracts were prepared as previously described (1) and pooled 
as a single lysate prior to purification. The lysate was incubated with HA 
binding resin at 4°C for 2 hours. At that point, the bait was eluted 3 times 
using excess HA peptide (1 mg/ml in 20 mM Tris-HCl [pH 7.4], 100 mM 
Moreover, NF-κB plays an important role in neuronal function 
and learning processes (41, 42) and is similarly important for 
myelination and Schwann cell function (43). Therefore, the altera-
tions in the NF-κB pathway seen in these patients may contribute 
to their neurologic phenotype.
With respect to the role of CCDC22 in immune function, our 
observations were mainly restricted to 6 individuals with the T17A 
mutation, with only 2 of them being of adult age at this point. 
Nevertheless, increased infections, autoimmunity, or unusual 
malignancies have not been noted thus far. This may indicate that 
chronic CCDC22 deficiency is better compensated in vivo than in 
isolated culture systems or that this hypomorphic mutation is not 
severe enough to result in an obvious immune phenotype in chil-
dren. Alternatively, the immune defects in vivo may be restricted 
to selective microorganisms; this has been observed with impor-
tant immune regulators, such as TRIF, for which inactivating 
mutations lead to a narrow and specific susceptibility to herpes 
encephalitis (44). If this were the case here, a larger patient cohort 
and longer-term follow-up may be needed to fully comprehend 
the immune phenotypes of CCDC22 mutations. Nevertheless, it 
is interesting to note that a genetic study has indicated that single 
nucleotide polymorphisms in the CCDC22 gene affect the risk for 
allergic rhinitis (45). However, because the CCDC22 gene is located 
in the complementary strand and in close proximity to FOXP3, a 
major regulator of immune function, it is possible that such poly-
morphisms may be more relevant to the function of FOXP3. In 
any event, it is important to note that the functional analysis of 
CCDC22 presented here, including various RNAi experiments, did 
not reflect FOXP3 function, and that the T17A mutation did not 
affect FOXP3 expression (Supplemental Figure 3B). Finally, the 
high level of CCDC22 expression observed in the immune system, 
particularly in myeloid and T cells (Supplemental Figure 1A), 
suggests an important immunological role, in keeping with the 
NF-κB regulatory function reported here.
The involvement of CCDC22 and COMMD8 in the ubiquitina-
tion of IκB represents a novel aspect in the regulation of this criti-
cal pathway that might be amenable to therapeutic manipulation. 
Disrupting CCDC22-COMMD interactions in a manner akin to 
the effect of the T17A mutation should result in impaired IκB 
degradation and NF-κB blockade, an effect that would be desir-
able in certain contexts, such as chronic inflammatory disorders 
or specific cancers.
Methods
Plasmids and siRNAs. Expression vectors for CCDC22 (pEBB-FLAG-
CCDC22, pEBB-HA-CCDC22, pEBB-YFP-CCDC22, pEBB-GFP-
CCDC22, and pEBG-CCDC22) were generated by PCR amplification of 
the coding sequence using IMAGE clone 3449051 as template. Expression 
vector for βTrCP1 (pEBB-FLAG-βTrCP1) was generated by PCR ampli-
fication of the coding sequence using as template a plasmid obtained 
from Y. Ben-Neriah (Hebrew University of Jerusalem, Jerusalem, Israel). 
Deletion constructs for CCDC22 were similarly generated by PCR, with 
the amino acid boundaries of the encoded mutant proteins being 1–320 
and 321–627. Point mutations T17A, T30A, R128Q, E239K, and R321W 
were introduced into pEBB-HA-CCDC22 by site-directed mutagenesis 
(Stratagene). The pEBB-2×HA-TB vector used for TAP screening was 
constructed using complementary oligonucleotides coding tandem HA 
tags, which were inserted into the BamHI site of pEBB-TB. Subsequently, 
pEBB-2×HA-COMMD9-TB and pEBB-2×HA-COMMD10-TB were con-
structed by subcloning the COMMD9 and COMMD10 sequences from 
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mittee of the Women’s and Children’s Health Network (Adelaide, South 
Australia, Australia). Animal studies were approved by the IACUC at UT 
Southwestern (protocol no. 2008-0327).
Note added in proof. Recent data from a genome-wide siRNA screen 
for regulators of NOD2-regulated pathways also identified that 
COMMD8 is required for NF-κB activation (53).
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NaCl, 0.1 mM EDTA). This pooled eluate was applied to a streptavidin 
agarose column to bind the bait at 4°C for 2 hours. The column was 
washed with detergent-free buffer, and beads were then submitted to the 
proteomic facility for trypsin digestion and LC/MS-MS analysis. Quan-
titative BAC-GFP interactomics (QUBIC) for CCDC22 was performed as 
described previously (29). A BAC harboring the locus for CCDC22 was 
modified to include a carboxyterminal (LAP) or aminoterminal (NFLAP) 
GFP tag by BAC transgenomic method (30). Engineered BACs were used as 
transgenes to generate HeLa cells stably expressing GFP-tagged CCDC22 
under endogenous control. Affinity purifications were performed and 
analyzed as described previously (29). Finally, bimolecular affinity puri-
fication of the Cul2-COMMD1 complex (GST-Cul2, COMMD1-TB) was 
performed as described previously (51).
κB pulldown assay. Nuclear extracts (100 μg) were incubated with a bioti-
nylated 2κB oligonucleotide and subsequently precipitated using strepta-
vidin agarose beads (Thermo Scientific), as described previously (52).
Confocal microscopy. HeLa or U2OS cells were plated in chambered cov-
erglass plates and transfected with the indicated plasmids. Cells were 
counterstained with Hoechst 33342 (8 μM) for 30 minutes, and images 
were obtained with a Zeiss LSM 510 META confocal microscope equipped 
with a Chameleon XR NIR laser. All confocal microscopy experiments were 
repeated at least twice; representative results are shown.
ChIP. ChIP was performed as previously reported (50). Briefly, HEK 293 
cells were cultured overnight in low serum media and stimulated with 
TNF (1,000 U/ml for 30 minutes) prior to ChIP. The antibodies used 
included RelA (Santa Cruz, sc-372), COMMD1 (1), CCDC22 (generated 
as described above), and normal rabbit IgG (Cell Signaling, 2729). After 
immunoprecipitation, DNA was extracted and used as template for PCR. 
The primers used for amplification of the BIRC3 promoter were 5′-GCAT-
GCTTACCAATACGTGC-3′ and 5′-ATTGCGCAATTGTAGCGGTA-3′.
Statistics. In all gene expression experiments, data represent mean ± SEM. 
A P value less than 0.05 was considered significant.
Study approval. All patient-related evaluation was performed with the 
written consent of the participants or their legal guardians, after review 
and approval of the study protocols by the human research ethics com-
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Wie jede Blüte welkt und jede Jugend
Dem Alter weicht, blüht jede Lebensstufe,
Blüht jede Weisheit auch und jede Tugend
Zu ihrer Zeit und darf nicht ewig dauern.
Es muß das Herz bei jedem Lebensrufe
Bereit zum Abschied sein und Neubeginne,
Um sich in Tapferkeit und ohne Trauern
In andre, neue Bindungen zu geben.
Und jedem Anfang wohnt ein Zauber inne,
Der uns beschützt und der uns hilft, zu leben.
Wir sollen heiter Raum um Raum durchschreiten,
An keinem wie an einer Heimat hängen,
Der Weltgeist will nicht fesseln uns und engen,
Er will uns Stuf ’ um Stufe heben, weiten.
Kaum sind wir heimisch einem Lebenskreise
Und traulich eingewohnt, so droht Erschlaffen,
Nur wer bereit zu Aufbruch ist und Reise,
Mag lähmender Gewöhnung sich entraffen.
Es wird vielleicht auch noch die Todesstunde
Uns neuen Räumen jung entgegensenden,
Des Lebens Ruf an uns wird niemals enden. . .
Wohlan denn, Herz, nimm Abschied und gesunde!
Hermann Hesse
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